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Abstract	  
Antineutrophil	   cytoplasmic	   antibody	   (ANCA)	   associated	   vasculitis	   (AAV)	   is	   a	   multi-­‐
systemic	   disease	   with	   autoantibody	   generation	   to	   myeloperoxidase	   (MPO)	   and	  
proteinase	   3	   (PR3),	   components	   of	   neutrophils	   and	  monocytes.	   It	   is	  widely	   believed	  
that	   ANCA	   are	   pathogenic.	   The	   most	   convincing	   evidence	   for	   this	   comes	   from	   the	  
ability	   to	   induce	  crescentic	  glomerulonephritis	   in	  mice	  with	  passive	   transfer	  of	  MPO-­‐
ANCA.	  Studies	  have	  also	  shown	  with	  limited	  numbers	  of	  ANCA,	  the	  autoantibodies	  can	  
activate	  neutrophils	  in	  vitro.	  The	  role	  of	  monocytes	  in	  pathogenesis	  though	  is	  scarcely	  
explored.	  The	  alternative	  pathway	  of	  complement	  has	  also	  been	  implicated	  as	  vital	  to	  
the	  pathogenesis	  of	  AAV,	  but	  the	  activating	  factors	  of	  complement	  are	  unknown.	  	  
Contrary	  to	  previous	  studies	  we	  failed	  to	  consistently	  activate	  neutrophils	  with	  a	  large	  
panel	   of	   randomly	   selected	   ANCA.	   We	   investigated	   the	   effect	   of	   these	   ANCA	   on	  
peripheral	   blood	   monocytes.	   Interestingly,	   we	   found	   that	   MPO-­‐ANCA	   derived	   from	  
AAV	   patients	   cause	   a	   reduction	   in	   IL6	   and	   IL10	   production	   from	   lipopolysaccharide	  
treated	  monocytes,	  which	   is	  Fc	  dependent	  and	  MPO	  enzyme	  dependent.	  Using	  gene	  
expression	  microarrays	  we	  show	  that	  MPO-­‐ANCA	  cause	  a	  widespread	  reduction	  in	  toll-­‐
like	  receptor	  (TLR)	  4	  signalling.	  We	  show	  using	  mass	  spectrometry	  analysis	  that	  MPO-­‐
ANCA	   leads	   to	   the	   production	   of	   a	   subset	   of	   oxidised	   phospholipids	   that	   can	   inhibit	  
TLR4.	   We	   also	   demonstrate	   that	   MPO-­‐ANCA	   lead	   to	   an	   increase	   in	   survival	   of	  
macrophages	   differentiated	   in	   vitro	   from	  monocytes,	   which	   is	   dependent	   on	   colony	  
stimulating	  factor-­‐1.	  The	  differentiated	  macrophages	  have	  an	  M2-­‐like	  phenotype	  that	  
induce	  IL10	  and	  TGFβ	  production	  from	  CD4	  T	  cells,	  which	  would	  have	  a	  potential	  role	  
in	  fibrosis.	  
Secondly,	  we	  address	  potential	  triggers	  for	  complement	  activation	  during	  disease	  and	  
show	   that	   there	   is	   a	   redundancy	   between	   the	   classical	   and	   alternative	   pathway.	   C3	  
deficient	  mice	  are	  protected	  from	  disease,	  but	  factor	  B	  deficient	  and	  C4	  deficient	  mice	  
are	   not.	  We	   also	   demonstrate	   cross	   talk	   between	   the	   coagulation	   and	   complement	  
cascade.	  Using	  bone	  marrow	  chimeras,	  we	  demonstrate	  a	  role	  for	  circulating	  and	  not	  
bone	  marrow-­‐derived	  C5	  in	  disease	  pathogenesis,	  which	  may	  help	  refine	  complement-­‐
targeted	  therapy.	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Chapter	  1	  -­‐	  Introduction	  
1.1	  ANCA-­‐Associated	  Vasculitis	  
Vasculitis	  is	  an	  inflammatory	  process	  of	  the	  blood	  vessels,	  which	  is	  histopathologically	  
characterised	  by	  inflammation	  and	  fibrinoid	  necrosis	  of	  the	  vessel	  wall	  resulting	  in	  end	  
organ	   injury.	   The	   pathogenesis	   of	   most	   cases	   of	   vasculitis	   is	   believed	   to	   be	   largely	  
autoimmune,	  although	  infection,	  drugs,	  malignancy	  and	  other	  diseases	  can	  manifest	  as	  
vasculitis.	  The	  clinical	  phenotype	  is	  heterogeneous	  and	  reflects	  the	  pattern	  of	  vessels	  
affected.	  It	  often	  has	  cutaneous	  and	  systemic	  features.	  	  
The	   International	   Chapel	   Hill	   Consensus	   Conference	   2012	   revised	   the	   nomenclature	  
and	   classification	   of	   vasculitides.	   Figure	   1.1	   below	   depicts	   the	   major	   categories	   of	  
vasculitis	  in	  relation	  to	  vessel	  size	  and	  in	  particular	  highlights	  the	  broader	  spectrum	  of	  
vessels	  affected	   in	  antineutrophil	   cytoplasmic	  antibody	   (ANCA)	   -­‐	  associated	  vasculitis	  
(AAV).	  
	  
Figure	   1.1	   –	  Overview	   of	   the	   International	   Chapel	   Hill	   Consensus	   Conference	   2012	  
nomenclature	  revision	  of	  vasculitides	  [1].	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AAV	   is	   a	   life	   threatening	   vasculitis	   characterised	   by	   the	   presence	   of	   circulating	  
autoantibodies	   (ANCA)	  targeted	  against	  antigens	   in	  the	  cytoplasm	  of	  neutrophils	  and	  
monocytes,	  namely	  proteinase	  3	  (PR3)	  and	  myeloperoxidase	  (MPO).	  A	  small	  subgroup	  
of	   patients	   are	   ANCA	   negative	   (discussed	   later).	   Figure	   1.1	   depicts	   the	   current	   sub-­‐
classification	   of	   ANCA	   vasculitides,	   however,	   there	   are	   proposals	   to	   categorise	   AAV	  
based	   on	   autoantibody	   specificity	   rather	   than	   disease	   phenotype.	   This	   is	   due	   to	  
fundamental	   differences	   between	  patients	  with	  MPO-­‐ANCA	  and	  PR3-­‐ANCA	   including	  
distinct	  genetic	  associations,	  clinical	  as	  well	  as	  histopathological	  differences.	  	  
There	  is	  historically	  a	  lack	  of	  immune	  complex	  deposition,	  hence	  the	  associated	  name	  
of	  pauci-­‐immune	  vasculitis.	  However,	  a	  study	  by	  Haas	  et	  al	  examined	  renal	  sections	  of	  
126	   cases	   of	   AAV	   and	   found	   that	   54%	   of	   the	   biopsies	   showed	   evidence	   of	   immune	  
complex	   deposits	   on	   electron	   microscopy	   [2].	   The	   initial	   inflammatory	   lesion	   is	  
characterised	   by	   segmental	   lytic	   necrosis,	   and	   neutrophil	   infiltration	   undergoing	  
leucocytoclastic	   changes.	   Monocytes	   and	   macrophages	   become	   the	   predominant	  
leucocytes	  within	  days,	  with	  macrophages	  persisting	  in	  vessels	  [3].	  Fibrinoid	  necrosis	  is	  
often	   noted,	   a	   consequence	   of	   activated	   coagulation	   factor	   spill	   over	   from	   necrotic	  
vessels,	  with	  macrophages	  as	   the	  predominant	  cell	   type	  and	  T	  cells.	  With	  chronicity,	  
the	  fibrinoid	  necrosis	  is	  replaced	  by	  collagenous	  material.	  
The	   first	   documented	   evidence	   of	   clinical	   disease	   in	   keeping	   with	   AAV	   was	   a	  
description	   by	   Peter	   McBride	   in	   1897	   of	   necrotising	   vasculitis,	   respiratory	   tract	  
granulomatous	   lesions	   and	   glomerulonephritis.	   Clinical	   manifestations	   of	   AAV	   are	  
variable	   from	   organ-­‐limited	   disease,	   for	   example	   renal	   limited	   vasculitis,	   to	   a	  multi-­‐
systemic	   disease	   affecting	   critical	   organs	   such	   as	   the	   skin,	   joints,	   lungs,	   kidneys	   and	  
gastrointestinal	   system.	   The	   clinical	   features	   as	   alluded	   to	   above	   are	   dependent	   on	  
organ	  involvement,	  disease	  stage,	  disease	  activity	  as	  well	  as	  the	  chronicity	  or	  extent	  of	  
damage	   involved.	  Prodromal	  symptoms	  are	  often	  present	  which	  are	  non-­‐specific	  and	  
constitutional,	  common	  to	  the	  three	  types	  of	  AAV.	  Renal	   involvement,	  which	   is	  most	  
commonly	   associated	   with	   microscopic	   polyangiitis	   (MPA)	   and	   granulomatosis	   with	  
polyangiitis	   (GPA),	   is	   one	   of	   the	   most	   significant	   and	   often	   the	   most	   severe	  
manifestation.	   It	   is	   associated	  with	   a	  worse	   outcome	   (see	   table	   1.1).	  MPA	   and	  GPA	  
possess	   similar	   clinical	   manifestations	   however	   MPA	   lacks	   the	   necrotising	  
|	  Page	  22	  
granulomatous	   inflammation	   associated	   with	   GPA.	   Eosinophilic	   granulomatosis	   with	  
polyangiitis	   (EGPA)	   is	   characterised	   by	   granulomatous	   eosinophil	   rich	   inflammation	  
associated	  with	  asthma	  and	  eosinophilia.	  Classically	  GPA	  is	  associated	  with	  PR3	  ANCA,	  
whilst	  MPA	  and	  EGPA	  are	  associated	  with	  MPO	  ANCA.	  
It	  is	  difficult	  to	  evaluate	  the	  heterogeneous	  nature	  of	  AAV.	  The	  Birmingham	  vasculitis	  
activity	   score	   (BVAS),	  now	   in	   its	   third	  version,	  can	  be	  used	   to	  assess	  disease	  activity.	  
The	  BVAS	  is	  a	  checklist	  of	  56	  pertinent	  symptoms,	  signs	  and	  features	  of	  active	  vasculitis	  
used	   to	   guide	   clinical	   activity	   and	   is	   applied	   as	   a	   research	   tool	   [4].	   The	   vasculitis	  
damage	   index	   (VDI)	  quantifies	  damage	  associated	  with	   vasculitis	   and	   is	   also	  a	  useful	  
prognostic	  tool	  [5].	  However,	  as	  the	  VDI	  does	  not	  indicate	  the	  full	  extent	  of	  damage	  in	  
small	   and	  medium	   sized	   vasculitis,	   a	   revised	   combined	   damage	   assessment	   index	   is	  
being	  developed.	  
The	   vasculitides	   are	   rare,	   AAV	   being	   the	  most	   common	   vasculitis	   in	   adults.	   A	   study	  
looking	   at	   the	   Norfolk	   UK	   registry	   between	   1998	   and	   2010	   revealed	   an	   annual	  
incidence	  of	  11.3	  per	  million	  for	  GPA	  and	  5.9	  per	  million	  for	  MPA	  cases,	  estimating	  the	  
prevalence	  of	  AAV	  at	  255	  per	  million	  [6].	  The	  peak	  age	  at	  diagnosis	  was	  65	  to	  74	  years	  
with	  a	  male	  preponderance.	  There	  are	  geographical	  variations	  in	  disease	  incidence	  and	  
presentation	  as	  shown	  by	  Fujimoto	  et	  al.	  The	  annual	  incidence	  of	  AAV	  between	  2005	  
and	   2009	   was	   21.8	   per	   million	   in	   the	   UK	   with	   an	   average	   age	   of	   60.5	   years	   at	  
presentation	  compared	  to	  22.6	  per	  million	  in	  Japan	  with	  a	  mean	  age	  of	  presentation	  at	  
69.7	   years	   [7].	   Furthermore,	   MPA	   was	   the	   predominant	   AAV	   subtype	   in	   Japan	  
compared	   to	  GPA	   in	   the	  UK.	  A	  multi-­‐centre	  European	  study	   revealed	   that	  10-­‐20%	  of	  
patients	   diagnosed	   with	   MPA,	   GPA,	   EGPA	   or	   idiopathic	   rapidly	   progressive	  
glomerulonephritis	  were	  ANCA	  negative	  [8].	  
The	   natural	   history	   of	   untreated	   AAV	   is	   a	   rapidly	   progressive	   fatal	   disease.	   If	   left	  
untreated	  mortality	  approximates	  80%,	  with	  a	  median	  survival	  of	  five	  months	  in	  multi-­‐
systemic	  disease	  [9].	  The	  use	  of	  cyclophosphamide	  (introduces	  alkyl	  radicals	  into	  DNA	  
strands	  which	  interferes	  with	  DNA	  replication)	  with	  steroids	  in	  the	  1970s	  dramatically	  
improved	  prognosis,	  with	  remission	  achieved	  in	  79-­‐93%	  of	  patients	  [10].	  Modifications	  
of	  the	  original	  management	  plan	  with	  the	  use	  of	  azathioprine	  (imidazolyl	  derivative	  of	  
mercaptopurine	   whose	  metabolites	   are	   incorporated	   into	   replicating	   DNA	   inhibiting	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replication	   and	   purine	   synthesis)	   and	   the	   introduction	   of	   rituximab	   (monoclonal	  
antibody	   directed	   against	   the	   CD20	   antigen	   on	   B	   lymphocytes)	   has	   improved	  
outcomes,	  however,	  remission	  does	  not	  result	  in	  cure.	  Treatment	  limitations	  including	  
limited	   efficacy,	   cumulative	   toxicity	   and	   infection	   risk	   persist.	   Table	   1.1	   below	  
summarises	   the	   outcome	   of	   disease	   from	   selected	   prospective	   and	   retrospective	  
studies.	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Table	  1.1	  –	  Summary	  of	  select	  retrospective	  and	  prospective	  studies	  of	  AAV.	  	  Studies	  
published	   between	   2011	   and	   2015	   were	   selected	   from	   Pubmed	  
(http://www.ncbi.nlm.nih.gov/pubmed)	   searching	   for	   AAV	   associated	   mortality	   and	  
prognosis.	  
A	   review	  of	   European	   trials	   data	   showed	   that	  59%	  of	  deaths	  within	   the	   first	   year	  of	  
diagnosis	  was	   associated	  with	   therapy	   compared	   to	   14%	   due	   to	   active	   disease	   [17].	  
These	  studies	  highlight	  that	  although	  prognosis	  in	  AAV	  has	  improved,	  patients	  remain	  
at	  risk	  of	  premature	  death,	  organ	  failure,	  a	  chronic	  relapsing	  disease	  and	  other	  adverse	  
outcomes.	  	  
1.2	  Pathogenesis	  
The	   precise	   aetiology	   of	   AAV	   remains	   elusive.	   However,	   several	   environmental	   and	  
genetic	  factors	  are	  considered	  important.	  	  
1.2.1	  Environmental	  factors	  
Case	   reports	   have	   shown	   that	   those	   with	   professional	   exposure	   to	   silica	   have	   a	  
significantly	  higher	  risk	  of	  being	  ANCA	  positive	  and	  have	  a	  diagnosis	  of	  GPA	  [18,	  19].	  
This	  may	  be	  due	   to	   the	   accelerated	  apoptosis	   of	   neutrophils	   and	  macrophages	   seen	  
with	  silica	  exposure	  as	  demonstrated	  in	  an	  animal	  model	  of	  intratracheal	  instillation	  of	  
silica	   [20].	   Furthermore,	   several	   drugs	   including	   propylthiouracil,	   hydralazine	   and	  
minocycline	  have	  been	  implicated	  in	  causing	  AAV	  [21-­‐23].	  There	  is	  also	  a	  link	  between	  
AAV	  and	  ingestion	  of	  levamisole-­‐contaminated	  cocaine	  [24].	  
There	   is	   a	   strong	   association	   between	   bacterial	   infections	   and	   the	   presentation	   or	  
relapse	  of	  AAV.	  An	  infectious	  trigger	  may	  precipitate	  an	  autoimmune	  reaction	  by	  the	  
formation	  of	  an	   inflammatory	  environment	   facilitating	  the	  exposure	  of	  auto-­‐antigens	  
or	  the	  generation	  of	  cross-­‐reacting	  auto-­‐antibodies.	  In	  comparison	  to	  healthy	  controls,	  
GPA	   patients	   have	   a	   higher	   incidence	   of	   Staphylococcus	   aureus	   nasal	   carriage	   and	  
colonised	   patients	   are	  more	   prone	   to	   relapses	   than	   non-­‐colonised	   patients	   [25,	   26].	  
Furthermore,	   treatment	   with	   co-­‐trimoxazole	   has	   been	   shown	   to	   reduce	   relapses	   in	  
GPA	  patients	  [27].	  	  
|	  Page	  25	  
An	   interesting	  observation	  by	  Pendergraft	  et	  al	   revealed	  that	  GPA	  patients	  with	  PR3-­‐
ANCA	  also	  had	  antibodies	  targeting	  complementary	  PR3	  (cPR3),	  the	  antisense	  peptide.	  
In	  a	  mouse	  model	  the	  authors	  were	  able	  to	  induce	  antibodies	  to	  both	  sense	  PR3	  and	  
cPR3	   following	   immunisation	   with	   cPR3.	   It	   is	   suggested	   that	   the	   PR3-­‐ANCA	   are	  
generated	   by	   an	   immune	   response	   against	   the	   anti-­‐cPR3	   antibody,	   an	   anti-­‐idiotypic	  
response.	   The	   cPR3	   protein,	   in	   contrast	   to	   PR3,	   exhibits	   homology	   to	   a	   variety	   of	  
microbial	   components,	   including	   Staphylococcus	   aureus	   and	   Entamoeba	   histolytica,	  
supporting	   the	   role	   of	   infection	   in	   pathogenesis	   [28].	   However,	   rodents	   immunized	  
with	   Staphylococcus	   aureus	   do	   not	   develop	   vasculitis	   nor	   is	   there	   evidence	   that	   the	  
anti-­‐cPR3	   antibodies	   cross-­‐react	   with	   Staphylococcus	   aureus.	   Furthermore,	   a	  
subsequent	   study	   found	   no	   difference	   in	   anti-­‐cPR3	   reactivity	   in	   PR3-­‐AAV	   patients	  
compared	  to	  healthy	  controls,	  challenging	  the	  theory	  of	  autoantigen	  complementarity	  
in	  AAV	  [29].	  
AAV	   patients	   are	   often	   also	   positive	   for	   autoantibodies	   to	   lysosomal	   associated	  
membrane	  protein	  2	  (LAMP2),	  a	  protein	  involved	  in	  cell	  adhesion,	  intracellular	  antigen	  
presentation	  and	  maintenance	  of	  microbicidal	  activity	  of	  phagosomes	   [30].	  LAMP2	   is	  
involved	  in	  regulating	  microbial	  clearance.	  Interestingly	  the	  LAMP2	  epitope	  P41–49	  is	  
homologous	  to	  bacterial	  FimH	  present	  in	  various	  gram-­‐negative	  bacteria	  species	  such	  
as	   Escherichia	   coli,	   Klebsiella	   pneumoniae	   and	   Proteus	   mirabilis.	   Patients’	  
autoantibodies	  cross-­‐react	  with	  FimH	  and	  WKY	  rats	   immunised	  with	  FimH	  developed	  
autoantibodies	   to	   LAMP2	   and	   pauci-­‐immune	   glomerulonephritis	   [31].	   This	   suggests	  
that	  FimH	  can	   induce	  disease	  by	  acting	  as	  a	  molecular	  mimic	   for	   LAMP2,	   implicating	  
bacterial	  infection	  in	  pathogenesis.	  
Furthermore,	  lipopolysaccharide	  (LPS),	  a	  major	  component	  of	  the	  outer	  membrane	  of	  
gram-­‐negative	  bacteria,	  has	  been	  shown	  to	  exacerbate	  disease	  in	  a	  MPO-­‐ANCA	  model	  
of	   disease	   in	   mice	   (discussed	   later)	   [32].	   LPS	   leads	   to	   increased	   circulating	   tumour	  
necrosis	  factor	  α	  (TNFα)	  levels,	  which	  has	  been	  shown	  to	  prime	  neutrophils.	  Anti-­‐TNFα	  
antibody	  attenuated	  disease	   in	  the	  murine	  model.	  LPS	  promotes	  MPO-­‐ANCA	  induced	  
lymphocyte	   function-­‐associated	   antigen	   (LFA)	   dependent	   glomerular	   leucocyte	  
adhesion	   and	   increases	   endothelial	   toll-­‐like	   receptor	   (TLR)	   4,	   chemokine	   CXC	   motif	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ligand	  (CXCL)	  1	  and	  2	  expression,	  which	  in	  turn	  increase	  neutrophil	  recruitment	  to	  the	  
glomeruli	  [33,	  34].	  
This	   suggests	   that	   infection	   has	   a	   role	   in	   MPO	   and	   PR3	   expression,	   neutrophil	  
recruitment	  and	  neutrophil	  adhesion	  in	  the	  glomeruli.	  
1.2.2	  Genetic	  factors	  
Although	  familial	  cases	  of	  AAV	  have	  been	  described,	  evidence	  for	  familial	  clustering	  is	  
poor.	   A	   study	   evaluating	   the	   Swedish	   register	   showed	   that	  GPA	  was	   present	   in	   2	   of	  
6,670	  first	  degree	  relatives	  of	  patients	  compared	  to	  13	  of	  68,994	  first	  degree	  relatives	  
of	   controls,	  with	  a	   relative	   risk	  of	  1.56	   (95%	  confidence	   interval	  of	  0.35	   to	  6.9)	   [35],	  
suggesting	  genetic	  risk	  factors	  for	  GPA.	  
A	  number	  of	  studies	  prior	  to	  the	  genomewide	  association	  study	  (GWAS)	  identified	  key	  
genetic	  associations.	  Several	  small	  studies	  have	  suggested	  associations	  between	  major	  
histocompatibility	   complex	   (MHC)	   loci	   including	   human	   leucocyte	   antigen	   (HLA)	   -­‐
DPB1*0401	  as	  well	  as	  HLA-­‐DR4	  and	  risk	  of	  AAV	  [36,	  37].	  	  
PRTN3,	   which	   encodes	   PR3,	   a	   target	   antigen	   in	   AAV,	   has	   also	   been	   implicated.	   The	  
neutrophil	   membrane	   expression	   pattern	   of	   PR3	   is	   bimodal	   in	   individuals,	   which	  
remains	   constant	   over	   time.	   The	   pattern	   of	   expression	   correlates	   more	   closely	   in	  
monozygotic	   twins	   rather	   than	   dizygotic	   twins	   suggesting	   that	   the	   neutrophil	  
membrane	   expression	   pattern	   of	   PR3	   is	   genetically	   predetermined	   [38].	   In	   AAV	  
patients	   there	   is	   a	   high	  membrane	   PR3	   expression	   phenotype	   compared	   to	   healthy	  
controls	   and	   elevated	   membrane	   bound	   PR3	   expression	   is	   associated	   with	   an	  
increased	   rate	   of	   relapse	   in	   GPA	   patients	   [38,	   39].	   Several	   single	   nucleotide	  
polymorphisms	  (SNP)	  have	  been	  identified	  in	  the	  PRTN3	  sequence.	  
α1-­‐antitrypsin,	   a	   serine	   protease	   (including	   PR3)	   inhibitor	   is	   encoded	   by	   SERPINA1	  
gene,	   which	   is	   highly	   polymorphic.	   Both	   the	   Z	   and	   S	   alleles	   of	   the	   SERPINA1	   gene	  
reduce	   the	   function	   of	   the	   protein	   and	   display	   associations	   with	   a	   higher	   risk	   of	  
developing	   GPA	   than	   the	   general	   population	   [40].	   The	   decreased	   activity	   of	   α1-­‐
antitrypsin	  may	  result	  in	  persistent	  PR3	  presence	  in	  tissue	  leading	  to	  direct	  damage	  as	  
well	  as	  resulting	  in	  the	  generation	  of	  ANCA.	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Cytotoxic	  T	   lymphocyte	  antigen	  4	   (CTLA4)	  expressed	  by	  CD4	  T	  cells,	  on	  binding	  to	   its	  
ligands	  CD80	  or	  CD86	  on	  antigen	  presenting	  cells	   (APC)	  act	  as	  an	   immune	  off	  switch.	  
CTLA4	  has	  a	  role	  in	  the	  regulation	  of	  autoreactive	  T	  cells,	  hence	  CTLA4	  polymorphisms	  
have	   a	   role	   in	   autoimmunity.	   Zhou	   et	   al	   demonstrated	   that	   patients	   with	   GPA	   had	  
significantly	   lower	   homozygosity	   frequency	   for	   the	   shortest	   allele	   86	   of	   CTLA4	  
microsatellite	  polymorphism	  (AT)n	  in	  the	  3’	  region	  [41].	  
In	   2012,	   the	   first	   GWAS	   of	   GPA	   and	   MPA	   performed	   in	   UK	   and	   Northern	   Europe	  
cohorts	  was	  published.	  The	  combined	  data	  of	  AAV	   found	  associations	  of	   significance	  
with	   the	  MHC	   (strongest	   in	  HLA-­‐DPB1)	  and	  a	  SNP	   in	   the	  SERPINA1	   locus.	  When	  sub-­‐
analysis	  was	  carried	  out	  differentiating	  between	  GPA	  and	  MPA	  or	  PR3-­‐ANCA	  and	  MPO-­‐
ANCA,	   the	   HLA	   and	   SERPINA1	   SNP	   differed	   significantly	   between	   the	   groups,	   with	  
association	   related	   mainly	   to	   GPA	   and	   PR3-­‐ANCA.	   The	   strongest	   association	   of	   the	  
genetic	  polymorphisms	  was	  related	  to	  ANCA	  specificity	  rather	  than	  clinical	  groups	  [42].	  
1.3	  ANCA	  and	  the	  Antigens	  
In	   1982	  Davies	  et	  al	   identified	  antibodies	   in	   the	   serum	  of	   8	  patients	  with	   segmental	  
necrotising	   glomerulonephritis	   that	   stained	   the	   cytoplasm	   of	   neutrophils	   by	   indirect	  
immunofluorescence	  [43].	  This	  was	  confirmed	  by	  another	  group	  in	  1984	  in	  4	  patients	  
with	   small	   vessel	   vasculitis	   [44].	   Subsequently	   Van	   der	  Woude	   et	   al	   suggested	   that	  
ANCA	   may	   well	   be	   pathogenic	   and	   that	   the	   detection	   of	   ANCA	   was	   an	   important	  
diagnostic	   as	   well	   as	   prognostic	   marker	   in	   GPA	   [45].	   Indirect	   immunofluorescence	  
analyses	   of	   ethanol	   fixed	   neutrophils	   reveal	   a	   cytoplasmic	   staining	   pattern	   (c-­‐ANCA)	  
later	   shown	   to	   be	   associated	  with	   PR3-­‐ANCA,	  while	  MPO-­‐ANCA	   cause	   a	   perinuclear	  
fluorescence	  pattern	  (p-­‐ANCA)	  [46-­‐48].	  
1.3.1	  MPO	  
MPO,	   previously	   termed	   verdoperoxidase	   because	   of	   its	   intense	   green	   colour,	   was	  
identified	   by	   Agner	   from	   purulent	   fluid	   of	   patients	  with	   tuberculous	   empyema	   [49].	  
MPO	   is	   a	   heme	   containing	   lysosomal	   enzyme	   present	   in	   the	   azurophilic	   granules	   of	  
neutrophils	  and	  cells	  of	  monocyte	  lineage.	  It	  is	  a	  product	  of	  a	  single	  11	  kb	  gene	  located	  
on	   chromosome	   17	   [50].	   Its	   initial	   translated	   product	   is	   an	   80	   kDa	   protein	   which	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undergoes	  proteolytic	  cleavage	  of	  a	  41	  amino	  acid	  peptide	  and	  N-­‐linked	  glycosylation	  
to	   generate	   an	   enzymatically	   inactive	   90	   kDa	   apoproMPO	   protein	   [51].	   In	   the	  
endoplasmic	  reticulum	  the	  apoproMPO	  product	  interacts	  with	  chaperones	  calreticulin	  
and	   calnexin,	  with	   incorporation	  of	   the	  heme	  group	  by	   three	   covalent	  bonds	  on	   the	  
backbone	  to	  generate	  the	  enzymatically	  active	  proMPO	  protein	  [52,	  53].	  
The	  active	  proMPO	  undergoes	  several	  proteolytic	  events	  and	  is	  cleaved	  into	  a	  75	  kDa	  
product	  with	  an	  approximately	  57.5	  kDa	  heavy	  (α)	  subunit	  and	  14	  kDa	  light	  (β)	  subunit	  
by	   glucosidases.	   Two	  αβ	   promoter	  units	   are	   linked	  by	   a	  disulfide	  bond	  between	   the	  
heavy	  subunits	  to	  produce	  mature	  MPO	  of	  approximately	  150	  kDa	  [54,	  55].	  
MPO	  oxidises	  chloride	  and	  other	  halides	  such	  as	  bromide	  and	  thiocyanate	  to	  generate	  
hypohalous	  acids.	  The	  reactions	  involve	  two	  electron	  oxidation	  of	  the	  respective	  halide	  
such	  as	  chloride	  by	  compound	  I	  with	  a	  net	  reaction	  of:	  
H2O2	  +	  Cl-­‐ HOCl	  +	  OH-­‐	  
Hydrogen	   peroxide	   (H2O2)	   is	   formed	   during	   respiratory	   burst.	   Generation	   of	   H2O2	   is	  
NADPH	   oxidase	   dependent,	   which	   transfers	   electrons	   into	   phagosomes	   generating	  
superoxide	  anion	  and	  H2O2	  from	  molecular	  oxygen.	  HOCl	  itself	  has	  strong	  microbicidal	  
effects	  [56].	  
MPO	  mediated	   damage	   is	   not	   limited	   to	   intraphagosomal	  microbes,	   the	   hypohalous	  
acids	  and	   their	  derivatives	  can	  halogenate	  other	  cell	   constituents	  causing	  damage	   to	  
surrounding	   tissue	   by	   modifying	   target	   molecules	   such	   as	   DNA,	   lipids	   and	  
(lipo)proteins.	  HOCl	  reacts	  with	  pyrimidine	  derivatives	   leading	  to	  altered	  nucleotides.	  
Cysteine	   and	  methionine	   residues	   are	   readily	   oxidised	   too.	   The	   derivatives	   are	   also	  
capable	   of	   causing	   further	   damage	   by	   other	   mechanisms	   including	   free	   radical	  
formation	  [57-­‐59].	  
The	  oxidised	  and	  chlorinated	  lipids	  derived	  under	  inflammatory	  conditions	  have	  been	  
implicated	  in	  specific	  disease	  pathogenesis	  including	  atherosclerosis,	  diabetes	  mellitus	  
and	  multiple	  sclerosis.	  They	  are	  thought	  to	  mediate	  both	  pro-­‐	  and	  anti-­‐	  inflammatory	  
roles	  through	  various	  mechanisms	  that	  will	  be	  discussed	  further	  in	  chapter	  4.	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MPO	  has	  also	  been	  shown	  to	  have	  non-­‐enzymatic	  functions	  and	  has	  been	  implicated	  in	  
neutrophil	   recruitment	   through	   electrostatic	   interactions	   in	   vitro.	   The	   same	   study	  
showed	   that	   MPO	   knockout	   mice	   had	   less	   neutrophil	   recruitment	   to	   areas	   of	  
inflammation	   in	   a	   hepatic	   ischaemia	   reperfusion	   model.	   Furthermore,	   injection	   of	  
catalytically	   inactive	  MPO	   resulted	   in	   significant	   neutrophil	   recruitment	   in	   otherwise	  
non-­‐inflamed	  vessels	  [60].	  
MPO	   is	   usually	   not	   expressed	   on	   the	   surface	   of	   resting	   neutrophils.	   However,	  
activation	  of	  neutrophils	  with	  TNFα	   results	   in	   increased	  membrane	  MPO	  expression,	  
which	   is	  mitogen	  activated	  protein	  kinase	   (MAPK)	  dependent	   [61,	  62].	  This	  may	  well	  
contribute	   to	   the	   pathogenesis	   of	   AAV	   by	   increasing	   exposure	   of	   the	   offending	  
antigens	   to	   ANCA.	   Circulating	   MPO	   levels	   are	   higher	   in	   patients	   with	   MPO-­‐ANCA	  
vasculitis	   compared	   to	   healthy	   controls	   and	   soluble	   MPO	   released	   by	   activated	  
neutrophils	  can	  make	  unprimed	  neutrophils	  reactive	  to	  MPO-­‐ANCA	  [63,	  64].	  
MPO	  is	  not	  a	  transmembrane	  protein,	  rather	   it	   is	  suggested	  that	  the	  cationic	  MPO	  is	  
anchored	   to	   the	   negatively	   charged	   cell	   surface	   through	   electrostatic	   interactions.	  
However,	   it	   has	   also	   been	   shown	   that	  MPO	   interacts	  with	   the	   CD11b/CD18	   integrin	  
complex	  (Mac-­‐1	  /	  CR3)	   leading	  to	  the	  activation	  of	   intracellular	  signalling,	  which	  may	  
be	   a	   plausible	   method	   of	   specific	   antigen	   presentation	   on	   the	   cell	   surface	   and	  
downstream	   signalling	   [65].	   It	   is	   also	   possible	   that	   ANCA	   are	   internalised	   by	  
neutrophils	  and	  monocytes	  and	  interact	  with	  their	  respective	  antigens	  intracellularly.	  
1.3.2	  PR3	  
PR3	   is	   a	   chymotrypsin-­‐like	   serine	   protease	   found	   in	   the	   azurophilic	   and	   secretory	  
granules	   of	   neutrophils	   as	   well	   as	   monocyte	   lysosomes.	   PR3	   and	   other	   neutrophil	  
proteases	   are	   multifunctional.	   They	   are	   directly	   involved	   in	   intracellular	   and	  
extracellular	   pathogen	   destruction	   and	   also	   have	   a	   role	   in	   inflammatory	   process	  
regulation	  [66].	  
The	   PR3	   gene,	   PRTN3	   is	   located	   on	   chromosome	   19	   [67].	   There	   are	   four	   post	  
translational	   steps	   involved	   in	   the	   formation	   of	   the	   mature	   enzyme	   (29-­‐32	   kDa).	  
Initially	  the	  signal	  peptide	  is	  cleaved,	  followed	  by	  glycosylation	  of	  the	  peptide.	  The	  N-­‐
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terminal	  dipeptide	  is	  cleaved	  by	  dipeptidyl	  peptidase	  I	  (DPPI)	  and	  subsequently	  the	  C-­‐
terminal	  propeptide	  cleavage	  occurs	  [68].	  	  
PR3	  is	  directly	  involved	  in	  the	  killing	  of	  bacteria	  within	  phagolysosomes	  and	  neutrophil	  
extracellular	   traps	   (NETs).	   In	   addition	   PR3	   cleaves	   cathelicidin	   hCAP-­‐18,	   an	  
antibacterial	  protein,	  to	  its	  active	  form	  LL-­‐37	  upon	  exocytosis	  [69].	  	  
PR3	  is	  also	  capable	  of	  modulating	  the	  immune	  response	  in	  other	  ways	  such	  as	  cleaving	  
pro-­‐form	   cytokines	   TNFα	  and	   interleukin	   (IL)-­‐1β	   to	   their	   active	   forms,	   as	  well	   as	   the	  
chemokine	  IL8,	  further	  perpetuating	  the	  immune	  response	  [70,	  71].	  PR3	  has	  also	  been	  
shown	   to	   increase	   expression	   of	   protease-­‐activated	   receptor	   2	   (PAR2),	   a	   G	   protein	  
coupled	  receptor	  that	  couples	  to	  Gαq/11	  and	  appears	  to	  have	  a	  role	  in	  inflammation	  as	  
well	  as	  pain	  [72].	  Furthermore,	  PR3	  has	  been	  shown	  to	  induce	  human	  endothelial	  cell	  
apoptosis.	  Human	  umbilical	  vein	  endothelial	   cells	   (HUVEC)	   internalise	  both	  MPO	  and	  
PR3.	  PR3	  cleaves	  p21	  the	  major	  cell	  cycle	  inhibitor	  and	  induces	  apoptosis	  [73,	  74].	  	  	  
Once	   secreted	   into	   the	   extracellular	   environment,	   a	   proportion	   of	   PR3	   bind	   the	   cell	  
membrane.	  As	  discussed	  earlier,	  PR3	  is	  expressed	  in	  a	  bimodal	  fashion	  on	  neutrophils.	  
Those	  with	  a	  higher	  expression	  of	  membrane	  PR3	  on	  their	  neutrophils	  are	  at	  a	  higher	  
risk	   of	   GPA	   and	   rheumatoid	   arthritis	   [75].	   PR3	   is	   present	   on	   the	   surface	   of	   resting	  
monocytes	  and	  neutrophils,	  and	   is	  upregulated	   following	  neutrophil	   stimulation	  with	  
formyl-­‐methionyl-­‐leucyl-­‐phenylalanine	  (fMLP)	  and	  cytokines	  such	  as	  TNFα	  [76].	  	  
PR3	   may	   be	   presented	   on	   the	   cell	   surface	   via	   direct	   insertion	   into	   the	   plasma	  
membrane	   through	   basic	   and	   hydrophobic	   amino	   acids	   or	   presentation	   by	   a	  
glycosylphosphatidylinositol	  (GPI)	  linked	  receptor,	  CD177	  or	  human	  neutrophil	  antigen	  
B1	  (NB1)	   [77,	  78].	  However,	  NB1	  does	  not	  possess	  an	   intracellular	  signalling	  domain,	  
and	   therefore	   cannot	   propagate	   a	   signal	   by	   itself.	   Jerke	   et	   al	  have	   shown	   that	   NB1	  
interacts	  with	  the	  CD11b/CD18	  complex	  and	  may	  induce	  intracellular	  signalling	  in	  this	  
manner.	   They	   showed	   that	   neutrophils	   that	   co-­‐express	   NB1	   and	   PR3	   have	   a	   higher	  
level	  of	  membrane	  PR3	  expression	  and	  undergo	  more	  robust	  degranulation	  as	  well	  as	  
extracellular	   superoxide	  production	  upon	  PR3-­‐ANCA	   induced	   activation	   compared	   to	  
the	   NB1	   negative	   neutrophils.	   Furthermore,	   CD11b	   blockade	   inhibited	   PR3-­‐ANCA	  
induced	  neutrophil	  activation	  [79].	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Primed	   neutrophils	   and	   monocytes	   release	   serine	   proteases	   including	   PR3,	   elastase	  
and	  cathepsin	  G.	  These	  other	  serine	  proteases,	  like	  PR3,	  are	  inactive	  proenzymes	  that	  
are	   cleaved	   by	  DPPI.	   DPPI	   deficient	  mice	   lacking	   functionally	   active	   serine	   proteases	  
are	   protected	   from	  disease	   in	   a	  model	   of	  MPO-­‐ANCA	   induced	  necrotising	   crescentic	  
glomerulonephritis.	   This	   was	   associated	   with	   reduced	   IL1β	   generation	   by	   DPPI	  
deficient	  neutrophils	  and	  monocytes	  upon	  ANCA	  stimulation	  [80].	  
1.3.3	  LAMP2	  
Kain	  et	  al	   in	  1995	   showed	   that	  14	  out	  of	  16	  patients	  with	  pauci-­‐immune	  necrotising	  
crescentic	  glomerulonephritis	  had	  antibodies	   to	  LAMP2	   in	  addition	  to	  autoantibodies	  
to	  MPO	  or	   PR3	   [30].	   LAMP2	   is	   a	   heavily	   glycosylated	   type	   I	   transmembrane	   protein	  
that	   is	   expressed	   by	   neutrophils	   and	   endothelial	   cells.	   It	   is	   a	   major	   lysosomal	  
membrane	  component	  with	  three	  splice	  variants	  that	  is	  also	  found	  within	  intracellular	  
vesicles	   and	   the	   cell	   plasma	   membrane	   itself.	   It	   has	   a	   polypeptide	   backbone	   of	  
approximately	   40	   kDa,	   however	   the	   end	  product	   after	   glycosylation	  has	   a	  molecular	  
weight	  of	  120	  kDa	  [81].	  	  
Deficiency	  of	  LAMP2	  in	  mice	  resembles	  the	  human	  Danon	  disease,	  which	  is	  an	  X	  linked	  
disorder	   of	   LAMP2	  mutation	   characterised	  by	  hypertrophic	   cardiomyopathy,	   skeletal	  
myopathy	   and	   mental	   retardation.	   The	   disease	   is	   characterised	   by	   late	   autophagic	  
vacuole	  accumulation	  [82].	  LAMP2	  deficient	  mice	  have	  severe	  periodontitis	  early	  in	  life	  
attributed	   to	   neutrophils	   that	   were	   unable	   to	   efficiently	   clear	   bacterial	   pathogens,	  
because	   of	   reduced	   acidification	   and	   recruitment	   of	   proteins	   within	   phagosomes.	  
Hence,	   LAMP2	   appears	   to	   have	   an	   important	   role	   in	   phagosome	  maturation	   within	  
neutrophils	   [83].	   Furthermore,	   in	   LAMP2	   deficient	   neutrophils,	   lysosomes	   appear	  
clustered	  in	  the	  centre	  of	  the	  cell,	  suggesting	  a	  role	  in	  lysosome	  shuttling.	  
LAMP2	  has	  also	  been	   implicated	   in	   the	  transport	  of	  cytosolic	  components	  across	   the	  
lysosomal	  membrane	  (termed	  chaperone	  mediated	  autophagy),	  which	  is	  important	  for	  
MHC	  class	  II	  presentation	  of	  cytoplasmic	  antigens.	  Cells	  with	  diminished	  expression	  of	  
LAMP2,	  have	  a	  decreased	  display	  of	  cytoplasmic	  epitopes	  via	  class	  II	  molecules	  [84].	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In	  follow	  up	  studies	  Kain	  et	  al	  showed	  a	  high	  prevalence	  of	  antibodies	  to	  LAMP2	  in	  AAV	  
patients,	   confirming	   the	   earlier	   data;	   93%	   in	   a	   cohort	   of	   84	   patients	   in	   Vienna	   and	  
Aberdeen,	   89%,	   91%	   and	   80%	   in	   cohorts	   from	   Vienna,	   Cambridge	   and	   Groningen	  
respectively	   [31,	   85].	   By	   contrast,	   in	   patients	   in	   remission	   following	  
immunosuppression	   anti-­‐LAMP2	   remained	   positive	   in	   only	   7%.	   Furthermore,	   anti-­‐
LAMP2	   was	   shown	   to	   activate	   neutrophils	   and	   induce	   endothelial	   cell	   apoptosis	   in	  
vitro.	   Passive	   immunisation	   of	   rats	   with	   polyclonal	   rabbit	   anti-­‐LAMP2	   antibodies	  
precipitated	  a	  pauci-­‐immune	  crescentic	  glomerulonephritis.	  The	  study	  also	  suggested	  
the	  potential	   for	  molecular	  mimicry	   in	  breaking	   tolerance	  and	   the	   formation	  of	  anti-­‐
LAMP2	  antibody	  [31].	  
A	  study	  by	  Roth	  et	  al	  appears	  to	  contradict	  the	  results	  of	  Kain	  et	  al	  [31,	  86].	  They	  found	  
a	   substantially	   lower	   prevalence	   of	   anti-­‐LAMP2	   antibody	   of	   21%	   in	   a	   cohort	   of	   329	  
patients	   with	   AAV	   in	   North	   Carolina	   and	   Massachusetts,	   which	   was	   comparable	   to	  
control	   groups	   [86].	   In	   addition,	   Roth	   et	   al	   did	   not	   observe	   any	   disease	   in	   rats	  
immunised	  with	  anti-­‐LAMP2.	  
The	   discrepancies	   are	   likely	   to	   be	   due	   to	   the	   differences	   in	   patient	   population	   and	  
assay	  designs.	  The	  BVAS	  scores	  for	  patients	  at	  presentation	  or	  in	  relapse	  in	  the	  Kain	  et	  
al	   studies	   ranged	   from	  10-­‐15	  whilst	   the	  BVAS	  score	   for	   the	  Roth	  et	  al	   study	  was	  >0.	  
Kain	  et	  al	  showed	  that	  the	  highest	  anti-­‐LAMP2	  titres	  were	  consistently	  found	  in	  newly	  
presented	  untreated	  patients.	  The	  majority	  of	  patients	  in	  the	  Roth	  et	  al	  study	  were	  on	  
treatment.	   Kain	  et	   al	   tested	   the	   sera	   in	   triplicate	  using	   three	   independent	  methods;	  
Enzyme	  linked	   immunosorbant	  assay	  (ELISA),	  Western	  blot	  and	   immunofluorescence,	  
whilst	   this	   was	   not	   the	   case	   for	   the	   American	   cohorts.	   Furthermore,	   the	   antigen	  
substrates	  used	  in	  the	  ELISA	  for	  both	  studies	  were	  not	  identical,	  another	  variable	  that	  
may	  account	  for	  the	  differences.	  
The	  differences	  noted	  with	  passive	  immunisation	  of	  rats	  are	  more	  difficult	  to	  explain.	  
Kain	  et	  al	  produced	  antibodies	  by	  injecting	  rabbits	  with	  complete	  recombinant	  human	  
LAMP2	  whilst	  Roth	  et	  al	  utilised	  a	  synthetic	  peptide	  corresponding	  to	  epitope	  P41-­‐49	  as	  
the	  immunogen	  in	  rabbits,	  which	  may	  offer	  a	  likely	  explanation.	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The	  role	  of	  anti-­‐LAMP2	   in	  pathogenesis	  and	  clinical	  phenotype	  needs	   to	  be	  explored	  
further.	  
1.4	  Are	  ANCA	  pathogenic?	  
Clinical,	  in	  vitro	  and	  in	  vivo	  findings	  suggest	  that	  ANCA	  are	  pathogenic.	  However,	  there	  
are	   several	   observations	   that	   suggest	   that	   not	   all	   ANCA	   are	   equally	   pathogenic	   and	  
other	   factors	   are	   necessary	   for	   disease	   induction.	   A	   neonate	   developed	   pulmonary	  
renal	  disease,	  which	  was	  thought	  to	  have	  occurred	  following	  transplacental	  transfer	  of	  
MPO-­‐ANCA	   IgG	   from	   the	  mother	   who	   had	  MPA	   [87].	   However,	   no	   additional	   cases	  
have	   been	   reported.	   Furthermore,	   a	   case	   whereby	   a	   neonate	   had	   acquired	  
transplacental	  MPO-­‐ANCA	  with	  no	  development	  of	  clinical	  features	  of	  the	  disease	  has	  
been	  reported	  [88].	  
In	   clinical	  practice,	   remission	   is	  often	  associated	  with	  a	   reduction	   in	  ANCA	   titres	  and	  
conversely	   a	   rise	   in	   ANCA	   levels	   can	   predict	   a	   relapse	  with	   a	   sensitivity	   of	   79%	   and	  
specificity	  of	  68%.	  However,	  the	  period	  from	  change	  in	  titre	  levels	  to	  disease	  relapse	  is	  
variable	  with	  a	  range	  of	  0	  to	  20	  months	  [89].	  Other	  studies	  have	  failed	  to	  confirm	  these	  
observations.	   In	   practice	   the	   relationship	   of	   ANCA	   titres	   to	   clinical	   outcome	   is	  
questionable	  and	  treatment	  is	  based	  on	  clinical	  signs	  and	  symptoms	  rather	  than	  titres.	  
In	  the	  literature,	  there	  is	  reference	  to	  the	  indirect	  association	  in	  the	  efficacy	  of	  plasma	  
exchange	  and	  ANCA	  pathogenicity,	  as	  plasma	  exchange	  therapy	   increases	  the	  rate	  of	  
renal	  recovery	  in	  those	  with	  severe	  AAV	  compared	  to	  intravenous	  methylprednisolone	  
[90].	   However,	   it	   is	   important	   to	   note	   that	   plasma	   exchange	   removes	   several	  
potentially	   pathogenic	   substances	   not	   only	   antibodies,	   such	   as	   cytokines,	   fibrinogen	  
and	  complement	  components.	  
Natural	  autoantibodies	  against	  MPO	  and	  PR3	  are	  found	  in	  healthy	  individuals,	  albeit	  at	  
significantly	   lower	   levels	   than	   in	   AAV	   [91].	   Furthermore,	   as	   mentioned,	   a	   subset	   of	  
patients	   test	   negative	   for	  ANCA	  despite	   fulfilling	   the	   criteria	   for	  AAV,	   contesting	   the	  
pathogenicity	  of	  ANCA.	  The	  pathogenicity	  of	   antibodies	   in	  AAV	  may	  be	  explained	  by	  
the	  subclass	  or	  epitope	  specificity.	  	  The	  natural	  autoantibodies	  are	  mainly	  restricted	  to	  
the	   IgG1	   subclass	   [92].	   In	   contrast,	   in	  AAV,	  ANCA	  are	   found	  as	   all	   four	   subclasses	  of	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IgG,	  with	  IgG3	  thought	  to	  be	  most	  pathogenic.	  But	  it	  is	  also	  important	  to	  highlight	  that	  
the	  IgG1	  subclass	  of	  ANCA	  are	  not	  benign	  and	  have	  been	  shown	  to	  activate	  neutrophils	  
in	  vitro	  [93].	  	  
Epitope	   specificity	   may	   determine	   the	   pathogenicity	   of	   ANCA.	   Roth	   et	   al	   recently	  
showed	  substantial	  MPO-­‐ANCA	  epitope	  diversity	  using	  high	  sensitivity	  epitope	  excision	  
and	  mass	  spectrometry.	  One	  linear	  epitope	  (aa447-­‐459)	  was	  exclusive	  to	  active	  disease	  
and	  reactivity	  to	  this	  epitope	  declined	   in	  remission.	  Purified	   IgG	  fractions	  from	  ANCA	  
negative	  patients’	  serum,	  as	  tested	  by	  multiple	  laboratories,	  showed	  reactivity	  against	  
this	   peptide,	   however	   serum	   did	   not.	   This	   discrepancy	   was	   due	   to	   masking	   of	   the	  
epitope	  by	  a	  caeruloplasmin	  fragment	  [94].	  
Several	   in	   vitro	  studies	  have	   shown	   that	  monoclonal	   and	   limited	  numbers	  of	  patient	  
derived	   polyclonal	   ANCA	   stimulate	   primed	   neutrophils	   to	   undergo	   respiratory	   burst	  
and	   degranulation	   [61,	   62,	   64].	   However,	   not	   all	   ANCA	   are	   equally	   effective	   in	  
activating	  neutrophils.	  Franssen	  et	  al	  compared	  the	  release	  of	  reactive	  oxygen	  radicals	  
as	   assessed	   by	   ferricytochrome	   C	   reduction	   and	   neutrophil	   degranulation	   upon	  
stimulation	  with	   IgG	   fractions	   from	   17	   PR3-­‐ANCA	   and	   14	  MPO-­‐ANCA	   patients.	   They	  
found	   no	   difference	   in	   respiratory	   burst	   or	   degranulation	   when	   neutrophils	   were	  
incubated	  with	  IgG	  from	  MPO-­‐ANCA	  positive	  patients	  as	  compared	  to	  IgG	  from	  healthy	  
controls	   [95].	   In	   this	   study,	   IgG	   from	   PR3-­‐ANCA	   positive	   patients	   did	   induce	   an	  
increased	   neutrophil	   respiratory	   burst	   and	   degranulation	   compared	   to	   controls,	  
although	  there	  was	  a	  high	  degree	  of	  variability	  and	  overlap.	  
It	   has	   also	   been	   shown	   that	   activation	   of	   neutrophils	   with	   monoclonal	   ANCA	   and	  
fragment	  antigen	  binding	  (F(ab)2)	  fragments	  from	  a	  small	  number	  of	  donors	  with	  AAV	  
results	  in	  endothelial	  cell	  injury	  [96].	  Activation	  of	  neutrophils	  with	  ANCA	  from	  patients	  
has	  been	  shown	  to	  result	  in	  the	  formation	  of	  NETs	  which	  harbour	  the	  antigens	  PR3	  and	  
MPO,	  suggesting	  that	  netosis	  is	  a	  form	  of	  antigen	  presentation	  [97].	  	  	  
As	   discussed	   earlier,	   neutrophil	   priming	   increases	   MPO	   and	   PR3	   surface	   antigen	  
expression.	   This	   would	   be	   a	   pre-­‐requisite	   for	   ANCA	   binding.	   Furthermore	   higher	  
membrane	  PR3	  expression	   is	   a	   risk	   factor	   for	  GPA.	  MPO	  and	  PR3	  gene	  expression	   is	  
normally	  suppressed	  before	  mature	  neutrophils	   leave	  the	  bone	  marrow.	  However,	   in	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AAV,	   patients	   have	   been	   shown	   to	   have	   abnormal	   epigenetic	   regulation	   of	   this	  
suppression,	  leading	  to	  continued	  inappropriate	  expression	  of	  MPO	  and	  PR3	  genes	  in	  
circulating	  neutrophils	  [98].	  The	  evidence	  does	  not	  necessarily	  suggest	  a	  direct	  role	  for	  
ANCA	  in	  pathogenesis	  but	  is	  highly	  suggestive.	  
The	  in	  vitro	  evidence	  suggesting	  that	  ANCA	  are	  possibly	  pathogenic	  is	  reliant	  on	  TNFα	  
priming	   of	   neutrophils.	   One	   could	   infer	   as	   a	   result	   that	   anti-­‐TNF	   therapy	   would	   be	  
beneficial	  in	  AAV.	  A	  randomised	  controlled	  trial	  using	  etanercept	  (human	  TNF	  receptor	  
p75	  Fc	  fusion	  protein	  that	  binds	  and	  inhibits	  TNF)	  did	  not	  show	  any	  favourable	  effect	  
on	   the	  maintenance	   of	   remission	   [99].	   This	   would	   suggest	   that	   the	   in	   vitro	   findings	  
might	   not	   necessarily	   reflect	   in	   vivo	   mechanisms	   or	   other	   factors	   are	   capable	   of	  
priming	  neutrophils	  in	  vivo.	  
In	   summary,	   it	   appears	   that	  not	   all	  ANCA	  are	  pathogenic,	   rather	   a	  distinct	   subset	  of	  
ANCA	  against	  a	  specific	  repertoire	  of	  epitopes	  is	  required	  for	  the	  development	  of	  AAV.	  
Furthermore,	   other	   factors	   as	   discussed	   in	   the	   following	   sections	   contribute	   to	  
pathogenesis.	  
The	  most	  convincing	  evidence	  for	  the	  pathogenicity	  of	  ANCA	  to	  date	  has	  come	  from	  in	  
vivo	   studies.	   Xiao	   et	   al	   raised	   MPO-­‐ANCA	   by	   immunizing	   MPO	   deficient	   mice	   with	  
murine	  MPO.	  Transfer	  of	  the	  MPO-­‐ANCA	  into	  recipient	  mice	  led	  to	  the	  development	  of	  
pauci-­‐immune	   necrotising	   crescentic	   glomerulonephritis	   [100].	   However,	   the	  
development	  of	   an	   animal	  model	   of	   PR3-­‐ANCA	  disease	  has	  been	   less	   successful	   and	  
hence	  do	  not	  prove	  that	  PR3-­‐ANCA	  are	  pathogenic	  (see	  section	  1.11).	  
1.5	  Potential	  ANCA	  signalling	  
Binding	  of	  ANCA	  to	  its	  respective	  antigen	  is	  thought	  to	  result	  in	  neutrophil	  activation.	  
The	   precise	   intracellular	   cascade	   that	   leads	   to	   neutrophil	   activation	   has	   not	   been	  
elucidated.	   Although	   there	   is	   conflicting	   data,	   it	   appears	   that	   both	   the	   fragment	  
crystallisable	  (Fc)	  and	  the	  antigen	  binding	  regions	  are	  important.	  	  
Receptors	   to	   the	   Fc	  portion	  of	   antibodies	   are	  widely	  expressed	  by	   various	   cell	   types	  
especially	  phagocytes.	  A	  variety	  of	  Fc	  receptor	  subtypes	  exist	  which	  display	  specificity	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for	  different	  immunoglobulin	  subtypes.	  FcγR	  are	  either	  activating	  (FcγRIA,	  IIA,	  IIc,	  IIIA,	  
IIIB	  in	  humans;	  FcγRI,	  III,	  IV	  in	  mice)	  or	  inhibitory	  (FcγRIIB)	  and	  bind	  IgG.	  Cross-­‐linking	  of	  
activating	   FcγR	   leads	   to	   the	   initiation	   of	   immunoreceptor	   tyrosine	   activation	   motif	  
(ITAM)	  dependent	   tyrosine	  kinase	   recruitment	  and	  downstream	  activation	  of	  various	  
targets	  including	  Src	  family	  protein	  Syk	  [101].	  
In	  one	  study,	  human	  ANCA	  F(ab)2	  or	  cross-­‐linked	  Fab	  activated	  neutrophils	   to	   induce	  
superoxide	   production,	   but	   mouse	   monoclonal	   F(ab)2	   fragments	   did	   not	   [102].	   The	  
ability	  of	  F(ab)2	  fragments	  to	  induce	  superoxide	  generation	  was	  confirmed	  in	  another	  
study	  [103],	  but	  not	  by	  others	  [104-­‐106].	  
The	   inability	   of	   F(ab)2	   fragments	   to	   induce	   neutrophil	   activation	   as	   shown	   by	   most	  
studies	  suggests	  that	  Fc	  receptors	  are	  important	  and	  indeed	  blocking	  FcγRIIA	  reduced	  
PR3-­‐ANCA	   induced	   superoxide	   production	   [104].	   Furthermore,	   in	   vivo	   data	   in	   FcγR	  
knockout	   mice	   revealed	   that	   administration	   of	   MPO-­‐ANCA	   IgG	   failed	   to	   induce	   a	  
reduction	   in	   leucocyte	   rolling,	   or	   increase	   leucocyte	   adhesion	   and	   transmigration	  
across	  cremasteric	  microvessels	  [107].	  
Other	   important	   factors	   in	   potential	   ANCA	   signalling	   include	   posttranslational	  
modification	   of	   antibodies	   such	   as	   sialylation	   and	   glycosylation,	   which	   modify	   the	  
capacity	  of	  ANCA	  to	  activate	  targets	  and	  potentially	  disease	  development	  [108].	  
As	  discussed	  MPO	  and	  PR3	  are	  not	  transmembrane	  molecules,	  but	  interact	  with	  other	  
molecules	  and	  the	  CD11b/CD18	   integrin	  complex	   (Mac-­‐1),	   resulting	   in	  ANCA	   induced	  
signalling.	  Williams	   et	   al	   showed	   that	   both	   tyrosine	   kinase	   activation	   as	  well	   as	   the	  
recruitment	   of	   G	   proteins	   are	   necessary	   for	   ANCA	   induced	   phosphoinositol	   3-­‐kinase	  
(PI3-­‐K)	   activation	   and	   subsequent	   superoxide	   generation.	   The	   generation	   of	  
phosphatidylinositol	   (3,4,5)	   –	   triphosphate	   (PIP3)	   and	   superoxide	   generation	   was	  
inhibited	   by	   pertussis	   toxin	   and	   a	   tyrosine	   kinase	   inhibitor,	   implicating	   Gi	   protein	  
induced	  Ras	  GTP	  activation	  and	  the	  tyrosine	  kinase	  pathway	  [106].	  
Radford	   et	   al	   showed	   with	   the	   use	   of	   inhibitors	   that	   protein	   kinase	   C	   (PKC)	   and	  
tyrosine	  kinases	  have	  a	  crucial	  role	  in	  ANCA	  induced	  superoxide	  generation	  too	  [109].	  
Subsequently	   it	   was	   demonstrated	   that	   p38	   MAPK	   is	   important	   in	   antigen	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translocation	  on	  priming	  of	  neutrophils	  with	  TNFα,	  whilst	   inhibition	  of	  p38	  MAPK	  or	  
ERK	  abrogates	  ANCA	  induced	  superoxide	  production	  [62].	  
Syk	   has	   been	   shown	   to	   be	   phosphorylated	   and	   hence	   activated	   upon	   ANCA	   IgG	  
stimulation	   of	   TNFα	   primed	   neutrophils	   but	   not	   ANCA	   F(ab)2	   fragments.	   This	   was	  
diminished	   by	   FcγRIIa	   and	   FcγRIIIb	   blockade,	   suggesting	   that	   FcγR	   engagement	   of	  
ANCA	   IgG	   is	   necessary	   for	   Syk	   activation.	   Furthermore,	   inhibition	   of	   Syk	   attenuated	  
ANCA	   induced	   superoxide	   release	   from	   primed	   neutrophils	   [110].	   Syk	   is	   able	   to	  
activate	   phospholipase	   Cγ	   (PLCγ)	   as	   well	   as	   PI3-­‐K,	   with	   subsequent	   cleavage	   of	  
phosphatidylinositol	   (4,5)	   –	   bisphosphate	   (PIP2)	   into	   diacylglycerol	   (DAG)	   which	  
activates	  PKC	  and	  inositol	  triphosphate	  (IP3)	  which	  mediates	  calcium	  mobilisation.	  
PI3-­‐K	   has	   a	   crucial	   role	   in	   ANCA	   signalling.	   LY294002	   and	   wortmannin,	   both	   PI3-­‐K	  
inhibitors	   suppress	   ANCA	   induced	   superoxide	   release.	   Furthermore,	   pertussis	   toxin	  
inhibits	   ANCA	   induced	   superoxide	   production	   suggesting	   that	   ANCA	   activate	   the	  
p101/p110γ	  isoform	  of	  PI3-­‐K	  [111].	  The	  importance	  of	  PI3-­‐Kγ	  was	  confirmed	  in	  vivo	  in	  
a	  bone	  marrow	  transfer	  model	  of	  MPO-­‐ANCA	  disease.	  Disease	  occurred	   in	   irradiated	  
MPO	  deficient	  mice	  that	  had	  previously	  been	  immunised	  with	  MPO	  and	  reconstituted	  
with	  wild	  type	  bone	  marrow	  but	  not	  PI3-­‐Kγ	  deficient	  marrow.	  Furthermore,	  treatment	  
with	  the	  PI3-­‐Kγ	  inhibitor	  AS605240,	  also	  protected	  from	  disease	  in	  this	  model	  [112].	  
The	  proposed	  signaling	  mechanism	  is	  summarized	  in	  figure	  1.2.	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Figure	   1.2	   –	   A	   summary	   of	   the	   signalling	   molecules	   involved	   in	   ANCA	   mediated	  
neutrophil	  activation.	  ANCA	  depicted	   in	   red	  binds	   to	   the	   respective	  antigen	   through	  
the	  Fab	  segment	  and	  engages	  the	  Fc	  receptor	  activating	  G	  protein	  coupled	  pathways	  
as	  well	  as	  tyrosine	  kinase	  pathways.	  
1.6	  Neutrophils	  
As	  discussed	  the	  interactions	  between	  ANCA	  and	  neutrophils	  are	  thought	  to	  be	  pivotal	  
to	  disease	  pathogenesis.	  Firstly,	  neutrophils	  house	  the	  antigenic	  stimuli	  necessary	  for	  
the	  cascade	  of	  events	  that	  are	  thought	  to	  lead	  to	  disease	  induction.	  In	  healthy	  mature	  
neutrophils	   MPO	   and	   PR3	   transcription	   is	   silenced.	   In	   patients	   with	   AAV	   aberrant	  
activation	  of	  transcription	  occurs	  [98].	  MPO	  and	  PR3	  are	  sequestered	  within	  neutrophil	  
and	   monocyte	   granules.	   With	   neutrophil	   priming	   by	   inflammatory	   cytokines,	  
complement	   components	   or	   bacterial	   products,	   membrane	   expression	   of	   MPO	   and	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PR3	   is	   induced.	   Subsequent	   binding	   of	   ANCA	   as	   reviewed,	   triggers	   neutrophil	  
activation	   leading	  to	  degranulation	  and	  NETs	  formation	  exposing	  further	  antigen	  and	  
potentiating	  the	  process	  of	  ANCA	  binding.	  
Neutrophil	   recruitment	   from	   the	   circulation	   to	   the	   site	   of	   inflammation	   involves	   a	  
sequence	   of	   events	   namely	   rolling,	   high	   affinity	   binding	   and	   transmigration.	  
Endothelial	  cells	  have	  a	  crucial	  role	  too.	  Endothelial	  cells	  respond	  to	  cytokines	  such	  as	  
TNFα	  by	  producing	  granulocyte	  colony	  stimulating	  factor	  (GCSF)	  and	  upregulating	  local	  
expression	   of	   P-­‐selectin	   and	   E-­‐selectin,	   which	   slow	   down	   neutrophil	   rolling.	   This	  
induces	   changes	   in	   integrin	   adhesion	  molecules	   on	   neutrophils	   such	   as	   CD11b/CD18	  
complex	   and	   LFA-­‐1,	   which	   bind	   to	   endothelial	   cell	   adhesion	   molecules	   intercellular	  
adhesion	   molecule	   (ICAM)	   1	   and	   ICAM	   2	   resulting	   in	   high	   affinity	   binding	   and	   firm	  
adhesion.	   Transmigration	   then	   occurs	   via	   two	   routes;	   paracellular	   in	   the	  majority	   of	  
cases	  and	  transcellular.	  Neutrophils	   then	  follow	  a	  chemotactic	  gradient	  to	  the	  site	  of	  
inflammation	   [113].	   Intravital	   microscopy	   studies	   of	   cytokine	   pretreated	   mice	  
cremasteric	   vasculature	   reveal	   that	   MPO-­‐ANCA	   reduced	   leucocyte	   rolling	   and	  
augmented	   firm	   adhesion	   and	   transmigration.	   Use	   of	   anti-­‐CD18	   blocking	   antibodies	  
prevented	  these	  effects	  [107].	  
GCSF	   is	   central	   to	   the	   production	   of	   neutrophils.	   Mice	   lacking	   GCSF	   have	   chronic	  
neutropaenia	   and	   impaired	   granulocyte	   mobilization	   [114].	   GCSF	   also	   has	   other	  
immunomodulatory	  roles	   including	  enhanced	  phagocytosis,	  superoxide	  generation	  as	  
well	   as	   enhanced	   neutrophil	   responses	   to	   fMLP	   [115].	   GCSF	   can	   be	   produced	   by	   a	  
variety	   of	   cells	   including	   endothelial	   cells	   (as	  mentioned),	   epithelial	   cells,	   fibroblasts	  
and	   immune	   cells	   such	   as	   monocytes,	   macrophages	   as	   well	   as	   neutrophils.	   GCSF	  
mediates	  its	  effects	  by	  binding	  to	  a	  homodimer	  transmembrane	  receptor.	  Mobilization	  
of	   neutrophils	   involves	   parallel	   but	   distinct	   mechanisms	   including;	   induction	   of	  
proteases	   such	   as	   elastase	   as	   well	   as	   matrix	   metalloproteinases,	   attenuation	   of	  
adhesion	   molecules	   such	   as	   integrins	   and	   disruption	   of	   signaling	   between	  
CXCL12/CXCR4	  [116].	  	  
It	   is	   thought	   that	   activated	   neutrophils	   undergo	   respiratory	   burst	   and	   degranulation	  
releasing	   reactive	   oxygen	   species	   (ROS)	   and	   proteases,	   which	   cause	   local	   tissue	  
destruction	   including	   endothelial	   cell	   necrosis	   and	   apoptosis	   ultimately	   leading	   to	  
|	  Page	  40	  
fibrosis.	  Renal	  histology	  samples	  of	  patients	  with	  AAV	  support	  the	  role	  of	  neutrophils	  
in	  tissue	  damage.	  The	  number	  of	  activated	  neutrophils	  in	  the	  renal	  biopsy	  samples	  of	  
patients	   with	   GPA	   correlates	   with	   severity	   of	   renal	   impairment	   [117].	   In	   addition,	  
murine	   studies	   of	   the	   MPO-­‐ANCA	   passive	   transfer	   model	   of	   AAV	   revealed	   that	  
neutrophil	  depletion	  using	   the	  monoclonal	  antibody	  NIMP-­‐R14	  directed	  against	  Ly6G	  
and	   Ly6C,	   protected	   mice	   from	   necrotising	   crescentic	   glomerulonephritis	   [118].	   We	  
have	   shown	   that	  GCSF	  primes	  neutrophils	   to	   induce	   respiratory	  burst	   in	   response	   to	  
MPO-­‐ANCA.	   Furthermore,	   patients	   with	   active	   AAV	   have	   higher	   serum	   GCSF	   levels	  
compared	   to	   controls.	   In	   vivo,	   administration	   of	   GCSF	   exacerbated	   disease	   in	   the	  
passive	  transfer	  model	  with	  an	  increment	  in	  peripheral	  blood	  neutrophil	  counts	  [119].	  	  
Neutrophils	  however	  are	  not	  just	  effector	  cells,	  they	  secrete	  cytokines	  and	  chemokines	  
following	  appropriate	  stimulation	  instructing	  and	  interacting	  with	  other	  immune	  cells.	  
For	  example	  neutrophils	  are	  a	  major	  source	  of	  B-­‐cell	  activating	  factor,	  which	  is	  crucial	  
for	  B	  cell	  survival,	  maturation	  and	  differentiation,	  hence	  neutrophils	  may	  have	  a	  role	  in	  
sustained	  autoantibody	  production.	  They	  also	  have	  the	  ability	  to	  recruit	  Th1	  and	  Th17	  
cells	  to	  sites	  of	  inflammation.	  
1.7	  T	  cells	  
There	   is	   extensive	   evidence	   implicating	   T	   cells	   in	   AAV	   pathogenesis.	   Weidner	   et	   al	  
demonstrated	   that	   the	   predominant	   interstitial	   infiltrating	   leucocytes	   in	   renal	   tissue	  
from	  AAV	  patients	  were	  T	  cells	  [3].	  T	  cell	  activation	  markers	  such	  as	  soluble	  IL2R	  and	  
CD30	  are	  elevated	   in	   the	  circulation	  of	  AAV	  patients	  and	  are	  associated	  with	  disease	  
activity	   [120].	   Moreover,	   ANCA	   are	   predominantly	   of	   the	   IgG1	   and	   IgG4	   subclass	  
suggesting	   that	   antigen-­‐driven	   T	   cell	   dependent	   class	   switching	   has	   occurred.	   ANCA	  
antigen	   specific	   T	   cells	   are	   detectable	   in	   AAV	   patients.	   T	   cells	   from	   AAV	   patients	  
proliferate	   in	  presence	  of	  MPO	  and	  PR3	   to	  a	  greater	  extent	   than	  controls	   and	   these	  
responses	  tend	  to	  persist	  with	  time,	  even	  in	  remission	  of	  disease	  [121].	  Furthermore,	  
anti-­‐T	  cell	  therapy	  has	  been	  shown	  to	  induce	  remission	  in	  the	  clinical	  setting	  [122].	  
Further	  observations	   from	  animal	  models	   support	   the	   role	  of	  CD4	  T	   cells.	   Ruth	  et	  al	  
demonstrated	   a	   crucial	   role	   of	   CD4	   T	   cells	   in	   an	   autoimmune	   mouse	   model	   of	  
crescentic	  glomerulonephritis.	  They	   immunised	  wild	  type	  mice	  with	  human	  MPO	  and	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subsequently	   challenged	   them	  with	   glomerular	   basement	  membrane	   (GBM)	   binding	  
antibodies.	   Mice	   that	   were	   depleted	   of	   CD4	   T	   cells	   at	   time	   of	   glomerular	   binding	  
antibody	   administration	   developed	   significantly	   less	   disease	   compared	   to	   controls	  
[123].	  	  
Further	  evidence	  for	  the	  pathogenic	  role	  of	  T	  cells	  emerged	  with	  the	  identification	  of	  
an	   immunodominant	  MPO	   T	   cell	   epitope	   using	   a	   peptide	   composed	   of	   amino	   acids	  
409-­‐428	  of	  the	  MPO	  heavy	  chain	  [124].	  Mice	  immunised	  with	  this	  peptide	  developed	  
disease	   similar	   to	   that	   seen	   in	  mice	   immunised	  with	  whole	  MPO.	  MPO	   amino	   acids	  
409-­‐428	   were	   subsequently	   implanted	   by	   conjugation	   to	   an	   anti-­‐GBM	   monoclonal	  
antibody	   in	   the	  glomeruli	  of	  Rag-­‐1	  deficient	  mice.	  Transfer	  of	  MPO	  amino	  acids	  409-­‐
428	   specific	   CD4	   T	   cell	   clones	   into	   these	   mice	   led	   to	   the	   development	   of	   focal	  
necrotising	  glomerulonephritis.	  	  
Attempts	   to	   define	   the	   Th1	   /	   Th2	   paradigm	   in	   AAV	   have	   also	   been	  made,	   although	  
there	  are	  concerns	  about	   the	  oversimplification	  of	   this	  distinction.	  Analysis	  of	   serum	  
for	  markers	  of	  Th1	  and	  Th2	  cells	  reveal	  a	  shift	  toward	  a	  Th2	  phenotype	  in	  patients	  with	  
active	   generalised	   disease	   and	   a	   predominant	   Th1	   response	   in	   those	   with	   localised	  
disease	  [125,	  126].	  
Th17	  cells	  also	  play	  a	  role	  in	  AAV.	  Neutrophils	  activated	  by	  MPO	  ANCA	  secrete	  IL17	  and	  
IL23	   both	   cytokines	   creating	   a	  milieu	   to	   promote	   Th17	   differentiation	   [127].	   IL17	   in	  
turn	   leads	   to	   inflammatory	   cytokine	   release	   including	   IL1β	   and	   TNFα	   from	  
macrophages	   and	   induces	   local	   neutrophil	   recruitment.	   In	   vivo	   Th17	   cells	   have	  been	  
shown	  to	  be	  crucial	  to	  pathogenesis.	  Spleen	  cells	  from	  MPO	  immunised	  mice	  produce	  
IL17	  and	  low	  amounts	  of	  IFN-­‐γ.	  Furthermore	  IL17	  deficient	  mice	  were	  protected	  from	  
disease	   induction	   in	   the	   autoimmune	  mouse	  model	   of	   crescentic	   glomerulonephritis	  
[128].	  
Treg	   cells,	   characterised	   by	   their	   expression	   of	   forkhead	   winged	   helix	   transcription	  
factor	   (FoxP3),	   have	   been	   implicated	   in	   autoimmunity.	   They	   regulate	   the	   immune	  
response	  of	  effector	  memory	  T	  cells.	  In	  GPA	  patients	  the	  suppressive	  function	  of	  Treg	  
cells	  has	  been	  shown	  to	  be	  defective	  compared	  to	  healthy	  controls	   [129].	  Circulating	  
CD4	   effective	   memory	   T	   cells	   on	   the	   other	   hand	   are	   increased	   in	   AAV	   patients	   in	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remission	  and	  reduced	  during	  active	  disease	  [130].	  This	  is	  associated	  with	  an	  increase	  
in	  CD4	  effective	  memory	  T	  cells	   in	   the	  urinary	  sediment	  of	  patients	  with	  active	  renal	  
involvement	   suggesting	   that	   in	   active	   disease	   these	   cells	   migrate	   to	   areas	   of	  
inflammation	  [131].	  
Studies	  of	  CD8	  T	  cells	  in	  AAV	  are	  sparse.	  During	  active	  AAV	  Iking-­‐Konert	  et	  al	  showed	  
that	  a	  distinct	   subset	  of	  CD8	  T	   cells	   that	  are	  CD11b	  positive	   (a	  marker	  of	   activation)	  
were	   found	   and	   these	   cells	   produced	   interferon	   (IFN)–γ	   [132].	   Furthermore,	   AAV	  
patients	   with	   poor	   prognosis	   have	   been	   shown	   to	   have	   an	   expanded	   CD8	   T	   cell	  
memory	  population	  [133].	  
1.8	  B	  cells	  
B	   cells	   have	   an	   important	   role	   in	   pathogenesis	   as	   evidenced	   by	   the	   presence	   of	  
autoantibodies	  in	  AAV.	  Not	  only	  do	  B	  cells	  differentiate	  into	  plasma	  cells	  that	  produce	  
autoantibodies,	   they	   also	   have	   a	   role	   as	   APCs	   and	   produce	   pro-­‐inflammatory	  
cytokines.	  	  
In	  patients	  with	  AAV	  tertiary	   lymphoid	  structures	  containing	  dendritic	  cells	  as	  well	  as	  
memory	   and	   non-­‐memory	   B	   cells	   have	   been	   found	   in	   involved	   tissue	   including	  
glomerulonephritis	   lesions	   [134].	   However,	   there	   was	   no	   evidence	   of	   antibody	  
production	  within	   the	   renal	   lesions,	   suggesting	   an	   antibody	   independent	   role	   in	   the	  
tissue.	  Bunch	  et	  al	  compared	  the	  peripheral	  B	  cell	  subsets	  in	  either	  active	  or	  quiescent	  
AAV	   to	   healthy	   controls	   and	   showed	   that	   those	   with	   active	   disease	   had	   a	   lower	  
proportion	   of	   CD5	   positive	   B	   cells	   to	   controls	   and	   those	   in	   remission	   [135].	  
Furthermore,	   normalisation	   of	   CD5	   B	   cells	   after	   rituximab	   therapy	   correlated	   with	  
more	   effective	   remission.	   CD5	   is	   one	   of	   several	   surface	   markers	   that	   characterise	  
regulatory	  B	  cells,	  which	  produce	  IL10.	  	  
Different	   subsets	   of	   B	   cells	   produce	   immunomodulatory	   cytokines	   that	   regulate	  
immune	   responses.	   As	   mentioned	   regulatory	   B	   cells	   produce	   IL10.	   Other	   cytokines	  
such	  as	  IL6	  and	  TNFα	  can	  be	  produced	  upon	  stimulation,	  which	  can	  down-­‐regulate	  the	  
function	   of	   T	   regulatory	   cells	   and	   boost	   T	   effector	   cell	   differentiation.	   TNFα,	   as	  
discussed,	  can	  also	  prime	  neutrophils	  to	   increase	  cell	  surface	  antigen	  presentation.	  B	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cell	  depletion	  using	  rituximab	  has	  been	  shown	  to	  decrease	  serum	  IL6	  and	  TNFα	  levels	  
[136].	  
These	  findings	  have	  fostered	  the	  use	  of	  B	  cell	  depleting	  agents	   in	  the	  clinical	  setting.	  
The	  effectiveness	  of	  B	  cell	  therapy	  further	  supports	  the	  role	  of	  B	  cells	  in	  pathogenesis.	  
1.9	  Monocytes	  /	  Macrophages	  
Monocytes,	   like	  neutrophils,	  harbour	   the	  antigenic	   targets	   (MPO	  and	  PR3)	   for	  ANCA.	  
The	  majority	  of	  AAV	  research	  has	  focused	  on	  neutrophils	  whilst	  the	  role	  of	  monocytes	  
is	  less	  well	  examined.	  	  
Monocytes	   are	   circulating	  mononuclear	  phagocytes	   that	   can	  differentiate	   into	   tissue	  
macrophages	  and	  dendritic	  cells.	  Circulating	  human	  monocytes	  can	  be	  subdivided	  into	  
classical	   (CD14++CD16-­‐,	   resemble	   mouse	   Ly6C	   high	   monocytes),	   intermediate	  
(CD14++CD16+)	   and	   non-­‐classical	   (CD14+CD16++,	   resemble	   mouse	   Ly6C	   low	  
monocytes).	   Classical	   monocytes	   are	   the	  most	   prevalent	   subset	   and	   are	   considered	  
pro-­‐inflammatory.	  
During	  early	  myeloid	  differentiation,	  colony	  stimulating	  factor	  1	  (CSF1)	  in	  synergy	  with	  
other	   growth	   factors	   produce	  mononuclear	   phagocyte	   progenitor	   cells	   and	   regulate	  
the	  proliferation	  and	  differentiation	  into	  monocytes	  and	  macrophages.	  CSF1	  exerts	  its	  
effects	  through	  the	  receptor	  CSF1R,	  a	  homodimeric	  tyrosine	  kinase	  receptor.	  CSF1	  also	  
enhances	  monocyte	   and	  macrophage	  mediated	   cytotoxicity,	   phagocytosis	   as	  well	   as	  
superoxide	   and	   cytokine	   production	   following	   appropriate	   stimulation.	   Thus	   CSF1	   is	  
strongly	   implicated	  in	   infection	  and	  autoimmunity.	   In	  an	  animal	  model	  of	   lupus	  using	  
the	  MRL/lpr	  mice,	  Lenda	  et	  al	  showed	  that	  these	  mice	  have	  elevated	  CSF1	  levels.	  CSF1	  
deficient	  MRL/lpr	  mice	  had	  reduced	  renal	  injury	  and	  systemic	  disease,	  fewer	  intrarenal	  
macrophage	  and	  T	  cell	  infiltrates,	  	  as	  well	  as	  reduced	  circulating	  autoantibodies	  [137].	  	  
Attempts	   have	   been	   made	   to	   classify	   macrophage	   subsets	   based	   on	   cell	   surface	  
markers,	   cytokine	   profile	   following	   various	   stimuli	   and	   the	   effects	   on	   adaptive	  
immunity.	  Macrophages	  are	  often	  subdivided	  into	  M1	  (cytotoxic)	  and	  M2	  (healing).	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The	  macrophage	  subsets	  were	  named	  M1	  and	  M2	  as	  they	  stimulate	  naïve	  T	  cells	  into	  
Th1	  or	  Th2	  type	  responses	  respectively.	  M1	  macrophages	  classically	  express	  inducible	  
nitric	  oxide	  synthase,	  CD86	  as	  well	  as	  MHC	  II	  and	  typically	  produce	  IL8,	  IL12	  and	  CCL2.	  
M2	   macrophages	   express	   CD163	   as	   well	   as	   CD206	   and	   produce	   arginase,	   vascular	  
endothelial	   growth	   factor	   and	   transforming	   growth	   factor	   (TGF)	   β	   [138].	   In	   vitro	   the	  
cell	  populations	  derived	  from	  culture	  with	  granulocyte	  macrophage	  colony	  stimulating	  
factor	  (GMCSF)	  or	  CSF1	  have	  been	  likened	  to	  M1	  or	  M2	  macrophages	  respectively.	  In	  
tissue,	  there	  appears	  to	  be	  plasticity	  as	  macrophages	  mature	  in	  a	  dynamic	  manner	  to	  
various	   stimuli	   and	  are	   thought	   to	  be	  adaptable,	  making	  a	   clear	  distinction	  between	  
M1	  and	  M2	  macrophages	  challenging.	  
Normal	   human	   peripheral	   blood	   monocytes	   have	   well	   defined	   cytoplasmic	   staining	  
with	  MPO	  and	  PR3	  ANCA	  as	  shown	  by	  indirect	  immunofluorescence.	  In	  vitro	  these	  cells	  
lose	  reactivity	  as	  they	  differentiate	  into	  macrophages,	  suggesting	  that	  ANCA	  can	  only	  
interact	  with	  monocytes	  but	  not	  mature	  macrophages	   [139].	   Limited	   in	   vitro	   studies	  
show	  that	  ANCA	  can	  activate	  monocytes.	  Casselman	  et	  al	  showed	  that	  ANCA	  isolated	  
from	  patients	  induced	  monocyte	  chemotaxis	  and	  induced	  monocyte	  chemoattractant	  
protein-­‐1	   (MCP-­‐1	   /	   CCL2)	   secretion	   [140].	   Ralston	   et	   al	   demonstrated	   that	   TNFα	  
priming	   of	   monocytes	   led	   to	   increased	   surface	   PR3	   expression	   on	   peripheral	   blood	  
mononuclear	   cells.	  Monoclonal	   and	   polyclonal	   PR3-­‐ANCA	   induced	   significantly	  more	  
IL8	   release	   from	  TNFα	  primed	  monocytes	   than	  control	   IgG,	  which	  was	  Fc	  dependent	  
[141].	   IL8	   is	   a	   powerful	   neutrophil	   chemotactic	   factor	   that	   can	   amplify	   neutrophil	  
induced	  injury,	  whilst	  MCP-­‐1	  regulates	  the	  migration	  of	  monocytes	  as	  well	  as	  memory	  
T	   cells	   and	   natural	   killer	   cells.	   Hence,	   ANCA	   through	   its	   actions	   on	  monocytes	   may	  
participate	  in	  the	  transition	  of	  neutrophil	  rich	  to	  monocyte	  /	  macrophage	  predominant	  
inflammation	  in	  AAV.	  
Others	   have	   shown	   that	   monocytes	   from	   patients	   with	   PR3-­‐ANCA	   disease	   had	  
upregulated	  CD11b,	  although	  these	  monocytes	  had	  reduced	  oxygen	  radical	  production	  
under	  basal	   conditions	  and	   in	   response	   to	   fMLP	  compared	   to	  healthy	  controls	   [142].	  
Weidner	  et	  al	  on	  the	  other	  hand	  showed	  that	  ANCA	  IgG	  isolated	  from	  patients	  induced	  
healthy	  TNFα	  primed	  monocytes	  to	  produce	  oxygen	  radicals	  compared	  to	  control	  IgG.	  
Interestingly,	   F(ab)2	   fragments	   of	   ANCA	   were	   also	   able	   to	   induce	   reactive	   oxygen	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species	  production	   to	  an	  extent	   that	  was	   similar	   to	  ANCA	   IgG.	  But	  pre-­‐incubation	  of	  
monocytes	  with	  a	  FcγRII	  blocking	  antibody	   reduced	   the	   formation	  of	  oxygen	   radicals	  
by	  ANCA	  IgG.	  A	  possible	  explanation	  for	  this	  inconsistency	  is	  that	  the	  F(ab)2	  fragments	  
and	   whole	   IgG	   were	   used	   at	   identical	   concentrations	   at	   50μg/ml	   yielding	   a	   higher	  
molar	  concentration	  of	  the	  F(ab)2	  fragments	  making	  the	  results	  incomparable	  [143].	  It	  
has	   also	   been	  demonstrated	   that	  ANCA	   IgG	   induce	   in	   vitro	   upregulation	  of	   CD14	  on	  
unprimed	  monocytes,	  a	  co-­‐receptor	  for	  LPS	  that	  contributes	  to	  monocyte	  adhesion	  to	  
stimulated	   endothelial	   cells	   [144].	   More	   recently,	   O’Brien	   et	   al	   showed	   that	   MPO-­‐
ANCA	   stimulated	   TNFα	   primed	  monocytes	   to	   produce	   IL1β,	   IL6	   and	   IL8	   [145].	   So	   it	  
appears	  from	  the	  limited	  studies	  ANCA	  are	  capable	  of	  activating	  monocytes.	  
Work	  by	  Weidner	  et	  al	  showed	  that	   in	  renal	  biopsies	  from	  patients	  with	  AAV	  related	  
glomerulonephritis	   monocytes	   /	   macrophages	   were	   the	   predominant	   leucocytes	   in	  
glomeruli	   [3].	   These	   results	   are	   in	   accord	   with	   those	   reported	   by	   Zhao	   et	   al,	   who	  
reported	   that	   monocytes	   /	   macrophages	   were	   the	   most	   frequent	   leucocytes	   in	  
patients	  with	  ANCA	  glomerulonephritis	   [146].	  They	  also	  demonstrated	  using	  electron	  
microscopy	  that	  macrophages	  predominated	  at	  areas	  of	  perforations	  and	  attenuations	  
of	  glomerular	  capillary	  basement	  membrane.	  Zhao	  et	  al	  attempted	  to	  characterise	  the	  
macrophages	   in	   renal	  biopsies	  as	  M1	  or	  M2	  using	  CD68	  and	  CD163	  antibodies.	  They	  
found	   that	   the	  majority	   of	  macrophages	   were	   CD163	   positive	   at	   sites	   of	   segmental	  
fibrinoid	  necrosis	   suggesting	   that	  M2	  macrophages	  predominate	   [146].	  Ohlsson	  et	  al	  
reported	  that	  serum	  from	  AAV	  patients	   induced	  macrophage	  polarisation	  toward	  the	  
M2c	  phenotype	  however	  it	  remains	  unclear	  if	  this	  was	  a	  direct	  result	  of	  ANCA	  or	  due	  
to	  the	  cytokine	  milieu	  [147].	  	  
1.10	  Complement	  and	  AAV	  
The	   complement	   system	  was	   first	   described	   in	   the	   late	   19th	   century	   as	   a	   heat	   labile	  
bactericidal	   factor	   initially	   termed	  alexin	  and	   later	   termed	  to	   its	  universally	  accepted	  
nomenclature	   by	   Paul	   Ehrlich	   [148].	   	   It	   consists	   of	   over	   fifty	   glycoproteins	   that	   are	  
either	  soluble	  or	  membrane	  bound,	  functioning	  as	  activators,	  receptors	  and	  regulators.	  
There	   are	   three	   known	   pathways	   of	   complement	   activation	   (figure	   1.3),	   which	  
culminate	  in	  the	  formation	  of	  the	  C3	  and	  C5	  convertase	  enzyme	  complexes	  that	  cleave	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C3	   and	   C5	   into	   the	   anaphylatoxins	   C3a	   and	   C5a,	   the	   opsonin	   C3b	   and	   C5b.	   C5b	  
deposition	   onto	   a	   target	   leads	   to	   the	   formation	   of	   the	   membrane	   attack	   complex	  
(MAC)	  C5b-­‐9,	  resulting	  in	  target	  lysis.	  The	  role	  of	  complement	  in	  innate	  immunity	  has	  
been	  widely	  acknowledged,	  however	  a	  renewed	  interest	  since	  the	  1970s	  has	  shown	  its	  
involvement	  in	  many	  other	  effector	  systems	  including	  adaptive	  immunity.	  
Figure	  1.3	  –	  The	  complement	  cascade.	  The	  three	  activation	  pathways	  of	  complement	  
activation	  are	  depicted	   (MBL	  –	  mannose-­‐binding	   lectin,	   CHO	  –	   carbohydrate,	  MAC	  –	  
membrane	  attack	  complex).	  The	  C3	  and	  C5	  convertases	  are	  highlighted	  in	  red.	  
1.10.1	  The	  classical	  pathway	  
The	  classical	  pathway	   is	   initiated	  when	  C1q	   (as	  part	  of	   the	  C1	  complex	  composed	  of	  
C1q,	  C1r	  and	  C1s)	  binds	   the	  Fc	  portion	  of	   IgG	  or	   IgM	   immune	  complexes,	  pentraxins	  
such	   as	   C	   reactive	   protein	   or	   moieties	   on	   microbial	   and	   apoptotic	   cells	   [148,	   149].	  
Binding	  of	  C1q	   leads	  to	  stepwise	  activation	  of	  C1r	  and	  C1s.	  C1s	  subsequently	  cleaves	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C4	  into	  C4a	  and	  C4b.	  The	  opsonin	  C4b	  deposits	  on	  the	  target	  surface	  and	  cleaves	  C2	  to	  
C2a	   and	   C2b,	   the	   former	   product	   binds	   to	   C4b,	   generating	   the	   classical	   pathway	   C3	  
convertase	  C4bC2a.	  
1.10.2	  The	  lectin	  pathway	  
The	   lectin	   pathway	   has	   some	   functional	   similarities	   to	   the	   classical	   pathway.	   In	   this	  
case,	   the	   mannose-­‐binding	   lectin	   (MBL),	   ficolins	   and	   collectins	   act	   as	   pattern	  
recognition	   molecules	   (PRMs)	   binding	   carbohydrate	   structures	   on	   pathogens	   or	  
glycocalyx	   patterns	   on	   apoptotic	   cells	   (pathogen	   associated	   molecular	   patterns	   or	  
damage	   associated	   molecular	   patterns).	   The	   PRMs	   associate	   with	   MBL-­‐associated	  
serine	  proteases	  (MASPs)	  1-­‐3	  forming	  an	  enzyme	  complex.	  MASP2	  cleaves	  C4	  and	  C4b	  
bound	  C2	  to	  generate	  the	  classical	  C3	  convertase	  C4bC2a,	  whilst	  MASP1	  cleaves	  C2	  but	  
not	  C4,	  and	  C3	  to	  a	  lesser	  extent	  [150].	  
1.10.3	  The	  alternative	  pathway	  
Inert	   C3	   is	   constantly	   hydrolysed	   to	   form	  C3(H2O)	  which	   is	   similar	   to	   C3b	   and	   binds	  
factor	  B.	  Bound	  factor	  B	  is	  cleaved	  by	  factor	  D	  to	  generate	  the	  C3	  convertase	  C3H2OBb.	  
Properdin	  has	  a	  role	  in	  stabilising	  the	  C3	  convertase	  as	  well	  as	  PRM	  based	  activation.	  
Properdin	  recognises	  pathogens	  and	  altered	  self	  cells	  through	  the	  detection	  of	  certain	  
glycosaminoglycans	   propagating	   the	   complement	   cascade	   by	   attracting	   C3b	   onto	  
surfaces,	  initiating	  further	  C3	  convertase	  formation	  [151-­‐153].	  
The	   C3	   convertases	   cleave	   C3	   into	   C3a	   and	   the	   opsonin	   C3b,	   leading	   to	   further	  
amplification	  of	  the	  alternative	  pathway.	   In	  addition,	  C3b	  further	  complexes	  with	  the	  
C3	  convertases	  to	   form	  the	  C5	  convertases	  C4bC2aC3b	  and	  C3bBbC3b,	  which	   in	  turn	  
cleave	  C5	  to	  form	  the	  anaphylatoxin	  C5a	  and	  C5b.	  C5b	  associates	  with	  C6-­‐9	  to	  form	  the	  
MAC,	  composed	  of	  a	  pore	   like	  structure	  that	  disrupts	  the	  phospholipid	  bilayer	  of	  the	  
target	  cell.	  
In	  addition	  to	  the	  conventional	  three	  activation	  pathways	  discussed,	  other	  factors	  are	  
capable	  of	  initiating	  the	  complement	  cascade	  (see	  complement	  and	  coagulation).	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1.10.4	  Regulators	  of	  complement	  	  
Activation	  of	  complement	  can	  be	  deleterious	  leading	  to	  undesirable	  tissue	  damage	  and	  
it	   is	   intuitive	   to	   perceive	   that	   C3b	   generated	   by	   the	   tick-­‐over	   process	   described	  will	  
bind	  non-­‐specifically	  to	  healthy	  cells.	  Hence	  the	  complement	  system	  has	  key	  regulators	  
in	  place	  to	  restrict	  unnecessary	  damage	  and	  activation.	  	  
The	  regulators	  can	  be	  divided	  into	  fluid	  phase	  and	  membrane-­‐bound	  regulators	  [154].	  
The	  fluid-­‐phase	  regulators	  are	  found	  in	  plasma	  and	  other	  bodily	  fluids	  such	  as	  synovial	  
fluid.	  They	  include:	  
• C1	  inhibitor	  -­‐	  inhibits	  C1r	  and	  C1s	  as	  well	  as	  MASP1	  and	  MASP2	  [155,	  156].	  
• C4bp	   -­‐	   accelerates	  decay	  of	   the	  C3	   convertase	  C4bC2a	  and	   facilitates	   factor	   I	  
mediated	  C3b	  and	  C4b	  cleavage	  [157].	  
• Factor	  H	  –	  inhibits	  the	  alternative	  pathway	  C3	  convertase	  C3bBb	  and	  acts	  as	  a	  
cofactor	  for	  factor	  I,	  which	  inactivates	  C3b	  and	  C4b	  [158,	  159].	  
• Carboxypeptidase	  N	  –	   cleave	   and	  partially	   inactivates	   the	   anaphylatoxins	  C3a	  
and	  C5a	  to	  C3a-­‐desArg	  and	  C5a-­‐desArg	  [160].	  
• Clusterin	   and	   S	   protein	   (vitronectin)	   –	   regulate	   the	   MAC	   by	   inhibiting	   the	  
membrane	  binding	  of	  the	  MAC	  [154].	  	  
The	   membrane	   bound	   regulators	   are	   found	   on	   the	   membrane	   of	   host	   cells	   and	  
include:	  
• Complement	   receptor	   (CR)	   type	   1	   –	   accelerates	   decay	   of	   the	   C3	   and	   C5	  
convertases	  and	  acts	  as	  a	  cofactor	  for	  factor	  I	  [161,	  162].	  
• Membrane	  cofactor	  protein	  (CD46)	  –	  acts	  as	  a	  cofactor	  for	  factor	  I	  and	  induces	  
C3b	   and	   C4b	   cleavage	   [163].	   As	   discussed	   later	   the	   definition	   of	   CD46	   as	  
exclusively	  a	  complement	  regulator	  is	  not	  accurate.	  
• Decay-­‐accelerating	  factor	  (DAF	  /	  CD55)	  –	  accelerates	  the	  decay	  of	  the	  classical	  
and	  alternative	  pathway	  C3	  convertases	  [164].	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1.10.5	  Effects	  of	  complement	  pathway	  activation	  
As	   discussed,	   complement	   pathway	   activation,	   regardless	   of	   the	   initiation	   pathway	  
culminates	  in:	  
-­‐ Generation	  of	  pro-­‐inflammatory	  anaphylatoxins	  C3a	  and	  C5a.	  
C3a	  and	  C5a	  are	  approximately	  10-­‐15	  kDa	  fragments	  that	  bind	  specific	  receptors	  to	  
mediate	  their	  actions	  on	  immune	  and	  non-­‐immune	  cells.	  They	  have	  been	  shown	  to	  
increase	  vascular	  permeability	  and	  induce	  smooth	  muscle	  contraction	  [165].	  They	  
are	   powerful	   chemoattractants	   of	  macrophages,	   neutrophils,	   B	   cells	   as	  well	   as	   T	  
cells	   and	   are	   capable	   of	   inducing	   neutrophil	   oxidative	   burst	   [166].	   Both	   C3a	   and	  
C5a	  are	  cleaved	   from	  the	  amino	   terminal	   region	  of	   the	  α	   chain	  of	   the	   respective	  
parent	  molecule	  C3	  or	  C5.	  
The	  anaphylatoxins	  bind	  7	  transmembrane	  spanning	  receptors	  that	  belong	  to	  the	  
G-­‐protein	  family	  of	  receptors,	  C3aR	  for	  C3a,	  C5aR1	  and	  C5L2	  for	  C5a.	  Of	  note	  C5L2	  
is	  not	   coupled	   to	  G	  proteins.	  C5aR1	   signalling	   is	  mediated	  by	   the	  G	  proteins	  Gαi	  
and	  Gα16	  with	  subsequent	  phosphorylation	  of	  G	  protein	  receptor	  kinases.	  C5L2	  on	  
the	  other	  hand	  may	  have	  a	   role	  as	  a	  decoy	  receptor	  making	  C5a	  and	  C5a-­‐desArg	  
inaccessible	   to	   C5aR1	   or	   it	  may	   play	   a	   role	   in	   shuttling	   C5a	   /	   C5a-­‐desArg	   to	   the	  
intracellular	   compartment	   [167].	   Of	   course	   G	   protein	   independent	   signalling	  
pathways	  may	  play	  a	  role	  and	  certainly	  C5L2	  has	  been	  shown	  to	  complex	  with	  β-­‐
arrestin	  [168].	  	  
-­‐ Clearance	  of	  target	  cells	  by	  the	  generation	  of	  opsonins	  such	  as	  C4b,	  C3b	  and	  iC3b.	  
This	  is	  accomplished	  through	  the	  recognition	  of	  the	  complement	  fragments	  on	  cells	  
by	  receptors	  CR1-­‐4	  and	  CRIg	  on	  phagocytic	  cells.	  CR1	  binds	  C4b,	  C3b,	  iC3b,	  C3dg	  as	  
well	   as	   C1q	   and	   MBL,	   mediating	   clearance	   of	   immune	   complexes	   as	   well	   as	  
phagocytosis.	   CR1	   also	   promotes	   proinflammatory	   cytokine	   release	   such	   as	   IL1β	  
[169].	  As	  discussed	  it	  also	  accelerates	  the	  C3	  and	  C5	  convertase	  decay	  and	  acts	  as	  a	  
cofactor	   for	   factor	   I.	  CR2	  has	  a	  key	  role	   in	  promoting	  B	  cell	   immunity,	  whilst	  CR3	  
and	  CR4	  play	  a	  role	  in	  phagocytosis	  as	  well	  as	  leucocyte	  trafficking.	  CRIg	  is	  found	  in	  
Kupfer	  cells	  and	  play	  a	  role	  in	  the	  clearance	  of	  C3	  coated	  particles	  [170].	  
-­‐ Direct	   lysis	   of	   cells	   through	   MAC	   assembly.	   Cell	   lysis	   requires	   the	   presence	   of	  
multiple	   MACs	   on	   the	   cell	   surface	   to	   overcome	   the	   elimination	   of	   C5b-­‐9	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components	  and	   repair	  process	  of	   the	   cell	  membrane.	   Sublytic	  C5b-­‐9	   can	   induce	  
cell	  activation	  and	  proliferation	  as	  well	  as	  enhance	  synthesis	  of	  pro-­‐inflammatory	  
cytokines	  such	  as	  TNFα	  from	  certain	  cell	  types	  [171,	  172].	  
1.10.6	  Role	  of	  complement	  in	  adaptive	  immunity	  
B	  cell	  responses	  
The	  role	  of	  complement	   in	  adaptive	   immunity	   is	  now	  widely	  acknowledged.	  Pepys	   in	  
1972	   showed	   that	   mice	   that	   were	   depleted	   of	   C3	   using	   cobra	   venom	   factor	   had	  
impaired	   humoral	   response	   against	   T	   cell	   dependent	   antigens	   [173].	   It	   was	  
subsequently	   shown	   that	   CR2	   (CD21),	  which	   binds	   C3d,	   forms	   a	   receptor	  with	   CD19	  
and	  CD81	  on	  B	  cells	  lowering	  the	  threshold	  of	  B	  cell	  activation	  [174,	  175].	  
Others	  have	  demonstrated	  that	  B	  cells	  express	  the	  C3a	  receptor	  and	  that	  both	  C3a	  and	  
C3a-­‐desArg	  have	  an	  immunomodulatory	  effect	  on	  B	  cells.	  C3a	  and	  C3a-­‐desArg	  supress	  
a	  polyclonal	  immune	  response	  as	  well	  as	  B	  cell	  TNFα	  and	  IL6	  secretion	  [176].	  
T	  cell	  responses	  
Complement	   plays	   a	  major	   role	   in	   T	   cell	   responses	   via	   two	   distinctive	  mechanisms;	  
affecting	  the	  function	  of	  APCs	  modulating	  the	  T	  cell	  effector	  responses	  and	  by	  directly	  
engaging	  complement	  receptors	  and	  regulators	  on	  T	  cells	  [177].	  
C3	   deficient	   mice	   have	   impaired	   CD4	   and	   CD8	   T	   cell	   responses	   in	   models	   of	   viral	  
infection	   and	   transplantation	   [178,	   179].	   Antigen	   uptake	   and	   presentation	   is	  
suboptimal	   in	   the	   absence	   of	   C3,	   reducing	   the	   potency	   of	   APCs	   to	   stimulate	   T	   cell	  
responses	   [180,	   181].	   The	   importance	   of	   the	   anaphylatoxins	   C3a	   and	   C5a	   in	   APC	  
maturation	  has	  also	  been	  highlighted.	  
Two	  major	  complement	  regulators	  have	  been	  implicated	  in	  T	  cell	  biology	  and	  have	  led	  
to	   interesting	   ideas	   about	   local	   complement	   function.	   DAF	   knockout	   mice	   have	   an	  
enhanced	   Th1	   response	   characterised	   by	   IFN-­‐γ	   and	   IL2	   hyper-­‐secretion	   due	   to	  
uncontrolled	  surface	  complement	  activation.	  The	  augmented	  response	  did	  not	  occur	  if	  
DAF	  and	  factor	  D	  double	  knockout	  APCs	  were	  used	  and	  the	  response	  was	  reduced	  in	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the	  presence	  of	  an	  anti-­‐C5	  monoclonal	  antibody	  whilst	  C5a	  addition	  amplified	  it	  [182].	  
This	  led	  to	  the	  hypothesis	  that	  locally	  produced	  complement	  products	  at	  the	  APC-­‐T	  cell	  
interface	  are	  crucially	  involved	  in	  T	  cell	  activation	  [183].	  
CD46	   is	  critical	   in	  regulating	  T	  cell	  mediated	   inflammatory	  responses.	  CD46	  functions	  
as	   a	   co-­‐stimulatory	   molecule	   with	   T	   cell	   receptor	   stimulation	   to	   induce	   CD4	   cell	  
activation	   and	   proliferation	   [184].	   T	   cells	   isolated	   from	   CD46	   deficient	   patients	  who	  
suffer	  from	  recurrent	   infections	  are	  unable	  to	  produce	  IFN-­‐γ,	  however	  Th2	  responses	  
are	  maintained	  [185].	  Interestingly	  in	  the	  presence	  of	  high	  IL2,	  CD46	  is	  involved	  in	  the	  
switch	   of	   IFN-­‐γ	   producing	   Th1	   cells	   into	   an	   IL10	   producing	   regulatory	   phenotype	  
contracting	  the	  Th1	  cell	  pool	  [186].	  Furthermore,	  engagement	  of	  C3aR	  is	  necessary	  for	  
Th1	  IFN-­‐γ	  production	  [183].	  
It	   appears	   that	   complement	  plays	   a	   vital	   role	   in	  orchestrating	   and	  bridging	  both	   the	  
innate	   and	   adaptive	   immune	   system	   through	   complex	   interactions.	   However,	  
complement	  has	  other	  roles	  including	  cell	  metabolism,	  in	  particular	  lipid	  synthesis	  and	  
amino	  acid	  metabolism.	  
1.10.7	  Local	  complement	  production	  
The	   liver	   is	   the	   established	   source	   of	   the	   majority	   of	   circulating	   complement	  
components,	   excluding	   C1q,	   factor	   D,	   properdin	   and	   C7.	   C1q,	   properdin	   and	   C7	   are	  
mainly	   produced	   by	   monocytes	   and	   macrophages	   whilst	   factor	   D	   is	   sourced	   by	  
adipocytes	   [187].	  Several	  cell	  populations	   in	  diverse	  organs	  are	  capable	  of	  producing	  
complement	   components,	  which	  can	  have	  paracrine	  and	  autocrine	  effects	   [188].	   For	  
example,	   resident	   renal	   cell	   types	   are	   capable	   of	   synthesising	   most	   if	   not	   all	  
complement	   cascade	   components.	   Furthermore,	   studies	   have	   shown	   that	   local	  
production	  of	  C3	   is	  an	   important	  mediator	  of	  tissue	  damage	   in	  models	  of	  adriamycin	  
induced	   injury	   and	   renal	   allograft	   rejection	   [189,	   190].	   As	   discussed	   above	   T	   cell	  
produced	  C3	  components	  have	  autocrine	  effects	  by	  engaging	  CD46	  and	  C3aR.	  
It	   was	   assumed	   that	   local	   C3	   and	   C5	   generation	   was	   mediated	   by	   serum-­‐derived	  
convertases,	  however,	  T	  cells	  and	  APCs	  are	  capable	  of	  producing	  factor	  B	  and	  factor	  D,	  
and	   hence	   the	   components	   necessary	   for	   C3	   and	   C5	   convertase	   formation	   [183].	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Furthermore,	  it	  has	  been	  shown	  that	  various	  cell	  types	  have	  the	  capability	  of	  cleaving	  
C3	  intracellularly.	  Resting	  CD4	  T	  cells	  harbour	  the	  protease	  cathepsin	  L,	  which	  cleaves	  
C3	  into	  C3a	  and	  C3b	  [191].	  Intracellular	  derived	  C3	  components	  may	  have	  a	  crucial	  role	  
in	  cell	  metabolism	  and	  it	  has	  been	  demonstrated	  that	  cathepsin	  L	  inhibition	  as	  well	  as	  
decreased	   intracellular	   C3aR	   expression	   reduces	   mTOR	   activity	   and	   induces	   T	   cell	  
apoptosis,	  which	  cannot	  be	  rescued	  by	  serum	  derived	  C3a	  [191].	  	  
This	   suggests	   that	   intracellular	   derived	   complement	   and	   intracellular	   complement	  
receptors	  have	  distinct	  functions	  compared	  to	  their	  extracellular	  counterparts.	  	  
1.10.8	  Complement	  and	  coagulation	  
There	   is	   extensive	   cross-­‐talk	   between	   the	   complement	   cascade	   and	   the	   coagulation	  
pathway.	  It	  appears	  that	  the	  two	  pathways	  are	  able	  to	  regulate	  one	  another	  at	  various	  
points	  (see	  figure	  1.4)	  [192,	  193].	  
The	   coagulation	  pathway	   is	   activated	  by	   two	  mechanisms;	   the	   intrinsic	   and	  extrinsic	  
pathway	  on	  cell	  surfaces	  or	  micro-­‐particles.	  It	  is	  believed	  that	  in	  vivo,	  tissue	  factor	  has	  
a	   central	   role	   and	   is	   the	  main	   instigator	   of	   the	   cascade.	   Both	   initiation	  mechanisms	  
lead	   to	   the	   activation	   of	   various	   serine	   proteases,	   which	   result	   in	   the	   release	   of	  
activated	  factor	  X	  (Xa).	  Factor	  Xa	  converts	  prothrombin	  to	  thrombin,	  which	  generates	  
fibrin	  that	  cross-­‐link	  to	  generate	  a	  stable	  clot.	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Figure	   1.4	   –	   The	   coagulation	   cascade	   and	   its	   interactions	   with	   complement	  
components.	  Factors	  of	  the	  coagulation	  cascade	  that	  are	  known	  to	  interact	  with	  C1,	  C3	  
and	   C5	   are	   highlighted	   in	   orange	   or	   red	   boxes,	  whilst	   the	   complement	   components	  
that	  influence	  coagulation	  are	  highlighted	  in	  grey.	  	  
Various	  proteases	  activate	   the	   complement	  pathway.	   Factor	  XIIa	  has	  been	   shown	   to	  
initiate	   the	   classical	   complement	   pathway	   by	   activating	   the	   C1	   complex	   [194].	  
Thrombin	  is	  able	  to	  cleave	  C3	  and	  C5	  to	  produce	  active	  components	  of	  each	  [195,	  196].	  
C3	  and	  C5	  can	  also	  be	  cleaved	  by	  factor	  IXa,	  factor	  Xa	  and	  factor	  XIa	  [196].	  	  
Similarly,	  complement	  components	  have	  the	  ability	  to	  initiate	  the	  coagulation	  cascade.	  
MASP2	   cleaves	   prothrombin	   into	   thrombin	   leading	   to	   fibrin	   clot	   formation	   [197].	  
MASP1	   cleaves	   the	   two	   substrates	   of	   thrombin,	   namely	   factor	   XIII	   and	   fibrinogen	  
although	  the	  catalytic	  activity	  is	  much	  lower	  than	  that	  of	  thrombin	  [198].	  C3a,	  C3a	  des-­‐
Arg	  and	  the	  MAC	  can	  induce	  platelet	  adhesion	  and	  aggregation	  [199].	  
C5a	   has	   multiple	   effects	   and	   is	   regarded	   as	   a	   procoagulant.	   In	   combination	   with	  
antibodies	   against	   endothelial	   cells,	   C5a	   triggers	   the	   shedding	   of	   endothelial	   surface	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proteoglycan	   heparin	   sulfate,	  which	   is	   normally	   responsible	   for	   the	   regulation	   of	   an	  
anticoagulant	   environment	   [200].	   Both	   C5a	   and	   MAC	   can	   also	   induce	   tissue	   factor	  
expression	  on	  human	  endothelial	  cells	  [201,	  202].	  
1.10.9	  Role	  of	  complement	  in	  AAV	  
The	  pauci-­‐immune	  nature	  of	  AAV	  initially	  gave	  rise	  to	  the	  belief	  that	  complement	  may	  
not	   play	   a	   role	   in	   pathogenesis.	   However,	   this	   dogma	   has	   since	   changed	   with	  
numerous	  studies	  showing	  the	  importance	  of	  complement	  in	  AAV.	  
Xing	  et	  al	  reported	  the	  presence	  of	  complement	  components	  C3d,	  factor	  B,	  properdin	  
and	  MAC	  in	  renal	  biopsies	  of	  7	  MPO-­‐ANCA	  positive	  AAV	  patients,	  whilst	  MBL	  and	  C4d	  
were	  not	  detected	  [203].	  Furthermore,	  circulating	  levels	  of	  C3a,	  C5a,	  soluble	  C5b-­‐9	  and	  
Bb	  have	  been	  reported	  to	  be	  significantly	  higher	  in	  patients	  with	  active	  AAV	  compared	  
to	   those	   in	   remission	   and	   controls.	   Properdin	   levels	   were	   reduced	   possibly	   due	   to	  
consumption.	  The	  plasma	  levels	  of	  Bb	  correlated	  with	  the	  degree	  of	  renal	  injury	  [204].	  
This	  suggested	  a	  potential	  role	  for	  the	  alternative	  pathway	  in	  pathogenesis.	  A	  further	  
study	  by	  the	  same	  group	  on	  12	  patients	  with	  ANCA	  negative	  pauci-­‐immune	  necrotising	  
crescentic	  glomerulonephritis	  revealed	  the	  detection	  of	  C4d	  in	  8	  patients	  and	  MBL	  in	  6	  
patients	  and	  this	  was	  thought	  to	  be	  associated	  with	  a	  poor	  renal	  outcome	  [205].	  More	  
recently	  Hilhorst	  et	  al	  analysed	  187	  renal	  biopsies	  of	  AAV	  patients	  and	  found	  C3d,	  C4d	  
as	  well	  as	  C5b-­‐9	  staining	  in	  most	  of	  the	  samples	  [206].	  
The	   first	   experimental	   evidence	   suggesting	   that	   complement	   had	   a	   role	   in	   AAV	  
pathogenesis	  was	  published	  in	  2007.	  The	  administration	  of	  cobra	  venom	  factor	  to	  mice	  
(a	   treatment	   that	   leads	   to	   the	   consumption	   and	   thus	   depletion	   of	   complement	  
component	  C3)	  conferred	  protection	  against	  the	  development	  of	  MPO-­‐ANCA	  induced	  
disease	  [207].	  The	  study	  showed	  that	  the	  alternative	  pathway	  played	  a	  crucial	  role	  in	  
disease	  onset.	  After	   injection	  of	  MPO-­‐ANCA	   IgG	  C4	  deficient	  mice	  developed	  disease	  
that	  was	  comparable	  to	  wild	  type	  mice.	  However,	  C5	  deficient	  and	  factor	  B	  deficient	  
mice	   developed	   no	   disease,	   implicating	   the	   alternative	   pathway	   in	   disease	  
pathogenesis.	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Subsequently	   Huugen	   et	   al	   showed	   that	   mice	   treated	   with	   an	   anti-­‐C5	   monoclonal	  
antibody	  prior	  to	  disease	  induction	  in	  the	  passive	  transfer	  model	  were	  protected	  from	  
disease	   [208].	 If	   the	   anti-­‐C5	   monoclonal	   antibody	   was	   administered	   1	   day	   after	  
disease	  induction,	  glomerular	  crescent	  formation	  in	  these	  mice	  was	  reduced	  by	  80%.	  
Furthermore,	   in	   vitro,	   supernatant	   from	   TNFα	   primed	   and	   ANCA	   stimulated	  
neutrophils	  has	  been	  shown	  to	  be	  sufficient	  to	  cause	  the	  generation	  of	  C3a	  and	  C5a	  in	  
normal	  serum.	  The	  factors	  which	  are	  released	  by	  the	  activated	  neutrophils	  that	  result	  
in	  the	  generation	  of	  C3a	  and	  C5a	  in	  normal	  serum	  were	  not	  identified	  [209].	  However,	  
neutrophils	   are	   capable	   of	   releasing	   C3,	   factor	   B	   and	   properdin,	   the	   machinery	   for	  
convertase	   formation	   [187,	   210].	   Blockade	   of	   the	   C5a	   receptor	   C5aR1	   (CD88)	   was	  
shown	  to	  inhibit	  ANCA	  induced	  respiratory	  burst	  in	  neutrophils.	  The	  importance	  of	  the	  
C5aR1	  was	  then	  confirmed	  in	  vivo	  using	  the	  bone	  marrow	  transplant	  model	  of	  disease,	  
with	  mice	  receiving	  C5aR1	  deficient	  bone	  marrow	  developing	  relatively	  mild	  disease	  in	  
response	   to	   MPO-­‐ANCA	   when	   compared	   to	   mice	   receiving	   wild	   type	   bone	   marrow	  
[209].	  	  
C5aR1	   knockout	  mice	  were	   also	   shown	   to	   be	   protected	   from	   disease	   in	   the	   passive	  
transfer	   model.	   However,	   C6	   knockout	   mice	   were	   not	   protected	   in	   this	   model,	  
suggesting	   that	   the	   MAC	   has	   no	   role	   in	   disease	   pathogenesis.	   Interestingly	   C5L2	  
knockout	  mice	  had	  the	  reverse	  effect,	  with	  more	  severe	  disease.	  The	  administration	  of	  
CCX168,	   an	   antagonist	   of	   human	   C5aR1,	   showed	   dose	   dependent	   amelioration	   of	  
disease	  in	  mice	  expressing	  the	  human	  C5aR1	  (knock	  in	  mice)	  [211].	  A	  phase	  II	  clinical	  
multicentre	  trial	   (ChemoCentryx)	  to	  test	  the	  effectiveness	  of	  CCX168	   in	  patients	  with	  
AAV	  where	   the	   primary	   endpoint	   was	   to	   determine	   whether	   CCX168	   could	   at	   least	  
partially	   substitute	   for	   glucocorticoid	   treatment	   in	   inducing	   remission,	   showed	   that	  
CCX168	  achieved	  statistical	   significance	   in	  a	   test	   for	  non-­‐inferiority	   in	  BVAS	  response	  
compared	   to	   standard	   care	   (Jayne	   DR	   et	   al	   EULAR	   2014	   abstract,	   Ann	   Rheum	   Dis	  
73:148).	  	  
1.11	  Animal	  models	  of	  ANCA	  vasculitis	  
Several	  animal	  models	  of	  glomerulonephritis	  exist.	  Glomerulonephritis	  encompasses	  a	  
wide	  range	  of	  immune	  mediated	  disorders	  that	  result	  in	  inflammation	  of	  the	  glomeruli.	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I	  will	  focus	  on	  animal	  models	  of	  ANCA	  vasculitis	  and	  also	  give	  a	  brief	  overview	  of	  other	  
models	  of	  glomerulonephritis.	  
Since	  the	  1990s	  there	  have	  been	  several	  attempts	  at	  developing	  robust	  rodent	  models	  
of	  ANCA	  vasculitis.	  The	  following	  paragraphs	  describe	  the	  models	  in	  brief.	  	  
1.11.1	  Models	  of	  MPO	  ANCA	  disease	  
The	  ability	  of	   susceptible	   rat	   strains	   such	  as	   the	  Brown	  Norway	   rat	   in	  developing	  an	  
autoimmune	  syndrome	  mediated	  by	  T	  cell	  dependent	  polyclonal	  B	  cell	  activation	  upon	  
exposure	   to	  mercuric	   chloride	  was	  utilised.	  The	   rats	   in	   this	  model	  developed	  several	  
autoantibodies	  including	  antibodies	  to	  the	  glomerular	  basement	  membrane,	  collagen,	  
DNA	  and	  MPO,	  making	   the	   contribution	  of	   each	  autoantibody	  difficult	   to	   judge.	   The	  
rats	   had	   characteristic	   small	   to	   medium	   sized	   vessel	   fibrinoid	   necrosis	   in	   multiple	  
organs,	   however,	   necrotising	   crescentic	   glomerulonephritis,	   a	   feature	   of	   human	  
disease,	  was	  not	  a	  prominent	  sequela.	  [212,	  213]	  
In	  1993	  Kinjoh	  et	  al	  described	  the	  spontaneous	  crescentic	  glomerulonephritis	  /	  Kinjoh	  
(SCG/Kinjoh)	   mouse,	   derived	   from	   the	   selective	   mating	   of	   siblings	   of	   (BXSB/Mp	   x	  
MRL/Mp-­‐lpr/lpr)	   F1	   hybrid	   mice	   [214].	   These	   mice	   developed	   rapidly	   progressive	  
crescentic	  glomerulonephritis	  with	  an	  incidence	  as	  high	  as	  58%	  in	  females	  and	  34%	  in	  
males.	  They	  produced	  high	  titres	  of	  MPO-­‐ANCA	  as	  well	  as	  other	  autoantibodies	  again	  
making	   it	   difficult	   to	   define	   the	   pathophysiological	   role	   of	   specific	   autoantibodies.	  
Furthermore,	   the	   disease	   was	   not	   pauci-­‐immune,	   scanty	   deposits	   of	   immune	  
complexes	  were	  noted	  on	  immunofluorescence.	  	  
Brouwer	   et	   al	   immunised	   Brown	   Norway	   rats	   with	   human	   MPO,	   which	   led	   to	   the	  
generation	  of	  MPO-­‐ANCA	  that	  cross-­‐reacted	  with	  rat	  MPO.	  Unilateral	  perfusion	  of	  the	  
kidney	  with	  extracts	  of	  activated	  neutrophils	  and	  hydrogen	  peroxide	  resulted	  in	  severe	  
necrotising	   crescentic	   glomerulonephritis	   [215].	   At	   24	   hours	   C3,	   IgG	   and	  MPO	  were	  
present	  along	  the	  basement	  membrane,	  but	  not	  at	  4	  and	  10	  days.	  	  
Further	  work	  utilising	   the	  nephrotoxic	  nephritis	  model	  of	  glomerulonephritis	   showed	  
that	  passive	  heterologous	  MPO-­‐ANCA	  transfer	  or	  active	   immunisation	  of	  the	  rat	  with	  
MPO	  exacerbated	  disease.	  Kobayashi	  et	  al	   showed	   that	  anti-­‐GBM	  nephritis	   in	   rats	   is	  
|	  Page	  57	  
aggravated	  by	   administration	  of	   rabbit	   anti	   rat	  MPO	  antibodies	   together	  with	   rabbit	  
anti	   rat	   GBM	   antibodies.	   There	   was	   increased	   neutrophil	   infiltration	   and	   fibrin	  
deposition	   but	   there	   was	   no	   evidence	   of	   crescentic	   disease	   [216].	   Heeringa	   et	   al	  
showed	   that	   rats	   immunised	   with	   human	   MPO	   and	   subsequently	   subnephritogenic	  
rabbit	  anti	  rat	  anti-­‐GBM	  antibodies	  developed	  more	  severe	  glomerulonephritis	  at	  day	  
10	  with	   fibrinoid	  necrosis,	  macrophage	   infiltration	  and	  crescent	   formation	  compared	  
to	  rats	  not	  immunised	  with	  MPO	  [217].	  
Although	   these	   models	   were	   very	   informative,	   they	   did	   not	   accurately	   model	   the	  
pathology	  of	  ANCA	  vasculitis.	  
The	  key	  breakthrough	  in	  animal	  models	  of	  MPO-­‐ANCA	  disease	  was	  published	  in	  2002.	  
Xiao	  et	  al	  offered	  a	  more	  definitive	  role	  in	  vivo	  for	  the	  pathogenic	  role	  of	  MPO-­‐ANCA.	  
MPO-­‐ANCA	  derived	  by	   immunising	  MPO	  knockout	  mice,	  when	   injected	   intravenously	  
into	   recombinase	   activating	   gene	   (RAG)	   2	   knockout	   or	   wild	   type	   mice	   caused	   a	  
crescentic	   pauci-­‐immune	   necrotising	   glomerulonephritis	   in	   10.8%	   and	   3.3%	   of	  
glomeruli	   sampled	   respectively	   at	   day	   6	   [100].	   This	   has	   been	   termed	   the	   passive	  
transfer	  model.	  They	  showed	  more	  severe	  disease	  following	  the	  transfer	  of	  anti-­‐MPO	  
splenocytes	   into	   RAG2	   knockout	  mice,	  with	   crescents	   and	   necrosis	   in	   approximately	  
80%	  glomeruli	  at	  day	  13.	  However,	  there	  were	  significant	  glomerular	  immune	  deposits	  
reported	  in	  these	  mice,	  making	  it	  a	  poor	  model	  of	  pauci-­‐immune	  disease.	  
The	  disease	  severity	  in	  the	  passive	  transfer	  model	  was	  shown	  to	  be	  exacerbated	  by	  the	  
use	  of	  systemic	  bacterial	  LPS	  in	  a	  dose	  dependent	  manner	  [32].	  The	  crescent	  count	  was	  
significantly	  increased	  with	  the	  use	  of	  0.5	  micrograms/g	  body	  weight	  LPS	  (5%	  crescents	  
with	   no	   LPS	   and	   approximately	   20%	   crescents	   with	   LPS	   use).	   LPS	   injection	   was	  
accompanied	  by	   increased	   circulating	  TNFα	  and	  MPO	   levels.	   Furthermore,	   anti-­‐TNFα	  
therapy	  attenuated	  LPS	  aggravated	  disease.	  
Further	   work	   as	   already	   discussed	   revealed	   that	   neutrophils	   are	   crucial	   in	   the	  
pathogenesis	   of	   disease	   induction	   in	   the	   passive	   transfer	   model,	   as	   depletion	   of	  
neutrophils	  completely	  protected	  mice	  from	  development	  of	  disease	  [118].	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The	  genetic	  background	  of	   the	  mouse	  has	   a	  profound	  effect	  on	   the	  development	  of	  
disease	   in	   the	   passive	   transfer	   model.	   129S6/SvEv	   and	   CAST/EiJ	   mice	   have	   a	  
significantly	   higher	   crescent	   count	   compared	   to	   C57BL/6	   mice,	   whilst	   DBA	   and	  
PWK/PhJ	  mice	  amongst	  others	  were	  protected	  [218].	  
We	   recently	   showed	   that	   the	   administration	   of	  GCSF	   in	   addition	   to	   LPS	   exacerbates	  
disease.	   In	   our	   experience	  mice	   administered	   GCSF	   with	   LPS	   had	   significantly	   more	  
crescents	   (29.1%	   versus	   5.8%),	   more	   glomerular	   macrophage	   infiltration	   and	   higher	  
serum	  creatinine	  compared	  to	  those	  that	  received	  LPS	  alone	  [119].	  	  
Using	  a	  similar	  approach	  in	  immunising	  MPO	  deficient	  mice	  with	  MPO,	  Schreiber	  et	  al	  
developed	   the	   bone	   marrow	   transfer	   model.	   The	   immunised	   knockout	   mice	   were	  
lethally	  irradiated	  and	  reconstituted	  with	  wild	  type	  bone	  marrow.	  Antibody	  producing	  
plasma	   cells	   survive	   the	   radiation	   dose	   and	   hence	   continue	   to	   produce	  MPO-­‐ANCA.	  
The	  antibody	  is	  exposed	  to	  MPO	  sufficient	  neutrophils	  and	  monocytes.	  At	  eight	  weeks	  
these	  mice	  developed	  pauci-­‐immune	  necrotising	  crescentic	  glomerulonephritis	  (7.3	  to	  
80.4%	  crescents	  when	  exposed	  to	  750	  rad)	  [219].	  They	  demonstrated	  the	  necessity	  of	  
MPO	  positive	  bone	  marrow	  cells	  rather	  than	  resident	  tissue	  cells	   in	  the	  pathogenesis	  
of	  disease	  and	  reinforced	  that	  ANCA	  are	  pathogenic.	  
Ruth	  et	  al	  demonstrated	  the	  importance	  of	  both	  cellular	  and	  humoral	  immunity	  using	  
a	  different	  model	   [123].	  Wild	   type	  mice	  were	   immunised	  with	  human	  MPO	   inducing	  
MPO-­‐ANCA	  and	  CD4	  cell	  reactivity.	  However,	  MPO-­‐ANCA	  levels	  were	  low	  and	  hence	  an	  
additional	  stimulus	  in	  the	  form	  of	  sheep	  anti	  mouse	  glomerular	  binding	  antibody	  was	  
used	  to	  induce	  disease.	  The	  glomerular	  binding	  antibody	  attracts	  neutrophils	  into	  the	  
kidney	   leading	   to	   glomerular	  MPO	  deposition,	   planted	   autoantigen	   for	  MPO	   specific	  
CD4+	   cells.	   Depletion	   of	   CD4	   cells	   attenuated	   crescentic	   glomerulonephritis	   without	  
altering	  ANCA	  titres.	  Furthermore,	  µ	  chain	  deficient	  mice,	  which	  are	  unable	   to	  make	  
antibody,	   remain	   susceptible	   to	   disease.	   The	   same	   group	   later	   demonstrated	   the	  
importance	  of	  Th17	  cells	  as	  discussed	  in	  section	  1.7	  [128].	  
Little	  et	   al	   immunised	  Wistar	   Kyoto	   (WKY)	   rats,	   a	   strain	   known	   to	   be	   susceptible	   to	  
glomerulonephritis,	  with	  human	  MPO	  in	  complete	  Freund’s	  adjuvant	  (CFA).	  These	  rats	  
developed	   anti-­‐human	  MPO,	   which	   cross-­‐reacts	   with	   rat	  MPO	   at	   2	   weeks	   and	   60%	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develop	  a	  pauci	  immune	  crescentic	  glomerulonephritis	  at	  6	  to	  8	  weeks.	  Crescents	  were	  
reported	  in	  6-­‐15%	  of	  glomeruli	  [220].	  Subsequently	  the	  group	  showed	  that	  disease	  was	  
inducible	  in	  all	  rats	  if	  a	  higher	  dose	  of	  MPO	  was	  used	  for	  immunisation	  [221].	  WKY	  rats	  
develop	  disease	  but	  Wistar	  Furth	  and	  Brown	  Norway	  rat	  strains	  do	  not	  despite	  similar	  
antibody	   titres	   post	   immunisation.	   Once	   again	   this	   suggests	   a	   strong	   genetic	  
component	  to	  disease	  susceptibility.	  
1.11.2	  Models	  of	  PR3	  ANCA	  disease	  
Unlike	  MPO	   ANCA	   disease,	   attempts	   to	   develop	  models	   of	   PR3	   ANCA	   disease	   have	  
remained	  unsuccessful.	  This	  is	  thought	  to	  be	  due	  to	  the	  difference	  in	  structure	  as	  well	  
as	   expression	   pattern	   of	   PR3	   in	   humans	   and	   rodents.	   PR3	   is	   not	   detectable	   on	   the	  
surface	  of	  murine	  neutrophils	  and	  hence	   the	  antigen	  availability	   to	  autoantibodies	   is	  
restricted.	  	  
Pfister	  et	   al	   immunised	  PR3	   and	  neutrophil	   elastase	  deficient	  mice	  with	  murine	  PR3	  
and	  transferred	  the	  antibody	  to	  LPS	  primed	  wild	  type	  mice.	  The	  mice	  did	  not	  develop	  
renal	   or	   pulmonary	   pathology.	   However,	   a	   stronger	   subcutaneous	   panniculitis	   was	  
noted	   following	   intradermal	   TNFα	   injection	   in	   the	   PR3	   ANCA	   passive	   transfer	   group	  
compared	  to	  controls	  [222].	  This	  suggests	  that	  anti-­‐PR3	  antibody	  has	  an	  effect	  at	  sites	  
of	   inflammation	   but	   does	   not	   cause	   histological	   or	   functional	   disease	   in	   murine	  
kidneys.	  Subsequently	  Van	  der	  Geld	  et	  al	  generated	  autoantibodies	  in	  mice	  and	  rats	  to	  
PR3	  by	   immunisation	  with	  human	  PR3,	  murine	  PR3	  or	   chimeric	  molecules,	  but	  again	  
showed	  no	  evidence	  of	  disease	  [223].	  	  
Immunisation	   of	   non-­‐obese	   diabetic	   (NOD)	   mice	   with	   murine	   PR3	   led	   to	   the	  
development	   of	   anti-­‐PR3	   antibody,	   but	   as	   with	   previous	   studies	   no	   evidence	   of	  
pathology.	   However,	   transfer	   of	   splenocytes	   from	   the	   immunised	   NOD	   mice	   into	  
immunodeficient	  NOD-­‐severe	  combined	   immunodeficiency	   (NOD-­‐SCID)	  mice	   resulted	  
in	   severe	   segmental	   necrotising	   crescentic	   glomerulonephritis	   (15-­‐31%	   crescent	  
counts)	   leading	   to	   acute	   kidney	   injury.	   In	   contrast	   NOD-­‐SCID	   mice	   that	   received	  
splenocytes	   from	   non-­‐immunised	   mice	   had	   no	   pathology.	   This	   suggests	   that	   PR3	  
immune	  responses	  are	  capable	  of	   inducing	  disease	   in	  vivo.	  No	  disease	  was	  observed	  
when	   splenocytes	   from	   PR3	   immunised	   C57BL/6	   mice	   were	   transferred	   into	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immunodeficient	  C57BL/6-­‐RAG1	  knockout	  mice,	  suggesting	  genetic	  factors	  play	  a	  role	  
in	   pathogenesis	   [224].	   It	   was	   unreported	   whether	   the	   disease	   observed	   was	   pauci-­‐
immune.	  
A	  more	  recent	  study	  used	  NOD-­‐SCID-­‐IL2Rγ	  knockout	  mice	  (lack	  native	  T,	  B	  and	  NK	  cells	  
as	   well	   as	   the	   IL2	   receptor),	   which	   enabled	   engraftment	   of	   primary	   human	  
haematopoietic	  cells.	  This	  allowed	  the	  development	  a	  human	  mouse	  chimeric	  immune	  
system	   potentially	   allowing	   the	   development	   of	   a	   model	   using	   ANCA	   derived	   from	  
patients.	   These	   mice	   developed	   very	   mild	   glomerulonephritis	   and	   patchy	   areas	   of	  
pulmonary	  haemorrhage	  following	  passive	  transfer	  of	  anti-­‐PR3	  antibody	  isolated	  from	  
patients	  [225].	  	  
1.11.3	  Models	  of	  LAMP2	  ANCA	  disease	  
As	  previously	  discussed	  the	  significance	  of	  anti-­‐LAMP2	  antibody	  remains	  contentious.	  
Kain	   et	   al	   showed	   that	   immunisation	   of	   WKY	   rats	   with	   rabbit	   anti-­‐human	   LAMP2	  
antibody	   (cross-­‐reacts	  with	   rat	   LAMP2)	  was	   sufficient	   to	   precipitate	   a	   pauci-­‐immune	  
crescentic	  glomerulonephritis	  [31].	  In	  contrast	  Roth	  et	  al	  found	  no	  evidence	  of	  disease	  
on	  injecting	  WKY	  rats	  with	  anti-­‐LAMP2	  IgG	  [86].	  
1.11.4	  Other	  models	  of	  glomerulonephritis	  
There	   are	   various	   forms	   of	   animal	   models	   of	   glomerulonephritis.	   Here	   I	   will	   briefly	  
discuss	  the	  more	  recognized	  and	  utilised	  models	  in	  the	  literature.	  
Nephrotoxic	  serum	  nephritis	   (NTN)	  is	  an	  established	  experimental	  model	  of	  antibody	  
mediated	   glomerular	   injury.	   NTN	  was	   first	   developed	   in	   rabbits	   whereby	   guinea	   pig	  
anti-­‐rabbit	  kidney	  antibody	  was	  injected	  and	  subsequently	  other	  species	  including	  rats	  
as	  well	  as	  mice	  have	  been	  used.	  It	  is	  induced	  by	  the	  binding	  of	  a	  foreign	  antibody	  to	  a	  
crude	  glomerular	  preparation.	  The	  antibody	  is	  often	  raised	  in	  rabbit	  or	  sheep.	  NTN	  is	  
composed	   of	   two	   distinct	   phases;	   the	   heterologous	   and	   autologous	   phases.	   The	  
primary	   acute	   phase	   peaks	   approximately	   two	   hours	   after	   the	   nephrotoxic	   antibody	  
administration,	  resulting	  in	  linear	  anti-­‐GBM	  antibody	  deposition,	  neutrophil	  influx	  and	  
proteinuria	   [226,	   227].	   This	   phase	   is	   exacerbated	  with	   the	   administration	   of	   LPS	   (or	  
other	   TLR2	   and	   TLR4	   ligands),	   TNF	   or	   IL1β	   as	   judged	   by	   albuminuria	   and	   increasing	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glomerular	  infiltrating	  neutrophils	  by	  almost	  six	  fold	  [228,	  229].	  This	  may	  explain	  why	  
intercurrent	   infection	   often	   exacerbates	   disease	   or	   induces	   relapses	   clinically.	   TLR2	  
and	   TLR4	   on	   circulating	   leucocytes	   as	  well	   as	   renal	   cells	   contribute	   to	   pathogenesis,	  
with	   TLR4	   deficiency	   on	   either	   cell	   groups	   leading	   to	   reduced	   neutrophil	   influx,	  
however	   albuminuria	   was	   reduced	   to	   a	   greater	   extent	   when	   the	   TLR2	   or	   TLR4	  
deficiency	  was	  on	  the	  circulating	  leucocytes	  [229,	  230].	  
The	  autologous	  phase,	  which	  occurs	  as	  a	  result	  of	  the	  host	  adaptive	  immune	  response	  
against	   foreign	   glomerular	   binding	   antibody,	   is	   encountered	   approximately	   five	   to	  
seven	   days	   after	   disease	   induction	   [226,	   231].	   It	   is	   suggested	   that	   an	   autoantibody	  
response	   to	   previously	   sequestered	   antigens	   contribute	   to	   pathogenesis.	   The	   host	  
mounts	   a	   humoral	   and	   cell	   mediated	   response	   resulting	   in	   immune	   complex	  
deposition	  and	  frank	  glomerulonephritis.	  The	  antibody	  mediated	  injury	  is	  reliant	  on	  Fc	  
receptors.	   Fcγ	   receptor	   deficient	   mice	   are	   protected	   from	   disease	   [232,	   233].	   Bone	  
marrow	   chimera	   models	   reveal	   that	   circulating	   leucocyte	   Fc	   receptors	   have	   the	  
predominant	  effect	  in	  pathogenesis	  [234].	  
Interestingly	   µ	   chain	   deficient	   mice,	   which	   have	   no	   circulating	   mature	   B	   cells	   and	  
hence	  no	  antibody	  production,	   are	  not	  protected	   from	  disease	   supporting	   a	   role	   for	  
cell	   mediated	   mechanisms	   [235].	   CD4	   T	   cells	   have	   a	   crucial	   role	   in	   pathogenesis	  
through	  activation	  of	  macrophages	  [236].	  	  
Serum	   sickness	   models	   are	   antibody-­‐mediated	   glomerulonephritis	   as	   a	   result	   of	  
immune	   complex	   production	   and	   deposition	   within	   glomeruli	   following	   repeated	  
injections	  of	  foreign	  protein.	  Rabbits	  were	  initially	  injected	  with	  bovine	  serum	  albumin	  
and	   subsequently	   BALB/c	   mice	   and	   Swiss	   mice	   were	   injected	   with	   horse	   spleen	  
apoferritin	  [237].	  Necrotising	  arteritis	  of	  medium	  sized	  vessels	  is	  a	  prominent	  feature.	  
Studies	  using	  this	  model	   implicated	  neutrophils	  and	  complement	   in	  the	  pathogenesis	  
of	  vasculitis.	  
Heymann	   nephritis	   is	   a	   model	   of	   membranous	   nephropathy	   in	   rats.	   Rats	   were	  
immunised	   with	   antigens	   from	   the	   proximal	   tubule	   brush	   border.	   A	   glycoprotein	  
named	   megalin	   gp330	   located	   in	   clathrin-­‐coated	   pits	   of	   glomerular	   and	   proximal	  
tubular	  epithelia	  was	  identified	  as	  the	  target	  antigen	  [238,	  239].	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Spontaneous	  and	  induced	  murine	  models	  of	  lupus	  nephritis	  exist	  (as	  reviewed	  in	  [240].	  
The	  most	  commonly	  used	  mouse	  strains	  that	  develop	  spontaneous	  disease	  include	  the	  
F1	  cross	  between	  New	  Zealand	  Black	  and	  New	  Zealand	  White	  (NZB/W)	  mice,	  MRL/lpr	  
mice	   and	   BXSB/Yaa	   mice.	   The	   NZB/W	   mice	   have	   a	   primary	   defect	   in	   the	   loss	   of	  
tolerance	  to	  nuclear	  antigens	  resulting	  in	  autoreactive	  T	  and	  B	  cells.	  The	  MRL/lpr	  mice	  
have	  a	  Fas	  gene	  mutation	  resulting	  in	  a	  defect	  in	  Fas	  induced	  T	  and	  B	  cell	  apoptosis.	  In	  
the	  BXSB/Yaa	  model	  the	  telomeric	  end	  of	  the	  X	  chromosome	  is	  translocated	  onto	  the	  Y	  
chromosome	   resulting	   in	   duplication	   of	   at	   least	   16	   genes	   including	   TLR7.	   Other	  
susceptibility	   loci	   including	  BXS1-­‐5	   thought	   to	  be	   crucial	   to	   the	  phenotype	  have	  also	  
been	   identified	   [240].	   	   Induced	   models	   of	   lupus	   nephritis	   include	   intraperitoneal	  
injection	   of	   pristane	   in	   most	   mice	   strains,	   injection	   of	   autoimmune	   sera	   or	  
lymphocytes	   from	   spontaneous	   lupus	   prone	  mice,	   immunisation	   of	   archetypal	   lupus	  
antigens	   such	  as	  DNA-­‐protein	  complexes	  or	  genetically	  engineered	  mouse	  models	  of	  
lupus	  bearing	  transgenes	  or	  knockouts.	  	  
1.12	  Conclusions	  
As	  summarised	  AAV	  is	  a	  severe	  systemic	  disease	  with	  complex	  multi-­‐faceted	  aspects	  to	  
the	  underlying	  pathogenesis.	  Substantial	  progress	  in	  the	  last	  two	  decades	  have	  begun	  
to	  unravel	  the	  key	  pathogenic	  features	  driving	  AAV,	  however,	  there	  are	  still	  unknowns	  
that	   need	   to	   be	   explored	   to	   bridge	   the	   gap	   towards	  more	  patient	   targeted	   therapy.	  
The	   factors	   that	   initiate	   the	   alternative	   pathway	   remain	   unknown.	   The	   roles	   of	  
monocytes	  in	  pathogenesis	  have	  not	  been	  fully	  elucidated.	  
1.13	  Aims	  
The	  aims	  of	  the	  present	  study	  have	  been	  summarised	  below.	  
• To	   set	   up	   a	   robust	   in	   vitro	   read	   out	   of	   polyclonal	   ANCA	   induced	   neutrophil	  
activation	  with	  reduced	  variability.	  
• To	   establish	   the	   expression	   of	   complement	   components	   C3	   and	   C5	   by	  
neutrophils	  and	  test	  the	  effect	  of	  ANCA	  on	  the	  expression	  pattern.	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• To	   assess	   the	   impact	   of	   ANCA	   on	   human	   peripheral	   blood	   monocytes	   with	  
regards	   to	   cytokine	   production	   and	   potentially	   the	   impact	   of	   ANCA	   on	  
macrophage	  development	  in	  vitro.	  
• To	  further	  elucidate	  the	  role	  of	  complement	  in	  AAV	  using	  the	  passive	  transfer	  
in	   vivo	   model	   of	   disease	   and	   in	   doing	   so	   explore	   potential	   activators	   of	   the	  
alternative	  pathway.	  	  
• To	  differentiate	  the	  role	  of	  local	  and	  systemic	  complement	  in	  the	  disease	  model	  
of	  AAV.	  
The	   following	   chapters	   detail	   the	   methods	   used	   and	   the	   results	   obtained	   as	   a	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Chapter	  2	  -­‐	  Materials	  and	  Methods	  
2.1	  Reagents	  	  
All	  reagents	  were	  purchased	  from	  Sigma	  Aldrich,	  UK	  unless	  indicated	  otherwise.	  	  
PBS++	  	  
2.24mls	  of	  7.5%	  Sodium	  Bicarbonate	  solution	  and	  1.11mls	  45%	  glucose	  in	  500mls	  PBS	  
(with	  Ca2+	  and	  Mg2+).	  	  
HBSS++	  	  
1.25g	   low	  endotoxin	  BSA	   in	   500mls	  HBSS	   (without	  Ca2+	   and	  Mg2+),	   19.75mls	   tissue	  
culture	  grade	  sterile	  water	   (Thermo	  Fisher	  Scientific,	  UK)	  and	  7.5mls	  1M	  Hepes	  (final	  
concentration	  15mM).	  	  
500mM	  Bicarbonate	  buffer	  	  
160mM	  Na2CO3	  and	  330mM	  NaHCO3,	  pH	  9.5.	  	  
20mM	  Sodium	  acetate	  buffer	  
2.72g	  sodium	  acetate	  trihydrate	  in	  1L	  tissue	  culture	  grade	  water,	  pH	  4.5.	  
MPO	  Purification	  buffer	  A	  	  
6.7mM	  sodium	  phosphate	  pH	  6.0,	  1mM	  MgCl2,	  3mM	  NaCl	  and	  0.5mM	  PMSF.	  
MPO	  Purification	  buffer	  B	  	  
100mM	  sodium	  acetate	  pH	  6.3	  and	  100mM	  NaCl.	  
MPO	  Purification	  elution	  buffer	  	  
100mM	   sodium	   acetate	   pH	   6.3,	   100mM	   NaCl,	   750mM	   methyl-­‐D-­‐mannopyranoside,	  
1mM	  CaCl2,	  1mM	  MgCl2	  and	  1mM	  MnCl2.	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0.1M	  Glycine	  	  
3.75g	  glycine	  in	  500mls	  tissue	  culture	  grade	  water.	  pH	  2.7	  using	  1M	  HCl.	  	  
1M	  Tris	  	  
24.23g	  Tris	  in	  200mls	  tissue	  culture	  grade	  water.	  pH	  9	  using	  1M	  HCl.	  	  
Formal	  Saline	  	  
1	  in	  4	  dilution	  of	  39%	  formaldehyde	  in	  PBS.	  
Bouin’s	  Solution	  	  
Solution	  A	  -­‐	  Saturated	  1.2%	  w/v	  picric	  acid.	  
Solution	  B	  -­‐	  Formaldehyde	  40%	  w/v.	  
Bouin’s	  stock	  solution	  is	  3	  volumes	  of	  A	  and	  1	  volume	  of	  B.	  1ml/20mls	  of	  acetic	  acid	  is	  
added	  immediately	  prior	  to	  use.	  	  
Phosphate-­‐Lysine-­‐Periodate	  (PLP)	  fixative	  	  
A	   lysine	   stock	   solution	   was	   prepared	   by	   adding	   3.65g/100mls	   (0.2M)	   lysine	  
monohydrochloride	   to	   an	   equal	   volume	   of	   disodium	   hydrogen	   orthophosphate	  
(3.58g/100mls).	  The	  solution	  was	  adjusted	  to	  pH	  7.4	  and	  stored	  at	  40C.	  Prior	  to	  use,	  4g	  
of	  paraformaldehyde	  was	  dissolved	  in	  100mls	  distilled	  water	  while	  stirred	  at	  600C	  in	  a	  
fume	  hood.	  This	  milky	  solution	  was	  cleared	  using	  1M	  NaOH.	  Immediately	  prior	  to	  use,	  
1	   volume	   of	   paraformaldehyde	   was	   added	   to	   3	   volumes	   of	   lysine	   solution	   and	  
0.214g/100mls	  sodium	  metaperiodate	  was	  added	  (final	  concentration	  of	  10mM).	  	  
1%	  Periodic	  Acid	  	  
5g	  of	  Periodic	  Acid	  in	  500mls	  of	  tissue	  culture	  grade	  water.	  
Sucrose	  Solution	  	  
38mM	  sucrose	  dissolved	  in	  PBS	  (13g/100mls).	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Anaesthetics	  	  
1.36mls	   vetalar	   -­‐	   ketamine	   hydrochloride,	   100mg/ml	   (Pharmacia,	   Animal	  Health	   Ltd,	  
UK)	   was	   added	   to	   2mls	   of	   domitor	   -­‐	   medetomidine,	   1mg/ml	   (Pfizer	   Ltd,	   UK)	   and	  
15.7mls	  of	  PBS.	  Mice	  were	  anaesthetized	  by	  IP	  injection	  of	  200μls	  of	  this	  solution.	  	  
Red	  blood	  cell	  lysis	  buffer	  	  
4.17g	  NH4Cl,	  0.00185g	  EDTA	  and	  0.5g	  NaHCO3	   in	  500mls	  tissue	  culture	  grade	  water.	  
Filter	  sterilized	  and	  stored	  in	  aliquots	  at	  -­‐200C.	  
1X	  Tail	  buffer	  	  
50mM	   Tris-­‐HCl	   pH	   8	   (5mls	   1M/100mls),	   100mM	   EDTA	   pH	   8	   (20mls	   0.5M/100mls),	  
100mM	  NaCl	  (2mls	  5M/100mls)	  and	  1%	  SDS	  (5mls	  20%/100mls).	  Immediately	  prior	  to	  
use	  proteinase	  K	  was	  added	  to	  a	  final	  concentration	  of	  0.5mg/ml.	  	  
1X	  TE	  Buffer	  	  
10mM	  Tris-­‐HCl	  pH8	  and	  1mM	  EDTA.	  
Saturated	  ammonium	  sulphate	  	  
A	   saturated	   ammonium	   sulphate	   solution	   was	   prepared	   by	   dissolving	   300g	   of	  
ammonium	  sulphate	  in	  500mls	  of	  tissue	  culture	  grade	  water.	  The	  solution	  was	  heated	  
to	  56-­‐600C	  with	  frequent	  shaking.	  It	  was	  then	  cooled	  overnight	  with	  crystal	  formation	  
indicating	  saturation.	  	  
Preparation	  of	  dialysis	  tubing	  	  
Dialysis	   tubing	   (Medicell,	   UK)	   was	   cut	   to	   an	   appropriate	   length	   and	   submerged	   in	  
200mls	  of	  tissue	  culture	  grade	  water	  with	  2%	  sodium	  bicarbonate	  and	  1mM	  EDTA.	   It	  
was	  incubated	  at	  800C	  for	  30	  minutes.	  It	  was	  then	  washed	  with	  200mls	  tissue	  culture	  
grade	  water.	  The	  tubing	  was	  kept	  wet	  until	  usage.	  Two	  knots	  were	  tied	  at	  the	  bottom	  
end	  of	  the	  tubing	  and	  a	  clip	  was	  attached	  between	  them	  to	  prevent	  leaks.	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Monoclonal	  antibodies	  
Target	   Isotype	   Clone	   Supplier	  
Human	  MPO	   IgG1	  κ	   266.6K2	   IQ	  Products,	  
Netherlands	  
Human	  PR3	   IgG1	  κ	   WGM2	   Hycult	  Biotech,	  
Netherlands	  
TNP	  (control)	   IgG1	  κ	   107.3	   BD	  Biosciences,	  UK	  
Table	  2.1	  –	  Mouse	  anti	  human	  monoclonal	  antibodies	  used	  in	  assays.	  
Flow	  cytometry	  and	  Western	  Blot	  antibodies	  




4H3	   APC	   1:1000	   Abcam,	  UK	  




2952	   PE	   1:200	   Abcam,	  UK	  
Human	  C5	   Rabbit	  IgG	   Polyclonal	   -­‐	   1:200	   Abcam,	  UK	  
Human	  
CD66b	  
Mouse	   IgM	  
k	  







ICRF44	   APC	   1:6	  
BD	  Biosciences,	  
UK	  




013-­‐16	   -­‐	   1:5000	   Abcam,	  UK	  
Rabbit	  IgG	   Goat	  IgG	   Polyclonal	  






Chicken	  IgG	   Goat	  IgG	   Polyclonal	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Goat	  IgG	   Donkey	  IgG	   Polyclonal	   HRP	   1:1000	   Santa	  Cruz,	  USA	  
Mouse	  IgG	   Sheep	  IgG	   Polyclonal	   HRP	   1:2000	  
GE	  Healthcare	  
Life	  Sciences,	  UK	  
Mouse	  
Ly6G	  




















2D10	   PE	   1:100	   Biolegend,	  UK	  
Table	  2.2	  –	  Antibodies	  used	  for	  flow	  cytometry	  and	  western	  blot	  analysis.	  
Immunohistochemistry	  antibodies	  
Target	   Isotype	   Clone	   Conjugate	   Dilution	   Supplier	  
Mouse	  
CD68	  
Rat	  IgG2a	   FA11	   -­‐	   1:200	   AbD	  Serotec,	  UK	  
Mouse	  
MBL	  
Rat	  IgG2a	   16A8	   -­‐	   1:50	  
Hycult	   Biotech,	  
Netherlands	  
Mouse	  C3	   Rat	  IgG2a	   RMC11H9	   -­‐	   1:200	   Cedar	  lane,	  Canada	  
Rat	   IgG	  
(H+L)	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ELISA	  kits	  	  
Target	  
Dilution	   of	   supernatant,	  
serum	  or	  urine	  used	  
Supplier	  
Mouse	  albumin	   1:200	   Bethyl	  laboratories,	  USA	  
Mouse	  C5a	   1:1000	   R&D	  DuoSet	  ELISA,	  UK	  
Human	  Lactoferrin	   1:500	   Hycult	  Biotech,	  UK	  
Human	  IL1β	   1:100	   R&D	  DuoSet	  ELISA,	  UK	  
Human	  MPO	   1:50	   R&D	  DuoSet	  ELISA,	  UK	  
Human	  MIP1α	   1:2000	   R&D	  DuoSet	  ELISA,	  UK	  
Human	  IL8	   1:1000	   R&D	  DuoSet	  ELISA,	  UK	  
Human	  CSF1	   1:2	   R&D	  DuoSet	  ELISA,	  UK	  
Human	  TGFβ	   1:1.4	   R&D	  DuoSet	  ELISA,	  UK	  
Table	  2.4–	  ELISA	  kits	  used.	  	  
2.2	  Mouse	  promyelocytic	  (MPRO)	  cell	  culture	  and	  MPO	  purification	  
The	  MPRO	  cell	   line	   (clone	  2.1	  ATCC,	   LGC	  Standards,	  UK)	   is	  a	  murine	  granulocyte	  cell	  
line	   derived	   from	  bone	  marrow	   cells	   of	  male	  BDF1	  mice	   infected	  with	   the	   retroviral	  
vector	   LRARalpha403SN.	   These	   cells	   differentiate	   in	   the	   presence	   of	   GMCSF	   into	  
neutrophil	  granulocytes	  with	  promyelocyte	  characteristics	  such	  as	  azurophilic	  granules	  
[241].	  
The	  medium	  used	  consisted	  of	  Iscove's	  Modified	  Dulbecco's	  Media	  (IMDM)	  (PAA	  /	  GE	  
Healthcare	   Life	   Sciences,	   UK)	   with	   20%	   foetal	   bovine	   serum	   (FBS),	   1%	  
Penicillin/Streptomycin	  (Thermo	  Fisher	  Scientific,	  UK)	  and	  10ng/ml	  GMCSF	  (Peprotech	  
Biotech,	  UK).	  
The	  cells	  were	  grown	  to	  a	  density	  of	  2	  x	  106cells/ml.	  Upon	  harvesting,	  the	  cell	  pellets	  
were	  resuspended	  in	  buffer	  A	  with	  100mM	  PMSF	  and	  stored	  at	  -­‐800C.	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MPRO	  cell	  pellets	  were	  defrosted	  and	  centrifuged	  at	  167xg	  for	  10	  minutes.	  The	  pellets	  
were	  pooled	   in	  buffer	  A	  containing	  100mM	  PMSF.	  The	  cells,	  while	  kept	  on	   ice,	  were	  
homogenized	  using	  a	  probe	  sonicator.	  The	  cell	  lysate	  was	  then	  centrifuged	  at	  20,000xg	  
for	   30	  minutes	   using	   a	   J2-­‐21MIE	  ultracentrifuge	   (Beckman	  Coulter,	  UK)	  with	   a	   JA-­‐14	  
rotor.	  The	  cell	  pellet	  was	  resuspended	  in	  buffer	  A	  containing	  100mM	  PMSF	  at	  a	  ratio	  of	  
10ml	  of	  buffer	  per	  1ml	  of	  cell	  pellet.	  Cetyltrimethylammonium	  bromide	  was	  added	  to	  a	  
final	  concentration	  of	  1%	  and	  the	  mixture	  was	  stirred	  vigorously	  for	  2	  hours	  at	  40C.	  The	  
solution	  was	  subsequently	  centrifuged	  at	  20,000xg	  for	  20	  minutes	  at	  40C	  and	  the	  pellet	  
was	  discarded.	  The	  sample	  has	  a	  distinct	  green	  colour	  by	  this	  stage	  (see	  figure	  2.1).	  	  
Figure	  2.1	  –	  MPRO	  cell	  pellet	  processing,	  revealing	  the	  green	  hue	  of	  the	  samples.	  
The	  sample	  was	  concentrated	  and	  buffer	  exchanged	  into	  buffer	  B	  using	  a	  Vivaflow	  50	  
filtration	   device	   (Sartorius	   Stedim,	   UK)	   with	   a	   30kDa	   molecular	   weight	   cut	   off,	   and	  
stored	   at	   40C	   overnight.	   CaCl2,	   MgCl2	   and	   MnCl2	   were	   then	   added	   to	   a	   final	  
concentration	  of	  1mM	  of	  each.	  	  
A	   1ml	   Concanavalin	   A	   Sepharose	   (GE	   Healthcare	   Life	   Sciences,	   UK)	   column	   was	  
equilibrated	  with	  50mls	  of	  0.2µm	  filter	  sterilized	  buffer	  B	  containing	  1mM	  of	  each	  of	  
the	  ions	  CaCl2,	  MgCl2	  and	  MnCl2	  at	  a	  flow	  rate	  of	  60mls/hr.	  The	  sample	  was	  diluted	  in	  
buffer	  B,	  containing	  the	  respective	  ions,	  filter	  sterilized,	  and	  run	  through	  the	  column	  at	  
12mls/hr.	  The	  column	  was	  washed	  with	  7mls	  of	  buffer	  B	  containing	  ions	  at	  12mls/hr.	  
The	  MPO	  was	  eluted	  using	  elution	  buffer	  (750mM	  mannopyranoside	  diluted	  in	  buffer	  
B	  with	  ions)	  at	  60mls/hr	  and	  1ml	  fractions	  were	  collected.	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The	   absorbance	   was	   measured	   at	   280nm	   and	   430nm	   using	   a	   spectrophotometer	  
(Beckman	  Coulter,	  DU-­‐530).	  MPO	  containing	  fractions	  have	  a	  distinct	  green	  colour.	  The	  
pooled	   aliquots	   containing	   MPO,	   as	   determined	   by	   absorbance	   measurements	   at	  
430nm,	  were	  dialysed	  against	  PBS	  at	  40C	   (dialysis	   tubing	  was	  prepared	  as	  previously	  
mentioned).	   After	   4	   hours	   the	   PBS	  was	   changed	   and	   the	   sample	  was	   left	   to	   dialyse	  
overnight	  at	  40C.	  	  
The	  purity	  of	  the	  MPO	  preparation	   in	  relation	  to	  total	  protein	  was	  determined	  by	   its	  
Reinheit	  Zahl	  (RZ)	  value,	  the	  ratio	  of	  430nm	  to	  280nm	  absorbance	  (RZ	  =	  A430/A280).	  
An	  RZ>0.84	  is	  considered	  to	  be	  of	  high	  purity	  [242].	  	  
A	   1ml	   HiTrap	   SP	   FF	   ion	   exchange	   column	   (GE	   Healthcare	   Life	   Sciences,	   UK)	   was	  
equilibrated	  with	   10mls	   of	   PBS	   at	   a	   flow	   rate	   of	   60mls/hr.	   It	  was	   then	  washed	  with	  
10mls	  of	  1M	  NaCl	  dissolved	  in	  PBS	  at	  60mls/hr	  before	  being	  subjected	  to	  a	  final	  wash	  
of	   10mls	   PBS	   at	   60mls/hr.	   The	   sample	  was	   passed	   through	   the	   column	   at	   30mls/hr.	  
The	  MPO,	  which	  is	  bound	  to	  the	  column,	  was	  eluted	  using	  stepwise	  increases	  of	  NaCl	  
in	  PBS.	  A	  starting	  concentration	  of	  0.075M	  NaCl	  was	  used	  to	  elute	  the	  majority	  of	  the	  
MPO.	   The	   remainder	   of	   the	   MPO	   was	   eluted	   using	   0.1M	   NaCl.	   1ml	   fractions	   were	  
collected	   and	   analysed	   at	   280nm	   and	   430nm	   using	   a	   spectrophotometer.	   The	  MPO	  
containing	  fractions	  were	  pooled	  and	  buffer	  exchanged	  into	  PBS	  using	  PD10	  columns	  
(GE	  Healthcare	   Life	   Sciences,	  UK).	   Each	  PD10	  column	  was	   first	   calibrated	  with	  50mls	  
PBS.	  After	  calibration,	  2.5mls	  of	  sample	  was	  added	  to	  each	  column	  followed	  by	  3mls	  of	  
PBS	  and	  the	  follow	  through	  which	  contained	  the	  MPO	  was	  collected.	  The	  absorbance	  
was	   then	   measured	   at	   280	   and	   430nm	   and	   the	   concentration	   calculated	   using	   the	  
following	  information.	  
Absorbance	  at	  430nm	  of	  0.19	  =	  125µg/ml	  MPO	  
The	   sample	   was	   adjusted	   to	   a	   final	   concentration	   of	   1mg/ml	   using	   Vivaspin	   20	  
ultrafiltration	  device	  with	  30kDa	  molecular	  weight	  cut	  off	  (Sartorius	  Stedim,	  UK).	  	  After	  
determination	  of	  the	  RZ	  value	  the	  MPO	  was	  stored	  in	  aliquots	  at	  -­‐200C.	  	  
At	  this	  stage	  a	  40	  litres	  culture	  of	  MPRO	  cells	  will	  yield	  approximately	  5mg	  of	  MPO	  (RZ	  
approximately	  0.6).	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2.3	  Animal	  experiments	  
The	   MPO	   deficient	   mice	   on	   a	   C57BL/6	   background	   were	   purchased	   from	   Jackson	  
Laboratories	   (Bar	   Arbour,	   Maine,	   USA)	   [243].	   The	   C57BL/6	   wild	   type	   mice	   were	  
purchased	  from	  Harlan	  (Bicester,	  Oxon,	  UK).	  The	  C3	  deficient	  mice	  were	  obtained	  from	  
Professor	  Michael	  C	  Carroll	  [244],	  MASP2	  deficient	  mice	  were	  obtained	  from	  Professor	  
Wilhelm	  Schwaeble	  [245]	  and	  factor	  B	  deficient	  mice	  were	  obtained	  from	  Dr	  Harvey	  R	  
Colten	   [246].	   Naturally	   occurring	   DBA/J2	   C5-­‐deficient	   mice	   backcrossed	   on	   to	   the	  
C57BL/6	  genetic	  background	  were	  a	  generous	  gift	   from	  Professor	  Matthew	  Pickering	  
[247].	   These	  mice	   had	   all	   been	   backcrossed	   at	   least	   10	   generations	   to	   the	   C57BL/6	  
background	  and	  were	  then	  bred	  in	  house.	  
All	  animal	  experiments	  were	  performed	  in	  accordance	  with	  Home	  Office	  regulations.	  
2.3.1	  Genotyping	  mice	  
Breeding	   mice	   from	   each	   strain	   were	   genotyped	   prior	   to	   in	   vivo	   experiments	   by	  
polymerase	   chain	   reaction	   (PCR)	   from	   DNA	   acquired	   in	   ear	   clippings.	   The	   clippings	  
were	  incubated	  overnight	  at	  550C	  in	  375µls	  of	  tail	  buffer	  with	  20mg/ml	  proteinase	  K.	  
The	  degraded	  ear	   tissue	  was	   vortexed	   thoroughly	   and	  125µls	   of	   saturated	  NaCl	  was	  
added.	   The	   solution	   was	   again	   mixed	   thoroughly	   and	   centrifuged	   at	   9000rcf	   for	   10	  
minutes.	  375µls	  of	  this	  solution	  (taken	  from	  the	  top	  without	  disturbing	  the	  pellet)	  was	  
placed	  into	  an	  empty	  eppendorf	  tube	  and	  250µls	  of	  isopropanol	  was	  added.	  The	  DNA	  
was	   precipitated	   out	   of	   solution	   by	   inverting	   the	   tube.	   It	   was	   then	   centrifuged	   at	  
9000xg	   for	   4	   minutes	   using	   a	   table-­‐top	   microcentrifuge	   and	   the	   supernatant	   was	  
discarded.	  The	  pellet	  was	  washed	  by	  adding	  750µls	  of	  70%	  ethanol.	  The	  ethanol	  was	  
discarded	  and	  the	  pellet	  allowed	  to	  air	  dry.	  Finally	  it	  was	  resuspended	  in	  150µls	  of	  TE	  
buffer	  and	  stored	  at	  -­‐200C.	  
The	  sequences	  of	   the	  primers	  used	  are	  as	  depicted	  below	   (forward	  primer	   first	   then	  
reverse	  primer	  listed):	  
MPO	   wild	   type:	   5’-­‐	   CTGGACGCCAGGAGTCAATCG	   -­‐	   3’,	   5’	   -­‐	  
GTGAAGAAGGAGAAGCGGGTAG	  -­‐	  3’	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MPO	   deficient:	   5’	   -­‐	   TCCTCGTGCTTTACGGTATCG	   -­‐	   3’,	   5’	   -­‐	  
GTGAAGAAGGAGAAGCGGGTAG	  -­‐	  3’	  
Reaction	  conditions:	  940C	  for	  15	  minutes,	  35	  cycles	  at	  550C	  for	  30	  seconds,	  720C	  for	  1	  
minute,	  and	  then	  720C	  for	  10	  minutes.	  
MASP2	   wild	   type:	   5’	   -­‐	   CATCTATCCAAGTTCCTCAGA	   -­‐	   3’,	   5’	   -­‐	  
AGCTGTAGTTGTCATTTGCTTGA	  -­‐	  3’	  
MASP2	   deficient:	   5’	   -­‐	   CTGATCAGCCTCGACTGTGC	   -­‐	   3’,	   5’	   -­‐	  
AGCTGTAGTTGTCATTTGCTTGA	  -­‐	  3’	  
Reaction	  conditions:	  940C	  for	  15	  minutes,	  35	  cycles	  at	  600C	  for	  30	  seconds,	  720C	  for	  1	  
minute,	  and	  then	  720C	  for	  10	  minutes.	  
Factor	  B	  wild	  type:	  	   5’	   -­‐	   CTTCTCAATCAAGTTGGTGAGGCACCGCTT	   -­‐	   3’,	   5’	   -­‐	  
GCAATACGCTGCCCACGACCGCAG	  -­‐	  3’	  
Factor	  B	  deficient:	  	   5’	   -­‐	   TGCGTGCAATCCATCTTGTTCAATG	   -­‐	   3’,	   5’	   -­‐	  
GCAATACGCTGCCCACGACCGCAG	  -­‐	  3’	  
Reaction	  conditions:	  940C	  for	  15	  minutes,	  35	  cycles	  at	  640C	  for	  30	  seconds,	  720C	  for	  1	  
minute,	  and	  then	  720C	  for	  10	  minutes.	  
Primers	  were	  diluted	  in	  sterile	  water	  to	  a	  concentration	  of	  2µM.	  For	  each	  PCR	  reaction	  
1µl	   of	   template	   DNA	   was	   added	   to	   11.5µls	   of	   primers	   and	   12.5µls	   of	   HotStarTaq	  
mastermix	  (Qiagen,	  UK)	  to	  give	  a	  final	  volume	  of	  25µls	  and	  a	  final	  primer	  concentration	  
of	   1µM.	   PCR	   reactions	  were	   run	   on	   a	   PE	   Applied	   Biosystems	  GeneAmp	   PCR	   System	  
9700	  under	  the	  respective	  conditions	  above.	  The	  samples	  were	  run	  on	  an	  agarose	  E-­‐
gel	  2%	  (Life	  technologies,	  UK)	  using	  a	  self-­‐contained	  power	  system	  for	  15	  minutes.	  	  
For	  C5	  deficient	  mice	  we	  confirmed	  that	  mice	  used	  were	  C5	  deficient	  by	  testing	  serum	  
using	   a	   mouse	   C5	   ELISA	   duoset	   (R&D	   Systems,	   UK).	   See	   general	   principles	   of	   ELISA	  
studies	  in	  section	  2.5.1.	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2.3.2	  Generating	  MPO-­‐ANCA	  	  
MPO	   for	   immunization	  was	   prepared	  by	  mixing	   50µls	   of	  MPO	   (1mg/ml)	  with	   450µls	  
PBS	  and	  500µls	  of	  complete	   freund’s	  adjuvant	   (CFA)	   for	   first	   immunisation	  or	  500µls	  
incomplete	  freund’s	  adjuvant	  (iCFA)	   for	  subsequent	  boosts.	  The	  mixture	  was	  kept	  on	  
ice	   and	   homogenized	   using	   a	   T-­‐10	   ultra-­‐turrax	   homogenizer.	   The	   extent	   of	  
homogenization	  was	  tested	  by	  aspirating	  a	  small	  drop	  of	  the	  solution	  onto	  water.	  If	  the	  
sample	   remained	   intact	   and	   did	   not	   disperse	   in	   the	  water	   it	  was	   deemed	   ready	   for	  
injection.	  
MPO	  deficient	  mice,	  approximately	  6-­‐8	  weeks	  old,	  were	  immunized	  with	  10µg	  (200µls	  
of	   MPO	   preparation)	   of	   murine	   MPO	   (purity	   stated	   in	   results	   sections)	   using	  
subcutaneous	  (SC)	  injection	  on	  day	  0	  in	  CFA.	  They	  received	  100µls	  of	  this	  solution	  on	  
either	  side	  of	  the	  flank.	  	  
To	  gain	  a	  higher	  yield	  of	  antibody	  per	  mouse	  and	  hence	  reduce	  the	  number	  of	  MPO	  
deficient	   mice	   used	   as	   a	   whole	   (the	   three	   Rs	   principle),	   we	   injected	   mice	   with	   a	  
sarcoma	  cell	  line	  to	  generate	  ascites.	  On	  day	  14	  wild	  type	  C57BL/6	  mice	  were	  injected	  
with	  1x106	  (in	  200µls	  PBS)	  Sarcoma	  180	  TIB-­‐66	  cells	  (ATCC,	  UK)	  by	  intraperitoneal	  (IP)	  
injection.	  These	  mice	  were	  assessed	  twice	  a	  day	  and	  sacrificed	  10	  to	  14	  days	  later	  for	  
ascitic	  fluid	  samples.	  The	  ascitic	  fluid	  samples	  were	  pooled	  and	  subsequently	  100µls	  of	  
the	  ascites	  was	  injected	  into	  each	  immunised	  MPO	  deficient	  mouse	  on	  days	  24	  to	  28	  
(depending	   on	   development	   of	   ascites	   in	   the	   wild	   type	   mice)	   of	   the	   immunization	  
protocol.	  The	  mice	  were	  examined	  twice	  a	  day	  
On	  days	  21	  and	  35	  of	  the	  immunization	  protocol	  the	  MPO	  deficient	  mice	  were	  boosted	  
with	  10µg	  MPO	  by	  IP	  injection	  in	  iCFA.	  On	  days	  38	  to	  42	  the	  mice	  were	  exsanguinated	  
and	   the	   serum	   was	   pooled.	   The	   ascitic	   fluid	   was	   collected	   by	   paracentesis	   after	  
sacrifice.	  MPO-­‐ANCA	  titres	  in	  serum	  were	  measured	  by	  ELISA.	  Refer	  to	  section	  2.4	  for	  
MPO-­‐ANCA	  IgG	  purification	  methodology.	  
2.3.3	  Generation	  of	  bone	  marrow	  chimera	  
Donor	  bone	  marrow	  cells	  were	  isolated	  from	  the	  tibia	  and	  femurs	  of	  mice.	  The	  muscle	  
and	   tissue	   was	   stripped	   away	   and	   the	   bones	   were	   flushed	   with	   PBS.	   Repeated	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pipetting	  dispersed	  the	  clumps	  of	  cells	  and	  the	  cell	  suspension	  was	  then	  centrifuged	  at	  
150xg	   for	   10	  minutes	   and	   the	   pellet	   resuspended	   in	   1ml	   PBS.	   The	   total	   number	   of	  
viable	  cells	  was	  counted	  using	  trypan	  blue	  viability	  stain	  and	  a	  haemocytometer.	  The	  
cells	  were	  then	  resuspended	  at	  a	  final	  concentration	  of	  25x106	  cells/ml.	  Recipient	  mice	  
were	   lethally	   irradiated	  with	  9	  Gy	   in	  a	   single	  dose	  using	  a	  caesium	  source	   irradiator.	  
They	   were	   then	   injected	   with	   200μls	   of	   the	   cell	   suspension	   (5x106	   cells)	   using	   the	  
intravenous	  (IV)	  route	  immediately	  after	  irradiation.	  	  
A	   parallel	   cohort	   of	   chimeras	   were	   made	   between	   wild	   type	   C57BL/6	   mice	   and	  
C57BL/6	   mice	   congenic	   for	   CD45.1	   (B6.SJL-­‐Ptprca	   Pepcb/BoyJ).	   Chimerism	   was	  
determined	   by	   flow	   cytometry	   for	   CD45.2	   on	  whole	   blood	   using	   anti	  mouse	   CD45.2	  
APC	   Clone	   104	   (eBioscience,	   UK)	   and	   chimerism	  was	   determined	   to	   be	   >90%	   in	   the	  
animals	  (n=7).	  
2.3.4	  Coagulation	  assays	  
100µls	  of	  trisodium	  citrate	  3.2%	  was	  drawn	  into	  a	  1	  ml	  syringe	  and	  900µls	  of	  blood	  was	  
taken	   by	   intra-­‐cardiac	   puncture	   under	   terminal	   anesthesia.	   Plasma	   was	   centrifuged	  
twice	  at	  800xg	  for	  10	  minutes,	  aliquoted	  and	  frozen	  at	  -­‐200C	  until	  analysed.	  	  
The	   coagulation	   assays	   were	   performed	   by	   Kiran	   Parmar	   and	   Agnieszka	   Kuffel	  
(Professor	  Beverley	  Hunt,	  Thrombosis	  &	  Vascular	  Biology,	  Guy’s	  and	  St	  Thomas’	  NHS	  
Foundation	  Trust,	  London,	  UK).	  Thrombin	  generation	  was	  monitored	  with	  a	  Fluoroskan	  
Ascent	   Thrombinoscope	   (Thermo	   Electron	   Corporation,	   UK)	   and	   Thrombinoscope	  
software	  version	  5.	  	  Samples	  were	  run	  at	  a	  dilution	  of	  1	  in	  3	  and	  at	  33o	  C	  [248].	  	  Clauss	  
Fibrinogen	   was	   measured	   using	   the	   ACL300R	   analyser,	   and	   using	   the	   HemosIL	  
Fibrinogen-­‐C	   reagent	   by	   Werfen	   UK.	   	   Prothrombin	   fragment	   1.2	   was	   measured	   by	  
ELISA	  using	  Enzygost	  F1+2	  Micro	  kit	  from	  Sysmex	  UK	  Ltd.	  	  
2.3.5	  Passive	  transfer	  model	  of	  ANCA	  associated	  vasculitis	  
On	  day	  -­‐8	  and	  -­‐4	  C57BL/6	  mice	  were	  given	  30µg	  of	  pegylated	  human	  GCSF	  (Neulasta®,	  
Amgen,	  UK)	  by	  SC	  injection.	  On	  day	  -­‐1,	  the	  mice	  were	  bled	  from	  the	  saphenous	  vein	  for	  
baseline	  serum	  creatinine	  measurement.	  Baseline	  urines	  were	  also	  collected.	  On	  day	  0,	  
each	  mouse	  was	   given	   2mg	   of	   the	   purified	  MPO-­‐ANCA	   (refer	   to	   section	   2.4	   for	   IgG	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purification	   methodology)	   via	   IV	   injection	   using	   the	   tail	   vein.	   They	   were	   also	   given	  
10µg	  of	  LPS	  (Escherichia	  Coli	  0111	  B4	  from	  Enzo	  Life	  sciences,	  UK)	  on	  day	  0	  and	  day	  3	  
by	  IP	  injection.	  Additionally	  they	  received	  doses	  of	  30µg	  GCSF	  on	  days	  0	  and	  4.	  Urine	  
was	   collected	   on	   day	   7.	   A	   terminal	   bleed	  was	   performed	   on	   day	   7.	   In	   the	   C5	   bone	  
marrow	  chimera	  experiment,	  2mg	  MPO-­‐ANCA	  was	  given	  via	   IP	   injection	  and	  30µg	  of	  
pegylated	  GCSF	  was	  given	  by	  SC	  injection	  on	  day	  -­‐4	  and	  day	  0.	  	  2.5µg	  LPS	  was	  given	  IP	  
on	  day	  0	  only.	  
Mouse	  kidneys	  were	  immediately	  dissected	  out	  and	  cut	  into	  half	  along	  the	  longitudinal	  
axis.	  Two	  halves	  were	  fixed	  in	  Bouin’s	  solution	  for	  4	  hours	  then	  transferred	  to	  formal	  
saline.	  These	  kidneys	  were	  processed	  overnight	  using	  Leica	  ASP	  300	  S	  processor	  and	  
embedded	  in	  hot	  wax.	  A	  single	  half	  was	  fixed	  in	  PLP	  at	  40C	  for	  4	  hours	  then	  transferred	  
into	  13%	  sucrose	  solution	  overnight.	  The	  samples	  were	  subsequently	  frozen	  in	  cooled	  
isopentane	   and	   fixed	   onto	   corkboards	   using	   OCT	   (Thermo	   Fisher	   Scientific,	   UK)	   and	  
stored	  at	  -­‐800C.	  The	  remaining	  half	  kidney	  was	  placed	  onto	  corkboards	  using	  OCT	  and	  
immediately	  snap	  frozen	  in	  pre-­‐cooled	  isopentane.	  The	  samples	  were	  stored	  at	  -­‐800C.	  
2.3.6	  Albuminuria	  measurement	  
Murine	   albuminuria	   was	   measured	   using	   a	   commercially	   available	   ELISA	   kit	   (Bethyl	  
laboratories,	  USA).	   	  The	   technique	   is	  explained	  separately	   to	   section	  2.5.1	   in	  view	  of	  
important	  differences	  in	  buffers.	  	  
ELISA	  plates	  were	  coated	  with	  100µls/well	  of	  a	  1	   in	  100	  dilution	  of	  capture	  antibody	  
diluted	  in	  500mM	  bicarbonate	  buffer.	  Plates	  were	  coated	  for	  1	  hour	  at	  370C	  and	  then	  
washed	   4	   times	   using	   a	  wash	   buffer	   (0.05%	   Tween	   20	   in	   PBS).	   Plates	  were	   blocked	  
using	   100µls/well	   1%	  bovine	   serum	  albumin	   (BSA)	   for	   30	  minutes.	   A	   standard	   curve	  
ranging	  from	  1000–7.8ng/ml	  was	  prepared	  from	  a	  murine	  albumin	  stock.	  Urines	  were	  
diluted	  1	  in	  200	  in	  1%	  BSA.	  After	  blocking	  for	  30	  minutes,	  100µls	  of	  each	  standard	  and	  
sample	  were	  added	  in	  duplicate	  to	  the	  plate	  for	  1	  hour	  at	  room	  temperature.	  The	  plate	  
was	  then	  washed	  4	  times	   in	  PBS/0.05%	  Tween	  20.	  The	  horseradish	  peroxidase	   (HRP)	  
conjugated	  detection	  antibody	  was	  diluted	  1	  in	  50,000	  in	  1%	  BSA	  and	  100µls/well	  was	  
added	  to	  the	  plate	   for	  1	  hour	   in	  the	  dark.	  The	  plate	  was	  washed	  as	  before.	  The	  HRP	  
substrate,	   O-­‐phenylenediamine	   dihydrochloride	   (OPD)	   was	   prepared	   by	   dissolving	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each	  of	  two	  tablets	  in	  20mls	  of	  deionized	  water.	  100µls	  of	  OPD	  solution	  was	  added	  to	  
each	  well	  and	  was	  allowed	  to	  develop	  in	  the	  dark	  for	  approximately	  20	  minutes.	  The	  
reaction	  was	  stopped	  by	  the	  addition	  of	  100µls	  1N	  H2SO4.	  The	  reaction	  was	  analysed	  at	  
490nm	   using	   a	   SpectraMax	   Plus384	  microplate	   reader	   (Molecular	   Devices,	   UK).	   The	  
total	  albumin	  content	  of	  the	  urine	  was	  calculated	  from	  albumin	  concentration	  and	  the	  
urine	  volume.	  
2.3.7	  Haematuria	  
Haematuria	  was	  measured	  by	  dipstick	   (Combur-­‐Test®	   from	  Roche,	  UK).	   Severity	  was	  
measured	  on	  a	  scale	  ranging	  from	  0	  (none)	  to	  4	  (severe).	  
2.3.8	  Serum	  and	  urine	  creatinine	  measurement	  
Serum	  and	  24	  hour	  urine	  creatinine	  concentrations	  were	  measured	  by	  Dr	  N	  Dalton	  and	  
Dr	   C	   Turner	   by	   electrospray	   mass	   spectrometry	   in	   the	   Department	   of	   Paediatric	  
Biochemistry	  at	  the	  Evelina	  Children’s	  Hospital,	  Guy’s	  and	  St	  Thomas’	  NHS	  Foundation	  
Trust,	  London.	  A	  volume	  of	  5µls	  of	  neat	  serum	  or	  urine	  was	  diluted	  into	  250µls	  of	  D3	  
creatinine	  isotope	  and	  250µls	  of	  acetonitrile	  containing	  0.05%	  formic	  acid.	  Creatinine	  
concentrations	  were	  measured	  using	  Applied	  Biosystems	  MDS	  Sciex	  API	  4000	  (Applied	  
Biosystems,	  UK)	  and	  Applied	  Biosystems	  Analysis	  Version	  1.4	  software.	  
When	   assessing	   spot	   urine	   albumin	   creatinine	   ratios,	   the	   urine	   creatinine	  
concentration	  was	  determined	  using	  a	  creatinine	  assay	  kit	  (Diazyme,	  Germany).	  Urine	  
samples	   were	   diluted	   1	   in	   20	   in	   PBS	   and	   the	   provided	   standard	   was	   prepared	   to	  
provide	   a	   range	   of	   concentrations	   from	   39.6	   to	   0	   μmol/L.	   32μls	   of	   each	   sample	   or	  
standard	   was	   added	   to	   a	   96	   well	   microplate	   in	   duplicates.	   246μls	   of	   reagent	   1	  
(sarcosine	  oxidase)	  was	  added	  to	  the	  sample	  and	  standard	  wells	  and	   incubated	  for	  5	  
minutes	   at	   370C.	   The	   plate	   was	   analysed	   at	   550nm	   using	   a	   SpectraMax	   Plus384	  
microplate	   reader	   (Molecular	   Devices,	   UK).	   90μls	   of	   reagent	   2	   (creatininase)	   was	  
added	   to	   all	   samples	   and	   incubated	   in	   the	   dark	   for	   5	  minutes	   at	   370C	   and	   analysed	  
again	  at	  550nm.	  The	  difference	  in	  optical	  density	  at	  the	  two	  time	  points	  was	  used	  to	  
extrapolate	  the	  creatinine	  concentration	  from	  the	  standard	  curve.	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2.3.9	  Peripheral	  blood	  neutrophil	  counts	  
A	   volume	   of	   100μls	   of	   heparin	   treated	   whole	   blood	  was	   added	   to	   each	   eppendorf.	  
25μls	  of	  a	  1	  in	  125	  pre-­‐diluted	  Fc	  block	  (Becton	  Dickinson,	  Oxford,	  UK)	  was	  added	  for	  
20	  minutes	  at	  room	  temperature.	  The	  appropriate	  Ly6G	  antibody	  (see	  table	  2.2)	  was	  
added	  and	  the	  blood	  was	  incubated	  at	  room	  temperature	  for	  20	  minutes	  in	  the	  dark.	  
Erythroyctes	   were	   lysed	   using	   2mls	   of	   a	   1	   in	   10	   dilution	   BD	   FACs	   Lysing	   solution	  
(Becton	  Dickinson,	  Oxford,	  UK)	  in	  deionized	  water.	  The	  blood	  was	  then	  centrifuged	  at	  
280xg	  for	  5	  minutes.	  The	  supernatant	  was	  discarded	  and	  the	  cells	  resuspended	  in	  2mls	  
of	  PBS	  and	  centrifuged	  at	  280xg	   for	  5	  minutes.	  Finally	   the	  cells	  were	  resuspended	   in	  
500μls	  of	  PBS	  with	  0.1%	  sodium	  azide.	  FACs	  analysis	  was	  carried	  out	  immediately	  after	  
staining	   using	   a	   FACS	   Canto	   flow	   cytometer	   (Becton	   Dickinson,	   Oxford,	   UK)	   and	  
FACsDIVA	  software	  (Becton	  Dickinson,	  Oxford,	  UK).	  Neutrophils	  were	  identified	  based	  
on	  their	  forward	  and	  side	  scatter	  profile.	  A	  minimum	  of	  10,000	  events	  were	  collected	  
for	  each	  sample	  and	  data	  was	  analysed	  using	  FlowJo	  software	  (Treestar,	  Ashland,	  OR,	  
USA).	   Total	   circulating	   neutrophil	   counts	   were	   determined	   from	   the	   percentage	   of	  
Ly6G	  positive	  cells	  and	  total	  leucocyte	  numbers.	  	  
2.3.10	  Periodic	  acid	  Schiff	  stain	  and	  Mayer’s	  Haematoxylin	  
Paraffin	  embedded	  sections	  of	  1µm	  thickness	  were	  cut	  using	  a	  microtome	  and	  placed	  
onto	   microscope	   slides.	   The	   sections	   were	   baked	   onto	   the	   slides	   at	   600C	   for	   a	  
minimum	   of	   30	   minutes	   before	   staining.	   The	   slides	   were	   placed	   in	   xylene	   for	   10	  
minutes	  in	  order	  to	  dissolve	  the	  wax.	  They	  were	  rehydrated	  by	  placing	  them	  in	  100%,	  
90%	  and	  70%	  alcohol	  for	  10	  seconds	  each.	  They	  were	  subsequently	  washed	  in	  running	  
distilled	  water	   for	   3	  minutes	   before	   being	   put	   into	   1%	  periodic	   acid	   for	   10	  minutes.	  
They	  were	  washed	   for	   3	  minutes	   in	   running	   distilled	  water.	   Using	   a	   pasteur	   pipette	  
each	  slide	  was	  covered	  in	  periodic	  acid	  schiff	  stain	  (Thermo	  Fisher	  Scientific,	  UK)	  for	  20	  
minutes	   in	   the	   fume	   hood	   and	   again	   washed	   for	   3	   minutes.	   The	   slides	   were	   then	  
treated	  with	  Mayer’s	  haematoxylin	  (VWR,	  UK)	  for	  5	  minutes	  and	  washed	  for	  a	  further	  
5	  minutes.	  They	  were	   then	  dehydrated	  by	  submerging	   the	  sections	   in	  70%,	  90%	  and	  
100%	  ethanol	  for	  10	  seconds	  each	  and	  were	  mounted	  in	  DPX	  (Thermo	  Fisher	  Scientific,	  
UK).	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These	   sections	  were	   used	   to	   score	   the	   number	   of	   glomerular	   crescents.	   Glomerular	  
crescents	   were	   defined	   as	   the	   occurrence	   of	   two	   or	   more	   layers	   of	   cells	   in	   the	  
Bowman’s	  space.	  The	  numbers	  of	  crescents	  identified	  were	  expressed	  as	  a	  percentage	  
of	  a	  total	  of	  100	  glomeruli	  per	  animal.	  	  
2.3.11	  Immunofluorescent	  staining	  for	  glomerular	  macrophages	  
Sections	  of	   frozen	  kidney	   (PLP	   fixed)	  were	  cut	   to	  5µm	  thickness	  using	  a	  cryostat	  and	  
placed	   onto	   multispot	   slides	   (C.A	   Hendley,	   UK).	   The	   slides	   were	   allowed	   to	   air-­‐dry	  
overnight	  at	  room	  temperature.	  A	  1	  in	  200	  dilution	  (in	  PBS)	  of	  a	  1mg/ml	  stock	  rat	  anti-­‐
mouse	   CD68	   antibody,	   clone	   FA11	   (AbD	   Serotec,	   UK)	   was	   prepared.	   100µls	   of	   this	  
staining	   solution	   was	   added	   to	   each	   kidney	   section	   and	   incubated	   in	   the	   dark	   in	   a	  
humidity	  tray	  for	  2	  hours.	  The	  slides	  were	  washed	  in	  PBS	  for	  5	  minutes.	  100µls	  of	  a	  1	  in	  
200	  dilution	  (in	  PBS)	  of	  a	  1.5mg/ml	  stock	  of	  a	  DyLight488	  mouse-­‐anti	  rat	  IgG	  (Jackson	  
Immunoresearch,	  USA)	  was	   added	   to	   each	   section	   and	   incubated	   for	   2	   hours	   in	   the	  
humidity	   tray.	   The	   slides	   were	   washed	   as	   before.	   The	   slides	   were	   mounted	   using	  
permafluor	   (Thermo	   Fisher	   Scientific,	   UK)	   and	   scored	   within	   48	   hours.	   Individual	  
macrophages	   infiltrating	   the	   glomeruli	   were	   counted	   and	   a	   mean	   number	   was	  
calculated	  from	  a	  minimum	  of	  20	  glomeruli	  per	  section.	  
2.4	  IgG	  purification	  
2.4.1	  MPO-­‐ANCA	  purification	  from	  mouse	  serum	  and	  ascites	  
IgG	   was	   purified	   from	   pooled	   mouse	   serum	   and	   ascites	   by	   ammonium	   sulphate	  
precipitation	  and	  subsequent	  protein	  G	  chromatography.	  	  
Large	   clumps	   of	   fat	   and	   fibrin	   from	   the	   thawed	   ascites	   samples	   were	   removed	  
manually.	  Cleanascite	  (Gentaur,	  USA)	  was	  added	  to	  the	  ascites	  sample	  at	  a	  ratio	  of	  1:4	  
(1	  part	  Cleanascite	  :	  4	  parts	  ascites)	  and	  incubated	  for	  2	  hours	  at	  40C	  on	  a	  shaker	  plate.	  
The	  sample	  was	  centrifuged	  at	  1,000xg	  for	  20	  minutes	  the	  supernatant	  was	  decanted.	  
The	  ascites	  sample	  was	  cooled	  to	  40C	  and	  acetic	  acid	  was	  used	  to	  lower	  the	  pH	  to	  4.9.	  
At	  this	  pH	  the	  sample	  was	   left	  on	   ice	  for	  1	  hour	  to	  precipitate	  the	  fibrin.	  The	  sample	  
was	  centrifuged	  at	  9,000xg	  for	  1	  hour	  at	  40C.	  The	  supernatant	  was	  collected	  and	  the	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pH	  was	  increased	  back	  to	  7	  with	  the	  use	  of	  1M	  sodium	  hydroxide.	  The	  serum	  sample	  
was	  pooled	  with	  the	  ascites	  samples	  at	  this	  stage.	  
An	  equal	  volume	  of	  saturated	  ammonium	  sulphate	  was	  added	  to	  the	  pooled	  sample,	  in	  
a	  drop-­‐wise	  manner	  while	  gently	  shaking	  the	  tube,	  to	  a	  final	  concentration	  of	  50%.	  The	  
sample	  was	   left	  at	  40C	  overnight	   for	   the	  antibody	   to	  precipitate	  out	  of	   solution.	  The	  
sample	  was	  centrifuged	  at	  1500xg	   for	  20	  minutes	  and	  the	  pellet	   resuspended	   in	  PBS	  
and	   aspirated	   until	   completely	   dissolved.	   The	   sample	   was	   dialysed	   against	   PBS	  
overnight,	  with	  the	  PBS	  being	  replaced	  after	  4	  hours.	  	  
The	   dialysed	   sample	   was	   diluted	   1	   in	   3	   in	   PBS	   in	   preparation	   for	   protein	   G	  
chromatography.	  A	  5ml	  HiTrap	  protein	  G	  column	  (GE	  Healthcare	  Life	  Sciences,	  UK)	  was	  
equilibrated	   with	   50mls	   of	   PBS	   at	   a	   flow	   rate	   of	   60mls/hr.	   The	   sample	   was	   filter	  
sterilized	  through	  a	  0.2µm	  filter	  (Sartorius	  Stedim,	  UK)	  and	  run	  through	  the	  column	  at	  
a	  flow	  rate	  of	  10mls/hr.	  The	  column	  was	  washed	  with	  40ml	  of	  PBS	  at	  60mls/hr.	  The	  IgG	  
was	  eluted	  using	  0.1M	  glycine-­‐HCl	  solution,	  pH	  2.7,	  into	  eppendorfs	  containing	  150µls	  
of	  Tris	  pH	  9.	  1.5ml	  fractions	  were	  collected.	  The	  absorbance	  at	  280nm	  of	  each	  fraction	  
was	   measured	   using	   a	   spectrophotometer	   (Beckmann	   Coulter	   DU-­‐530).	   Selected	  
fractions	  were	   pooled	   and	   buffer	   exchanged	   into	   PBS	   using	   PD10	   desalting	   columns	  
(GE	  Healthcare	  Life	  Sciences,	  UK).	  The	  absorbance	  at	  280nm	  of	  the	  pooled	  sample	  was	  
determined	  using	  the	  following	  information.	  
Absorbance	  at	  280nm	  of	  1.4	  =	  1mg/ml.	  
The	   concentration	   of	   the	   antibody	   was	   adjusted	   to	   10mg/ml	   using	   a	   Vivaspin	   20	  
ultrafiltration	  device	  with	  30kDa	  molecular	  weight	  cut	  off	   (Sartorius	  Stedim,	  UK).	  The	  
antibody	  was	  stored	  in	  1ml	  aliquots	  at	  -­‐200C.	  
2.4.2	   IgG	   Purification	   from	   patient	   and	   control	   plasma	   samples	   –	   Sodium	   chloride	  
precipitation	  
Plasma	  stored	  at	   -­‐800C	  was	  defrosted	   in	  a	  water	  bath	  at	  370C.	  Solid	   sodium	  chloride	  
was	  added	  at	  18g/100mls	  of	  plasma	  to	  remove	  fibrin.	   I	  had	  previously	  compared	  the	  
use	  of	  sodium	  chloride	  and	  ammonium	  sulphate	  precipitation	  for	  the	  removal	  of	  fibrin	  
with	   Dr	   Alice	   Coughlan	   (Coughlan	   A.	   2012	   The	   development	   of	   a	   humanised	  mouse	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model	  of	  ANCA	  associated	  vasculitis,	  King’s	  College	  London)	  prior	  to	  starting	  my	  PhD.	  
The	   two	   techniques	   were	   similar	   in	   yield,	   with	   the	   sodium	   chloride	   precipitation	  
method	  not	  requiring	  an	  extra	  dialysis	  step;	  hence	  this	  was	  the	  method	  of	  choice	  for	  
the	   PhD.	   The	   plasma	   was	   left	   to	   precipitate	   overnight	   at	   40C.	   The	   sample	   was	  
centrifuged	  at	  1000xg	  for	  30	  minutes	  and	  the	  supernatant	  was	  removed	  and	  diluted	  1	  
in	  5	  in	  endotoxin	  free,	  tissue	  culture	  water	  before	  being	  passed	  through	  a	  0.2μm	  filter	  
for	  purification	  using	  a	  Protein	  G	  column	  (GE	  Healthcare	  Life	  Sciences,	  UK).	  1ml	  Protein	  
G	  columns	  were	  first	  equilibrated	  with	  10mls	  0.2μm	  filtered	  PBS	  using	  a	  syringe	  pump	  
set	  at	  20mls/hr	  before	   the	   filtered	  sample	  was	   run	   through	   the	  column	  at	  10mls/hr.	  
The	  column	  was	  washed	  with	  5mls	  sterile	  filtered	  PBS	  and	  the	  bound	  IgG	  was	  eluted	  
by	  passing	  0.2μm	  filtered	  0.1M	  glycine,	  pH	  2.7,	  through	  the	  column	  at	  20mls/hr.	  The	  
eluate	  was	  collected	  in	  1.5ml	  fractions	  into	  eppendorf	  tubes	  containing	  150μls	  1M	  Tris,	  
pH	  9.	  The	  wavelength	  of	  each	  fraction	  of	  the	  eluted	  antibody	  was	  measured	  at	  280nm	  
using	  a	  spectrophotometer	  and	  samples	  with	  an	  OD	  greater	  than	  1.5	  were	  pooled	  and	  
buffer	  exchanged	  into	  PBS	  using	  a	  PD10	  desalting	  column	  (GE	  Healthcare	  Life	  Sciences,	  
UK).	   The	   final	   concentration	   of	   antibody	   was	   calculated	   and	   the	   antibody	   was	  
aliquoted	  and	  stored	  at	  -­‐200C.	  
The	  endotoxin	  concentration	  in	  the	  final	  IgG	  preparations	  was	  measured	  externally	  by	  
Lonza	   Company	   (Vervier,	   Netherlands)	   using	   a	   limulus	   amebocyte	   lysate	   kinetic	  
chromogenic	   assay.	   For	   all	   30	   polyclonal	   IgG	   preparations	   used,	   the	   endotoxin	   level	  
was	  less	  than	  0.25	  eU/250ug	  IgG.	   	  
2.4.3	  Generation	  of	  F(ab)2	  fragments	  
Whole	   IgG	   (>5mg/ml)	  was	  buffer	  exchanged	  using	  PD10	  columns	   (GE	  Healthcare	  Life	  
Sciences,	   UK)	   into	   20mM	   sodium	   acetate	   buffer.	   The	   pepsin	   preparation	   (Thermo	  
Fisher	  Scientific,	  UK)	  was	  prepared	  as	  follows;	  0.25mls	  of	  the	  50%	  slurry	  of	  immobilised	  
pepsin	  was	   added	   to	   the	   20mM	   sodium	   acetate	   buffer,	   centrifuged	   at	   1000xg	   for	   5	  
minutes	   and	   the	   buffer	   was	   decanted	   and	   discarded.	   This	   step	   was	   repeated	   once	  
more	   and	   the	   immobilised	   pepsin	  was	   resuspended	   in	   0.5mls	   of	   the	   20mM	   sodium	  
acetate	  buffer.	  1ml	  of	   IgG	  was	  added	  to	   the	   immobilised	  pepsin	  and	   incubated	   for	  4	  
hours	   at	  370C	   in	   a	  high	   speed	   shaking	  water-­‐bath.	   The	   contents	  were	   centrifuged	  at	  
1000xg	  for	  5	  minutes	  and	  the	  crude	  digest	  was	  aspirated	  into	  a	  new	  eppendorf	  tube.	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The	   F(ab)2	   fragments	   were	   separated	   from	   undigested	   IgG	   using	   protein	   A	   affinity	  
columns	   (GE	  Healthcare	  Life	  Sciences,	  UK).	  1ml	  protein	  A	  columns	  were	  utilised.	  The	  
column	  was	  first	  washed	  with	  10mls	  of	  the	  sodium	  acetate	  buffer	  at	  30mls/hr	  and	  then	  
the	  sample	  was	  run	  through	  the	  column	  at	  10mls/hr.	  1ml	  aliquots	  were	  collected.	  The	  
wavelength	  of	  each	  fraction	  of	  F(ab)2	  (diluted	  at	  1:20)	  was	  measured	  at	  280nm	  using	  a	  
spectrophotometer	  and	  samples	  with	  an	  OD	  greater	  than	  0.1	  were	  pooled.	  
Sodium	   dodecyl	   sulphate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	  
chromatography	  was	  performed	  to	  demonstrate	  the	  purity	  of	  whole	  IgG	  and	  the	  F(ab)2	  
fragments	   for	   all	   preparations.	   5μg	   of	   each	   antibody	   or	   F(ab)2	   	   fragment	  was	  mixed	  
with	  a	  LDS	  loading	  buffer	  4X	  (Life	  Technologies,	  UK)	  and	  a	  volume	  of	  20µls	  was	  loaded	  
onto	  a	  4-­‐12%	  NuPage	  Bis	  Tris	  gel	  (Life	  Technologies,	  UK).	  A	  volume	  of	  10µls	  of	  SeeBlue	  
Plus	  2	  pre-­‐stained	  standard	  (Life	  Technologies,	  UK)	  was	  added	  in	  a	  separate	  well.	  The	  
gel	  was	  run	  using	  a	  PowerEase500	  power	  supply	  (Life	  Technologies,	  UK)	  at	  200V	  for	  30	  
minutes.	   The	   gel	   was	   removed	   from	   the	   cassette	   and	   washed	   3	   times	   in	   deionized	  
water	  for	  5	  minutes	  each	  time	  on	  a	  shaker	  plate.	  20mls	  of	  SimplyBlue	  SafeStain	  (Life	  
Technologies,	   UK)	   was	   added	   to	   cover	   the	   gel	   and	   the	   manufacturer’s	   microwave	  
procedure	  was	  used.	  The	  gel	  was	  scanned.	  	  
2.4.4	  Use	  of	  polyclonal	  IgG	  or	  F(ab)2	  fragments	  
For	   all	   in	   vitro	   assays	  when	  patient	  ANCA	  were	  used	   to	   stimulate	   the	  neutrophils	  or	  
monocytes,	  the	  polyclonal	  ANCA	  samples	  were	  thawed	  out	  from	  -­‐200C	  and	  centrifuged	  
at	   16,000xg	   at	   40C	   using	   a	   microcentrifuge	   to	   remove	   aggregates.	   Patient	   derived	  
polyclonal	   ANCA	   were	   used	   at	   a	   final	   concentration	   of	   250μg/ml.	   F(ab)2	   fragments	  
were	  used	  at	  the	  same	  molarity	  as	  the	  corresponding	  polyclonal	  antibodies.	  
2.5	  In	  vitro	  studies	  
2.5.1	  General	  principles	  of	  ELISA	  studies	  
The	  ELISA	  kits	  used	  are	  highlighted	   in	   table	  2.4.	   The	  general	   ELISA	  protocol	   involved	  
the	  use	  of	  a	  96	  well	  microplate	  that	  was	  coated	  with	  the	  respective	  capture	  antibody	  
(100µls/well)	   diluted	   to	   the	   manufacturer’s	   recommendation	   in	   PBS.	   The	   plate	   was	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sealed	  and	  incubated	  overnight	  at	  room	  temperature.	  The	  following	  day	  the	  plate	  was	  
washed	   using	   0.05%	   Tween	   20	   in	   PBS	   and	   blotted	   against	   clean	   paper	   towels.	   The	  
plates	  were	  blocked	  using	  300µls/well	   1%	  BSA	   in	  PBS	   for	   all	   ELISAs	  except	   the	  TGFβ	  
ELISA	   where	   5%	   Tween	   20	   was	   used	   instead	   as	   recommended.	   The	   plate	   was	  
incubated	  for	  1	  hour	  at	  room	  temperature.	  The	  wash	  was	  repeated.	  100µls/well	  of	  the	  
respective	   prepared	   standards	   or	   samples	   were	   added	   in	   duplicates,	   the	   plate	   was	  
sealed	   and	   incubated	   for	   2	   hours	   at	   room	   temperature.	   For	   the	   TGFβ	   ELISA,	   the	  
samples	  were	   initially	   activated	   in	   polypropylene	   tubes	  with	   the	   addition	   of	   1N	   HCl	  
(20µls	  1N	  HCl	  to	  100µls	  supernatant),	  incubation	  at	  room	  temperature	  for	  10	  minutes	  
then	  neutralisation	  with	  1.2N	  NaOH/0.5M	  HEPES	  at	   the	   same	  volume	  as	   the	  1N	  HCl	  
used.	  
The	  wash	  step	  was	  repeated	  and	  100µls/well	  of	  the	  detection	  antibody	  was	  added	  at	  
the	   recommended	   dilution.	   The	   plate	   was	   again	   incubated	   for	   2	   hours	   at	   room	  
temperature.	  The	  wash	  was	  repeated	  and	  100µls/well	  of	  streptavidin-­‐HRP	  was	  added	  
to	   each	  well.	   The	   plate	  was	   covered	   and	   incubated	   in	   the	   dark	   for	   20	  minutes.	   The	  
wash	   step	   was	   repeated	   for	   the	   final	   time	   and	   100µls/well	   of	   the	   substrate	   OPD	  
solution	   was	   added	   to	   each	   well	   and	   was	   allowed	   to	   develop	   in	   the	   dark	   for	  
approximately	   20	   minutes.	   The	   reaction	   was	   stopped	   by	   the	   addition	   of	   100µl	   1N	  
H2SO4.	   The	   reaction	  was	   analysed	   at	   490nm	  using	   a	   SpectraMax	   Plus384	  microplate	  
reader	   (Molecular	   Devices,	   UK).	   The	   average	   of	   the	   duplicate	   readings	   for	   each	  
standard	  or	  sample	  was	  calculated	  and	  the	  average	  zero	  standard	  optical	  density	  was	  
subtracted.	  A	  standard	  curve	  was	  created	  using	  Graphpad	  Prism	  software	   (Graphpad	  
Software	  Inc,	  USA)	  and	  the	  concentrations	  of	  the	  measured	  samples	  were	  extrapolated	  
and	  multiplied	  by	  the	  dilution	  factor	  used.	  	  
Other	  modifications	   to	   the	  ELISA	   techniques	  are	  described	   in	  detail	   in	   the	   respective	  
sub-­‐sections.	  
2.5.2	  Human	  neutrophil	  isolation	  from	  blood	  
Heparinised	   blood	   from	   healthy	   controls	   was	   diluted	   1:1	   with	   Hanks	   Balanced	   Salt	  
Solution	  (HBSS).	  In	  15ml	  tubes,	  8mls	  of	  the	  blood/HBSS	  mixture	  was	  carefully	  layered	  
|	  Page	  84	  
on	   top	   of	   4mls	   Ficoll-­‐Paque™	   PLUS	   (GE	   Healthcare	   Life	   Sciences,	   UK).	   This	   was	  






Figure	   2.2	   –	   Diagrammatic	   representation	   of	   layers	   of	   blood	   and	   respective	  
constituents	  prior	  to	  and	  after	  centrifugation	  following	  Ficoll	  layering.	  
The	   upper	   layer	   including	   the	   lymphoctyes	   was	   aspirated	   with	   circular	   movement.	  
Gentle	   tapping	   loosened	   the	   sedimented	  pellet	   and	  10mls	   red	  blood	   cell	   lysis	  buffer	  
was	  added	  to	  lyse	  the	  erythrocytes.	  The	  tube	  was	  inverted	  several	  times	  and	  incubated	  
on	  ice	  for	  5	  minutes,	  with	  occasional	  mixing.	  This	  was	  centrifuged	  at	  380xg,	  200C	  for	  5	  
minutes.	   The	   supernatant	  was	   aspirated,	   being	   careful	   not	   to	   disturb	   the	   cell	   pellet,	  
which	  was	  then	  resuspended	  in	  10mls	  red	  blood	  cell	  lysis	  buffer	  and	  incubated	  on	  ice	  
for	   5	   minutes.	   This	   was	   spun	   at	   280xg,	   200C	   for	   5	   minutes.	   The	   supernatant	   was	  
removed	  and	  the	  pellet	  was	  washed	  with	  ice-­‐cold	  HBSS	  and	  centrifuged	  at	  200xg	  for	  5	  
minutes.	   The	   cells	   were	   resuspended	   in	   HBH	   (500mls	   HBSS	   +	   5mls	   1M	   HEPES)	   or	  
PBS++.	  
The	  cells	  were	  counted	  using	  a	  1	   in	  10	  dilution	  of	  Turk's	  Solution.	  An	  Olympus	  BX51	  
microscope	  (Olympus	  Microscopy,	  UK)	  set	  to	  phase	  contrast	  and	  a	  counting	  chamber	  
(improved	  Neubauer	  haemocytometer)	  was	  used	  for	  calculating	  cells	  numbers.	  Turk's	  
solution	  is	  a	  mixture	  of	  acetic	  acid	  and	  gentian	  violet	  that	  haemolyses	  red	  blood	  cells	  
and	  stains	  the	  nuclei	  of	  white	  cells	  purple.	  The	  total	  number	  of	  cells	  within	  the	  25	  grid	  
square	  was	  counted.	  This	  was	  multiplied	  by	  the	  dilution	  factor	  and	  104	  to	  obtain	  the	  
number	   of	   cells/ml	   of	   medium	   i.e.	   cell	   concentration.	   The	   cell	   concentration	   was	  
multiplied	  by	  the	  volume	  of	  the	  cell	  suspension	  to	  obtain	  the	  total	  cell	  yield.	  
Blood	  /	  HBSS	  mixture	  
Ficoll	  




Erythrocytes	  and	  granulocytes	  
Layers	  after	  centrifugation	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2.5.3	  Mouse	  neutrophil	  isolation	  from	  bone	  marrow	  
Bone	  marrow	  cells	  were	   isolated	   from	  the	   tibia	  and	   femurs	  of	  mice.	  The	  muscle	  and	  
tissue	  was	  stripped	  away	  and	  the	  bones	  were	  flushed	  with	  HBSS++	  using	  a	  27G	  needle.	  
Clumps	   of	   cells	  were	   dispersed	   by	   repeated	   pipetting.	   The	   cells	  were	   centrifuged	   at	  
385xg	  for	  10	  minutes.	  In	  the	  meantime	  62%	  and	  55%	  Percoll	  were	  prepared	  using	  HBSS	  
for	  dilution	  of	  sterile	  Percoll.	  6mls	  of	  62%	  Percoll	  was	  gently	  underlayed	  beneath	  3mls	  
of	  55%	  Percoll	  to	  create	  a	  gradient.	  The	  cell	  pellet	  was	  resuspended	  in	  HBSS++,	  gently	  
placed	   onto	   the	   Percoll	   gradient	   and	   centrifuged	   at	   1256xg	   for	   30	   minutes	   at	   low	  
deceleration.	  The	  neutrophil	   layer	  was	  harvested	  from	  the	  gradient	  and	  resuspended	  
in	   HBSS++.	   The	   cell	   pellet	   was	   washed	   in	   HBSS++	   and	   resuspended	   for	   1	  minute	   in	  
Geyes	  solution	  then	  in	  HBSS++	  and	  centrifuged	  at	  385xg	  for	  10	  minutes.	  Finally	  the	  cell	  
pellet	  was	  resuspended	  in	  PBS++	  and	  a	  cell	  count	  was	  performed	  as	  above	  using	  Turk’s	  
solution.	  When	  using	  mice	  neutrophils	   for	  assays,	   the	  cells	  were	  primed	  with	  5ng/ml	  
TNFα	  (Peprotech,	  UK)	  and	  200ng/ml	  GMCSF	  for	  1	  hour	  at	  370C.	  
2.5.4	  Human	  monocyte	  isolation	  from	  blood	  
As	  for	  neutrophil	   isolation,	  the	  blood/HBSS	  mixture	  was	  centrifuged	  after	   layering	  on	  
Ficoll.	   This	   time	   the	   peripheral	   blood	   mononuclear	   cell	   layer	   (PBMC)	   was	   gently	  
aspirated	  and	  isolated	  for	  use	  (see	  figure	  2.2).	  	  
The	  PBMC	  layer	  was	  washed	  with	  PBS/FBS	  buffer.	  CD14	  microbeads	  (Miltenyi	  Biotec,	  
UK)	   were	   added	   and	   the	   suspension	   was	   incubated	   at	   40C	   for	   15	   minutes.	   The	  
suspension	   was	   washed	   with	   the	   PBS/FBS	   buffer	   and	   applied	   to	   a	   magnetic	   25LS	  
column	   (Miltenyi	   Biotec,	   UK)	   after	   the	   column	   was	   prepped	   with	   the	   buffer.	   The	  
column	   was	   washed	   three	   times	   with	   PBS/FBS	   buffer	   to	   limit	   contamination.	   The	  
column	   was	   then	   removed	   from	   the	  magnetic	   separator	   and	   the	   buffer	   was	   added	  
onto	  the	  column	  to	  flush	  out	  magnetically	  labelled	  cells	  with	  a	  plunger.	  The	  cells	  were	  
washed	  and	  counted.	  
Monocytes	  were	   resuspended	  at	   1x106	   cells/ml	   in	  RPMI	  1640	  media	   containing	  10%	  
foetal	   bovine	   serum	   or	   human	   AB	   serum	   for	   the	   monocyte	   to	   macrophage	  
differentiation	   (PAA	   labs,	   UK),	   and	   1%	   Penicillin/Streptomycin	   (Thermo	   Fisher	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Scientific,	  UK).	  Monocytes	  were	   cultured	   in	   48	  well	   plates	   for	   selective	   time	  periods	  
with	   or	   without	   100ng/ml	   LPS	   (from	   Escherichia	   Coli	   055:B5,	   γ-­‐irradiated)	   and	  
polyclonal	   ANCA	  or	   control	   IgG	   at	   a	   final	   concentration	   of	   250μg/ml.	   The	   cells	  were	  
incubated	  at	  370C	  for	  varying	  time	  points,	  after	  which	  supernatants	  were	  collected	  and	  
cell	  counts	  were	  performed.	  When	  used,	  inhibitors	  were	  added	  30	  minutes	  prior	  to	  the	  
addition	  of	  ANCA	  or	  control	   IgG	  and	  the	  cells	  were	   incubated	  at	  370C	  (MPO	  inhibitor	  
AZD5904	   Astra	   Zeneca,	   UK	   variable	   concentration	   [249],	   CSF1R	   inhibitor	   GW2580	  
BioVision,	  UK	  variable	  concentration,	  anti	  CD11b	  clone	  ICRF44	  Biolegend,	  UK	  10μg/ml	  
and	  anti	  CD18	  clone	  TS1/18	  Biolegend,	  UK	  10μg/ml).	  	  
2.5.5	  Human	  CD4	  T	  cell	  isolation	  from	  blood	  
PBMC	   were	   isolated	   and	   processed	   as	   described	   above.	   CD4	   microbeads	   (Miltenyi	  
Biotec,	  UK)	  were	  used	  to	   isolate	  CD4	  T	  cells	   instead	  of	  CD14	  beads.	  The	  T	  cells	  were	  
resuspended	  in	  complete	  RPMI	  medium.	  
2.5.6	  Human	  monocyte	  to	  macrophage	  differentiation	  
There	  are	  protocols	  in	  the	  literature	  detailing	  skewing	  of	  naïve	  monocytes	  into	  M1	  or	  
M2	  macrophages	  using	  growth	  factors	  and	  cytokines.	  However,	  we	  wanted	  to	  analyse	  
how	  MPO-­‐ANCA	  skew	  the	  macrophages,	  if	  at	  all,	  into	  a	  specific	  phenotype.	  As	  a	  result	  
we	  cultured	  monocytes	  in	  complete	  RPMI	  using	  10%	  AB	  serum	  instead	  of	  FBS	  to	  mirror	  
physiological	   conditions	  without	   influencing	  differentiation	   into	  a	   certain	  phenotype.	  
Cells	  were	   incubated	  with	  MPO-­‐ANCA	  or	  control	   IgG	   for	  6	  days	  after	  which	  cells	  and	  
supernatant	  were	  collected.	  The	  cells	  were	  stained	  with	  anti	  CD80	  (PE	  clone	  2D10)	  and	  
anti	   CD206	   (APC	   clone	   15-­‐2).	   Samples	   were	   analysed	   using	   a	   FACS	   Canto	   flow	  
cytometer	  (Becton	  Dickinson,	  UK)	  using	  FACSDiva	  software	  (Becton	  Dickinson,	  UK).	  At	  
least	   10,000	   events	  were	   collected	   per	   sample	   and	   data	  was	   analysed	   using	   FlowJo	  
software	  (Treestar,	  USA).	  
The	   supernatant	   collected	   from	   the	  macrophage	   cultures	   described	   above	  were	   co-­‐
incubated	  with	   activated	  CD4	  T	   cells.	   T	   cells	  were	  activated	   in	  48	  well	   plates	   coated	  
with	   antibodies	   to	   CD3	   (2μg/ml	   OKT-­‐3	   in-­‐house	   from	   a	   hybridoma	   line)	   and	   CD28	  
(2μg/ml	  BD	  Biosciences).	  A	  final	  concentration	  of	  10U/ml	  recombinant	  IL2	  was	  added.	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Supernatants	   from	   the	  monocyte	   to	  macrophage-­‐differentiated	   cells	  were	   used	   at	   a	  
ratio	  of	  2:1	  with	   the	  T	  cells.	  Supernatants	   from	  the	  T	  cell	  cultures	  were	  harvested	  at	  
day	  3	  and	  5	  to	  assay	  the	  cytokine	  profile.	  
2.5.7	  Respiratory	  burst	  assays	  
-­‐ Dihydrorhodamine	  (DHR)	  123	  assay	  
DHR	  123	  is	  a	  non-­‐reduced	  non-­‐fluorescent	  molecule	  that	  in	  the	  presence	  of	  hydrogen	  
peroxide	   is	   converted	   to	   rhodamine	   123,	   which	   fluoresces	   at	   a	   wavelength	   of	  
approximately	  534nm,	  and	  can	  therefore	  be	  detected	   in	  the	  FITC	  (FL-­‐1)-­‐light	  channel	  
on	  flow	  cytometry.	  Neutrophils	  were	  isolated	  as	  described	  in	  section	  2.5.2	  and	  used	  at	  
a	  concentration	  of	  2.5	  x	  106	  cells/ml	  resuspended	  in	  HBH.	  The	  cells	  were	  loaded	  with	  
17μg/ml	  DHR123	   (Calbiochem,	  UK)	   together	  with	  5μg/ml	  Cytochalasin	  B	  as	  well	  as	  2	  
mM	  sodium	  azide	  and	  incubated	  in	  the	  dark	  for	  10	  minutes	  at	  370C.	  Cells	  were	  primed	  
by	  incubation	  with	  2ng/ml	  TNFα	  for	  15	  minutes	  at	  370C	  with	  gentle	  mixing	  at	  5	  minute	  
intervals.	   They	   were	   subsequently	   incubated	   with	   a	   respective	   stimulant.	   fMLP	   at	  
100ng/ml	  was	  used	  as	  the	  positive	  control.	  The	  reaction	  was	  stopped	  by	  the	  addition	  
of	  a	  30-­‐fold	  volume	  of	  cold	  HBSS	  containing	  1%	  BSA.	  This	  was	  spun	  at	  280xg	  and	  40C	  
for	   5	   minutes.	   The	   cells	   were	   resuspended	   in	   300μls	   HBSS.	   Flow	   cytometry	   was	  
performed	   on	   a	   FACS	   Canto	   flow	   cytometer	   (Becton	   Dickinson,	   UK)	   using	   FACSDiva	  
software	  (Becton	  Dickinson,	  UK).	  At	  least	  10,000	  events	  were	  collected	  per	  sample	  and	  
data	  was	  analysed	  using	  FlowJo	  software	  (Treestar,	  USA).	  
-­‐ Luminometer	  assay	  
Luminol	  and	  isoluminol	  are	  chemicals	  that	  exhibit	  chemiluminescence	  in	  the	  presence	  
of	   an	   oxidant	   such	   as	   hydrogen	   peroxide.	   Luminol	   measures	   intacellular	   and	  
extracellular	   reactive	  oxygen	   species	   (ROS),	  whilst	   isoluminol,	   a	  hydrophilic	  molecule	  
that	   cannot	   enter	   the	   cell	   and	   therefore	   can	   be	   used	   to	  measure	   extracellular	   ROS	  
production.	  
A	   luminometer	   plate	   (PAA	   labs,	   UK)	   was	   coated	  with	   200μls	   of	   FBS	   per	   well	   for	   12	  
hours	  prior	  to	  use.	  Neutrophils	  were	  isolated	  as	  described	  in	  section	  2.5.2	  and	  used	  at	  
a	  concentration	  of	  6.25x106	  cells/ml	  resuspended	  in	  PBS++.	  Luminol	  /	  HRP	  (3mls	  PBS++	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add	  1μl	  of	  1M	  luminol	  and	  200μls	  of	  0.8U/μl	  HRP)	  or	  isoluminol	  /	  HRP	  (3mls	  PBS++	  add	  
1μl	   of	   1M	   isoluminol	   and	  200μls	   of	   0.8U/μl	  HRP)	  was	   prepared.	   The	   cell	   suspension	  
was	  mixed	  with	   1.25	   times	   the	   volume	   of	   (iso)luminol	   /	   HRP.	   Cells	   were	   primed	   by	  
incubation	  with	  2ng/ml	  TNFα	   for	  15	  minutes	  at	  370C	  with	  gentle	  mixing	  at	  5	  minute	  
intervals.	   In	   the	   meantime	   the	   unbound	   FBS	   was	   discarded	   from	   the	   luminometer	  
plate	  and	  the	  plate	  was	  washed	  with	  PBS.	  The	  appropriate	  stimulant	  was	  placed	  into	  
the	   appropriate	   well	   and	   prewarmed	   to	   370C	   in	   the	   luminometer	   (Mithras	   LB940,	  
Berthold	  Technologies,	  UK).	  fMLP	  at	  100ng/ml	  was	  used	  as	  the	  positive	  control.	  Finally	  
200μls	   of	   cells	   per	   well	   were	   transferred	   to	   the	   luminometer	   plate	   swiftly	   using	   a	  
multi-­‐pipette	  and	  the	  reaction	  was	  recorded.	  
2.5.8	  Degranulation	  assays	  
Degranulation	   of	   neutrophils	   is	   frequently	   measured	   by	   the	   release	   of	   granular	  
contents	   such	   as	   MPO	   (azurophilic	   granules),	   lysozyme	   (azurophilic	   and	   specific	  
granules),	   neutrophil	   elastase	   (azurophilic	   granules),	   lactoferrin	   (specific	   granules),	  
CD63	   (azurophilic	   granules),	   CD66b	   (specific	   granules)	   and	   CD11b	   (secretory,	  
gelatinase	  and	  specific	  granules).	  
Neutrophils	  were	  isolated	  as	  described	  in	  section	  2.5.2	  and	  used	  at	  a	  concentration	  of	  
2.5x106	  cells/ml	  resuspended	  in	  HBH.	  The	  cells	  were	  primed	  and	  stimulated	  as	  stated	  
in	   the	   results	   section.	   fMLP	   at	   100ng/ml	  was	   used	   as	   the	   positive	   control	   activating	  
agent.	  
-­‐ Lactoferrin	  ELISA	  
Once	  the	  neutrophils	  were	  primed	  and	  stimulated,	  the	  cell	  suspension	  was	  centrifuged	  
at	  380xg	  for	  5	  minutes	  at	  40C	  and	  the	  supernatant	  was	  collected	  and	  stored	  at	  -­‐200C.	  A	  
human	   lactoferrin	   ELISA	   kit	   (Hycult	   Biotech,	   UK)	   was	   used.	   100µls/well	   standard	   or	  
sample	  was	  added	  to	  an	  antibody	  pre-­‐coated	  plate.	  The	  plate	  was	   incubated	  at	  370C	  
for	   1	   hour.	   The	   plate	  was	  washed	   4	   times	  with	   the	   provided	  wash	   buffer.	   A	   diluted	  
tracer	   (100µls/well)	   was	   added	   and	   the	   tray	   was	   incubated	   for	   1	   hour	   at	   room	  
temperature.	   The	   wash	   procedure	   was	   repeated.	   100µls/well	   of	   streptavidin-­‐
peroxidase	  was	  pipetted	  and	  the	  tray	  was	  incubated	  for	  1	  hour.	  Following	  a	  wash,	  the	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provided	  TMB	  substrate	  was	  added	  (100µls/well)	  and	  the	  plate	  was	   incubated	   in	  the	  
dark	   for	   30	  minutes.	   The	   reaction	   was	   stopped	   with	   the	   provided	   solution	   and	   the	  
plate	  was	   read	   at	   450nm	   using	   a	   SpectraMax	   Plus384	  microplate	   reader	   (Molecular	  
Devices,	  UK).	  
-­‐ MPO	  Detection	  
The	   supernatant	   from	   neutrophils	   primed	   and	   stimulated	   were	   collected	   as	   for	   the	  
Lactoferrin	   ELISA.	   75µls/well	   of	   the	   supernatant	   was	   pipetted	   into	   respective	   ELISA	  
plate	   wells	   and	   as	   a	   positive	   control	   75µls	   of	   2.5x106	   neutrophils/ml	   was	   used.	  
100µls/well	   of	   OPD	   solution	   was	   added	   and	   incubated	   in	   the	   dark	   at	   room	  
temperature	  for	  30	  minutes.	  The	  reaction	  was	  stopped	  by	  adding	  100µls/well	  of	  100%	  
acetic	   acid.	   The	   plate	   was	   read	   at	   450nm	   using	   a	   SpectraMax	   Plus384	   microplate	  
reader	  (Molecular	  Devices,	  UK).	  
-­‐ CD66b	  and	  CD11b	  Flow	  cytometry	  
Neutrophil	   activation	   was	   stopped	   by	   adding	   cold	   1%	   BSA/HBSS	   and	   the	   cell	  
suspension	  was	  then	  centrifuged	  at	  380xg	  for	  5	  minutes	  at	  40C.	  The	  neutrophils	  were	  
stained	   with	   anti-­‐human	   antibodies	   CD66b	   FITC	   and	   CD11b	   APC.	   The	   respective	  
antibodies	  were	  added	  and	  incubated	  for	  20	  minutes	  at	  room	  temperature	  in	  the	  dark.	  
The	   suspension	   was	   later	   centrifuged	   at	   280xg	   for	   5	  minutes.	   The	   supernatant	   was	  
discarded	   and	   the	   cells	   resuspended	   in	   2mls	   of	   PBS	   and	   centrifuged	   at	   280xg	   for	   5	  
minutes.	  Finally	  the	  cells	  were	  resuspended	  in	  500µls	  of	  PBS	  with	  0.1%	  sodium	  azide.	  
FACs	   analysis	   was	   carried	   out	   immediately	   after	   staining	   using	   a	   FACS	   Canto	   flow	  
cytometer	  (Becton	  Dickinson,	  UK)	  and	  FACsDIVA	  software	  (Becton	  Dickinson,	  UK).	  
2.5.9	  Intracellular	  and	  extracellular	  staining	  of	  C3,	  C5,	  C3a	  and	  C5a	  
Neutrophils	   were	   isolated,	   primed	   and	   stimulated	   as	   described	   in	   section	   2.5.2	   and	  
2.5.7.	   Neutrophil	   activation	   was	   stopped	   with	   cold	   1%	   BSA/HBSS	   and	   cells	   were	  
resuspended	   in	   FACS	   buffer	   (PBS,	   0.5%	   BSA	   and	   2mM	   EDTA).	   Fc	   receptor	   block	  
(Miltenyi	   Biotec,	   UK)	   was	   added	   at	   20μls	   per	   10⁷	   total	   cells	   in	   60μls	   buffer	   and	  
incubated	  or	  10	  minutes	  on	  ice.	  The	  cell	  suspension	  was	  washed	  with	  the	  FACS	  buffer.	  
A	  fixation	  /	  permeabilization	  kit	  (Becton	  Dickinson	  (BD),	  UK)	  was	  used.	  For	  extracellular	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staining,	   the	   cells	   were	   washed	   using	   BD	   permwash	   solution.	   The	   relevant	   primary	  
antibody	  (see	  table	  of	  antibodies)	  was	  added	  and	  incubated	  for	  20	  minutes	  at	  40C.	  The	  
suspension	  was	  washed	   twice	  and	   if	  needed	   the	   secondary	  antibody	  was	  added	  and	  
incubated	   for	   20	  minutes	   at	   40C.	   Excess	   unbound	   antibody	  was	  washed	   off	   and	   the	  
cells	  were	  resuspended	  in	  FACS	  buffer.	  For	  intracellular	  staining,	  the	  cells	  were	  treated	  
similarly,	   however,	   prior	   to	   the	   use	   of	   the	   primary	   antibody,	   the	   cells	   were	  
permeabilised	  by	  incubation	  with	  BD	  cytofix/cytoperm	  plus	  for	  20	  minutes	  at	  40C.	  
FACs	   analysis	   was	   carried	   out	   immediately	   after	   staining	   using	   a	   FACS	   Canto	   flow	  
cytometer	  (Becton	  Dickinson,	  UK)	  and	  FACsDIVA	  software	  (Becton	  Dickinson,	  UK).	  
2.5.10	  Cytometric	  bead	  assay	  (CBA)	  –	  Human	  anaphylatoxins	  	  
Neutrophils	  were	  isolated	  as	  described	  and	  used	  at	  a	  concentration	  of	  2.5x106	  cells/ml	  
resuspended	   in	  HBH.	   The	   cells	  were	   primed	   and	   stimulated	   as	   appropriate.	   fMLP	   at	  
100ng/ml	  was	  used	  as	  the	  positive	  control.	  The	  cells	  were	  centrifuged	  at	  380xg	  for	  5	  
minutes	   to	   attain	   the	   supernatants.	   The	   supernatant	   was	   divided	   into	   aliquots	   and	  
stored	  at	  -­‐200C.	  
A	   BD	   anaphylatoxin	   CBA	   kit	   was	   used	   (Becton	   Dickinson,	   UK).	   The	   standards	   were	  
prepared	  at	  different	  concentrations	  using	  the	  assay	  diluent.	  The	  samples	  were	  diluted	  
either	   1:2	   or	   1:5.	   The	   capture	   bead	   suspension,	   which	   consisted	   of	   three	   detection	  
beads	   (one	   for	   each	   of	   the	   anaphylatoxins,	   C3a,	   C4a	   and	   C5a),	   was	   added	   to	   the	  
samples	  and	  standards.	  The	  samples	  were	   incubated	  for	  2	  hours	   in	  the	  dark	  at	  room	  
temperature.	   The	   suspensions	   were	   washed	   to	   eradicate	   unbound	   beads	   and	   the	  
human	  anaphylatoxin	  PE	  detection	  antibody	  mixture	  was	  added	  and	   incubated	   for	  1	  
hour	  in	  the	  dark.	  The	  suspension	  was	  washed	  and	  resuspended	  in	  FACS	  buffer.	  	  
FACS	  analysis	  was	  carried	  out	  immediately	  using	  a	  FACS	  calibur	  (Becton	  Dickinson,	  UK)	  
and	  analysed	  using	  CellQuest	  Pro.	  
2.5.11	  CBA	  –	  Th1,	  Th2	  and	  Th17	  cytokines	  
Monocytes	  were	   isolated	   as	   described	   in	   section	   2.5.4	   and	   subsequently	   stimulated	  
with	   or	   without	   LPS	   (100ng/ml)	   and	   respective	   patient	   ANCA	   or	   control	   IgG	   at	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250µg/ml	  for	  18	  hours	  at	  370C.	  The	  cells	  were	  harvested	  and	  centrifuged	  at	  380xg	  for	  5	  
minutes	  to	  attain	  the	  supernatants,	  which	  were	  stored	  at	  -­‐200C.	  
A	   BD	   Th1,	   Th2	   and	   Th17	   cytokine	   CBA	   kit	   was	   used	   (Becton	   Dickinson,	   UK).	   The	  
standards	  were	  prepared	  and	  samples	  were	  thawed	  out.	  The	  capture	  bead	  suspension	  
was	   added	   to	   the	   samples	   (used	   at	   1:40	   dilution)	   and	   standards,	   as	   was	   the	   PE	  
detection	   antibody	  mixture.	   The	   samples	  were	   incubated	   for	   3	   hours	   in	   the	   dark	   at	  
room	   temperature.	   The	   suspensions	   were	   washed	   to	   remove	   unbound	   beads	   and	  
excess	  PE	  detection	  antibody	  and	  resuspended	  in	  FACS	  buffer.	  	  
FACS	  analysis	  was	  carried	  out	  immediately	  using	  a	  FACS	  calibur	  (Becton	  Dickinson,	  UK)	  
and	  analysed	  using	  CellQuest	  Pro.	  
2.5.12	  Reverse	  Transcription	  Quantitative	  PCR	  (RT-­‐qPCR)	  
RNA	  was	  isolated	  from	  monocytes	  incubated	  with	  MPO-­‐ANCA	  or	  control	  IgG	  +/-­‐	  LPS	  for	  
18	   hours	   using	   a	   Qiagen	   RNeasy	   mini	   kit	   (Qiagen,	   UK)	   according	   to	   manufacturer’s	  
instructions.	   Cells	   were	   lysed	   using	   350μls	   RLT	   buffer	   provided	   and	   vortexing.	   The	  
samples	  were	  transferred	  to	  the	  QIAshredder	  spin	  column	  and	  centrifuged	  at	  13,000xg	  
for	  4	  minutes.	  350μls	  of	  70%	  ethanol	  was	  added	  to	  the	  homogenised	  lysate	  and	  mixed	  
well	  by	  pipetting.	  700μls	  of	  the	  sample	  was	  transferred	  to	  the	  RNeasy	  spin	  column	  and	  
centrifuged	  at	  8,000xg	   for	  30	  seconds.	  The	  supernatant	  was	  discarded	  and	  700μls	  of	  
the	  RW1	  wash	  buffer	  (removes	  biomolecules	  such	  as	  carbohydrates,	  proteins	  and	  fatty	  
acids	   that	   are	   non-­‐specifically	   bound	   to	   the	   silica	  membrane)	   added	   to	   the	   column,	  
centrifuged	  at	  8,000xg	  for	  30	  seconds	  and	  once	  again	  the	  supernatant	  was	  discarded.	  
500μls	  of	   the	  RPE	  wash	  buffer	   (removes	   salts	   from	  previous	  buffers	  adherent	   to	   the	  
column)	   was	   added	   to	   the	   column	   and	   centrifuged	   at	   8,000xg	   for	   30	   seconds.	   The	  
supernatant	   was	   discarded	   and	   the	   wash	   step	   repeated.	   The	   RNeasy	   column	   was	  
placed	  into	  a	  new	  collection	  tube.	  35μls	  of	  RNase	  free	  water	  was	  added	  to	  the	  column	  
and	  centrifuged	  at	  8,000xg	  for	  1	  minute.	  The	  eluted	  RNA	  was	   immediately	  placed	  on	  
ice.	  
The	   RNA	   concentration	   and	   purity	   was	   quantified	   using	   a	   Nanodrop	   ND-­‐1000	  
spectrophotometer	   (Thermo	   Fisher	   Scientific,	   Wilmington,	   USA).	   RNA	   purity	   and	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integrity	   was	   screened	   by	   analysing	   the	   ratio	   of	   absorbance	   A260/280	   with	   a	   value	  
equal	  or	  great	  than	  2	  indicating	  high	  purity	  of	  RNA.	  RNA	  was	  stored	  at	  -­‐800C.	  	  
200ng	   RNA	   was	   converted	   to	   cDNA	   using	   a	   RevertAid	   H	   Minus	   kit	   (Thermo	   Fisher	  
Scientific).	  The	  mastermix	  was	  generated	  using	  1μl	  of	  primer,	  4μls	  of	   reaction	  buffer	  
(5x),	   1μl	   of	   RiboLock	   RNase	   inhibitor,	   2μls	   of	   10mM	   dNTP	  mix,	   1μls	   of	   RevertAid	   H	  
Minus	  M-­‐MuLV	  Reverse	  Transcriptase	  and	  11μls	  of	  RNA	  sample	  (total	  volume	  20μls).	  
The	  reverse	  transcription	  reaction	  was	  carried	  out	  by	   incubating	  the	  samples	  at	  250C	  
for	   5	  minutes,	   followed	   by	   a	   step	   of	   30	  minutes	   at	   420C	   and	   a	   final	   incubation	   of	   5	  
minutes	  at	  850C.	  The	  cDNA	  was	  stored	  at	  -­‐800C	  and	  used	  for	  RT-­‐qPCR.	  
Hydrolysis	   probes	   (TaqMan)	   were	   used	   for	   CSF1	   (Hs00174164_M1)	   and	   CSF1R	  
(Hs00911250_M1)	   labelled	   with	   a	   fluorescent	   reporter	   dye	   FAM	   (Thermo	   Fisher	  
Scientific,	  UK),	  which	  is	  covalently	  bound	  to	  its	  5’	  end	  and	  a	  dark	  quencher	  dye	  at	  the	  
3’	  end.	  During	  the	  PCR	  reaction,	  the	  polymerase	  will	  degrade	  the	  probe	  releasing	  the	  
reporter	   dye	   from	   its	   quencher	   and	   allowing	   it	   to	   fluoresce.	   The	   fluorescent	   dye	  
release	   corresponds	   to	   amplification	   of	   the	   specific	   target	   sequence.	   The	   reaction	  
mastermix	  was	   created	   using	   1μl	   of	   the	   20x	   Taqman	   assay	   probe	   including	   primers,	  
10μls	   Taqman	  universal	  mastermix	   II	  with	  Uracil-­‐DNA	   glycosylase	   (UNG),	   5μls	   RNase	  
free	  water	  and	  4μls	  cDNA.	  The	  reference	  gene	  beta	  glucuronidase	  (bGUS)	  was	  used	  as	  
an	   endogenous	   control	   (forward	   primer	   5’-­‐GAAAATATGTGGTTGGAGAGCTCATT-­‐3’,	  
reverse	   primer	   5’-­‐CCGAGTGAAGATCCCCTTTTTA-­‐3’	   and	   Taqman	   probe	   5’-­‐
CCAGCACTCTCGTCGGTGACTGTTCA-­‐3’).	   The	   reference	   gene	   mastermix	   was	   set	   up	  
using	  0.6μl	  of	   the	   forward	  primer,	  0.6μl	  of	   the	   reverse	  primer,	  0.664μl	  of	   the	  probe,	  
10μls	  Taqman	  universal	  mastermix	  II	  with	  UNG,	  4.136μls	  of	  RNase	  free	  water	  and	  4μls	  
cDNA.	  For	  each	  set	  of	  primers	  a	  water	  control	  was	  used	  to	  control	  for	  contamination.	  
The	   cDNA	   was	   amplified	   in	   384	   well	   plates	   using	   ABI	   Prism	   7900	   HT	   Sequence	  
Detection	   System	   (Applied	   Biosystems,	   Foster	   City,	   CA)	   in	   duplicates.	   The	   thermal	  
cycling	  conditions	  used	  were	  hold	  at	  500C	  for	  2	  minutes,	  hold	  at	  950C	  for	  10	  minutes,	  
45	  cycles	  of	  15	  seconds	  at	  950C	  and	  1	  minute	   for	  600C.	  Results	  of	   individual	  samples	  
were	   normalized	   to	   that	   of	   human	   bGUS.	   The	   sequence	   detector	   SDS	   2.4	   software	  
(Applied	  Biosystems)	  was	  used	  to	  export	  the	  Ct	  values.	  The	  Ct	  value	  is	  the	  PCR	  cycle	  at	  
which	   the	   fluorescent	   signal	   of	   the	   reporter	   dye	   surpasses	   an	   arbitrary	   threshold.	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Hence,	   the	   lower	   the	   Ct	   value	   the	   greater	   the	   amount	   of	   amplification.	   ΔCt	   was	  
obtained	   by	   normalising	   the	   data	   through	   subtraction	   of	   the	   Ct	   value	   of	   the	  
endogenous	   reference	   gene	   control	   from	   the	   gene	   of	   interest	   Ct.	   The	   ΔCt	   of	   the	  
control	   sample	   was	   next	   subtracted	   from	   the	   ΔCt	   of	   the	   other	   samples	   to	   give	   the	  
ΔΔCt.	   Subsequently,	   the	   relative	   quantity	   of	   target	   gene	   mRNA	   expression	   was	  
calculated	  using	  the	  equation	  of	  the	  comparative	  Ct	  method	  (2-­‐ΔΔCt)	  for	  quantification	  
allowing	  presentation	  of	  data	  as	  a	  fold	  change	  in	  expression	  [250].	  
2.5.13	  Microarray	  experiments	  
The	  microarray	  experiments	  were	  performed	  with	  Julie	  Watson	  and	  Dr	  Paul	  Lavender	  
(MRC	  and	  Asthma	  UK	  Centre	  in	  Allergic	  Mechanisms	  of	  Asthma,	  King's	  College	  London,	  
Guy's	  Hospital,	  UK).	  RNA	  was	  isolated	  from	  5X105	  monocytes	  incubated	  with	  100ng/ml	  
LPS	  and	  MPO-­‐ANCA	  or	  control	   IgG	   (250μg/ml)	   for	  6	  hours	  using	  a	  Qiagen	  Allprep	  kit	  
(Qiagen,	  UK)	  according	  to	  manufacturer’s	  instructions	  (see	  above).	  	  
Potential	   genomic	   DNA	   contamination	   was	   removed	   by	   Turbo	   DNase	   treatment	  
(Ambion/Life	  Technologies,	  UK).	  0.1	  volume	  10xTURBO	  DNase	  Buffer	  and	  1μL	  TURBO	  
DNase	  was	  added	  to	  the	  RNA,	  mixed	  gently	  and	   incubated	  at	  370C	  for	  45	  minutes.	  A	  
DNase	   inactivating	   reagent	  was	  added	  at	  0.1	  volume	  and	   incubated	   for	  5	  minutes	  at	  
room	  temperature	  with	  gentle	  mixing.	  The	  samples	  were	  centrifuged	  at	  10,000xg	  for	  
90	  seconds	  and	  the	  RNA	  was	  transferred	  to	  a	  fresh	  tube.	  100%	  ethanol	  was	  added	  at	  
2.5x	   the	   volume,	   the	   sample	   was	   mixed	   well,	   transferred	   to	   the	   RNeasy	   MinElute	  
column	  (Qiagen,	  UK)	  and	  centrifuged	  at	  8,000xg	  for	  15	  seconds.	  The	  flow	  through	  was	  
discarded,	   500μls	   of	   RPE	  wash	   buffer	   was	   added	   and	   centrifuged	   at	   8,000xg	   for	   30	  
seconds.	  The	   flow	  through	  was	  discarded	  and	  500μls	  of	  80%	  ethanol	  was	  added	  and	  
again	   the	   column	   was	   centrifuged,	   this	   time	   at	   10,000xg	   for	   2	   minutes.	   The	   flow	  
through	   was	   discarded,	   the	   column	   was	   left	   open	   to	   dry	   the	   membrane	   and	  
transferred	  to	  a	  new	  collection	  tube.	  The	  RNA	  was	  eluted	  by	  adding	  14μls	  RNase	  free	  
water	  to	  the	  column	  membrane	  and	  centrifugation	  at	  8,000xg	  for	  1	  minute.	  
As	  for	  the	  RT-­‐qPCR,	  a	  nanodrop	  was	  used	  to	  quantify	  the	  purity	  and	  concentration	  of	  
the	  RNA.	  5ng	  total	  RNA	  per	  sample	  (5μls	  volume)	  was	  reverse	  transcribed	  and	  labeled	  
using	  Ovation	   Pico	  WTA	   System	  V2	   and	   Encore	   BiotinIL	   Kits	   (NuGen	   Inc.,	   USA).	   	   For	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each	  sample,	  2μls	  of	  the	  first	  strand	  primer	  mix	  was	  added	  to	  the	  RNA	  and	  mixed.	  The	  
tubes	  were	  heated	  to	  650C	  for	  2	  minutes	  then	  cooled	  at	  40C.	  2.5μls	  of	  the	  first	  strand	  
buffer	   mix	   and	   0.5μl	   of	   the	   enzyme	   mix	   were	   added	   to	   each	   sample	   and	   pipetted	  
gently.	   The	   samples	  were	  placed	   in	   a	   thermal	   cycler	   (Bio-­‐Rad	   S1000	   Thermal	   Cycler,	  
UK)	  at	  40C	  for	  2	  minutes,	  250C	  for	  30	  minutes,	  420C	  for	  15	  minutes,	  700C	  for	  15	  minutes	  
and	  held	  at	  40C.	  
The	   second	   strand	   reagents	  were	   thawed;	   9.7μls	   of	   the	   buffer	  mix	   and	   0.3μl	   of	   the	  
enzyme	  mix	  were	  added	  to	  each	  first	  strand	  reaction	  tube	  and	  mixed.	  The	  tubes	  were	  
again	  placed	  in	  a	  thermal	  cycler	  at	  40C	  for	  1	  minute,	  250C	  for	  10	  minutes,	  500C	  for	  30	  
minutes,	  800C	  for	  20	  minutes	  and	  held	  at	  40C.	  
The	  double	  stranded	  cDNA	  was	  purified	  using	  RNAClean	  XP	  beads	  (NuGen	  Inc.,	  USA).	  
32μls	  of	  the	  beads	  were	  added	  to	  each	  reaction,	  mixed	  and	  incubated	  for	  10	  minutes	  
at	  room	  temperature.	  The	  tubes	  were	  placed	  on	  a	  magnet	  for	  5	  minutes	  to	  completely	  
clear	  the	  beads.	  45μls	  of	   the	  buffer	  was	  carefully	  removed	  and	  discarded.	  The	  beads	  
were	  washed	  while	  still	  on	  the	  magnet	  for	  30	  seconds	  with	  200μls	  of	  freshly	  prepared	  
70%	  ethanol	  three	  times	  and	  dried	  for	  20	  minutes.	  	  
Next,	   the	   single	   primer	   isothermal	   amplification	   (SPIA)	   protocol	  was	   used.	   100μls	   of	  
the	   SPIA	   master	   mix	   provided	   was	   added	   to	   each	   second	   strand	   reaction	   tube	  
containing	  the	  dried	  beads.	  They	  were	  gently	  mixed	  and	  centrifuged	  at	  8,000xg	  for	  10	  
seconds.	  The	  tubes	  were	  again	  placed	  in	  a	  thermal	  cycler	  at	  40C	  for	  1	  minute,	  470C	  for	  
75	  minutes,	  950C	  for	  5	  minutes	  and	  held	  at	  40C.	  The	  tubes	  were	  centrifuged	  at	  8,000xg	  
for	  10	  seconds,	  transferred	  to	  the	  magnet	  and	  allowed	  to	  stand	  for	  5	  minutes	  and	  the	  
eluted	  SPIA	  cDNA	  was	  pipetted	  into	  a	  new	  tube.	  	  
The	   MinElute	   reaction	   Cleanup	   kit	   (Qiagen,	   UK)	   was	   used	   for	   DNA	   purification	  
following	   enzymatic	   reactions.	   300μls	   of	   the	   ERC	   buffer	   provided	  was	   added	   to	   the	  
samples,	   vortexed	   and	   transferred	   to	   the	   MinElute	   spin	   columns,	   which	   were	  
centrifuged	  at	  8,000xg	  for	  1	  minute.	  The	  flow	  through	  was	  discarded	  and	  750μls	  of	  the	  
PE	  buffer	  was	  added	  and	  similarly	  centrifuged	  twice	  to	  remove	  any	  remaining	  buffers.	  
The	  columns	  were	  blotted	  gently	  and	  placed	  onto	  new	  collection	  tubes.	  	  To	  elute	  the	  
cDNA	  20μls	  of	  nuclease	  free	  water	  was	  added,	  the	  columns	  were	  allowed	  to	  stand	  for	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1	  minute	  then	  centrifuged	  at	  10,000xg	  for	  1	  minute.	  The	  cDNA	  was	  quantified	  using	  a	  
nanodrop	  (see	  RNA	  quantification).	  
The	  Encore	  BiotinIL	  kit	  (NuGen	  Inc.,	  USA)	  was	  used.	  UNG	  was	  added	  first	  to	  remove	  the	  
uracil	  base	  incorporated	  during	  the	  cDNA	  amplification	  process.	  This	  creates	  an	  abasic	  
site	  in	  the	  cDNA	  strand,	  which	  is	  subsequently	  labelled	  with	  a	  biotin	  moiety.	  5μls	  of	  the	  
UNG	   buffer	   then	   5μls	   of	   the	   UNG	   enzyme	   was	   added	   per	   sample,	   vortexed	   and	  
centrifuged	  briefly	  to	  ensure	  mixing.	  The	  samples	  were	  heated	  to	  500C	  for	  30	  minutes	  
then	  cooled	  to	  40C.	  Next,	  5μls	  of	  the	  labelling	  buffer	  was	  added	  to	  each	  sample,	  mixed	  
then	   5μls	   of	   the	   labelling	   reagent	   was	   added	   and	   mixed	   by	   pipetting	   and	   brief	  
centrifugation.	  The	  samples	  were	  heated	   to	  500C	   for	  60	  minutes	   then	  cooled	   to	  40C.	  
The	   MinElute	   reaction	   Cleanup	   kit	   (Qiagen,	   UK)	   was	   used	   as	   in	   described	   in	   the	  
previous	  paragraph	  and	  the	   labelled	  cDNA	  samples	  were	  eluted	  and	  quantified	  using	  
the	  nanodrop.	  
The	  cDNA	  was	  hybridized	  to	   Illumina	  HT12V4	  Microarrays,	  scanned	  using	  an	   Illumina	  
iScan	  System	  and	  subjected	  to	  quantile	  normalization	  within	  the	  Genome	  Studio	  Suite	  
v1.0	   (Illumina).	   Expression	   data	   were	   analysed	   using	   Partek	   Genomics	   Suite	   (Partek	  
Inc.,	   USA)	   version	   6.6,	   Ingenuity	   Pathway	   Analysis	   (Qiagen,	   UK)	   and	   Gene	   Set	  
Enrichment	  Analysis,	  GSEA	  (Broad	  Institute	  of	  MIT	  and	  Harvard,	  USA)	  by	  Dr	  Ben	  Afzali	  
(Division	   of	   Transplant	   Immunology	   and	   Mucosal	   Biology,	   MRC	   Centre	   for	  
Transplantation,	  King's	  College	  London,	  Guy's	  Hospital,	  UK)	  and	  Dr	  Paul	  Lavender	  (MRC	  
and	  Asthma	  UK	  Centre	  in	  Allergic	  Mechanisms	  of	  Asthma,	  King's	  College	  London,	  Guy's	  
Hospital,	  UK).	  
2.5.14	  Cellular	  lipid	  extraction	  and	  mass	  spectrometry	  
The	   cellular	   lipid	   extraction	   and	  mass	   spectrometry	   was	   performed	   in	   collaboration	  
with	   Dr	   Corinne	   M	   Spickett	   and	   Alpesh	   Thakker	   (School	   of	   Life	   &	   Health	   Sciences,	  
Aston	   University,	   Aston	   Triangle,	   Birmingham,	   UK).	   These	   experiments	   were	  
performed	  in	  their	  laboratory	  under	  their	  supervision.	  The	  mass	  spectrometry	  was	  run	  
with	   the	   help	   of	   Alpesh	   Thakker	   and	   the	   analyses	   was	   performed	   by	   Dr	   Corinne	  M	  
Spickett.	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Monocytes	  from	  a	  healthy	  donor	  were	  incubated	  with	  MPO-­‐ANCA	  or	  control	  IgG	  for	  18	  
hours	   as	   described	   before	   (3X106	   cells/condition).	   The	   cell	   pellets	  were	  washed	   and	  
stored	  at	   -­‐800C.	  All	  organic	   solvents	  used	   for	   lipid	  extraction	  and	  mass	   spectrometry	  
were	  of	  high	  performance	  liquid	  chromatography	  grade.	  	  
The	  extraction	  of	  phospholipids	  were	  performed	  using	  a	  double	  extraction	  technique	  
by	  addition	  of	   ice	  cold	  500μls	  methanol	  containing	  0.005%	  butylated	  hydroxytoluene	  
and	  500μls	  deionised	  water	  to	  each	  cell	  pellet	  sample.	  The	  sample	  was	  vortexed	  and	  
100µls	   of	   a	   1μg/ml	   solution	   of	   1,2-­‐ditridecanoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	   (13:0,	  
13:0	  PC)	  in	  methanol	  containing	  0.005%	  butylated	  hydroxytoluene	  was	  added	  to	  each	  
sample	   (used	   as	   an	   internal	   standard).	   The	   samples	   were	   sonicated	   at	   40C	   for	   15	  
minutes	   in	   a	   waterbath.	   500μls	   of	   chloroform	   was	   added	   and	   the	   samples	   were	  
sonicated	   further	   as	   described.	   The	   samples	  were	   then	   centrifuged	   for	   5	  minutes	   at	  
5000xg	  and	  the	  upper	  aqueous	  phase	  was	  removed	  and	  the	  extraction	  procedure	  was	  
repeated	   as	   above.	   Both	   organic	   phases	   (bottom	   layer)	   were	   combined	   and	   dried	  
under	  a	  stream	  of	  oxygen-­‐free	  nitrogen	  and	  stored	  at	  -­‐800C.	  
Before	  analysis	   the	  extracts	  were	   reconstituted	   in	  200μls	  methanol:chloroform	   (1:1).	  
Two	  solvents	  A	  and	  B	  were	  used	  at	  a	  ratio	  of	  3:7;	  solvent	  A	  was	  made	  of	  water,	  0.1%	  
formic	   acid	   and	   5mM	   ammonium	   formate	   whilst	   solvent	   B	   was	  made	   of	  methanol,	  
0.1%	   formic	   acid	   and	   5mM	   ammonium	   formate.	   The	   extracts	   were	   diluted	   in	   the	  
solvent	  A:B	  mixture	  at	  1:5	  or	  1:10.	  
Phospholipids	  were	   separated	  by	   reverse	  phase	   chromatography	  on	  an	  HPLC	   system	  
(Dionex	  Ultimate	  3000	   system)	   controlled	  by	  Chromoleon	   software,	   using	   a	   Proswift	  
RP-­‐4H	   column	   (1mm	   x	   250mm)	   at	   room	   temperature.	   The	   eluents	   used	   were	   (A)	  
aqueous	   0.1%	   formic	   acid	   containing	   5	   mM	   ammonium	   formate	   and	   (B)	   methanol	  
containing	  0.1%	  formic	  acid	  and	  5	  mM	  ammonium	  formate.	  The	  LCMS	  run	  time	  was	  50	  
minutes	   with	   a	   chromatographic	   gradient	   of	   70%	   B	   at	   0	   –	   4,	   followed	   by	   3-­‐step	  
gradient	  increase	  to	  80%	  B	  at	  8	  minutes,	  90%	  B	  at	  15	  and	  100%	  B	  at	  20	  minutes.	  The	  
gradient	  was	  maintained	  at	  100%	  B	  until	  38	  minutes	  and	  then	  decreased	  back	  to	  70%	  B	  
by	  50	  minutes.	  The	  flow	  of	  the	  mobile	  phase	  was	  set	  to	  50µls/minute.	  Samples	  were	  
diluted	  1:5	  or	  1:10	  as	  described	  above	   in	   the	  starting	  solvent	  and	  10µls	  were	   loaded	  
onto	  the	  column.	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The	   phospholipids	   were	   detected	   using	   targeted	   and	   data	   dependent	   scanning	  
routines	  performed	  on	  a	  Absciex	  5500	  QTrap	  mass	  spectrometer	  controlled	  by	  Analyst	  
software.	  Precursor	  ion	  scanning	  (PIS)	  of	  184	  Da	  was	  carried	  out	  over	  the	  mass	  range	  
400	  Da	  -­‐	  1000	  Da	  to	  identify	  phosphatidylcholines	  and	  oxidised	  phosphatidylcholines.	  
The	  declustering	  potential	  was	  set	  to	  50V	  for	  all	  scans	  and	  collision	  energy	  for	  PIS	  was	  
set	  to	  45eV.	  Information	  dependent	  data	  acquisition	  (IDA)	  was	  used	  to	  collect	  MS/MS	  
data	  based	  on	   following	   criteria:	   the	  most	   intense	   ion	  with	  +1	   charge	  and	  minimum	  
intensity	  of	  1000cps	  was	  chosen	  for	  analysis,	  using	  dynamic	  exclusion	  for	  20	  seconds	  
after	   2	   occurrences	   and	   a	   fixed	   collision	   energy	   setting	   of	   47eV.	   Other	   source	  
parameters	  were	  adjusted	  to	  give	  optimal	  response	  from	  the	  direct	  infusion	  of	  a	  dilute	  
solution	  of	  standards.	  
Data	   analysis	   was	   performed	   manually	   using	   Peakview	   2.0	   software	   by	   generating	  
extracted	   ion	   chromatograms	   for	   individual	   mass	   to	   charge	   ratios	   corresponding	   to	  
different	   modified	   and	   unmodified	   phospholipid	   species	   and	   calculating	   peak	   area.	  	  
The	  peak	  area	  was	  normalised	  to	  the	  peak	  area	  of	  the	   internal	  standard	  to	  check	  for	  
extraction	   variability,	   but	   subsequently	   the	   signal	   intensities	   were	   expressed	   as	   a	  
percentage	  of	  the	  intensity	  of	  the	  dipalmitoyl	  phosphatidylcholine	  at	  m/z	  734	  to	  take	  
into	  account	  variability	  in	  the	  total	  phospholipid	  present	  in	  the	  samples.	  
2.5.15	   PR3	   Cleaving	   C3	   Assay	   -­‐	   Sodium	   dodecyl	   sulphate	   polyacrylamide	   gel	  
electrophoresis	  (SDS-­‐PAGE)	  and	  Western	  blot	  
Human	   PR3	   (Calbiochem,	  UK)	  was	   incubated	  with	   purified	   human	   C3	   (10µg/ml)	   and	  
C3b	   (10µg/ml)	   (from	   Complement	   Technologies	   Inc.	   USA)	   to	   help	   determine	   the	  
potential	   of	   C3	   cleavage	   by	   PR3	   for	   15	   minutes	   or	   60	   minutes	   at	   370C.	   Different	  
concentrations	   of	   PR3	  were	   used	   (5-­‐15µg/ml).	   A	   reducing	   sample	   buffer	  was	   added	  
and	   the	   eppendorfs	   containing	   the	   proteins	   were	   placed	   on	   a	   thermomixer	   for	   3	  
minutes	  at	  1000C.	  The	  samples	  were	  then	   loaded	  onto	  a	  4%	  NuPage	  Bis	  Tris	  gel	   (Life	  
Technologies,	  UK),	  at	  a	  volume	  of	  25µls	  sample	  per	  well.	  A	  volume	  of	  12µls	  of	  SeeBlue	  
Plus	   2	   pre-­‐stained	   standard	   (Life	   Technologies,	  UK)	  was	   added	   too.	   The	   gel	  was	   run	  
using	  a	  PowerEase500	  power	   supply	   (Life	  Technologies,	  UK)	  at	  200V	   for	  30	  minutes.	  
The	  gel	  was	  removed	  from	  the	  cassette	  and	  washed	  3	  times	  in	  deionized	  water	  for	  5	  
minutes	  each	  time	  on	  a	  shaker	  plate.	  The	  gel	  was	  fixed	  using	  deionized	  water	  (90mls)	  /	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methanol	   (100mls)	   /	   acetic	   acid	   (20mls),	   sensitized	  using	  deionized	  water	   (105mls)	   /	  
methanol	   (100mls)	   /	   sensitizer	   (5mls)	   and	   washed	   again.	   The	   gel	   was	   stained	   with	  
stainer	   A	   and	   B	   (Life	   Technologies,	   UK),	   and	   washed	   again	   as	   above.	   5mls	   of	   the	  
developer	   was	   added	   to	   95mls	   of	   deionized	   water	   and	   the	   gel	   was	   soaked	   in	   this	  
diluted	  developer.	  The	  reaction	  was	  stopped	  and	  the	  gel	  washed.	  The	  gel	  was	  scanned.	  	  
The	   samples	  were	   also	   analysed	   by	  western	   blotting	   technique.	  Western	   blots	  were	  
carried	  out	  using	   the	   iBlot	   gel	   transfer	  device	  as	  per	   the	  manufacturer’s	   instructions	  
(Life	  Technologies,	  UK).	  The	  iBlot	  NC	  anode	  stack	  bottom	  (Life	  Technologies,	  UK)	  was	  
placed	  onto	  the	  blotting	  surface	  of	  the	  iBlot	  machine	  at	  20	  volts.	  After	  completion,	  the	  
SDS-­‐PAGE	   gel	  was	   removed	   from	   the	   cassette	   and	   placed	   directly	   onto	   the	   transfer	  
membrane	  of	  the	  anode	  stack.	  iBlot	  filter	  paper	  that	  had	  been	  pre-­‐soaked	  in	  deionized	  
water	  was	  placed	  over	  the	  gel	  and	  air	  bubbles	  were	  removed	  using	  the	  iBlot	  roller.	  The	  
iBlot	   cathode	   stack	   top	   (Life	  Technologies,	  UK)	  was	  placed	  over	   the	   filter	  paper	  with	  
the	  electrode	  side	  facing	  up	  and	  aligned	  to	  the	  right	  edge.	  The	  disposable	  sponge	  was	  
placed	  with	  the	  metal	  contact	  on	  the	  upper	  right	  corner	  of	  the	  lid.	  The	  lid	  was	  closed	  
and	  the	  gel	  was	  transferred	   in	  seven	  minutes.	  The	  completed	  blot	  was	  blocked	  for	  1	  
hour	  in	  1xTBS	  tween/5%	  powdered	  milk	  (shaking	  vigorously)	  after	  which	  it	  was	  washed	  
in	  1xTBS	  tween	  three	  times	  for	  15	  minutes	  each	  time	  whilst	  being	  shaken	  vigorously.	  	  
A	   volume	  of	  15mls	  of	   the	  appropriately	  diluted	   (in	  1xTBS	   tween/5%	  powdered	  milk)	  
primary	  antibody	  (see	  table	  of	  antibodies)	  was	  added	  to	  the	  blot	  and	  incubated	  at	  40C	  
overnight	   (shaking	  gently).	  The	  blot	  was	  washed	  as	  before.	  A	  horseradish	  peroxidase	  
(HRP)	   secondary	   antibody	   was	   diluted	   appropriately	   (in	   1xTBS	   tween/5%	   powdered	  
milk)	  and	  15mls	  was	  added	  to	  the	  blot	  for	  2	  hours	  at	  room	  temperature	  (with	  gentle	  
shaking).	  The	  blot	  was	  washed	  as	  before.	  The	  HRP	  substrate	  was	  prepared	  by	  mixing	  
equal	  volumes	  of	  Supersignal	  west	  pico	  chemiluminescent	  substrates	   (Thermo	  Fisher	  
Scientific,	  UK)	  (7.5ml	  +	  7.5ml)	  and	  was	  added	  to	  the	  blot	  (shaking	  gently)	  for	  5	  minutes.	  
The	  blot	  was	  put	   into	  a	  polythene	  pocket	  and	  secured	   into	  a	  Kodak	  BioMax	  cassette	  
(Anachem,	  UK).	  In	  a	  dark	  room	  the	  Kodak	  BioMax	  Light	  film	  (Anachem,	  UK)	  was	  placed	  
inside	   and	   the	   cassette	  was	   closed	   for	   the	   appropriate	   exposure	   time.	   The	   film	  was	  
developed.	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2.6	  Statistics	  
Data	  was	  analysed	  using	  Graphpad	  Prism	  version	  6	  software	  (Graphpad	  Software	  Inc,	  
La	  Jolla,	  CA,	  USA).	  The	  specific	  tests	  used	  in	  each	  experiment	  are	  stated	  in	  the	  results	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Chapter	  3	  –	  Activation	  of	  neutrophils	  by	  ANCA	  
3.1	  Introduction	  
ANCA	   recognise	   antigens	   that	   are	   present	   in	   primary	   granules	   of	   neutrophils	   and	  
lysosomes	  of	  monocytes,	  namely	  PR3	  and	  MPO.	  ANCA	  were	  first	  thought	  to	  represent	  
a	  serological	  marker	  of	  disease	  but	  subsequent	  studies	  have	  shown	  that	   they	  have	  a	  
more	  significant	  role	  in	  pathogenesis.	  Initial	  studies	  of	  the	  potential	  pathogenic	  role	  of	  
ANCA	  were	  performed	  in	  vitro	  and	  revealed	  that	  primed	  neutrophils	  can	  be	  activated	  
to	   undergo	   respiratory	   burst	   and	   degranulation	   [61].	   They	   showed	   that	   ANCA	   IgG	  
increased	   ROS	   release	   from	   primed	   neutrophils	   in	   comparison	   to	   control	   IgG	   as	  
measured	   by	   a	   chemiluminescence	   assay	   and	   a	   ferricytochrome	   C	   reduction	   assay.	  
They	  also	  assessed	  primary	  granule	  degranulation	  as	  measured	  by	  β-­‐glucuronidase	  and	  
N-­‐acetylglucosaminidase	  release	  and	  showed	  that	  ANCA	  IgG	   in	  the	  presence	  of	  TNFα	  
led	   to	   increased	   degranulation	   in	   comparison	   to	   control	   IgG	   [61].	   Since	   then	   other	  
published	  literature	  has	  corroborated	  that	  monoclonal	  and	  polyclonal	  patient	  derived	  
ANCA	  in	  the	  presence	  of	  TNFα	  leads	  to	  neutrophil	  respiratory	  burst	  [62,	  64,	  111,	  251].	  
However,	  they	  had	  relatively	  small	  numbers	  of	  patient	  ANCA	  and	  control	   IgG,	  as	  well	  
as	  often	  a	  single	  donor	  for	  neutrophils.	  Furthermore,	  it	  is	  not	  apparent	  in	  the	  literature	  
how	  the	  ANCA	  or	  control	  IgG	  samples	  were	  selected.	  Anecdotally,	  it	  has	  been	  reported	  
that	  the	  neutrophil	  activating	  capacity	  of	  different	  IgG	  preparations	  from	  different	  AAV	  
patients	  vary	  in	  their	  ability	  to	  activate	  neutrophils.	  	  
The	  role	  of	  neutrophils	  in	  AAV	  has	  been	  discussed	  in	  chapter	  1,	  there	  is	  convincing	   in	  
vivo	  evidence	  to	  support	  the	   in	  vitro	  data	  that	  neutrophils	  have	  a	  crucial	   role	   in	  AAV	  
pathogenesis.	   The	   contribution	   of	   neutrophils	   to	   pathogenesis	   seems	   to	   be	  
multifaceted.	  As	  reviewed	  in	  section	  1.6,	  the	  damage	  mediated	  by	  neutrophils	  appears	  
to	   be	   dependent	   on	   generation	   of	   ROS,	   degranulation,	   generation	   of	   NETs	   and	  
subsequent	   complement	   activation.	   Neutrophils	   are	   capable	   of	   other	   functions	  
including	   release	   of	   cytokines,	   chemokines,	   leucotrienes,	   prostaglandins	   as	   well	   as	  
proteases	   and	   antigen	   presentation	   via	   MHC	   class	   II,	   which	   all	   contribute	   to	  
pathogenesis.	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The	   generation	   of	   oxidants	   by	   neutrophils	   results	   from	   the	   activation	   of	   the	   multi-­‐
protein	   enzyme	   complex	   NADPH	   oxidase,	   an	   electron	   transporting	   system,	   which	   is	  
formed	  by	  four	  oxidase	  specific	  proteins	  (p22phox,	  p47phox,	  p67phox	  and	  gp91phox)	  as	  well	  
as	   a	   GTPase	   (Rac1/2)	   component	   [252].	   Upon	   cell	   activation	   the	   cytosolic	   proteins	  
translocate	  to	  the	  membrane	  bound	  component	  (gp91phox)	  and	  catalyse	  the	  formation	  
of	   superoxide	   anions	   through	   oxygen	   reduction.	   This	   occurs	   once	   the	   electrons	   are	  
ferried	  from	  NADPH	  in	  the	  cytosol	  over	  the	  membrane	  in	  question	  and	  is	  delivered	  to	  
the	  oxygen	  molecule	  in	  the	  intracellular	  or	  extracellular	  milieu.	  Other	  ROS	  species	  such	  
as	  hydrogen	  peroxide	   (H2O2),	  hydroxyl	   radicals	  and	  hypochlorous	  acid	  are	  derived.	  A	  
number	  of	  techniques	  have	  been	  developed	  to	  assess	  respiratory	  burst	  activity	  and	  the	  
work	  shown	  in	  this	  chapter	  describes	  two	  methods	  we	  utilised.	  
DHR	   123,	   a	   non-­‐fluorescent	  molecule	   is	   taken	   up	   by	   phagocytes	   and	   oxidised	   to	   its	  
fluorescent	   derivative	   rhodamine	   123	   by	   reactive	   oxygen	   intermediates,	   primarily	  
H2O2,	  produced	  during	   the	   respiratory	  burst	   response.	  This	  assay	  primarily	  measures	  
intracellular	   ROS	   production.	   Several	   dyes	   release	   energy	   in	   the	   form	   of	   light	  
(chemiluminescence)	  following	  excitation	  by	  ROS.	  Luminol	  is	  an	  example	  and	  the	  most	  
commonly	   investigated.	   It	   is	   an	  activity	   amplifier,	  which	   reduces	   the	  detection	   limits	  
making	   the	   respiratory	   burst	   assay	   technique	   sensitive.	   Luminol	   measures	   both	  
intracellular	  and	  extracellular	  ROS	  production.	  Isoluminol	  is	  another	  chemiluminescent	  
molecule	  that	  is	  used	  to	  exclusively	  measure	  extracellular	  ROS	  released	  by	  the	  cell.	  By	  
moving	   the	   amino	   group	   away	   from	   the	   first	   carbon	   atom	   in	   the	   phthalate	   ring	   of	  
luminol,	  isoluminol	  is	  more	  hydrophilic	  and	  less	  able	  to	  transverse	  the	  cell	  membrane	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Upon	   stimulation	   neutrophil	   granules	   translocate	   to	   the	   cell	   surface	   or	   phagosomal	  
membrane	   where	   they	   fuse	   with	   the	   membrane	   to	   release	   their	   contents	  
(degranulation).	  Neutrophils	  contain	  at	  least	  four	  different	  granule	  types	  [254]:	  
-­‐ Azurophilic	  (primary)	  granules,	  which	  contain	  CD63,	  MPO,	  PR3,	  elastase,	  cathepsins	  
and	  α1-­‐antitrypsin	  amongst	  other	  constituents.	  
-­‐ Specific	   (secondary)	   granules,	   which	   contain	   CD11b/CD18,	   CD66,	   lactoferrin,	  
lysozyme,	  collagenase	  and	  TNF-­‐receptors.	  
-­‐ Gelatinase	  (tertiary)	  granules	  contain	  CD11b/CD18,	  fMLP-­‐receptors,	   lysozyme	  and	  
gelatinase.	  
-­‐ Secretory	   vesicles,	   which	   contain	   CD11b/CD18,	   fMLP-­‐receptors,	   DAF	   and	   other	  
plasma	  proteins.	  
Degranulation	  of	  neutrophils	  can	  be	  quantified	  by	  measuring	  granule	  contents	   in	  the	  
supernatant.	   Other	   methods	   include	   measuring	   surface	   expression	   of	   granule	  
membrane	   components	   with	   flow	   cytometry.	   In	   this	   chapter	   we	   measured	   MPO	  
activity	  and	  lactoferrin	  in	  the	  neutrophil	  supernatant,	  and	  cell	  surface	  CD66	  and	  CD11b	  
as	  	  markers	  of	  degranulation.	  
The	   role	  of	   complement	   in	  AAV	  has	  been	  discussed	  extensively	   in	   chapter	  1,	   section	  
1.10.	  Most	  studies	  have	  centred	  on	  in	  vivo	  models	  to	  demonstrate	  the	  pathogenic	  role	  
of	  complement	  components.	  Camous	  et	  al	  showed	  that	  human	  neutrophils	  stimulated	  
by	   cytokines	   or	   coagulation	   system	   derived	   factors	   activate	   exogenous	   complement	  
(from	   serum)	   with	   the	   consequence	   that	   C3	   activation	   fragments,	   C5a	   and	   C5b-­‐9	  
complexes	  are	  detectable	  on	  the	  neutrophil	  surface	  [255].	  Neutrophils	  are	  capable	  of	  
releasing	   C3,	   factor	   B	   and	   properdin,	   the	  machinery	   for	   convertase	   formation	   [187,	  
210]	   and	   hence	   like	   other	   leukocytes	   such	   as	   T	   cells,	   may	   be	   able	   to	   generate	   the	  
complement	  components	  C5a	  and	  C5b.	  	  	  
3.2	  Aims	  	  
In	   this	   chapter	   we	   aimed	   to	   set	   up	   a	   robust	   in	   vitro	   read	   out	   of	   polyclonal	   ANCA	  
induced	  neutrophil	  activation	  with	  reduced	  variability	  and	  in	  doing	  so	  show	  the	  impact	  
of	  ANCA	  on	  neutrophil	  respiratory	  burst	  and	  degranulation.	  We	  also	  aimed	  to	  examine	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the	  expression	  of	  complement	  components	  C3	  and	  C5	  by	  neutrophils	  and	  the	  effect	  of	  
ANCA	  on	  C3	  and	  C5.	  	  
3.3	  Polyclonal	  ANCA	  are	  not	  consistently	  able	  to	  activate	  neutrophils	  to	  
produce	  ROS	  in	  comparison	  to	  control	  IgG	  
We	  began	  by	   investigating	  the	  activation	  of	  neutrophils	   isolated	  from	  healthy	  donors	  
in	  response	  to	  ANCA.	  	  To	  obtain	  a	  non-­‐biased	  and	  objective	  measure	  of	  this	  effect,	  we	  
examined	   the	   responses	   of	   unselected	   IgG	   purified	   from	   the	   blood	   of	   10	   healthy	  
donors,	   11	  patients	  with	  MPO-­‐ANCA	  disease	   and	  9	  patients	  with	  PR3-­‐ANCA	  disease.	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Treatment	  at	  time	  of	  
sample	  collection	  
68	   F	   MPO	   12	   22	   ENT,	  Chest	   MP	  day	  3	  
72	   F	   MPO	   12	   18	   Chest	   MP	  day	  1	  
55	   F	   MPO	   12	   15	   No	   Nil	  
77	   F	   MPO	   12	   18	   ENT,	  Chest	   LDOP	  
38	   M	   MPO	   6	   10	   Eyes,	  Skin	   Nil	  
66	   M	   MPO	   12	   18	   Chest	   Nil	  
82	   F	   MPO	   12	   15	   No	   LDOP	  
74	   F	   MPO	   12	   12	   No	   MP	  day	  3	  
73	   F	   MPO	   12	   12	   No	   Nil	  
74	   F	   MPO	   12	   15	   No	   MP	  day	  1	  
63	   M	   MPO	   12	   25	   ENT,	  Eyes,	  Skin	   Nil	  
42	   M	   PR3	   12	   35	   ENT,	  NS,	  Eyes,	  
Chest	  
Oral	  cyclo,	  high	  dose	  
oral	  pred	  
74	   M	   PR3	   12	   31	   ENT,	  NS,	  Skin,	  
Chest	  
Nil	  
75	   M	   PR3	   12	   19	   NS,	  Eyes,	  Skin	   Nil	  
59	   M	   PR3	   12	   27	   ENT,	  Eyes,	  Chest	   Methotrexate	  
76	   M	   PR3	   12	   19	   Skin	   Nil	  
51	   M	   PR3	   12	   23	   Eyes,	  Chest	   Oral	  cyclo,	  MP	  day	  2	  
51	   M	   PR3	   10	   14	   ENT,	  Eyes	   Nil	  
73	   M	   PR3	   12	   19	   Eyes,	  Skin	   Nil	  
72	   F	   PR3	   12	   18	   ENT	   Nil	  
Table	  3.1	   -­‐	   Characteristics	  of	   the	  20	  patients	   from	  who	   samples	  were	   collected	   for	  
ANCA	   isolation.	   Samples	  were	   attained	   from	   patients	   in	   a	   number	   of	   renal	   units	   in	  
Southeast	   England.	   All	   patients	   had	   active	   ANCA	   vasculitis	   and	   all	   were	   new	  
presentations	  of	  ANCA	  vasculitis.	   (BVAS	  =	  Birmingham	  vasculitis	  activity	   score,	  ENT	  =	  
ear,	  nose	  or	  throat,	  NS	  =	  nervous	  system,	  MP	  =	  methylprednisolone,	  LDOP	  =	  low	  dose	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Age	   Sex	  
27	   M	  
27	   F	  
50	   M	  
52	   M	  
41	   M	  
35	   M	  
33	   F	  
24	   F	  
36	   F	  
40	   M	  
Table	  3.2	  -­‐	  Characteristics	  of	  10	  healthy	  controls	  used	  for	  control	  IgG	  purification.	  
The	   antibodies	   were	   purified	   as	   described	   in	   section	   2.4.2	   using	   sodium	   chloride	  
precipitation.	   The	   purity	   of	   the	   antibodies	   were	   tested	   using	   SDS-­‐PAGE	  








Figure	   3.2	   –	   SDS-­‐PAGE	   gel	   of	   IgG	   preparations.	   Example	   of	   reducing	   SDS-­‐PAGE	   gel	  
showing	  in	  A	  the	  standard	  ladder,	  whilst	  B-­‐E	  reveal	  the	  separation	  of	  2	  control	  and	  2	  














A B C D E
|	  Page	  106	  
3.3.1	  DHR	  123	  assays	  
The	  DHR	  123	  assay	  was	  initially	  performed	  using	  TNFα	  primed	  neutrophils	  from	  control	  
donors,	   which	   were	   subsequently	   stimulated	   with	   fMLP,	   monoclonal	   MPO-­‐ANCA	  
(clone	   266.6K2),	   monoclonal	   PR3-­‐ANCA	   (WGM2)	   or	   an	   equivalent	   isotype	   control	  
(clone	  107.3)	  to	  discount	  non-­‐specific	  rhodamine	  123	  production	  (see	  section	  2.5.7	  for	  
methodology).	  Figure	  3.3	  below	  shows	  typical	  FACS	  histogram	  plots	  using	  one	  donor’s	  






Figure	  3.3	  –	  Representative	  DHR	  123	  FACS	  histogram	  plots	  and	  MFI	  values	  of	  TNFα	  
primed	  neutrophils	   stimulated	  with	  monoclonal	  antibodies.	   The	  primed	  neutrophils	  
were	  stimulated	  with	  fMLP	  (100ng/ml)	  or	  monoclonal	  ANCA	  (PR3	  mAb	  and	  MPO	  mAb)	  
(5μg/ml)	   or	  monoclonal	   isotype	   control	   (control	   mAb)	   (5μg/ml).	   Non	   activated	   cells	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  123	  
|	  Page	  107	  
Primed	   neutrophils	   exposed	   to	   fMLP	   were	   used	   as	   a	   positive	   control.	   There	   was	   a	  
response	  in	  rhodamine	  123	  production	  to	  monoclonal	  MPO-­‐ANCA.	  There	  was	  a	  slight	  
increase	  in	  median	  fluorescence	  intensity	  (MFI)	  with	  monoclonal	  PR3-­‐ANCA	  compared	  
to	  the	  monoclonal	  isotype	  control.	  
TNFα	  primed	  neutrophils	   from	   two	  donors	   (27	   year	   old	  male	   and	   50	   year	   old	  male)	  
were	   then	   stimulated	  with	   unselected	   polyclonal	   antibodies	   highlighted	   in	   table	   3.1	  
and	  table	  3.2	  from	  patients	  (11	  patients	  with	  MPO-­‐ANCA	  disease	  and	  9	  patients	  with	  
PR3-­‐ANCA	   disease)	   and	   10	   control	   subjects.	   Surprisingly,	   we	   found	   no	   significant	  
difference	   in	   DHR	   123	   plot	   MFI	   between	   polyclonal	   ANCA	   samples	   and	   control	   IgG	  
































Figure	  3.4	  –	  Representative	  DHR	  123	  FACS	  histogram	  plots	  and	  MFI	  values	  of	  TNFα	  
primed	   neutrophils	   from	   one	   donor	   stimulated	   with	   polyclonal	   antibodies.	   The	  
primed	   neutrophil	   were	   stimulated	   with	   polyclonal	   control	   IgG	   (A),	   patient	   derived	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Figure	  3.5	  –	  Summary	  of	  the	  MFI	  of	  TNFα	  primed	  neutrophils	  DHR	  123	  responses	  to	  
polyclonal	   antibodies.	   TNFα	   primed	   neutrophils	   from	   two	   healthy	   donors	   were	  
stimulated	  with	   control	   IgG	   (n=10),	  MPO-­‐ANCA	   (n=11)	   or	   PR3-­‐ANCA	   (n=9).	   All	   ANCA	  
represents	   the	   combined	   results	   for	   MPO-­‐ANCA	   and	   PR3-­‐ANCA	   (n=20).	   Data	   was	  
analysed	  using	  one-­‐way	  ANOVA	  with	  Dunnett’s	  post	   test	   (NS	  =	  non	  significant).	  Data	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3.3.2	  Luminometer	  assays	  
The	   luminol	   neutrophil	   respiratory	   burst	   assay	   was	   initially	   set	   up	   as	   described	   in	  
section	  2.5.7	  using	  the	  positive	  control	  fMLP,	  in	  varying	  concentrations	  as	  shown	  in	  a	  
typical	  plot	  in	  figure	  3.6.	  Increasing	  concentrations	  of	  fMLP	  led	  to	  a	  stronger	  response	  
in	  TNFα	  primed	  neutrophils	  as	  expected.	  
	  
Figure	   3.6	   –	   Representative	   luminol	   assay	   plot	   of	   human	   neutrophils	   primed	  with	  
TNFα	  and	  stimulated	  with	  different	  concentrations	  of	  fMLP.	  RLU	  =	  Relative	  light	  units.	  
The	   response	   of	   TNFα	   primed	   neutrophils	   to	  monoclonal	   ANCA	  were	   also	   tested	   in	  
comparison	   to	   a	  monoclonal	   isotype	   control	   antibody.	   Figure	   3.7	   is	   a	   representative	  
plot	   of	   the	   luminol	   assay	   response	   and	   as	   depicted	   the	   response	   is	   different	   to	   the	  
typical	  fMLP	  response	  seen	  in	  timing	  and	  duration.	  The	  response	  of	  monoclonal	  ANCA	  
is	  also	   relatively	  muted	   in	   comparison.	   Isoluminol	   (extracellular	  ROS	  measure)	   traces	  
were	   similar	   to	   the	   luminol	   (intracellular	   and	   extracellular	   ROS	   measure)	   traces	  
displayed	  but	  with	  a	  lower	  RLU	  as	  anticipated.	  
	  
	  












TNFα + fMLP 1ng/ml
TNFα + fMLP 10ng/ml
TNFα + fMLP 25ng/ml
TNFα + fMLP 100ng/ml
|	  Page	  111	  
Figure	   3.7	   –	   Representative	   luminol	   assay	   plot	   of	   one	   donor’s	   neutrophils	   primed	  
with	  TNFα	  and	  stimulated	  with	  monoclonal	  antibodies.	  fMLP	  	  was	  used	  as	  a	  positive	  
control	  (A).	  The	  second	  plot	  is	  a	  replica	  of	  plot	  A	  without	  the	  fMLP	  trace	  detailing	  the	  
activation	   of	   TNFα	   primed	   neutrophils	   with	   monoclonal	   MPO-­‐ANCA,	   PR3-­‐ANCA	   or	  
monoclonal	  isotype	  control	  (B).	  
Isoluminol	   and	   luminol	   assays	   were	   next	   performed	   using	   TNFα	   primed	   neutrophils	  
from	   two	   donors	   (same	   donors	   as	   for	   the	   DHR	   assays)	   and	   polyclonal	   control	   IgG	  
(n=10)	  or	  patient	  derived	  ANCA	  (11	  MPO-­‐ANCA	  and	  9	  PR3-­‐ANCA).	  
A	  
B	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TNFα + PR3 mAb
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TNFα + control mAb
TNFα + PR3 mAb
TNFα + MPO mAb
TNFα + fMLP
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Figure	   3.8	   –	   Representative	   isoluminol	   and	   luminol	   assay	   plots	   of	   one	   donor’s	  
neutrophils	   primed	   with	   TNFα	   and	   stimulated	   with	   polyclonal	   antibodies.	   Plot	   A	  
represents	  the	  Isoluminol	  traces	  whilst	  plot	  B	  demonstrates	  the	  luminol	  traces	  of	  TNFα	  
primed	   neutrophils	   activated	   with	   fMLP	   (positive	   control),	   polyclonal	   control	   IgG,	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Due	  to	  logistical	  reasons,	  the	  30	  polyclonal	  antibody	  samples	  had	  to	  be	  analysed	  over	  3	  
separate	  experiments	  for	  each	  of	  the	  two	  neutrophil	  donors.	  The	  highest	  RLU	  for	  each	  
experiment	  was	   plotted	   and	   compared	   (figure	   3.9	   isoluminol	   assays	   and	   figure	   3.10	  
luminol	  assays).	  
Figure	  3.9	  -­‐	  Highest	  RLU	  values	  from	  isoluminol	  assay	  plots	  in	  two	  different	  donors.	  
TNFα	  primed	  neutrophils	  were	  activated	  with	  control	  IgG	  (n=10)	  or	  ANCA	  (MPO-­‐ANCA	  
n=11,	  PR3-­‐ANCA	  n=9).	  Data	  analysed	  using	  a	  two-­‐way	  ANOVA	  (all	  p	  values	  >	  0.05).	  
Donor	  1	  
Donor	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Figure	   3.10	   -­‐	  Highest	  RLU	  values	   from	   luminol	   assay	  plots	   in	   two	  different	  donors.	  
TNFα	  primed	  neutrophils	  were	  activated	  with	  control	  IgG	  (n=10)	  or	  ANCA	  (MPO-­‐ANCA	  
n=11,	  PR3-­‐ANCA	  n=9).	  Data	  analysed	  using	  a	  two-­‐way	  ANOVA	  (all	  p	  values	  >	  0.05).	  
There	  was	  no	  significant	  difference	   in	  ROS	  production	   in	  either	  human	  donor’s	  TNFα	  
primed	  neutrophils	  activated	  with	  MPO-­‐ANCA	  or	  PR3-­‐ANCA	  compared	  to	  control	   IgG	  
with	  both	  the	  isoluminol	  and	  luminol	  assays.	  	  
Donor	  1	  
Donor	  2	  




















|	  Page	  115	  
We	  then	  used	  bone	  marrow-­‐derived	  TNFα	  primed	  mouse	  neutrophils	  to	  assess	  if	  there	  
was	  a	  difference	  in	  comparison	  to	  human	  neutrophils.	  The	  luminometer	  assay	  (luminol	  
based)	   was	   used	   with	   polyclonal	   mouse	   derived	   MPO-­‐ANCA	   in	   comparison	   to	  
polyclonal	  mouse	  control	  IgG	  (figure	  3.11).	  	  
Figure	  3.11	  –	  Representative	  traces	  of	  mouse	  neutrophil	  activation	  by	  luminol	  assay.	  
Non	  activated	  or	  TNFα	  primed	  bone	  marrow-­‐derived	  neutrophils	  from	  three	  different	  
mice	  were	  stimulated	  with	  fMLP	  (10mM),	  polyclonal	  MPO-­‐ANCA	  (500μg/ml)	  or	  control	  
IgG	   (500μg/ml).	  The	  second	  graph	   is	  a	   copy	  of	   the	   top	  one	  with	   the	  omission	  of	   the	  
fMLP	  trace.	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The	  mouse	   luminol	  assays	   showed	   that	  out	  of	   the	   three	  different	  batches	  of	  murine	  
generated	  polyclonal	  MPO-­‐ANCA	  only	  one	  significantly	  stimulated	  mouse	  neutrophils	  
compared	  to	  control	  polyclonal	  IgG.	  	  
The	   capacity	   of	   ANCA	   to	   activate	   TNFα	   primed	   human	   or	   mouse	   neutrophils	   to	  
undergo	  respiratory	  burst	  is	  variable	  and	  certainly	  not	  significantly	  different	  to	  control	  
IgG	  in	  our	  experiments.	  We	  also	  observed	  that	  the	  ANCA	  that	  led	  to	  higher	  respiratory	  
burst	  read-­‐outs	  in	  one	  donor	  were	  not	  necessarily	  the	  same	  ANCA	  that	  led	  to	  the	  high	  
read-­‐outs	   in	   the	   second	   donor.	   Furthermore,	   repeating	   the	   assays	   on	   the	   same	  
individual	  neutrophil	  donor	  on	  different	  days	  did	  not	  always	  lead	  to	  reproducible	  data	  
with	  the	  same	  ANCA	  (data	  not	  shown).	  	  
3.4	  Polyclonal	  ANCA	  do	  not	  consistently	  induce	  neutrophil	  degranulation	  
We	  next	  assessed	  if	  patient	  derived	  polyclonal	  ANCA	  affects	  neutrophil	  degranulation.	  
The	  20	  ANCA	  and	  10	  control	  IgG	  used	  for	  the	  respiratory	  burst	  assays	  were	  also	  used	  
to	   assess	   degranulation	   in	   vitro	   in	   two	   donors.	   Two	   different	   degranulation	   assays,	  
lactoferrin	   release	   and	  MPO	   release	   assays	  were	   used	   as	  well	   as	   neutrophil	   surface	  
CD66b	   and	   CD11b	   FACS	   staining	   to	   potentially	   assess	   all	   four	   types	   of	   vesicle	  
degranulation	  (see	  section	  2.5.8	  for	  methodology).	  
3.4.1	  Lactoferrin	  ELISA	  
The	  Lactoferrin	  ELISA	  was	  set	  up	  as	  described	  in	  section	  2.5.8.	  As	  shown	  in	  figure	  3.12	  
there	  was	  no	  significant	  difference	  in	  the	  concentration	  of	  lactoferrin	  in	  either	  donor’s	  
TNFα	   primed	   and	  ANCA	   stimulated	   neutrophil	   supernatant	   compared	   to	   control	   IgG	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Figure	   3.12	   -­‐	   Concentration	   of	   lactoferrin	   in	   the	   supernatant	   of	   TNFα	   primed	   and	  
activated	   neutrophils	   from	   two	   donors.	   The	  NA	   (non	   activated)	   sample	   serves	   as	   a	  
negative	  control	  whilst	  the	  fMLP	  stimulated	  sample	  serves	  as	  a	  positive	  control.	  Data	  
was	   analysed	  using	   one-­‐way	  ANOVA	  with	  Dunnett’s	   post	   test	   (NS	   =	   non	   significant).	  
Data	  for	  all	  ANCA	  was	  compared	  to	  control	  IgG	  samples	  using	  a	  student’s	  t	  test.	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3.4.2	  MPO	  assay	  
Similarly,	   the	  MPO	   assay	   showed	  no	   significant	   difference	   in	   degranulation	   in	   either	  
donor’s	   TNFα	   primed	   and	   ANCA	   stimulated	   neutrophil	   supernatant	   compared	   to	  
control	  IgG	  (see	  figure	  3.13).	  	  
Figure	  3.13	   -­‐	  MPO	  degranulation	  assay	  using	  TNFα	  primed	  and	  ANCA	  /	   control	   IgG	  
activated	   neutrophil	   supernatant.	   The	   data	   is	   presented	   as	   a	   percentage	   of	   the	  
positive	   control	   (2.5	   x	   106	   neutrophils/ml)	   OD.	   Data	   was	   analysed	   using	   one-­‐way	  
ANOVA	  with	  Dunnett’s	  post	  test	  (NS	  =	  non	  significant).	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3.4.3	  CD66b	  neutrophil	  staining	  
As	  described	   in	  section	  2.5.8,	  the	  treated	  neutrophils	  were	  stained	  for	  CD66b.	  Figure	  
3.14	  shows	  no	  significant	  difference	  in	  MPO-­‐ANCA	  or	  PR3-­‐ANCA	  treated	  TNFα	  primed	  
neutrophils	  CD66b	  expression	  compared	  to	  control	  IgG	  treated	  neutrophils.	  	  
Figure	  3.14	  –	  CD66b	  expression	  on	  neutrophil	  cell	  surface.	  The	  MFI	  for	  neutrophil	  cell	  
surface	  CD66b	  expression	   for	  each	   treated	  condition	  using	  either	  non-­‐activated	   (NA)	  
neutrophils	   or	   TNFα	   primed	   and	   fMLP	   /	   control	   IgG	   /	   ANCA	   stimulated	   neutrophils	  
from	  two	  donors.	  Data	  was	  analysed	  using	  one-­‐way	  ANOVA	  with	  Dunnett’s	  post	   test	  
(NS	  =	  non	  significant).	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3.4.4	  CD11b	  neutrophil	  staining	  
As	   for	   the	   CD66b	   staining,	   neutrophils	   from	   the	   different	   treatment	   groups	   were	  
stained	  for	  CD11b	  on	  the	  cell	  surface	  (figure	  3.15).	  	  
Figure	  3.15	  –	  CD11b	  expression	  on	  neutrophil	  cell	  surface.	  The	  MFI	  for	  neutrophil	  cell	  
surface	  CD11b	  expression	   for	  each	   treated	  condition	  using	  either	  non-­‐activated	   (NA)	  
neutrophils	   or	   TNFα	   primed	   and	   fMLP	   /	   control	   IgG	   /	   ANCA	   stimulated	   neutrophils	  
from	  two	  donors.	  Data	  was	  analysed	  using	  one-­‐way	  ANOVA	  with	  Dunnett’s	  post	   test	  
(NS	  =	  non	  significant).	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3.5	  Human	  neutrophils	  express	  C3,	  C5	  and	  the	  respective	  anaphylatoxins	  
In	  our	  experience,	  unselected	  patient	  derived	  polyclonal	  ANCA	  do	  not	  affect	  neutrophil	  
respiratory	   burst	   or	   degranulation	   consistently.	   However,	   ANCA	   may	   alter	   other	  
functions.	  We	  were	   interested	   in	  not	  only	   assessing	   this	  but	   also	   investigating	   if	   like	  
other	  cell	  types,	  neutrophils	  are	  capable	  of	  generating	  complement	  components,	  and	  
if	  so	  how	  ANCA	  may	  affect	  this.	  These	  experiments	  were	  performed	  in	  the	  absence	  of	  
serum	  and	  the	  anti-­‐C3a	  FACs	  antibody	  recognises	  the	  neo-­‐epitope.	  
We	   first	  demonstrate	  using	  permeabilisation	  of	  primed	  and	  activated	  neutrophils	   (as	  
described	  in	  section	  2.5.9)	  that	  neutrophils,	  even	  in	  the	  resting	  state	  contain	  C3a	  and	  
C3	  /	  C3b	  (figure	  3.16)	  as	  well	  as	  C5a	  and	  C5	  /	  C5b	  (figure	  3.17).	  	  
The	  neutrophil	  cell	  surface	  also	  appears	  to	  express	  C3a,	  whole	  C3	  /	  C3b	  and	  C5	  /	  C5b	  
and	  to	  some	  extent	  C5a	   in	  the	  resting,	  non-­‐activated	  state	   (figures	  3.18	  and	  3.19)	  as	  
shown	  by	  FACS.	  It	  is	  unclear	  why	  the	  non-­‐permeabilised	  cells	  express	  high	  levels	  of	  C3a	  
on	  the	  cell	  surface.	  We	  did	  not	  expect	  to	  see	  the	  marked	  shift	  in	  MFI	  noted	  (see	  figure	  
3.18).	   One	   would	   assume	   that	   on	   binding	   the	   C3a	   receptor	   the	   complex	   would	   be	  
internalised.	   It	   is	   possible	   that	   there	   is	   non-­‐specific	   binding	  of	   the	   staining	  antibody,	  














Figure	   3.16	   –	   C3a	   and	   C3	   FACS	   histogram	   plots	   of	   permeabilised	   neutrophils.	   Non	  
activated	  or	  TNFα	  primed	  neutrophils	  stimulated	  with	  monoclonal	  ANCA	  or	  control	  IgG	  
were	  permeabilised	  and	  stained	  for	  C3a	  and	  C3.	  MFI	  for	  each	  condition	  listed.	  
C3a	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C3a C3















Figure	   3.17	   –	   C5a	   and	  C5	   FACS	  histogram	  plots	   of	   permeabilised	  neutrophils.	   FACS	  
plots	   of	   permeabilised	   neutrophils	   either	   non	   activated	   or	   primed	   with	   TNFα	   and	  
stimulated	  with	  monoclonal	  ANCA	  or	  control	  IgG	  stained	  for	  C5a	  and	  C5.	  MFI	  for	  each	  
condition	  listed.	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Figure	  3.18	  –	  Neutrophil	  cell	  surface	  C3a	  and	  C3	  expression.	  FACS	  histogram	  plots	  of	  
neutrophils	  either	  non	  activated	  or	  primed	  with	  TNFα	  and	  stimulated	  with	  monoclonal	  
ANCA	   or	   control	   IgG	   stained	   for	   C3a	   and	   C3	   (cell	   surface	   expression).	  MFI	   for	   each	  
condition	  listed.	  
C3a	   C3a	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Figure	  3.19	  -­‐	  Neutrophil	  cell	  surface	  C5a	  and	  C5	  expression.	  FACS	  histogram	  plots	  of	  
neutrophils	  either	  non	  activated	  or	  primed	  with	  TNFα	  and	  stimulated	  with	  monoclonal	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We	   next	   assessed	   expression	   of	   the	   anaphylatoxins	   C3a	   and	   C5a	   in	   TNFα	   primed	  
neutrophils	  (permeabilised	  in	  figure	  3.20	  and	  cell	  surface	  in	  figure	  3.21)	  incubated	  with	  
polyclonal	  control	  IgG	  or	  patient	  ANCA.	  
	  
Figure	   3.20	   –	   C3a	   and	   C5a	   expression	   in	   permeabilised	   neutrophils.	   MFI	   for	  
permeabilised	   neutrophil	   C3a	   (A)	   and	   C5a	   (B)	   expression	   for	   each	   treated	   condition	  
using	  either	  non-­‐activated	  (NA)	  neutrophils	  or	  TNFα	  primed	  and	  polyclonal	  control	  IgG	  
or	  patient	  derived	  ANCA	  stimulated	  neutrophils.	  Data	  analysed	  using	  one-­‐way	  ANOVA	  
with	  Dunnett’s	  post	  test.	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Figure	  3.21	   -­‐	  C3a	  and	  C5a	  expression	  on	  neutrophil	   cell	   surface.	  MFI	   for	  neutrophil	  
cell	  surface	  C3a	  (A)	  and	  C5a	  (B)	  expression	  for	  each	  treated	  condition	  using	  either	  non-­‐
activated	   (NA)	   neutrophils	   or	   TNFα	   primed	   and	   polyclonal	   control	   IgG	   or	   patient	  
derived	   ANCA	   stimulated	   neutrophils.	   Data	   were	   analysed	   using	   a	   one-­‐way	   ANOVA	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There	  was	  no	  significant	  difference	  in	  C3a	  or	  C5a	  expression	  in	  permeabilised	  and	  non-­‐
permeabilised	   TNFα	   primed	   neutrophils	   treated	   with	   polyclonal	   ANCA	   compared	   to	  
control	  IgG.	  The	  resulting	  question	  was	  whether	  the	  anaphylatoxins	  observed	  by	  FACS	  
within	   neutrophils	   were	   expelled	   by	   the	   TNFα	   primed	   neutrophils	   incubated	   with	  
polyclonal	   ANCA	   into	   the	   supernatant.	   The	   supernatant	   of	   the	   activated	   neutrophils	  
were	  acquired	  as	  described	  in	  section	  2.5.10	  and	  analysed	  using	  a	  CBA	  anaphylatoxin	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Figure	   3.22	   –	   C3a	   levels	   in	   the	   supernatant	   of	   non	   activated	   or	   TNFα	   primed	  
neutrophils	  from	  two	  separate	  donors.	  The	  primed	  neutrophils	  were	  stimulated	  with	  
monoclonal	   (mAb)	   or	   polyclonal	   antibodies	   from	   controls	   or	   patients.	   Data	   were	  
logarithmically	  transformed	  and	  analysed	  using	  a	  one	  way	  ANOVA	  with	  Dunnett’s	  post	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Figure	   3.23	   –	   C5a	   levels	   in	   the	   supernatant	   of	   non	   activated	   or	   TNFα	   primed	  
neutrophils	  from	  two	  separate	  donors.	  The	  primed	  neutrophils	  were	  stimulated	  with	  
monoclonal	   (mAb)	   or	   polyclonal	   antibodies	   from	   controls	   (n=10)	   or	   patients	   (MPO-­‐
ANCA	   n=11,	   PR3-­‐ANCA	   n=9).	   Data	   were	   logarithmically	   transformed	   and	   analysed	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The	   level	   of	   C5a	   in	   the	   supernatant	   of	   TNFα	   primed	   neutrophils	   from	   two	   separate	  
donors	  was	  significantly	  increased	  following	  incubation	  with	  polyclonal	  antibody	  from	  
patients	  with	  MPO-­‐ANCA	   or	   PR3-­‐ANCA	   disease.	   The	   level	   of	   C3a	   in	   the	   supernatant	  
was	  variable	  amongst	  the	  two	  neutrophil	  donors	  under	  similar	  treatment	  conditions.	  	  
The	   concern	   was	   that	   the	   anaphylatoxins	  might	   be	   carried	   through	   in	   our	   antibody	  
preparations	  upon	   isolation	  from	  human	  serum	  samples.	  Hence	  the	  measured	  rise	   in	  
C5a	   noted	   after	   incubation	   with	   MPO-­‐ANCA	   and	   PR3-­‐ANCA	   polyclonal	   antibodies	  
might	  well	  be	  an	  artefact.	  As	  a	   result	  we	  measured	   the	   levels	  of	  C3a	  and	  C5a	   in	  our	  
antibody	  preparations	  and	  in	  the	  supernatants	  of	  TNFα	  primed	  neutrophils	  incubated	  
with	  the	  respective	  polyclonal	  antibodies	  in	  one	  donor	  (figure	  3.24).	  
The	   levels	   of	   C3a	   and	  C5a	  were	   significantly	   higher	   in	   the	   supernatants	  of	   the	   TNFα	  
primed	  neutrophils	   following	   incubation	  with	  the	  polyclonal	  MPO-­‐ANCA	  preparations	  
compared	  to	  the	  antibody	  preparations	  alone	  suggesting	  that	   indeed	  the	  neutrophils	  
release	  the	  anaphylatoxins	  on	  exposure	  to	  MPO-­‐ANCA.	  C3a	  levels	  were	  elevated	  in	  the	  
supernatants	  of	   all	   polyclonal	   treated	  TNFα	  primed	  neutrophils	   including	   control	   IgG	  
and	   PR3-­‐ANCA.	  When	   C3a	   and	   C5a	   levels	   were	   compared	   in	   the	   baseline	   antibody	  
samples	   there	   was	   no	   statistically	   significant	   difference	   in	   the	   anaphylatoxin	   levels	  
between	  control	  IgG	  samples	  and	  MPO-­‐ANCA	  samples	  or	  PR3-­‐ANCA	  samples	  (student’s	  
t	  test).	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Figure	   3.24	   –	   C3a	   and	   C5a	   levels	   in	   the	   antibody	   preparations	   and	   activated	  
neutrophil	   supernatant.	   Anaphylatoxin	   levels	   measured	   in	   antibody	   preparations	  
alone	  and	   in	   the	  supernatant	  of	  TNFα	  primed	  neutrophils	   stimulated	  with	  polyclonal	  
antibodies	   from	   controls	   (n=10)	   or	   patients	   (MPO-­‐ANCA	  n=11,	   PR3-­‐ANCA	  n=9).	   Each	  
antibody	   in	   each	   group	   is	   numbered	   with	   corresponding	   supernatant.	   Data	   were	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As	  discussed	  neutrophils	  are	  capable	  of	  expressing	  all	   the	  components	   that	  make	  up	  
the	  C5	  convertase	  and	  hence	  C5a	  may	  well	  be	  produced	  locally	  by	  the	  neutrophils.	  C3	  
has	  been	  previously	  shown	  to	  be	  enzymatically	  cleaved	  in	  a	  non-­‐convertase	  dependent	  
manner	  by	  cathepsin	  L	  [191].	  Neutrophils	  harbour	  a	  range	  of	  serine	  proteases	  that	  are	  
possibly	  able	  to	  cleave	  C3.	  As	  a	  result,	  we	  tested	  whether	  PR3	  was	  able	  to	  cleave	  C3	  as	  
desc	  	  ribed	  in	  section	  2.5.15,	  by	  incubating	  purified	  human	  C3	  with	  PR3	  and	  performing	  










Figure	  3.25	  –	  Representative	  Western	  blot	  of	  C3	  product	  breakdown	  by	  PR3.	  Serum	  
purified	  C3	  was	   incubated	  with	  differing	   concentrations	  of	  PR3	   for	  15	  or	  30	  minutes	  
and	  analysed	  by	  Western	  blot	  with	  the	  use	  of	  an	  anti-­‐C3	  antibody.	  Serum	  purified	  C3	  
and	  C3b	  were	  used	  as	  controls.	  The	  possible	  components	  of	  C3	  are	  listed.	  










































Figure	   3.26	   –	   Representative	   silver	   stain	   of	   C3	   product	   breakdown	   by	   PR3.	   Serum	  
purified	  C3	  was	  incubated	  with	  differing	  concentrations	  of	  PR3	  and	  analysed	  by	  silver	  
stain	   blot.	   Serum	   purified	   C3	   and	   C3b	   were	   used	   as	   controls.	   The	   possible	   C3a	  
component	  is	  highlighted.	  
It	   seems	   that	   PR3	   is	   capable	   of	   cleaving	   C3	   into	   various	   identifiable	   but	   also	   non-­‐
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3.6	  Discussion	  
Since	  the	  first	  report	  of	  ANCA	  in	  1982,	  advances	  have	  been	  made	  in	  the	  understanding	  
of	  the	  pathogenesis	  of	  AAV.	  However,	  plenty	  of	  unknowns	  remain.	  The	  use	  of	  in	  vitro	  
assays	  and	  in	  vivo	  models	  has	  advanced	  the	  field,	  but	  inconsistencies	  remain.	  
It	   is	   widely	   accepted	   in	   the	   field	   that	   ANCA	   are	   pathogenic,	   although	   cell-­‐mediated	  
immunity	  to	  MPO	  and	  PR3	  probably	  plays	  a	  role	  as	  well.	  The	  most	  convincing	  evidence	  
for	   the	  pathogenicity	  of	  ANCA,	  as	  discussed,	   comes	   from	  the	  passive	   transfer	   in	  vivo	  
model,	  whereby	  injecting	  MPO-­‐ANCA	  causes	  a	  crescentic	  glomerulonephritis	  [100].	  In	  
vitro	   studies,	   as	   discussed,	   have	   shown	   with	   often	   limited	   neutrophil	   donors	   and	  
numbers	  of	   IgG	  preparations	  from	  control	  subjects	  and	  patients	  that	  ANCA	  stimulate	  
primed	  neutrophils	  to	  undergo	  respiratory	  burst	  and	  degranulation.	  
There	  are	  a	  few	  reports	  in	  the	  literature	  where	  investigators	  have	  studied	  large	  panels	  
of	  MPO-­‐ANCA	  or	  PR3-­‐ANCA.	  	  Franssen	  et	  al	  purified	  ANCA	  IgG	  from	  17	  PR3-­‐ANCA	  and	  
14	   MPO-­‐ANCA	   positive	   patients	   with	   pauci-­‐immune	   necrotising	   crescentic	  
glomerulonephritis	   who	   presented	   to	   the	   hospital	   consecutively,	   thus	   reducing	  
selection	  bias.	  Control	   IgG	  from	  16	  healthy	  volunteers	  was	  used	  for	  comparison.	  Two	  
different	   healthy	   donors	   were	   used	   to	   isolate	   neutrophils.	   They	   showed	   that	   PR3-­‐
ANCA	   significantly	   increased	   TNFα	   primed	   neutrophil	   ROS	   production	   (using	   the	  
ferricytochrome	   C	   reduction	   assay	   and	   DHR	   123	   assay)	   and	   degranulation	   (β-­‐
glucuronidase	  release)	  compared	  to	  control	  IgG	  but	  MPO-­‐ANCA	  did	  not.	  Most	  but	  not	  
all	  PR3-­‐ANCA	  IgG	  fractions	  were	  capable	  of	  inducing	  respiratory	  burst	  or	  degranulation	  
to	  an	  extent	  that	  was	  greater	  than	  that	  observed	  with	  control	   IgG	  [95].	  Furthermore,	  
they	  found	  no	  significant	  correlation	  between	   in	  vitro	  capacity	  of	  the	  IgG	  fractions	  to	  
activate	   neutrophils	   and	   disease	   severity	   parameters	   such	   as	   creatinine	   level	   and	  
BVAS.	  
Harper	  et	  al	  used	  23	  MPO-­‐ANCA	  and	  15	  PR3-­‐ANCA	  fractions	  from	  patients	  with	  pauci-­‐
immune	   necrotising	   crescentic	   glomerulonephritis,	   as	  well	   as	   8	   control	   IgG.	   At	   least	  
five	  different	  donor	  neutrophils	  were	  used.	   In	  contrast	  they	  showed	  that	  MPO-­‐ANCA	  
fractions	  were	  significantly	  more	  potent	  at	  causing	  respiratory	  burst	  (ferricytochrome	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C	   reduction	   assay)	   and	   degranulation	   (MPO	   assay)	   of	   TNFα	   primed	   neutrophils	  
compared	  to	  PR3-­‐ANCA	  or	  control	  IgG	  [256].	  	  
We	  found	  that	  our	  group	  of	  randomly	  selected	  twenty	  polyclonal	  patient	  samples	  (11	  
MPO-­‐ANCA	  and	  9	  PR3-­‐ANCA)	  did	  not	  significantly	  lead	  to	  a	  greater	  level	  of	  respiratory	  
burst	  or	  degranulation	  of	  TNFα	  primed	  human	  neutrophils	  from	  two	  separate	  donors	  
compared	  to	  randomly	  selected	  10	  control	  IgG	  fractions.	  This	  was	  corroborated	  by	  the	  
mouse	   neutrophil	   luminol	   assays.	   Polyclonal	   mouse	   MPO-­‐ANCA	   did	   not	   cause	   a	  
significant	   rise	   in	   ROS	   production	   as	   measured	   by	   the	   luminometer	   assay	   in	  
comparison	  to	  polyclonal	  control	  IgG.	  	  
The	   data	   are	   highly	   inconsistent	   and	   it	   is	   not	   entirely	   apparent	   why.	   The	  
ferricytochrome	  C	  reduction	  assays	  measure	  extracellular	  ROS	  production	  and	  can	  be	  
very	  variable	  and	  inconsistent	  in	  our	  experience.	  Hence,	  we	  assessed	  ROS	  production	  
by	   chemiluminescence	   using	   luminol,	   which	   measures	   both	   extracellular	   and	  
intracellular	   ROS	   production	   as	   well	   as	   the	   isoluminol	   assay,	   which	   measures	  
extracellular	   ROS	   only.	  We	   also	   used	   the	   DHR	   123	   assay,	   which	   primarily	  measures	  
intracellular	  ROS	  production.	  
There	   are	   several	   compounding	   factors.	   The	   use	   of	   whole	   non-­‐affinity	   purified	   IgG	  
fractions	   means	   that	   the	   percentage	   of	   MPO-­‐ANCA	   or	   PR3-­‐ANCA	   in	   the	   samples	   is	  
unknown.	   It	  may	  be	  that	  ANCA	  that	   induce	  strong	  neutrophil	  responses	  do	  so	  simply	  
because	  they	  are	  composed	  of	  a	  higher	  proportion	  of	  PR3-­‐ANCA	  or	  MPO-­‐ANCA	  IgG	  as	  
opposed	   to	   other	   contaminating	   IgG.	   However,	   we	   found	   no	   significant	   correlation	  
between	   ANCA	   titres	   and	   neutrophil	   respiratory	   burst	   or	   degranulation	   read-­‐outs	   in	  
our	  studies.	  	  
Furthermore,	  other	   IgG	   in	   the	  samples	  may	  bind	   to	  neutrophil	   Fc	   receptors	   required	  
for	   ANCA	   activation	   thus	   inhibiting	   ANCA	   induced	   responses.	   The	   polyclonal	   IgG	  
purified	  from	  patients	  may	  also	  differ	  in	  regards	  to	  subclass,	  which	  has	  been	  shown	  to	  
influence	  the	  ability	  of	  ANCA	  to	  cause	  respiratory	  burst	  [257].	  	  
The	   ANCA	   preparations	  will	   also	   differ	   in	   epitope	   specificity	   and	   affinity,	  which	  may	  
account	  for	  differences	  in	  neutrophil	  activation.	  Roth	  et	  al	  recently	  showed	  substantial	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MPO-­‐ANCA	   epitope	   diversity.	   They	   used	   high	   sensitivity	   epitope	   excision	   and	   mass	  
spectrometry	   investigating	   patients	   in	   remission,	   those	   with	   active	   disease,	   ANCA-­‐
negative	  patients	  and	  healthy	  controls.	  They	  identified	  a	  total	  of	  25	  different	  epitopes,	  
12	   of	   which	   were	   exclusive	   to	   active	   disease	   and	   8	   were	   also	   present	   in	   healthy	  
subjects.	  One	  epitope	  (aa447-­‐459)	  was	  exclusive	  to	  active	  disease	  and	  reactivity	  to	  this	  
epitope	  declined	  in	  remission.	  Interestingly,	  anti-­‐MPO447–459	  antibodies	  could	  induce	  
the	  release	  of	  ROS	  from	  neutrophils,	  whereas	  antibodies	  specific	  for	  natural	  epitopes	  
barely	  induced	  ROS	  release.	  Furthermore	  transfer	  of	  IgG	  from	  mice	  immunized	  with	  a	  
murine	  MPO	  peptide	  that	  overlaps	  with	  peptide	  aa447–459,	  induced	  glomerular	  injury	  
and	   neutrophil	   accumulation	   in	   recipient	   mice.	   This	   study	   suggests	   that	   epitope	  
specificity	  defines	  the	  pathogenicity	  of	  ANCA	  [94].	  
It	   is	   also	  possible	   that	   the	   role	  of	  ANCA	   in	  disease	  pathogenesis	   is	   not	   related	   to	   its	  
ability	   to	   activate	   neutrophil	   respiratory	   burst	   or	   degranulation.	   In	   support	   of	   this	   a	  
recent	  article	  showed	  mice	  deficient	  in	  NADPH	  oxidase	  (and	  hence	  have	  an	  inability	  to	  
produce	  ROS)	  have	  more	  severe	  disease	  compared	  to	  wild	  type	  controls	  [258].	  	  
Lastly,	  extrapolating	  results	  from	   in	  vitro	  assays	  to	  the	   in	  vivo	  situation	  must	  be	  done	  
with	  caution.	   In	  vitro	  assays	  may	  not	  necessarily	  reflect	   in	  vivo	  mechanisms.	  The	  cells	  
are	  treated	  outside	  their	  normal	  milieu,	  not	  accounting	  for	  exposure	  to	  other	  cells	  as	  
well	  as	  factors	  such	  as	  systemic	  or	  local	  complement,	  cytokines	  and	  chemokines.	  It	   is	  
highly	   likely	   that	   isolated	   neutrophils	   behave	   differently	   to	   in	   vivo	   neutrophils.	   The	  
interaction	  of	  neutrophils	  and	  the	  endothelium	  in	  vivo	  may	  be	  crucial	  to	  the	  way	  ANCA	  
interacts	  with	  its	  antigens.	  Further	  efforts	  could	  be	  made	  to	  more	  closely	  mirror	  these	  
conditions	   in	  vitro.	  Endothelial	  cell	  and	  neutrophil	  co-­‐cultures	  could	  be	  employed	  for	  
example,	  or	  even	  a	  more	  simple	  measure	  such	  as	  plate-­‐bound	  ANCA	  rather	  than	  ANCA	  
in	   solution.	   Furthermore,	   we	   did	   not	   assess	   nor	   control	   for	   MPO	   or	   PR3	   surface	  
expression	   in	   response	   to	   TNFα	   priming	   in	   our	   neutrophil	   donors,	   which	   may	   be	   a	  
confounding	  factor.	  Another	  factor	  that	  we	  have	  not	  accounted	  for	  is	  the	  ages	  of	  the	  
control	  IgG	  donors.	  The	  control	  IgG	  donors	  were	  not	  age	  matched	  to	  the	  ANCA	  donors	  
which	   may	   lead	   to	   a	   discrepancy	   in	   the	   read-­‐outs	   as	   IgG	   glycoform	   structure	   and	  
function	  varies	  with	  age.	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So,	  although	  we	  have	  not	  shown	  in	  vitro	  that	  ANCA	  activate	  TNFα	  primed	  neutrophils	  
in	  terms	  of	  respiratory	  burst	  or	  degranulation	  they	  may	  do	  so	  in	  vivo.	  
Although	  we	  did	   not	   find	   a	   difference	   in	   the	   classical	   functional	   roles	   of	   neutrophils	  
with	   ANCA,	   we	   show	   that	   neutrophils	   express	   C3	   and	   C5	   and	   have	   the	   ability	   to	  
process	   these	   complement	   components	   to	   their	   respective	   anaphylatoxins.	  
Furthermore,	  it	  seems	  ANCA	  alter	  the	  processing	  of	  the	  anaphylatoxins.	  
C5a	  is	  a	  potent	  inflammatory	  mediator	  that	  acts	  as	  a	  chemoattractant	  for	  myeloid	  cells	  
and	  can	  elicit	  superoxide	  generation	  in	  neutrophils.	  Plasma	  levels	  of	  C5a	  are	  raised	  in	  
patients	  with	  active	  AAV	  than	  those	  in	  remission	  [204].	  It	  has	  been	  shown	  in	  vitro	  that	  
recombinant	  C5a	  dose	  dependently	  primes	  neutrophils	   for	  ANCA	   induced	  respiratory	  
burst	  [209].	  Furthermore,	  C5a	  is	  able	  to	  prime	  neutrophils	  resulting	  in	  the	  expression	  
of	  PR3	  on	  the	  neutrophil	  membrane	  and	  leading	  to	  degranulation	  as	  measured	  by	  the	  
release	   of	   lactoferrin.	   The	   use	   of	   p38	  MAPK,	   ERK,	   and	   PI3K	   inhibitors	   decrease	   C5a	  
induced	   membrane	   expression	   of	   PR3	   and	   lactoferrin	   release	   from	   neutrophils	  
activated	  by	  PR3-­‐ANCA	  following	  C5a	  priming	  [259].	  	  
We	  have	  shown	  that	  resting	  neutrophils	  have	  intracellular	  C3,	  C5,	  C3a	  and	  C5a,	  as	  well	  
as	  extracellular	  C3	  and	  C5.	  The	  expression	  of	  these	  complement	  components	  was	  not	  
altered	  by	  polyclonal	  ANCA	  or	   fMLP	   induced	  activation	  either	  within	   the	   intracellular	  
compartment	  or	  on	  the	  cell	  surface.	  However,	  upon	  incubation	  with	  patient	  polyclonal	  
ANCA,	  the	  TNFα	  primed	  neutrophils	  expel	  C5a	  into	  their	  supernatants	  at	  a	  significantly	  
higher	   level	  than	  that	  seen	  with	  control	   IgG.	  This	  suggests	  that	  upon	  ANCA	  mediated	  
activation	  neutrophils	  may	  well	  be	  more	  capable	  of	  readily	  breaking	  down	  C5	  into	  its	  
anaphylatoxin	  and	  possibly	  C5b	  components.	  This	  may	  have	  effects	  on	  the	  donor	  cell	  
and	  act	  in	  an	  autocrine	  fashion	  or	  contribute	  to	  paracrine	  functions	  of	  C5a.	  It	  appears	  
that	   neutrophils	   have	   the	   innate	   ability	   to	   cleave	   C3	   and	   C5	   into	   its	   respective	  
components	  and	  the	  mechanism	  of	  this	  still	  remains	  to	  be	  elucidated.	  The	  process	  may	  
occur	   with	   the	   use	   of	   conventional	   C3	   and	   C5	   convertases	   or	   may	   be	   convertase	  
independent	  using	  local	  proteases	  such	  as	  PR3.	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Chapter	  4	  –	  The	  role	  of	  monocytes	  in	  AAV	  
4.1	  Introduction	  
The	  term	  ANCA	   is	  a	  misnomer	  as	   the	  autoantibodies	   recognise	  antigens	   that	  are	  not	  
specific	   solely	   to	   neutrophils.	   Monocytes	   are	   the	   other	   subset	   of	   leucocytes	   that	  
express	  the	  classical	  antigens	  to	  ANCA,	  namely	  MPO	  and	  PR3,	  as	  described	  in	  chapter	  
1.	  Whilst	   the	   pathological	   effects	   of	   ANCA	   on	   neutrophils	   are	   broadly	   explored,	   the	  
impact	  of	  ANCA	  on	  monocyte	  function	  is	  less	  well	  understood.	  	  
Monocytes	  and	  macrophages	  are	  present	  within	  early	  segmental	  lesions	  seen	  on	  renal	  
biopsies	   from	   patients	   with	   AAV	   and	   have	   been	   shown	   to	   be	   the	   predominant	  
glomeruli	   infiltrating	   leucocytes	   [3,	   146].	   This	   certainly	   implicates	   monocytes	   in	  
addition	   to	   neutrophils	   in	   the	   tissue	   damage	   associated	   with	   AAV.	   As	   discussed	   in	  
section	   1.9,	   some	   in	   vitro	   studies	   have	   shown	   that	   ANCA	   can	   modulate	   monocyte	  
function.	  Ralston	  et	  al	  described	   the	  production	  of	   IL8	   in	   response	   to	  PR3-­‐ANCA	  and	  
O’Brien	  et	   al	   recently	   described	   the	  production	  of	   IL1β,	   IL6	   and	   IL8	  by	   TNFα	  primed	  
monocytes	  in	  response	  to	  MPO-­‐ANCA	  but	  not	  to	  PR3-­‐ANCA	  [141,	  145].	  In	  addition,	  the	  
production	   of	   oxygen	   radicals	   by	   TNFα-­‐primed	  monocytes	   in	   response	   to	   ANCA	   has	  
been	  described	  [143].	  	  
Monocytes	   are	   circulating	   leucocytes	   that	   are	  present	   in	   the	  bloodstream	   for	   3	   to	   5	  
days	  and	  have	  the	  potential	  to	  differentiate	  into	  and	  replenish	  tissue	  macrophages	  and	  
dendritic	  cells.	  Monocytes	  as	  a	  result	  have	  a	  key	  role	  in	  inflammation	  and	  tissue	  repair.	  
Human	  monocytes	  are	  divided	  into	  subsets	  on	  the	  basis	  of	  CD14	  and	  CD16	  expression	  
as	   discussed	   in	   chapter	   1.	   Classical	   monocytes	   (CD14++CD16-­‐),	   which	   account	   for	  
approximately	   90%	   of	   the	   total	  monocyte	   population,	   are	   thought	   to	   have	   a	   role	   in	  
phagocytosis,	  produce	  high	  levels	  of	  IL10	  and	  low-­‐grade	  levels	  of	  TNFα	  in	  response	  to	  
LPS.	   Intermediate	  monocytes	   (CD14++CD16+)	  have	  a	  higher	  capacity	  to	  release	  TNFα	  
and	   IL1β	   in	   response	   to	   LPS.	   Non-­‐classical	   monocytes	   (CD14+CD16++)	   release	   TNFα	  
and	  IL1β	  in	  response	  to	  DNA	  and	  RNA	  particles	  [260,	  261].	  	  
Macrophages	  were	  classically	  thought	  to	  only	  originate	  from	  blood	  monocytes.	  More	  
recent	   understanding	   of	   macrophage	   biology	   has	   revealed	   that	   tissue	   macrophages	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can	  in	  fact	  be	  established	  during	  embryology	  and	  persist	  into	  adulthood	  [262].	  During	  
an	   inflammatory	   insult,	   circulating	  monocytes	   are	   recruited	   and	   thought	   to	   undergo	  
differentiation	   into	   two	   subsets	   of	   macrophages	   M1	   and	   M2	   depending	   on	  
environmental	  cues.	  	  
M1	  macrophages	  are	  classically	  pro	  inflammatory	  whilst	  M2	  macrophages	  are	  thought	  
to	   stimulate	   tissue	   repair	   and	   fibrosis.	  M2	  macrophages	   are	   further	   subdivided	   into	  
M2a	  (induced	  by	  IL4	  or	  IL13),	  M2b	  (upon	  exposure	  to	  immune	  complexes	  and	  IL1β	  or	  
LPS)	  or	  M2c	  (stimulated	  by	  IL10	  or	  TGFβ).	  M1	  macrophages	  are	  induced	  by	  IFN–γ	  and	  
LPS	  or	   TNFα	   [263].	  GMCSF	  polarises	  macrophages	   to	   the	  M1	  phenotype	  whilst	   CSF1	  
promotes	  a	  M2	  phenotype	  [264].	  There	  are	  various	  markers	  used	  to	  differentiate	  M1	  
and	   M2	   macrophages.	   M1	   macrophages	   typically	   express	   inducible	   nitric	   oxide	  
synthase	   (iNOS),	  CD80	  and	  CD86,	  whilst	  M2	  macrophages	  express	  arginase	  1,	  CD163	  
and	   CD206	   [265].	   Furthermore,	   macrophages	   have	   a	   role	   in	   directing	   Th1	   and	   Th2	  
responses	  as	  well	  as	  being	  influenced	  by	  the	  CD4	  T	  cell	  cytokines	  themselves	  [266].	  
Nonetheless,	   macrophages	   are	   highly	   plastic	   and	   heterogeneous,	   it	   is	   felt	   that	  
classification	  into	  the	  M1	  and	  M2	  subsets	  is	  relatively	  simplistic.	  Instead	  macrophages	  
display	   a	   continuum	   of	   phenotypes	   and	   co-­‐exist	   with	   the	   resulting	   phenotype	  
depending	  on	  the	  local	  milieu.	  Hence	  clear	  distinctions	  are	  often	  not	  possible.	  
Inflammation	   is	   a	  normal	   response	   to	   tissue	   injury	  and	   is	  highly	   regulated	  with	  both	  
pro-­‐	   and	   anti-­‐	   inflammatory	   events	   in	   place	   to	   ensure	   prompt	   restoration	   of	   tissue	  
homeostasis.	   Macrophages	   are	   vital	   in	   inflammation	   as	   well	   as	   tissue	   repair	   and	  
remodelling.	   However,	   persistent	   macrophage	   presence	   is	   associated	   with	   tissue	  
destruction	   and	   fibrosis.	   Fibrosis,	   the	   excessive	   accumulation	   of	   fibrous	   connective	  
tissue,	  is	  a	  common	  pathological	  sequela	  of	  many	  chronic	  inflammatory	  diseases	  and	  is	  
often	   linked	   to	   outcome.	   In	   AAV,	   a	   greater	   degree	   of	   renal	   glomerulosclerosis	   on	  
biopsies	  has	  been	  shown	  to	  be	  a	  predictor	  of	  poor	  prognosis	  [267].	   In	  the	  kidney,	  an	  
accumulation	   of	   the	   extracellular	   matrix	   is	   thought	   to	   result	   from	   proliferation	   of	  
resident	   fibroblasts	   and	   epithelial	   to	  mesenchymal	   transition	   (EMT)	   of	   tubular	   cells.	  
TGFβ1	  is	  thought	  to	  be	  an	  important	  inducer	  of	  EMT	  [268].	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The	  importance	  of	  monocyte	  /	  macrophage	  influx	  in	  renal	  injury	  has	  been	  highlighted	  
by	   various	   groups.	   Kitagawa	   et	   al	   induced	   renal	   fibrosis	   using	   a	   unilateral	   ureteric	  
obstruction	  model	  in	  mice.	  Administration	  of	  a	  CCR2	  (MCP-­‐1	  receptor)	  inhibitor	  led	  to	  
a	   reduction	   in	   cellular	   infiltrate	  and	  an	  amelioration	  of	   interstitial	   renal	   fibrosis.	   This	  
was	   confirmed	   in	   CCR2	   knockout	   mice.	   There	   was	   an	   associated	   reduction	   in	   TGFβ	  
expression	  in	  the	  CCR2	  knockout	  mice	  [269].	  Using	  the	  same	  model	  of	  injury,	  Pan	  et	  al	  
showed	   that	   the	   recruited	   macrophages	   were	   of	   an	   M2	   phenotype.	   This	   was	  
associated	   with	   increased	   expression	   of	   TGFβ1	   and	   alpha	   smooth	   muscle	   actin	   (a	  
marker	   of	   myofibroblasts)	   in	   the	   affected	   kidney	   and	   reduced	   levels	   of	   bone	  
morphogenic	  protein	  7	  (inhibitor	  of	  TGFβ1)	  and	  E-­‐cadherin,	  suggesting	  increased	  drive	  
for	  EMT	  [270].	  Lloyd	  et	  al	  showed	  that	  blockade	  of	  MCP-­‐1	  in	  the	  nephrotoxic	  nephritis	  
model	   led	   to	   a	   reduction	   in	   infiltrating	   leucocytes	   as	   well	   as	   reduced	   glomerular	  
crescent	   formation	   and	   type	   1	   collagen	   deposition	   [271].	   In	   renal	   pathology,	  
macrophages,	   a	   source	   of	   TGFβ	   has	   a	   crucial	   role	   in	   fibrosis	   and	   potentially	  
development	  of	  chronic	  kidney	  disease.	  
4.2	  Aims	  	  
As	   a	   result,	   we	   set	   out	   to	   assess	   the	   impact	   of	   ANCA	   on	   human	   peripheral	   blood	  
monocytes	  with	  regards	  to	  cytokine	  production	  and	  potentially	  the	  impact	  of	  ANCA	  on	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4.3	   MPO-­‐ANCA	   decreases	   IL10	   and	   IL6	   production	   from	   monocytes	   in	  
response	  to	  LPS	  
We	  examined	  the	  effect	  of	  the	  same	  panel	  of	  unselected	  MPO-­‐ANCA,	  PR3-­‐ANCA,	  and	  
control	  IgGs	  (see	  table	  3.1	  and	  3.2)	  on	  peripheral	  blood	  monocytes	  isolated	  from	  three	  
healthy	  donors	  as	  described	  in	  section	  2.5.4.	  The	  purity	  of	  CD14	  cells	  was	  measured	  to	  
be	  >95%	  using	  FACS	  analysis	  in	  the	  experiments	  described	  in	  the	  following	  sections.	  To	  
mirror	   the	   in	   vivo	   situation	   where	   ANCA	   bind	   monocytes	   in	   the	   context	   of	   an	  
inflammatory	   response,	   we	   stimulated	   monocytes	   with	   LPS	   and	   explored	   whether	  
ANCA	  modulated	  the	  response	  to	  LPS.	  The	  stimulated	  monocytes	  were	  incubated	  with	  
ANCA	  or	  control	  IgG	  for	  18	  hours	  and	  the	  supernatants	  were	  harvested.	  	  
The	  Th1,	   Th2	  and	  Th17	  CBA	  kit	   (described	   in	   section	  2.5.11)	   as	  well	   as	   IL1β,	   IL8	  and	  
MIP1α	  ELISA	  kits	  were	  used	  to	  measure	  cytokines	  in	  the	  supernatants	  (see	  figure	  4.1).	  	  
After	  incubation	  of	  monocytes	  with	  MPO-­‐ANCA,	  PR3-­‐ANCA	  or	  control	  IgG	  without	  LPS,	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Figure	  4.1	  –	  Cytokine	  production	  from	  peripheral	  blood	  monocytes.	  Monocytes	  from	  
3	  donors	  were	  incubated	  with	  polyclonal	  control	  IgG	  (n=10),	  MPO-­‐ANCA	  (n=11)	  or	  PR3-­‐
ANCA	   (n=9).	   All	   monocyte	   samples	   were	   stimulated	   with	   LPS	   except	   the	   NA	   group	  
(non-­‐activated).	  Plots	   in	  A	   show	   IL10,	   IL6	  and	  TNFα	   levels	  whilst	   the	  plots	   in	  B	   show	  
IL1β,	   IL8	  and	  MIP1α	   levels	   in	   the	  supernatants.	  Data	  were	  analysed	  using	  a	  one	  way	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As	  depicted,	  both	  IL6	  and	  IL10	  were	  consistently	  and	  significantly	  decreased	  by	  MPO-­‐
ANCA	  across	  all	  three	  donors,	  with	  the	  most	  profound	  effect	  seen	  for	  IL10.	  We	  did	  not	  
observe	  an	  effect	  of	  MPO-­‐ANCA	  on	   IL8	  and	  MIP1α	  production	  by	  monocytes,	  and	   its	  
effects	   on	   TNFα	   and	   IL1β	   production	  were	   variable	   among	   donors,	   Addition	   of	   PR3-­‐
ANCAs	  only	  had	  a	  consistent	  down-­‐modulatory	  effect	  on	  IL10,	  which	  was	  less	  marked	  
than	  that	  of	  MPO-­‐ANCA.	  
Previously	  described	  effects	  of	  ANCA	  on	  neutrophils	  have	  been	  reported	  to	  require	  Fc	  
receptor	  binding	  and	  involve	  interaction	  with	  the	  β2	  integrin	  CD11b/CD18	  complex	  as	  
discussed	  in	  chapter	  1	  [79,	  110,	  272].	  We	  therefore	  examined	  if	  this	  was	  also	  the	  case	  
for	  the	  observed	  effects	  of	  MPO-­‐ANCA	  on	  monocytes.	  We	  generated	  F(ab)2	  fragments	  
from	  4	  MPO-­‐ANCAs	  and	  2	  control	  IgGs	  as	  described	  in	  section	  2.4.3	  and	  compared	  the	  
responses	   of	   the	   F(ab)2	   fragments	   to	   that	   of	   whole	   IgG	   using	   monocytes	   from	   two	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Figure	   4.2	   –	   Cytokine	   production	   from	   LPS	   stimulated	   monocytes	   incubated	   with	  
whole	  IgG	  or	  F(ab)2	  fragments.	  Monocytes	  from	  2	  donors	  were	  incubated	  with	  whole	  
control	   IgG	   (n=2),	   MPO-­‐ANCA	   (n=4),	   control	   F(ab)2	   fragments	   (n=2)	   or	   MPO-­‐ANCA	  
F(ab)2	   fragments	   (n=4)	   for	  16	  hours.	  All	  monocyte	  samples	  were	  stimulated	  with	  LPS	  
except	  the	  NA	  group	  (non-­‐activated).	  Data	  were	  analysed	  using	  a	  one	  way	  ANOVA	  with	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While	   the	  MPO-­‐ANCA	  whole	   IgG	   fraction	   elicited	   the	   expected	   reduction	   in	   IL6	   and	  
IL10,	   the	   MPO-­‐ANCA	   F(ab)2	   failed	   to	   have	   the	   same	   effect,	   suggesting	   that	   co-­‐
engagement	  of	  the	  Fc	  receptors	  on	  the	  cell	  surface	  is	  also	  needed	  for	  ANCA	  effects	  on	  
monocytes.	  Notably	  we	  saw	  a	  significant	   increase	  in	  TNFα	  levels	  following	  incubation	  
with	  the	  selected	  MPO-­‐ANCA	  IgG	  fractions	  in	  both	  donors,	  which	  is	  atypical	  (see	  figure	  
4.1).	  	  
We	   confirmed	   the	   importance	   of	   Fc	   receptor	   engagement	   in	   one	   monocyte	   donor,	  
whereby	  monocytes	  were	   stimulated	  with	  MPO-­‐ANCA	  with	  or	  without	   the	  use	  of	   Fc	  
block,	  a	  purified	  recombinant	  Fc	  protein	  (figure	  4.3).	  
	  
Figure	  4.3	  –	  Effect	  of	  Fc	  blockade	  on	  LPS	  stimulated	  monocytes	  incubated	  with	  MPO-­‐
ANCA.	   Monocytes	   from	   one	   donor	   were	   stimulated	   with	   LPS	   and	   incubated	   with	  
polyclonal	  MPO-­‐ANCA	   (n=4)	  or	   control	   IgG	   (n=4)	  with	  or	  without	   Fc	  block.	  Data	  was	  
analysed	  using	  a	  student’s	  t	  test	  (*	  =	  p	  <	  0.05,	  **	  =	  p	  <	  0.01).	  
We	  also	  blocked	  CD11b,	  CD18	  or	  both	  to	  deduce	  if	  the	  CD11b/CD18	  complex	  has	  a	  role	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Figure	  4.4	  –	  Effect	  of	  CD11b/CD18	  blockade	  on	  LPS	  stimulated	  monocytes	  incubated	  
with	  MPO-­‐ANCA.	  	  IL10	  and	  IL6	  production	  from	  peripheral	  blood	  monocytes	  incubated	  
for	   18	   hours	  with	   LPS	   and	  MPO-­‐ANCA	   (n=4)	   or	   control	   IgG	   (n=4)	   in	   the	   presence	   of	  
monoclonal	   CD11b	   and/or	   CD18	   blocking	   antibodies,	   no	   monoclonal	   antibodies	   or	  
monoclonal	  isotype	  control	  antibody.	  Data	  was	  analysed	  using	  a	  student’s	  t	  test	  (NS	  =	  
non	  significant,	  *	  =	  p	  <	  0.05,	  **	  =	  p	  <	  0.01,	  ***	  =	  p	  <	  0.001).	  
Interestingly	   it	   appears	   that	   co-­‐engagement	   of	   the	   CD11b/CD18	   complex	   is	   not	  
required	   for	   MPO-­‐ANCA-­‐induced	   reduction	   of	   IL6	   and	   IL10,	   as	   blockade	   of	   CD11b,	  
CD18	   or	   both	   did	   not	   impact	   on	   altered	   cytokine	   production.	   This	   suggested	   that	  
perhaps	   downstream	   signalling	   of	   Fc	   receptor	   engagement	   may	   not	   necessarily	   be	  
involved	  in	  the	  effects	  noted.	  We	  hypothesised	  that	  perhaps	  MPO-­‐ANCA	  tether	  MPO	  
to	   the	   cell	   surface	   and	  MPO	   itself	  may	   cause	   the	   effects	   noted.	   To	   crudely	   test	   this	  
hypothesis,	  we	  firstly	  added	  exogenous	  MPO	  to	  our	  monocyte	  cultures	  to	  ascertain	  if	  
an	  effect	  on	  IL10	  and	  IL6	  could	  be	  found.	  We	  then	  added	  an	  enzymatic	  MPO	  inhibitor	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indeed	  dependent	  on	   the	  enzymatic	  action	  of	  MPO.	  LPS	   stimulated	  monocytes	  were	  
incubated	   with	   exogenously	   added	  MPO	   protein	   in	   the	   presence	   or	   absence	   of	   the	  













Figure	  4.5	  –	  The	  effect	  of	  MPO	  protein	  and	  MPO	  inhibitor	  on	  IL6	  and	  IL10	  production.	  
Representative	   plot	   of	   the	   effects	   of	   exogenous	   MPO	   protein	   (2μg/ml)	   alone	   or	   in	  
combination	   with	   the	   MPO	   inhibitor	   AZD5904	   (in	   variable	   doses)	   on	   IL10	   and	   IL6	  
production	  from	  LPS	  stimulated	  monocytes.	  
We	  found	  that	  exogenously	  added	  MPO	  mirrors	  the	  effect	  of	  MPO-­‐ANCA	  and	  causes	  a	  
reduction	   in	   IL6	  and	   IL10	   that	   is	   reversed	  by	  AZD5904	   in	  a	  dose	  dependent	  manner.	  
We	  then	  incubated	  monocytes	  (+/-­‐	  LPS)	  with	  exogenously	  added	  MPO	  protein,	  MPO-­‐




































































































Figure	  4.6	  -­‐	  Effect	  of	  varying	  doses	  of	  MPO	  inhibitor	  on	  IL6	  and	  IL10	  production	  from	  
peripheral	  blood	  monocytes.	  Monocytes	   from	  two	  donors	  were	   incubated	  with	  LPS,	  
MPO	   protein	   (2μg/ml),	   polyclonal	   control	   IgG	   (n=2)	   or	   MPO-­‐ANCA	   (n=2),	   with	   or	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AZD5904	  partially	   reversed	  the	  reduction	   in	   IL6	  and	   IL10	  caused	  by	  MPO-­‐ANCA	   in	  all	  
donors	   tested	   in	   a	   dose	   dependent	  manner.	   These	   data	   suggest	   that	  MPO-­‐ANCA	   is	  
inhibiting	   IL6	   and	   IL10	   release	   in	   response	   to	   LPS	   by	   a	   mechanism	   that	   is	   partially	  
dependent	  on	  the	  enzymatic	  activity	  of	  MPO.	  
We	  hypothesised	  that	  MPO-­‐ANCA	  tether	  MPO	  released	  by	  activated	  monocytes	  to	  the	  
cell	   surface.	   To	   test	   this	   we	   first	   showed	   that	   the	   concentration	   of	   MPO	   in	   the	  
supernatant	  of	  MPO-­‐ANCA	  activated	  monocytes	  was	  reduced	  whilst	  the	  corresponding	  
monocyte	  surface	  expression	  of	  MPO	  was	  increased	  compared	  to	  control	  IgG	  treated	  











Figure	   4.7	   –	   MPO	   in	   the	   supernatant	   and	   cell	   surface	   of	   monocytes.	   (A)	   Graph	  
showing	   the	   level	  of	  MPO	   in	   the	  supernatants	  of	  monocytes	   incubated	  with	  LPS	  and	  
control	   IgG	   (n=10)	   or	   MPO-­‐ANCA	   (n=10).	   NA	   depicts	   non	   activated	   cells.	   Data	   was	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showing	   the	   cell	   surface	   expression	   of	   MPO	   following	   incubation	   of	   LPS	   stimulated	  
monocytes	  with	  control	  IgG	  (n=2)	  or	  MPO-­‐ANCA	  (n=2).	  
Addition	  of	  MPO-­‐ANCA	  to	  LPS	  stimulated	  monocytes	  led	  to	  a	  decrease	  in	  free	  MPO	  in	  
the	   supernatant	   compared	   to	   control	   IgG.	   This	   was	   associated	   with	   a	   concomitant	  
increase	  in	  cell	  surface	  MPO	  expression	  on	  monocytes	  incubated	  with	  MPO-­‐ANCA.	  
IL6	   has	   been	   shown	   to	   promote	   IL10	   secretion	   in	   T	   cells	   [273]	   and	   we	   therefore	  
assessed	   whether	   the	   reduction	   in	   IL10	   production	   by	   monocytes	   upon	   ANCA-­‐MPO	  
addition	  was	   secondary	   to	   the	   reduction	   in	   IL6.	  Exogenous	   IL6	  protein	  was	  added	   to	  
monocytes	  incubated	  with	  either	  control	  IgG	  or	  MPO-­‐ANCA	  (see	  figure	  4.8).	  
	  
Figure	  4.8	  –	  Effect	  of	  addition	  of	  exogenous	  IL6	  on	  IL10	  production	  by	  LPS	  stimulated	  
monocytes.	  Monocytes	  from	  one	  donor	  were	  incubated	  with	  varying	  concentrations	  of	  
IL6	  and	  control	  IgG	  or	  MPO-­‐ANCA.	  
Unlike	   T	   cells,	   IL6	   seems	   not	   to	   drive	   IL10	   production	   in	   monocytes	   as	   addition	   of	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4.4	  MPO-­‐ANCA	  affects	  TLR	  signalling	  pathways	  
To	  define	  the	  pathways	  driven	  by	  MPO-­‐ANCA	  leading	  to	  altered	  cytokine	  production	  in	  
monocytes,	  we	  performed	  gene	  expression	  microarrays	  on	  samples	   treated	  with	  LPS	  
and	  MPO-­‐ANCA	  (n=3)	  or	  control	  IgG	  (n=3)	  for	  six	  hours	  as	  described	  in	  section	  2.5.13.	  
We	  observed	  566	  genes	  differentially	  expressed	  between	  the	  groups,	  with	  a	  threshold	  
of	  1.75	  in	  either	  direction	  (see	  figure	  4.9	  and	  appendix	  for	  list	  of	  genes).	  	  
	  
	  
Figure	   4.9	   –	   Volcano	   plot	   and	   heatmap	   of	   gene	   expression	   data.	   (A)	   Volcano	   plot	  
comparing	  monocytes	  activated	  for	  6h	  with	  either	  MPO-­‐ANCA	  (V,	  n=3)	  or	  IgG	  control	  
(L,	  n=3)	  in	  the	  presence	  of	  LPS.	  Threshold	  for	  significance	  is	  1.75	  fold	  in	  either	  direction	  
and	   p-­‐value	   of	   <0.05.	   From	   this,	   566	   genes	   were	   differentially	   expressed.	   (B)	  
Hierarchical	  clustering	  of	  these	  genes.	  
A	   B	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Subsequent	  pathway	  enrichment	   analyses	   revealed	   that	   the	  altered	  gene	  expression	  
profile	   pertains	   overall	   to	   pathways	   involved	   in	   immune	   cell	   activation	   and	  
inflammatory	   responses.	   These	   analyses	   demonstrated	   that	   one	   of	   the	   most	  
















Figure	  4.10	  -­‐	  Gene	  Ontology	  (GO)	  and	  KEGG	  enrichment	  analyses	  of	  genes.	  	  
Specific	  examination	  of	   the	  expression	  of	  genes	  known	   to	  be	   regulated	  by	  LPS	  or	  by	  
the	   Myd88	   pathways	   confirmed	   a	   profound	   inhibitory	   effect	   on	   these	   genes	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engendered	   by	   the	   presence	   of	  MPO-­‐ANCA	   (Z-­‐scores	   -­‐5.2	   and	   -­‐3.6	   respectively).	   An	  
unbiased	  gene	  set	  enrichment	  (GSEA)	  analysis	  was	  carried	  out,	  comparing	  expression	  
of	   all	   genes	   expressed	   by	   MPO-­‐ANCA	   and	   IgG-­‐treated	   monocytes	   in	   our	   arrays	   for	  
enrichment	  of	  genes	   in	   the	  KEGG	  TLR	  signaling	  pathway	  and	   found	   that	   these	  genes	  








Figure	   4.11	   -­‐	   Gene	   Set	   Enrichment	   Analysis	   of	   genes	   in	   the	   KEGG	   TLR	   signalling	  
pathway.	  
The	  core	  genes	  inhibited	  in	  this	  gene	  set	  are	  shown	  in	  figure	  4.12.	  In	  summary,	  MPO-­‐
ANCA	  caused	  a	  general	  reduction	  in	  normal	  LPS/TLR-­‐triggered	  TLR-­‐mediated	  pathways	  















Figure	  4.12	  –	  Heatmap	  of	  core	  genes	  altered	  in	  this	  gene	  set	  and	  ingenuity	  pathway	  
analysis.	  The	  ingenuity	  pathway	  analysis	  illustrates	  the	  profound	  inhibition	  of	  both	  LPS	  








Ingenuity	  Pathway	  Analysis	  
	   	   Z-­‐score	  	   Overlap	  p-­‐Value	   	   Effect	  direction	  
Myd88	  	   -­‐3.33	   	   1.56x10-­‐9	   Inhibited	  by	  MPO-­‐ANCA	  relative	  to	  control	  IgG	  
LPS	   	   -­‐4.96	   	   1.87x10-­‐58	   Inhibited	  by	  MPO-­‐ANCA	  relative	  to	  control	  IgG	  
|	  Page	  158	  
4.5	  MPO-­‐ANCA	  generates	  oxidised	  phospholipids	  
MPO	   is	   a	   powerful	   oxidant	   and	   has	   the	   ability	   to	   oxidise	   glycerophospholipids,	   the	  
building	  blocks	  of	  the	  cell	  membrane.	  Oxidation	  of	  these	  phospholipids	  can	  affect	  the	  
integrity	  of	  the	  cell	  structure	  and	  also	  lead	  to	  the	  formation	  of	  oxidised	  phospholipids,	  
which	   have	   biological	   functions.	   Oxidised	   phospholipids	   can	   be	   pro-­‐	   or	   anti-­‐	  
inflammatory.	   There	   is	   increasing	   evidence	   that	   certain	   species	   of	   oxidised	  
phospholipids	  are	  antagonists	  of	  LPS-­‐induced	  TLR4	  activation	  [274-­‐276].	  
We	  hypothesized	   that	  MPO-­‐ANCA	  anchor	  MPO	  protein	  on	   the	   cell	   surface,	  which	   in	  
turn	  may	  lead	  to	  local	  production	  of	  oxidised	  phospholipids	  and	  block	  the	  effect	  of	  LPS	  
noted	  in	  the	  microarray	  experiments	  (section	  4.4).	  
	  We	   incubated	   peripheral	   blood	  monocytes	  with	   LPS	   and	   control	   IgG	   (n=3)	   or	  MPO-­‐
ANCA	   (n=3)	   for	   18	   hours	   and	   extracted	   phospholipids	   as	   detailed	   in	   section	   2.5.14.	  
Liquid	   chromatography	   mass	   spectrometry	   was	   used	   to	   assess	   the	   extracted	  
phospholipids.	  	  
Treatment	  with	  MPO-­‐ANCA	  did	  not	  affect	  the	  native	  phospholipid	  profile	  and	  a	  variety	  
of	   chain-­‐shortened	   oxidised	   phospholipids	   were	   observed	   in	   both	   control	   IgG	   and	  
MPO-­‐ANCA	   incubated	  monocytes	   (see	   figure	   4.13).	   Table	   4.1	   provides	   the	   probable	  
identities	   of	   native	   and	   oxidised	   phosphatidylcholine	   species	   detected	   in	   the	   lipid	  

























Figure	   4.13	   -­‐	   Summed	   phospholipid	   spectra	   from	   treatments	   of	   monocytes	   with	  
control	  IgG	  or	  MPO-­‐ANCA.	  Sum	  of	  spectra	  in	  the	  region	  m/z	  700-­‐900	  corresponding	  to	  
unmodified	  phospholipids	  and	  sum	  of	  spectra	  in	  the	  region	  m/z	  490-­‐700	  corresponding	  
to	  chain-­‐shortened	  and	  oxidised	  phospholipids	  from	  control	  IgG	  (n=3)	  and	  MPO-­‐ANCA	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m/z Chemical formula Identification 
496.5 C24H51NO7P+	   Lyso-PC 16:0 
524.5 C26H55NO7P+	   Lyso PC 18:0 
544.5 C28H51NO7P+ Lyso-PC 20:4 
572.5 - Unidentified 
596.5 C28H55NO10P+ 1-Palmitoyl-2-Succinoyl-PC (16:0, 4-COOH)  SSPC 
622.5 C31H61NO9P+ 1-Stearoyl-2-Oxovaleroyl-PC (18:0, 5-CHO) SOVPC 






1-Palmitoyl-2-Oxononanoyl-PC (16:0, 9-CHO) 
PONPC 
666.5 C33H65O10NP+ 1-Palmitoyl-2-Azelaoyl-PC (16:0, 9-COOH) PAzPC 
720.8 C39H79NO8P+ PC (31:0) 
720.8 C40H83NO7P+ PC (16:0,16:0) ether 
734.8 C40H81NO8P+ PC (16:0,16:0) 1,2-Dialmitoyl-PC DPPC 
746.8 C42H85NO7P+ PC (16:0, 18:1) Plasmenyl 
758.8 C42H81NO8P+ PC (16:0/18:2) 
760.8 C42H83NO8P+ PC (16:0,18:1) 
762.8 C42H85NO8P+ PC (16:0, 18:0) 
768.8 C43H79NO8P+ PC (16:0. 20:4) Plasmenyl 
782.8 C44H81NO8P+ PC (16:0/20:4) PAPC 
786.8 C44H85NO8P+ PC (18:0/18:2) 
788.8 C44H87NO8P+ PC (18:0/18:1) 
798.8 C44H81NO9P+ PC (16:0/20:4)-OH 
806.8 C46H81NO8P+ PC (16:0/22:6) 
810.8 C46H85NO8P+ PC (18:0/20:4) 
828.8 C44H79NO11P+ 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-PC PEIPC 
834.8 C48H85NO8P+ PC (18:0/22:6) 
Table	   4.1	   -­‐	   Probable	   identities	   of	   native	   and	   oxidised	   phosphatidylcholine	   species	  
detected	   in	   lipid	   extracts	   of	   monocytes	   by	   liquid	   chromatography	   mass	  
spectrometry.	   Identities	   are	   based	   on	   retention	   time,	  m/z	   and	   previously	   published	  
identifications. PC	   corresponds	   to	   sn-­‐glycero-­‐3-­‐phosphocholine;	   plasmenyl	  
corresponds	  to	  a	  vinyl	  ether	  linkage	  instead	  of	  an	  ester.	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The	  relative	  intensities	  of	  8	  oxidatively	  modified	  and	  phosphatidylcholine	  species	  that	  
were	  found	  to	  be	  most	  abundant	  are	  plotted	  in	  figure	  4.14.	  The	  data	  are	  presented	  as	  
a	   percentage	   of	   the	   signal	   of	   the	   saturated	   phospholipid	   dipalmitoyl	  
phosphatidylcholine	  at	  m/z	  734,	  as	  this	  is	  relatively	  resistant	  to	  oxidative	  damage.	  This	  
approach	   allows	   correction	   for	   variability	   in	   the	   total	   phospholipid	   content	   of	   the	  
samples	  and	  provides	  a	  better	  assessment	  of	  the	  levels	  of	  oxidised	  species	  within	  the	  
total	  phospholipid	  pool.	  	  
Figure	   4.14	   –	   Most	   abundant	   oxidised	   phospholipids	   extracted	   from	   the	   treated	  
monocytes.	   (A)	  Lyso	   lipids	   (B)	  Short	  chained	  oxidised	  phospholipids	   (C)	  Long	  chained	  
oxidised	  phospholipids	   and	   their	   corresponding	  m/z	   values	   for	   control	   IgG	   (n=3)	   and	  
MPO-­‐ANCA	   (n=3)	   treated	   LPS	   stimulated	   monocytes.	   Please	   refer	   to	   table	   4.1	   for	  
identification	  of	  m/z	  values.	  Data	  was	  analysed	  using	  a	  student’s	  t	  test	  (*	  =	  p	  <	  0.05).	  
For	   most	   of	   the	   oxidatively	   modified	   phosphatidylcholine	   species,	   there	   was	   no	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treated	   monocytes,	   and	   the	   levels	   of	   some	   commonly	   observed	   chain-­‐shortened	  
oxidised	   phosphatidylcholines	   such	   as	   1-­‐palmitoyl-­‐2-­‐oxovaleroyl-­‐PC	   (POVPC)	   and	   1-­‐
palmitoyl-­‐2-­‐glutaroyl-­‐PC	  (PGPC)	  were	  on	  the	  limit	  of	  detection.	  However,	  it	  was	  found	  
that	   a	   phosphatidylcholine	   species	   at	  m/z	   828.8	   eluting	   in	   the	   range	   of	   long-­‐chain	  
oxidised	  phospholipids	  was	  significantly	  higher	  in	  MPO-­‐ANCA	  treated	  monocytes.	  	  
Extracted	   ion	   chromatograms	   for	  m/z	   828.8	   for	   each	  of	   the	  6	   samples	   are	   shown	   in	  
figure	   4.15.	   This	   phospholipid	   was	   tentatively	   identified	   as	   1-­‐palmitoyl-­‐2-­‐(5,6-­‐
epoxyisoprostane	  E2)-­‐	  phosphatidylcholine	  (PEIPC).	  
Thus,	  we	  have	  found	  evidence	  of	  at	  least	  one	  oxidised	  phospholipid,	  which	  is	  increased	  































Figure	  4.15	  -­‐	  Extracted	  ion	  chromatograms	  for	  the	  control	  IgG	  (n=3)	  and	  MPO-­‐ANCA	  
(n=3)	   treated	   samples.	   The	   chromatograms	   show	   the	   intensity	   of	   the	   long-­‐chain	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4.6	   MPO-­‐ANCA	   increase	   monocyte	   survival	   and	   differentiation	   to	  
macrophages	  
Whilst	  monitoring	  monocyte	  cultures	  over	  six	  days,	  we	  noticed	  that	  monocytes	  treated	  
with	  MPO-­‐ANCA	  were	  more	  abundant	  than	  those	  treated	  with	  control	   IgG.	  Based	  on	  
these	  observations,	  we	  next	  explored	   the	  effect	  of	  MPO-­‐ANCA	  on	  monocyte	  survival	  
and	  differentiation	   in	   comparison	   to	   control	   IgG.	   To	   avoid	   the	  potential	   (M1	  or	  M2)	  
skewing	   effects	   of	   growth	   factor	   addition,	   we	   performed	   these	   experiments	   in	   the	  
absence	  of	  LPS	  and	  in	  the	  presence	  of	  10%	  AB	  serum	  as	  discussed	  in	  section	  2.5.6.	  
Using	   the	   same	   10	   control	   IgG	   and	   10	   MPO-­‐ANCA	   samples	   as	   in	   the	   previous	  
experiments	  (see	  tables	  3.1	  and	  3.2),	  we	  found	  that	  MPO-­‐ANCA	  significantly	  increased	  
cell	  survival	  after	  6	  days	  in	  culture	  using	  monocytes	  from	  2	  distinct	  donors	  (see	  figure	  
4.16).	  
Figure	  4.16	  –	  Cell	  counts	  after	  culturing	  peripheral	  blood	  monocytes	  from	  2	  donors	  
for	  6	  days.	  The	  number	  of	  cells	  remaining	  after	  culturing	  peripheral	  blood	  monocytes	  
with	  10%	  AB	  serum	  and	  MPO-­‐ANCA	  (n=10)	  or	  control	  IgG	  for	  6	  days	  (n=10)	  are	  shown.	  
Data	  were	  analysed	  using	  a	  student’s	  t	  test	  (***	  =	  p	  <	  0.001).	  
Since	  CSF1	  is	  a	  key	  survival	  and	  differentiation	  factor	  for	  monocytes	  and	  macrophages,	  
we	  measured	   CSF1	   production	   by	  monocytes	   using	   RT-­‐qPCR	   as	   described	   in	   section	  
2.5.12.	  We	  found	  a	  marked	  increase	  in	  CSF1	  mRNA	  expression	  in	  the	  presence	  of	  MPO-­‐
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Figure	  4.17	  -­‐	  CSF1	  gene	  expression	  in	  peripheral	  blood	  monocytes	  after	  18	  hours	   in	  
culture	  with	  control	  IgG	  or	  MPO-­‐ANCA.	  Data	  are	  expressed	  as	  a	  fold	  change	  in	  mRNA	  
expression	  compared	  to	  the	  non-­‐activated	  cells.	  Data	  were	  analysed	  using	  a	  student’s	  t	  
test	  (***	  =	  p	  <	  0.001).	  
However,	  when	  CSF1	  production	  was	  assessed	  at	  the	  protein	  level	  in	  the	  supernatants	  
using	  an	  ELISA,	  we	  did	  not	  observe	  a	  consistent	  increase	  with	  MPO-­‐ANCA	  treatment	  in	  
both	  donors	  (figure	  4.18).	  The	  discrepancy	  in	  gene	  expression	  and	  protein	  production	  
is	  not	  clear	  as	  yet,	  but	  could	  be	  based	  on	  the	  fact	  that	  monocytes	  may	  consume	  CSF1	  
in	  an	  autocrine	  fashion	  to	  sustain	  proliferation.	  
Figure	  4.18	  –	  CSF1	  protein	  in	  the	  supernatants	  of	  peripheral	  blood	  monocytes	  after	  
18	   hours	   in	   culture	   with	   control	   IgG	   or	   MPO-­‐ANCA.	   Data	   were	   analysed	   using	   a	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We	  analysed	  CSF1	  receptor	  (CSF1R)	  mRNA	  expression	  in	  the	  presence	  of	  MPO-­‐ANCA	  or	  
control	  IgG	  to	  support	  this	  notion,	  however	  we	  found	  that	  the	  CSF1R	  mRNA	  expression	  
was	  lower	  in	  the	  MPO-­‐ANCA	  treated	  monocytes	  compared	  to	  the	  control	  IgG	  treated	  
monocytes,	  although	  by	  a	  small	  margin	  (figure	  4.19).	  
Figure	  4.19	  -­‐	  CSF1R	  gene	  expression	  in	  peripheral	  blood	  monocytes	  after	  18	  hours	  in	  
culture	  with	  control	  IgG	  or	  MPO-­‐ANCA.	  Data	  are	  expressed	  as	  a	  fold	  change	  in	  mRNA	  
expression	  compared	  to	  the	  non-­‐activated	  cells.	  Data	  were	  analysed	  using	  a	  student’s	  t	  
test	  (***	  =	  p	  <	  0.001).	  
These	   results	   do	   not	   negate	   the	   hypothesis	   that	   CSF1	   protein	  may	   be	   consumed	   by	  
monocytes	   in	  an	  autocrine	   fashion.	  We	  used	  a	  CSF1R	   inhibitor	  GW2580	  and	   found	  a	  
dose-­‐dependent	   reversal	   of	   the	   increase	   in	   cell	   survival	   at	   day	   6	   documented	   with	  
MPO-­‐ANCA.	   This	   confirms	   that	   the	   cell	   survival	   advantage	   seen	   with	   MPO-­‐ANCA	   is	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Figure	   4.20	   –	   Effect	   of	   a	   CSF1R	   inhibitor	   (GW2580)	   on	   cell	   counts	   after	   6	   days	   of	  
peripheral	  blood	  monocyte	  culture.	  Monocytes	  from	  one	  donor	  were	  incubated	  with	  
control	  IgG	  or	  MPO-­‐ANCA	  with	  or	  without	  GW2580	  at	  different	  doses.	  
We	   next	   assessed	   whether	   the	   MPO-­‐ANCA/CSF1-­‐driven	   effects	   on	   monocyte	  
proliferation	  depended	  on	  enzymatic	  activity	  of	  MPO	  as	  we	  had	  found	  this	  to	  be	  the	  
case	  for	  the	  reduction	  in	  IL10	  and	  IL6	  (see	  section	  4.3).	  The	  MPO	  inhibitor	  AZD5904	  did	  
not	  prevent	  the	  increase	  in	  CSF1	  mRNA	  expression	  due	  to	  MPO-­‐ANCA,	  in	  fact	  it	  led	  to	  a	  
further	  increase	  in	  CSF1	  mRNA	  in	  the	  presence	  of	  MPO-­‐ANCA	  (figure	  4.21	  A).	  The	  MPO	  
inhibitor	  had	  no	  effect	  on	  CSF1	  protein	  secretion	  into	  the	  supernatants	  of	  monocytes	  
incubated	  with	  MPO-­‐ANCA	   (figure	   4.21	   B).	   However,	   the	  MPO	   inhibitor	   did	   cause	   a	  
partial	  reversal	  of	  the	  increase	  in	  macrophage	  numbers	  at	  day	  6	  associated	  with	  MPO-­‐
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Figure	  4.21	  –	  Effect	  of	  MPO	  inhibitor	  AZD5904	  on	  CSF1	  gene	  expression,	  CSF1	  protein	  
secretion	  and	  cell	  counts.	  (A)	  The	  effect	  of	  AZD5904	  on	  CSF1	  gene	  expression	  18	  hours	  
after	  monocyte	  culture	  with	  control	   IgG	  or	  MPO-­‐ANCA.	  Data	  are	  expressed	  as	  a	   fold	  
change	  in	  mRNA	  expression	  compared	  to	  the	  non-­‐activated	  cells.	  Data	  were	  analysed	  
using	   a	   student’s	   t	   test	   (**	   =	   p	   <	   0.01).	   (B)	   CSF1	   protein	   in	   the	   supernatants	   of	  
monocytes	   cultured	  with	   control	   IgG	   or	  MPO-­‐ANCA	  with	   or	   without	   AZD9504.	   Data	  
were	  analysed	  using	  a	  student’s	  t	  test	  (NS	  =	  non	  significant).	  (C)	  The	  effect	  of	  AZD5904	  
on	  cell	   counts	  after	  6	  days	  of	  peripheral	  blood	  monocyte	  culture	  with	  control	   IgG	  or	  
MPO-­‐ANCA.	  Data	  were	  analysed	  using	  a	  one	  way	  ANOVA	  with	  Dunnett’s	  post	  test	  (*	  =	  
p	  <	  0.05,	  ***	  =	  p	  <	  0.001).	  
Since	  MPO-­‐ANCA	  had	  been	   shown	   to	   interfere	  with	  TLR	   signalling	  pathways	   (section	  
4.4)	  and	  human	  serum	  contains	  endogenous	  ligands	  for	  TLR2	  and	  TLR4,	  we	  assessed	  if	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Combined	   blockade	   of	   TLR2	   and	   TLR4	   with	   neutralising	   Abs	   had	   no	   effect	   on	   cell	  







Figure	  4.22	  –	  Effect	  of	  TLR2/4	  antagonists	  on	  cell	   counts	  after	  6	  days	  of	  peripheral	  
blood	  monocyte	  culture.	  Monocytes	  from	  one	  donor	  were	  incubated	  with	  control	  IgG	  
or	   MPO-­‐ANCA	   with	   either	   control	   monoclonal	   antibodies	   or	   anti-­‐TLR2	   and	   TLR4	  
antagonists.	  Data	  were	  analysed	  using	  a	  student’s	  t	  test	  (NS	  =	  non	  significant).	  
Overall	  these	  data	  show	  a	  marked	  increase	  in	  cell	  proliferation	  after	  peripheral	  blood	  
monocytes	   are	   incubated	   for	   6	   days	  with	  MPO-­‐ANCA	   compared	   to	   control	   IgG.	   The	  
effect	   is	   largely	   due	   to	   an	  MPO-­‐ANCA	  mediated	   increase	   in	   CSF1	   production,	  which	  
itself	   seems	  not	   to	  depend	  on	  MPO	  enzyme	  activity.	  However,	   through	  an	  unknown	  
mechanism	   that	   is	   non-­‐TLR2	   and	   TLR4	   dependent,	   the	   MPO	   enzyme	   activity	   also	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4.7	  MPO-­‐ANCA	  differentiated	  macrophages	  have	  an	  M2-­‐like	  phenotype;	  
they	   express	   increased	   CD206,	   secrete	   TGFβ	   and	   promote	   CD4	   T	   cell	  
production	  of	  IL10	  and	  TGFβ	  
To	  explore	  the	  functional	  consequences	  of	  MPO-­‐ANCA	  on	  macrophage	  maturation	   in	  
human	   serum,	   we	   measured	   cytokines	   in	   the	   supernatant	   at	   day	   6	   in	   culture	   as	  
described	   in	   sections	  2.5.1	  and	  2.5.11.	   IL2,	   IL4,	   IL6,	   IL10,	   IFNγ,	   IL17A	  and	  TNFα	  were	  
undetectable	   (data	   not	   shown).	   However,	   TGFβ	   was	   detected	   at	   levels	   above	   that	  
found	  in	  the	  culture	  medium,	  and	  was	  specifically	   increased	  in	  the	  presence	  of	  MPO-­‐
ANCA	  in	  cultures	  (figure	  4.23).	  	  
Figure	  4.23	  –	  TGFβ	  levels	  in	  the	  macrophage	  supernatants	  at	  day	  6.	  Peripheral	  blood	  
monocytes	  from	  two	  donors	  were	  cultured	  with	  10%	  AB	  serum	  and	  no	  IgG,	  control	  IgG	  
(n=3)	   or	   MPO-­‐ANCA	   (n=3)	   for	   6	   days.	   TGFβ	   levels	   in	   supernatants	   were	   measured.	  
Baseline	   whole	   medium	   TGFβ	   levels	   were	   subtracted	   from	   the	   supernatant	   TGFβ	  
levels.	  Data	  were	  logarithmically	  transformed	  and	  analysed	  using	  a	  student’s	  t	  test	  (*	  =	  
p	  <	  0.05).	  	  
Further,	  expression	  of	  the	  macrophage	  marker	  CD206,	  which	  is	  more	  readily	  expressed	  
by	  M2	  macrophages,	  was	  induced	  in	  both	  MPO-­‐ANCA	  and	  control	  IgG	  treated	  cells	  at	  
day	   6	   but	   was	   higher	   in	   the	   groups	   treated	   with	   MPO-­‐ANCA	   (figure	   4.24).	   This	  
observation,	  together	  with	  the	  lower	  CD80	  expression	  induction	  we	  observed	  in	  MPO-­‐
ANCA	  treated	  monocytes	  (figure	  4.24)	  suggests	  that	  the	  macrophages	  maturing	  in	  the	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presence	  of	  MPO-­‐ANCA	  have	  an	  M2	  phenotype	  in	  keeping	  with	  the	  role	  that	  we	  have	  











Figure	  4.24	  –	  Representative	  FACS	  histogram	  plots	  of	  CD206	  and	  CD80	  expression	  on	  
macrophages.	  Monocytes	  from	  2	  donors	  were	  cultured	  for	  6	  days	  with	  10%	  AB	  serum	  
and	   control	   IgG	   (n=2)	  or	  MPO-­‐ANCA	   (n=2).	  Histograms	   shown	   for	  one	  donor.	  CD206	  
MFIs	  were	  (donor	  1)	  3182,	  3227	  /	  (donor	  2)	  33466,	  33287	  	  for	  MPO-­‐ANCA	  treated	  cells	  
and	  (donor	  1)	  2202,	  2624	  /	  (donor	  2)	  20565,	  8357	  	  for	  control	  IgG	  treated	  cells.	  CD80	  
MFIs	  were	  (donor	  1)	  222,	  228	  /	  (donor	  2)	  1113,	  1213	  for	  MPO-­‐ANCA	  treated	  cells	  and	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We	  next	  went	  on	  to	  assess	  the	  functional	  impact	  of	  the	  macrophage	  skewing	  observed	  
on	  CD4	  T	  cells.	  Patients	  with	  vasculitis	  have	  T	  cells	  within	  affected	  glomeruli	  and	  also	  
changes	   in	   and	   persistence	   of	   local	   Th1	   and	   Th2	   responses	   [277].	   Therefore,	   we	  
transferred	  supernatants	  from	  antibody-­‐treated	  macrophages	  onto	  anti-­‐CD3	  and	  anti-­‐
CD28	   activated	  CD4	   T	   cells	   as	   described	   in	   section	   2.5.6	   and	  measured	   the	   cytokine	  
profile	   of	   the	   activated	   T	   cells.	   The	   CD4	   T	   cells	   were	   not	   acquired	   from	   the	   same	  
donors	  as	  the	  monocytes.	  Separate	  healthy	  donors	  were	  utilised.	  
TGFβ	   levels	   in	   the	   CD4	   T	   cell	   supernatants	   were	   increased	   when	   the	   T	   cells	   were	  
stimulated	   in	   the	   presence	   of	   supernatants	   from	   MPO-­‐ANCA	   treated	   macrophages	  
(figure	   4.25).	   The	   TGFβ	   levels	   were	   higher	   than	   those	   found	   in	   the	   macrophage	  
supernatants	  or	  the	  basal	  T	  cell	  medium	  and	  so	  they	  reflected	  production	  from	  CD4	  T	  
cells.	  	  
Figure	   4.25	   -­‐	   TGFβ	   levels	   in	   anti-­‐CD3	   and	   anti-­‐CD28	   activated	   CD4	   T	   cells	  
supernatants	   at	   day	   3	   and	  day	   5.	   The	   anti-­‐CD3	   and	   anti-­‐CD28	   activated	  CD4	   T	   cells	  
were	   incubated	  with	   supernatants	   from	  untreated	  macrophages;	   control	   IgG	   treated	  
(n=3)	  or	  MPO-­‐ANCA	  (n=3)	  treated	  macrophages.	  Baseline	  whole	  medium	  TGFβ	   levels	  
were	   subtracted	   from	   the	   supernatant	   TGFβ	   levels.	   Data	   were	   analysed	   using	   a	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To	   ensure	   that	   the	   ELISA	   data	   in	   figure	   4.23	   and	   figure	   4.25	   were	   comparable	   a	  
standard	  sample	  was	  analysed	  on	  both	  ELISA	  sets	  (749.4	  and	  830.6	  pg/ml	  respectively).	  
IL17A	  was	   not	   affected	   consistently	   by	  macrophage-­‐derived	   factors	   and	   IL4	  was	   not	  
detected	   (data	   not	   shown),	   however,	   we	   observed	   a	   consistent	   decrease	   in	   IFNγ	  
production	  accompanied	  with	  an	  increase	  in	  IL10	  specifically	  in	  CD4	  T	  cells	  activated	  in	  
the	   presence	   of	   supernatants	   from	   MPO-­‐ANCA	   treated	   macrophages	   with	   a	  
statistically	   significant	  and	  persistent	   increase	   in	   the	   IL10	   to	   IFNγ	   ratio	  on	  day	  3	  and	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Figure	  4.26	  –	  Cytokine	  profile	  of	  CD4	  T	  cells	  activated	  with	  anti-­‐CD3	  and	  anti-­‐CD28	  in	  
the	  presence	  or	  absence	  of	  added	  supernatant	   from	  macrophages.	  Activated	  CD4	  T	  
cells	   from	   two	  donors	   cultured	   for	   3	   (A)	   or	   5	   (B)	   days	  with	   or	  without	   supernatants	  
from	  macrophages	   incubated	  with	   control	   IgG	   (n=3)	   or	  MPO-­‐ANCA	   (n=3).	   IL10,	   IFNγ	  
and	   IL10	   /	   IFNγ	   ratio	   in	   the	   supernatants	  of	   the	  CD4	  T	   cells	  are	  depicted.	  Data	  were	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4.8	  Discussion	  
We	   have	   discovered	   some	   novel	   effects	   of	   MPO-­‐ANCA	   on	   human	   monocytes	   with	  
potential	   implications	   for	   AAV	   pathogenesis.	   These	   include	   MPO-­‐ANCA	   induced	  
reduction	  in	  IL6	  and	  IL10	  production	  from	  monocytes	  in	  response	  to	  stimulation	  with	  
LPS,	  which	  requires	  the	  Fc	  and	  MPO	  binding	  portion	  of	  ANCA.	  The	  effect	  seems	  to	  be	  
dependent	  on	  MPO	  enzyme	  activity	  and	  is	  possibly	  mediated	  by	  MPO	  driven	  increase	  
in	   oxidised	   phospholipids.	   The	   phosphatidylcholine	   species	   at	   m/z	   828.8	   that	   was	  
increased	  in	  MPO-­‐ANCA	  treated	  monocytes	  was	  tentatively	  identified	  as	  PEIPC,	  which	  
has	   been	   reported	   previously	   to	   be	   generated	   in	   LPS-­‐stimulated	   monocytes	   and	  
neutrophils	   [59].	  Oxidised	  phospholipids	  have	  been	   shown	   to	  have	  a	  wide	  variety	  of	  
bioactivities,	  which	  can	  be	  both	  pro-­‐	  and	  anti-­‐inflammatory	  depending	  on	  the	  cell	  type	  
and	  oxidised	  phospholipid	  species	  in	  question.	  
An	   important	  anti-­‐inflammatory	  mechanism	  of	  oxidised	  phospholipids	   is	   through	   the	  
inhibition	   of	   TLR2	   and	   TLR4	   signalling,	   in	   part	   by	   competitive	   interaction	   with	   LPS	  
binding	  protein,	  CD14	  and	  myeloid	  differentiation	  protein	  2	  [274-­‐276].	  There	  has	  been	  
little	  work	  on	   the	  effects	  of	  PEIPC	  as	   an	   individual	   species,	   but	   it	   has	  been	   reported	  
previously	  that	  it	  can	  induce	  IL8	  production	  by	  endothelial	  cells and it	  can	  inhibit	  LPS-­‐
induced	   E-­‐selectin	   expression	   at	   concentrations	   approximately	   10-­‐fold	   lower	   than	  
those	   that	   induce	   IL8	   production	   [276,	   278,	   279].	   Currently,	   it	   is	   not	   clear	   why	   a	  
significant	   increase	  was	   only	   observed	   for	   a	   single	   oxidised	   species,	   or	   whether	   the	  
increase	  observed	  would	  be	  sufficient	   to	  cause	   inhibition	  of	  TLR	  signalling.	  However,	  
PEIPC	   is	   indeed	   one	   of	   the	   most	   abundant	   esterified	   products	   produced	   during	  
oxidation	  of	  PAPC	   in	  vitro,	  and	  has	  also	  been	  detected	  as	  a	  major	  product	   in	  various	  
inflammatory	   lesions	   [280].	   Furthermore,	   if	  MPO-­‐ANCA	   is	   tethering	  MPO	   to	   the	   cell	  
surface,	   this	   would	   cause	   localized	   oxidation	   that	   might	   not	   be	   readily	   apparent	   in	  
extracts	  of	  total	  cellular	  phospholipids.	  
The	  effects	  of	  a	  reduction	  in	  IL6	  are	  difficult	  to	  predict,	  as	  this	  cytokine	  has	  both	  pro-­‐	  
and	   anti-­‐inflammatory	   effects	   mediated	   by	   classical	   membrane-­‐bound	   receptor	  
signalling	   and	   trans-­‐signalling	   via	   a	   soluble	   receptor	   [281,	   282].	   For	   example	   IL6	  
regulates	   neutrophil	   recruitment	   to	   inflammatory	   sites	   by	   promoting	   granulopoeisis	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[283],	   but	   following	   neutrophil	   recruitment	   and	   soluble	   IL6	   receptor	   shedding,	   IL6	  
signalling	  limits	  neutrophil	  influx	  [284].	  IL6	  protein	  levels	  were	  consistently	  reduced	  in	  
the	   supernatant	   of	   LPS	   stimulated	  monocytes	   treated	  with	  MPO-­‐ANCA	   for	   18	   hours	  
and	   in	   the	   microarray	   studies	   of	   MPO-­‐ANCA	   treated	   monocytes	   at	   6	   hours	   of	   cell	  
culture	  studies.	  
In	   contrast	   IL10	   is	   an	   anti-­‐inflammatory	   cytokine	   and	   moreover	   the	   reduction	   in	  
response	   to	   MPO-­‐ANCA	   was	   more	   pronounced	   than	   that	   seen	   for	   IL6	   in	   our	  
experiments.	   Many	   mechanisms	   are	   in	   place	   to	   prevent	   exaggerated	   inflammatory	  
responses	  and	   IL10	  has	  proved	   to	  be	  an	  essential	   factor	   in	   this	  protection	   [285].	   For	  
example,	  animals	  that	  are	  genetically	  deficient	  for	  IL10	  or	  are	  treated	  with	  antibodies	  
that	   neutralize	   IL10	   die	   rapidly	   when	   infected	   with	   pathogens	   due	   to	   the	  
overproduction	  of	  pro-­‐inflammatory	  cytokines	  rather	  than	  a	  lack	  of	  control	  of	  infection	  
[286,	   287].	   In	   the	   context	   of	   tissue	   inflammation	   in	   AAV,	   cells	   such	   as	   tissue	  
macrophages,	  dendritic	  cells,	  epithelial	  cells	  and	  renal	  mesangial	  cells,	  do	  not	  contain	  
MPO	  and	  will	  not	  be	  affected	  by	  MPO-­‐ANCA	  directly.	  However,	  they	  will	  be	  influenced	  
by	  cytokines	  released	  locally	  by	  monocytes.	  A	  reduction	  in	  monocyte	  IL10	  production	  
would	   therefore	   be	   expected	   to	   increase	   the	   responsiveness	   of	   these	   cells	   to	  
stimulation	   by	   TLRs	   and	   other	   inflammatory	   stimuli	   and	   to	   lead	   to	   an	   exaggerated	  
inflammatory	  response.	  This	  protective	  effect	  of	  IL10	  is	  demonstrated	  in	  the	  context	  of	  
renal	   inflammation	   in	   the	   unilateral	   ureteral	   obstruction	   (UUO)	  model.	  More	   severe	  
inflammation	   develops	   in	   the	   kidney	   of	   mice	   lacking	   IL10	   compared	   to	   wild	   type	  
controls	  [288].	  Overall,	  the	  dominant	  effect	  of	  MPO-­‐ANCA	  on	  monocytes	  is	  a	  reduction	  
in	   IL10	   secretion,	  which	  would	  be	  expected	   to	  promote	   inflammation	  and	  disease	   in	  
patients.	   Surprisingly	   we	   did	   not	   see	   a	   suppression	   of	   IL10	   gene	   expression	   in	   the	  
microarray	   studies	  of	  monocytes	   treated	  with	  MPO-­‐ANCA.	  This	  may	  be	  due	   to	   the	  6	  
hour	   time-­‐point	  we	   selected	   to	   analyse	   the	  microarray	   data.	   It	   is	   possible	   that	   IL10	  
levels	  are	  suppressed	  at	  an	  earlier	  or	  later	  time-­‐point.	  
We	  also	  showed	  that	  MPO-­‐ANCA	  causes	  an	  increase	  in	  survival	  and	  differentiation	  of	  
monocytes	   to	  M2-­‐like	  macrophages	   in	   culture	  primarily	   through	   an	   increase	   in	   CSF1	  
production.	  Macrophages	  play	  an	  important	  role	  in	  wound	  healing	  as	  well	  as	  fibrosis.	  
They	  stimulate	  and	  activate	   fibroblasts	   to	  produce	  extracellular	  matrix	  proteins	   [270,	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289]. It	  is	  increasingly	  recognised	  that	  the	  phenotype	  of	  macrophages	  does	  not	  fall	  into	  
a	  simple	  M1	  or	  M2	  category	  as	  discussed.	  However,	  the	  increased	  CD206	  and	  reduced	  
CD80	   expression,	   together	   with	   higher	   TGFβ	   secretion	   on	   exposure	   to	   MPO-­‐ANCA	  
compared	  to	  control	  IgG,	  suggests	  that	  the	  macrophages	  fit	  most	  closely	  with	  an	  M2-­‐
like	  phenotype,	  consistent	  with	  their	  induction	  by	  an	  increased	  concentration	  of	  CSF1	  
[137,	  138].	  Ramirez	  et	  al	  have	  shown	  that	  patients	  with	  AAV	  have	  higher	  levels	  of	  CSF1	  
compared	  to	  healthy	  controls,	  this	  correlated	  with	  the	  BVAS	  score	  [290]	  supporting	  our	  
data.	  
TGFβ	   has	   been	   established	   for	   over	   a	   decade	   as	   a	   key	   cytokine	   that	   promotes	   the	  
induction	  of	  regulatory	  T	  cells	  [291].	   In	  mice,	  macrophages	  polarised	  to	  secrete	  TGFβ	  
have	   been	   shown	   to	   inhibit	   adriamycin-­‐induced	   nephrosis	   by	   a	   mechanism	   that	  
includes	  the	  induction	  of	  regulatory	  T	  cells	  [292].	  A	  further	  report	  has	  also	  shown	  that	  
human	  M2	  macrophages	  can	  induce	  CD4	  T	  cells	  with	  a	  regulatory	  phenotype	  [293].	  In	  
both	   of	   these	   examples,	   the	  mechanism	   of	   suppression	  was	   thought	   to	   require	   cell	  
contact	   whereas	   we	   have	   shown	   the	   effect	   of	   a	   soluble	   factor	   in	   the	   supernatant.	  
Nonetheless	   there	   are	   parallels	   with	   our	   data	   suggesting	   the	   M2	   macrophages,	  
generated	  from	  monocytes	  incubated	  with	  MPO-­‐ANCA,	  limit	  T	  cell	  activation	  via	  TGFβ.	  
Our	   current	   data	   suggest	   that	   macrophages	   generated	   from	  MPO-­‐ANCA	   stimulated	  
monocytes	  act	   to	   limit	   the	  activation	  of	   IFNγ	  producing	  CD4	  T	  cells	  and	  promote	  the	  
switch	   to	  an	   IL10	  producing	  phenotype.	  Over	   the	  past	   few	  years	   the	   life	  cycle	  of	   the	  
Th1	  cell	  as	  it	  changes	  from	  producing	  predominantly	  IFNγ	  to	  producing	  both	  IFNγ	  and	  
IL10	  and	  then	  to	  producing	  predominantly	  IL10	  and	  acquiring	  suppressive	  capacity,	  has	  
been	  described	  [186].	  This	  represents	  a	  key	  pathway	  in	  the	  lifecycle	  of	  Th1	  cells	  as	  they	  
switch	   from	  an	   inflammatory	   to	   a	   regulatory	  phenotype.	   These	   IL10	   secreting	  CD4	   T	  
cells	   may	   be	   similar	   to,	   if	   not	   the	   same	   as,	   those	   that	   have	   been	   called	   induced	  
regulatory	   T	   cells	   [294].	   It	   has	   been	   shown	   that	   CD46	   activated	   CD4	   T	   cells	   indeed	  
express	   increased	   TGFβ	  (Kemper	   et	   al	   unpublished	   data).	  We	   now	   show	   that	   CD4	   T	  
cells	   activated	   in	   the	   presence	   of	   supernatants	   from	   MPO-­‐ANCA	   stimulated	  
monocytes/macrophages	  also	  produce	  TGFβ.	  T	  cells	  have	  been	  shown	  to	  be	  important	  
in	  both	  pulmonary	  and	  renal	  fibrosis	  with	  several	  potential	  mechanisms	  that	  have	  not	  
been	   fully	   defined	   [295,	   296].	   A	   direct	   effect	   of	   TGFβ	  produced	   by	   T	   cells	   is	   one	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possibility	  and	  we	  have	  shown	  how	  this	  may	  be	  promoted	  by	  MPO-­‐ANCA	  via	  its	  actions	  
on	   monocytes.	   Effects	   of	   TGFβ	   include	   a	   direct	   stimulation	   of	   fibroblasts	   to	   cause	  
differentiation	  into	  myofibroblasts	  with	  concomitant	  collagen	  secretion	  [268,	  297].	  The	  
amount	  of	  fibrosis	  remaining	  in	  vital	  end	  organs	  such	  as	  the	  lung	  and	  kidney	  is	  a	  major	  
prognostic	  factor	  for	  patients	  with	  AAV	  [267].	  
In	   summary	   we	   have	   shown	   two	   novel	   effects	   of	   MPO-­‐ANCA	   on	   monocytes	   with	  
implications	  for	  disease	  in	  patients.	  These	  are	  firstly,	  a	  reduction	  in	  IL10	  in	  response	  to	  
LPS	   stimulation,	   potentially	   due	   to	   inhibition	   of	   TLR	   signalling	   by	   oxidised	  
phospholipids,	   which	   are	   known	   to	   be	   TLR4	   antagonists.	   Secondly	   MPO-­‐ANCA	  
promotes	  monocyte	   survival	   and	   differentiation	   to	  macrophages,	   which	   instruct	   the	  
generation	  of	  regulatory	  T	  cells	  that	  produce	  IL10	  and	  TGFβ	  and	  may	  promote	  fibrosis.	  





Figure	   4.27	   –	   Summary	   of	   proposed	   actions	   of	  MPO-­‐ANCA	   on	  monocytes	   and	   the	  
subsequent	  downstream	  effects.	  1.	  MPO-­‐ANCA	  tether	  MPO	  via	  the	  Fc	  receptors	  (FcR)	  
onto	   the	   monocyte	   surface	   and	   generates	   local	   oxidised	   phospholipids	   (OxPL)	   from	  
native	  cell	  phospholipids	   (PL).	  2.	  The	  oxidised	  phospholipids	   inhibit	  LPS	   induced	  TLR4	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the	   acute	   phase	   of	   the	   disease.	   3.	   MPO-­‐ANCA	   also	   increase	   CSF1	   production	   from	  
monocytes	   through	   an	   unknown	   mechanism.	   4.	   These	   set	   of	   events	   increase	   the	  
survival	   and	   generation	   of	   M2-­‐like	   macrophages	   that	   generate	   TGFβ.	   5.	   The	  
macrophages	  create	  a	  milieu	  that	  leads	  to	  the	  generation	  of	  regulatory	  CD4	  T	  cells	  that	  
produce	   IL10	  and	  TGFβ,	  which	   is	   thought	   in	   turn	  to	  promote	  fibrosis	  and	  possibly	  an	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Chapter	  5	  –	  The	  role	  of	  complement	  in	  AAV	  
5.1	  Introduction	  
The	  various	  animal	  models	  of	  AAV	  have	  been	  discussed	   in	   section	  1.11.	  We	   recently	  
published	   a	   modification	   of	   the	   passive	   transfer	   model	   using	   GCSF	   to	   exacerbate	  
disease	  [119].	  The	  passive	  transfer	  model	  was	  first	  established	  by	  Xiao	  et	  al	  [100].	  The	  
disease	  severity	  in	  the	  passive	  transfer	  model	  was	  exacerbated	  by	  the	  use	  of	  systemic	  
bacterial	  LPS	  [32].	  The	  model,	  which	  needed	  minor	  modifications,	  has	  been	  established	  
in	  our	  laboratory.	  The	  methodology	  is	  summarised	  below	  in	  figure	  5.1.	  Please	  refer	  to	  










Figure	  5.1	  –	  The	  overall	  passive	  transfer	  model	  protocol	  of	  AAV	  used	  for	  this	  PhD.	  	  
The	   histological	   features	   of	   glomerulonephritis	   induced	   with	   the	   passive	   transfer	  
model	   closely	   mirror	   the	   situation	   in	   patients	   presenting	   with	   AAV.	   The	   crescentic	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features	   recapitulate	   characteristics	   of	   the	   histology	   seen	   in	   clinical	   renal	   biopsy	  
samples.	  Furthermore,	  the	  proteinuria	  observed	  is	  in	  the	  non-­‐nephrotic	  range,	  as	  is	  the	  
case	   for	   patients	  with	   AAV.	   	   These	   features	  make	   this	   a	   good	  model	   of	  MPO-­‐ANCA	  
disease.	  
Several	  pathogen	  associated	  molecular	  pattern	  molecules	   including	   LPS	  activate	  TLR.	  
LPS	  is	  a	  structural	  component	  of	  the	  outer	  membrane	  of	  gram-­‐negative	  bacteria.	  LPS	  
induced	   activation	   occurs	   through	   a	   series	   of	   interactions	   with	   LPS	   binding	   protein,	  
CD14,	   myeloid	   differentiation	   protein	   2	   and	   TLR4	   [298].	   The	   LPS	   binding	   protein	  
facilitates	  binding	  of	  LPS	  and	  CD14	  which	   in	  turn	  transfers	  LPS	  to	  the	  TLR4	  /	  myeloid	  
differentiation	  protein	  2	  complex.	  Upon	  LPS	  binding,	  TLR4	  undergoes	  oligomerisation	  
[298].	  TLR4	  activation	  in	  this	  manner	  leads	  to	  further	  interaction	  with	  Toll-­‐interleukin-­‐1	  
receptor	   domains	   (namely	   MyD88,	   MAL,	   TRIF,	   TRAM	   and	   SARM),	   which	   recruit	  
downstream	   signalling	   cascades	   generally	   separated	   into	   MyD88	   dependent	   and	  
independent	  pathways	  that	  lead	  to	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  and	  
type	  1	  interferons	  respectively	  [299].	  	  
Huugen	   et	   al	   showed	   that	   in	   C57BL/6	  mice	   administration	   of	   LPS	   led	   to	   a	   transient	  
increase	  in	  systemic	  TNFα	  levels	  as	  well	  as	  circulating	  MPO	  levels	  [32].	  The	  rise	  in	  TNFα	  
levels	  was	   thought	   to	  prime	  neutrophils	  exposing	  more	  of	   the	  antigens	   to	   the	  MPO-­‐
ANCA	  administered,	  worsening	  disease	  in	  the	  passive	  transfer	  model.	  
GCSF	   as	   discussed	   in	   section	   1.6	   acts	   via	   a	   transmembrane	   protein	   to	   mobilise,	  
proliferate,	  differentiate	  and	  maintain	   the	   survival	  of	  myeloid	   cells.	  We	   showed	   that	  
GCSF	  also	  primes	  neutrophils	   to	   induce	  respiratory	  burst	  on	  exposure	   to	  monoclonal	  
MPO-­‐ANCA	  [119].	  Together	  these	  functions	  lead	  to	  more	  antigen	  containing	  cells	  that	  
propagate	  further	  inflammation.	  	  
As	   a	   result	   it	   is	   comprehensible	   that	   both	   LPS	   and	   GCSF	   exacerbate	   disease	   in	   the	  
passive	  transfer	  model.	  However,	  it	  is	  not	  known	  whether	  GCSF	  alone	  can	  exacerbate	  
disease	  without	  LPS.	  
In	  section	  1.10	  we	  discussed	  the	  role	  of	  complement	  in	  AAV.	  Previous	  published	  work	  
using	  the	  passive	  transfer	  model	  implicates	  the	  alternative	  pathway	  of	  complement	  in	  
|	  Page	  183	  
pathogenesis.	   The	   administration	   of	   cobra	   venom	   factor	   to	  mice	   offered	   protection	  
against	  the	  development	  of	  MPO-­‐ANCA	  disease,	  furthermore,	  mice	  deficient	  in	  factor	  
B	  but	  not	  C4	  were	  protected	  from	  disease	  [207].	  C5	  deficient	  mice	  are	  also	  protected	  
and	  treatment	  with	  an	  anti-­‐C5	  monoclonal	  antibody	  inhibited	  disease	  induction	  [208].	  
MPO	  deficient	  mice	   immunised	  with	  MPO	  and	   transplanted	  with	  bone	  marrow	   from	  
C5aR1	   deficient	   mice	   were	   protected	   from	   disease	   when	   compared	   with	   mice	   that	  
received	   wild	   type	   bone	   marrow,	   suggesting	   that	   the	   anaphylatoxin	   C5a	   is	   a	   key	  
mediator	  [209].	  This	  work	  was	  extended	  with	  evidence	  of	  therapeutic	  efficacy	  for	  the	  
CCX168,	  a	  C5aR1	  antagonist,	  in	  human	  C5aR1	  knock	  in	  mice	  [211].	  
The	   trigger	   that	   leads	   to	   the	   activation	   of	   the	   alternative	   pathway	   has	   not	   been	  
elucidated.	  We	  showed	  data	  in	  section	  3.5	  to	  suggest	  that	  neutrophils	  are	  capable	  of	  
expressing	   C3	   and	   C5.	   Furthermore,	   we	   suggested	   that	   PR3	   could	   cleave	   C3	   into	  
different	  components.	  This	  may	  have	  a	  role	  to	  play	  in	  the	  generation	  of	  C3a	  and	  C3b.	  
We	   discussed	   that	   neutrophils	   are	   capable	   of	   releasing	   the	   machinery	   for	   the	  
formation	   of	   a	   C5	   convertase,	   which	  may	   propagate	   the	   downstream	   events	   of	   the	  
complement	  pathway	  [187,	  210].	  There	  are	  other	  potential	  initiators	  of	  the	  alternative	  
pathway.	  
Properdin	  is	  established	  as	  a	  key	  stabiliser	  of	  the	  alternative	  pathway	  but	  it	  also	  binds	  
to	   various	   cell	   surfaces	   including	   apoptotic	   cells	   and	   serves	   as	   a	   platform	   for	   C3bBb	  
assembly,	   leading	   to	   C3	   cleavage	   and	   complement	   activation	   [151-­‐153].	   Hence,	  
properdin	   itself	   may	   serve	   as	   a	   PRM	   for	   alternative	   pathway	   activation.	   However,	  
previous	  work	   in	   our	   laboratory	  done	  by	   Freeley	  et	   al	   (The	   role	   of	   complement	   and	  
GCSF	   in	  ANCA	  associated	  vasculitis,	  PhD	  Thesis	  2013,	  King’s	  College	  London)	   showed	  
that	  properdin	  knockout	  mice	  were	  not	  protected	  from	  disease	  in	  the	  passive	  transfer	  
model.	  The	  percentage	  of	  glomerular	  crescents	  between	  the	  groups	  was	  similar	  (mean	  
of	   27.5±6.9%	   and	   27.8±8.2%	   for	   the	   wild	   type	   and	   properdin	   deficient	   mice	  
respectively),	  as	  was	  the	  glomerular	  macrophage	  count,	  albuminuria,	  haematuria	  and	  
serum	   creatinine.	   This	   makes	   properdin	   an	   unlikely	   candidate	   for	   initiating	   and	  
propagating	  the	  alternative	  pathway.	  
Another	   candidate	   for	   initiating	   activation	   of	   the	   alternative	   pathway	   is	   possibly	   the	  
lectin	   pathway.	   Recent	   work	   has	   shown	   that	   C4	   is	   not	   required	   for	   lectin	   pathway	  
|	  Page	  184	  
activation,	  so	  it	  is	  possible	  that	  the	  lectin	  pathway	  in	  a	  C4-­‐independent	  manner	  may	  be	  
important	   in	   initiating	   complement	   activation,	  with	   subsequent	   amplification	   by	   the	  
alternative	   pathway	   [245].	   Interestingly	   work	   in	   our	   laboratory	   (Simon	   Freeley,	   The	  
role	  of	   complement	  and	  GCSF	   in	  ANCA	  associated	  vasculitis,	  PhD	  Thesis	  2013,	  King’s	  
College	   London)	   showed	   that	  MASP2	   deficiency	   led	   to	   a	   significant	   exacerbation	   of	  
renal	  disease	  when	  compared	  to	  controls	  in	  the	  context	  of	  the	  passive	  transfer	  model.	  
MASP2	  knockout	  mice	  had	  significantly	  more	  glomerular	  crescents	  (mean	  of	  30.9±4%	  
and	  17.1±2.8%	  respectively),	  higher	  albumin	  creatinine	  ratios	  and	  more	  haematuria	  as	  
well	   as	   raised	   serum	   creatinine	   than	   wild	   type	  mice.	   This	   result	   was	   surprising;	   we	  
anticipated	  as	  in	  the	  ischaemia	  reperfusion	  model,	  MASP2	  deficiency	  would	  lead	  to	  an	  
attenuation	   of	   disease	   [245].	   This	   data	   suggested	   that	   in	   the	   context	   of	   the	   passive	  
transfer	  model,	  MASP2	  has	  a	  protective	  effect.	  The	  exact	  mechanisms	  responsible	  for	  
this	  effect	  were	  unclear.	  MBL	  binds	  and	  clears	  modified	  immunoglobulins	  and	  immune	  
complexes.	   MBL	   deficiency	   has	   been	   shown	   in	   a	   mouse	   model	   of	   vaccination	   to	  
increase	  antibody	  responses.	  As	  a	  result	  the	  MPO-­‐ANCA	  levels	  were	  measured	  at	  day	  7	  
in	  the	  MASP2	  deficient	  mice	  and	  wild	  type	  mice	  serum	  but	  no	  significant	  difference	  in	  
titres	  were	  found.	  The	  possibility	  of	  whether	  this	  effect	  on	  disease	  severity	  is	  mediated	  
through	  the	  alternative	  pathway	  was	  not	  determined	  at	  the	  time.	  	  
The	  other	   interesting	   aspect	   of	   complement	   activation,	  which	   to	  our	   knowledge	  has	  
not	   been	   previously	   addressed	   in	   AAV,	   is	   the	   differential	   role	   of	   systemic	   and	   local	  
complement	  production	   in	  pathogenesis.	  As	  discussed	   in	   section	  1.10.7,	   intracellular	  
derived	   complement	   and	   intracellular	   complement	   receptors	   may	   have	   distinct	  
functions	  compared	  to	  their	  extracellular	  counterparts.	  	  
5.2	  Aims	  
In	  this	  chapter	  we	  aimed	  to	  assess	  whether	  LPS	  and	  GCSF	  were	  both	  required	  for	  the	  
generation	  of	  robust	  disease	  in	  the	  passive	  transfer	  model.	  We	  also	  set	  out	  to	  explore	  
the	  possible	  mechanism	  for	  the	  attenuation	  in	  disease	  noted	  in	  MASP2	  knockout	  mice	  
and	  in	  doing	  so	  confirming	  a	  role	  for	  complement	  in	  pathogenesis.	  Lastly	  we	  explored	  
the	   role	   of	   leucocyte	   local	   C5	   production	   in	   comparison	   to	   systemic	   complement	  
component	  C5	  in	  the	  pathogenesis	  of	  AAV.	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5.3	  LPS	  and	  GCSF	  have	  a	  synergistic	  effect	  in	  the	  passive	  transfer	  model	  	  
MPO-­‐ANCA	   was	   generated	   from	   a	   group	   of	   MPO-­‐deficient	   mice	   that	   had	   been	  
immunised	  with	  10μg	  MPO	  (RZ=0.44)	  as	  described	  in	  section	  2.3.2	  and	  2.4.1.	  	  
The	  passive	  transfer	  model	  was	  set	  up	  as	  described	  in	  section	  2.3.5	  with	  four	  groups	  of	  
wild	  type	  mice	  (C57BL/6);	  group	  1	  received	  PBS	  and	  dextrose	  (in	  place	  of	  LPS	  and	  GCSF	  
respectively)	  n	  =	  5,	  group	  2	  received	  LPS	  and	  dextrose	  (in	  place	  of	  GCSF)	  n	  =	  6,	  group	  3	  
received	  PBS	  (in	  place	  of	  LPS)	  and	  GCSF	  n	  =	  6,	  group	  4	  received	  LPS	  and	  GCSF	  n	  =	  5	  on	  
the	   respective	   days	   highlighted	   in	   figure	   5.1.	   Urine,	   blood	   and	   tissue	  was	   harvested	  
and	  processed	  as	  detailed	  in	  sections	  2.3.6	  to	  2.3.11.	  
As	   shown	   in	   figure	   5.2,	   at	   day	   7,	   the	   glomerular	   crescent	   counts	   were	   significantly	  
higher	  in	  the	  group	  of	  mice	  that	  had	  both	  LPS	  and	  GCSF	  administered	  compared	  to	  the	  
other	  three	  groups	  (mean	  group	  1	  0±0%,	  group	  2	  0.33±0.33%,	  group	  3	  0.17±0.17%	  and	  
group	  4	  31.6±5.2%).	  Similarly	  and	  as	  expected,	  the	  glomerular	  macrophage	  infiltration	  
was	  significantly	  higher	  in	  the	  group	  receiving	  both	  LPS	  and	  GCSF	  together	  compared	  
to	   the	   other	   three	   experimental	   groups	   as	   depicted	   in	   figure	   5.3	   (mean	   group	   1	  























Figure	   5.2	   -­‐	   Glomerular	   crescent	   formation	   following	   disease	   induction.	   A)	   Graph	  
depicting	  day	  7	  glomerular	   crescent	  counts	   in	   the	   four	  experimental	  groups	  of	  mice.	  
Each	  symbol	  is	  data	  from	  a	  separate	  mouse.	  Data	  were	  analysed	  using	  one	  way	  ANOVA	  
and	   a	   Tukey’s	   multiple	   comparison	   post	   test	   (***	   =	   p	   <	   0.001).	   B)	   Representative	  
periodic	  acid	  schiff	  stain	  slides	  of	  glomerular	  sections	  on	  day	  7	  of	  the	  passive	  transfer	  




















































Figure	   5.3	   –	  Glomerular	  macrophage	   infiltration	   following	   disease	   induction	   in	   the	  
passive	   transfer	  model.	  A)	  Day	  7	  CD68	  positive	  macrophage	   infiltration	  counts.	  Data	  
were	  analysed	  using	  a	  one	  way	  ANOVA	  and	  a	  Tukey’s	  multiple	   comparison	  post	   test	  
(***	   =	   p	   <	   0.001).	   B)	   Representative	   immunofluorescence	   staining	   of	   CD68	   positive	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We	  measured	  pre-­‐	  and	  post-­‐disease	  induction	  24	  hour	  albuminuria	  (day	  -­‐4	  and	  day	  7	  
respectively)	  as	  described	  in	  section	  2.3.6.	  As	  shown	  in	  figure	  5.4A,	  at	  baseline,	  prior	  to	  
MPO-­‐ANCA	   IV	   injection	   the	   four	   groups	   had	   low	   grade	   albuminuria	   which	   was	   not	  
significantly	  different	  among	  the	  groups.	  At	  day	  7,	  the	  mice	  that	  received	  both	  LPS	  and	  















Figure	   5.4	   –	   Albuminuria	   levels	   prior	   to	   and	   after	   disease	   induction.	   Albuminuria	  
measurements	   in	  the	  four	  experimental	  groups	  of	  mice	  prior	  to	  disease	   induction	  on	  
day	  -­‐4	  (A)	  and	  after	  disease	  induction	  on	  day	  7	  (B).	  Data	  were	  analysed	  by	  a	  one	  way	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Haematuria	  was	   assessed	   as	   described	   in	   section	   2.3.7	   and	   there	  was	   no	   significant	  
difference	   in	   haematuria	   severity	   between	   groups	   on	   day	   7	   (data	   not	   shown).	  
Measurements	   of	   serum	   creatinine	   on	   day	   -­‐1	   revealed	   no	   significant	   differences	  
between	  groups,	  however	  on	  day	  7	  the	  group,	  which	  received	  both	  LPS	  and	  GCSF	  had	  














Figure	   5.5	   –	   Serum	   creatinine	   levels	   prior	   to	   and	   after	   disease	   induction.	   Serum	  
creatinine	  measures	  at	  day	  -­‐1	  (A)	  and	  day	  7	  (B)	  in	  the	  four	  groups	  of	  mice.	  Data	  were	  
analysed	  using	  a	  one	  way	  ANOVA	  and	  a	  Tukey’s	  multiple	  comparison	  post	  test	  (*	  =	  p	  <	  
0.05,	  **	  =	  p	  <	  0.01,	  ***	  =	  p	  <	  0.001).	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5.4	   MASP2/C3	   deficient	   and	   C3	   deficient	   mice	   are	   protected	   from	  
disease	  
We	  sought	  to	  examine	  if	  the	  increased	  disease	  in	  MASP2	  knockout	  mice	  depended	  on	  
complement	  activation.	  We	  compared	  disease	  in	  wild	  type	  mice,	  mice	  deficient	  in	  both	  
C3	  and	  MASP2	  with	  mice	  deficient	  in	  C3.	  
MPO-­‐ANCA	   was	   generated	   from	   a	   group	   of	   MPO-­‐deficient	   mice	   that	   had	   been	  
immunised	  with	  10μg	  MPO	  (RZ=0.69)	  as	  described	  in	  section	  2.3.2	  and	  2.4.1.	  	  
There	  was	   no	   significant	   difference	   in	   the	   neutrophil	   counts	   on	   day	   -­‐1	   in	   peripheral	  
blood	  between	  mice	  in	  the	  three	  groups	  (mean	  neutrophil	  counts	  X107/ml	  in	  wild	  type	  
mice	  0.68±0.04,	  MASP2/C3	  knockout	  0.65±0.1	  and	  C3	  knockout	  mice	  0.68±0.08).	  
As	   shown	   in	   figure	   5.6,	   compared	   to	  wild	   type	  mice,	   there	  was	   very	  mild	   disease	   in	  
both	  MASP2/C3	   double	   deficient	   and	   C3	   deficient	  mice	   (glomerular	   crescent	   counts	  
mean	  for	  wild	  type	  mice	  20.4±5.8%,	  MASP2/C3	  double	  knockout	  mice	  1.5±0.86%	  and	  
C3	  knockout	  mice	  2.8±0.98%).	  Similarly	  the	  glomerular	  macrophage	   infiltration	  count	  
was	   low	   in	   the	  MASP2/C3	   double	   deficient	   and	   C3	   deficient	  mice	   compared	   to	  wild	  
type	  mice	  as	  demonstrated	  in	  figure	  5.7	  (CD68	  positive	  cell	  count	  mean	  for	  wild	  type	  
mice	   6.2±0.5	   cells,	  MASP2/C3	  double	   knockout	  mice	   2.8±0.28	   cells	   and	  C3	   knockout	  





















Figure	  5.6	  –	  Glomerular	  crescents	   in	  wild	   type,	  MASP2/C3	  double	  knockout	  and	  C3	  
knockout	   mice.	   A)	   Graph	   depicting	   day	   7	   glomerular	   crescent	   counts	   in	   the	   three	  
experimental	  groups	  of	  mice.	  Each	  symbol	  is	  data	  from	  a	  separate	  mouse.	  Data	  were	  
analysed	  using	  one	  way	  ANOVA	  and	  a	  Tukey’s	  multiple	  comparison	  post	  test	  (***	  =	  p	  <	  
0.001).	  B)	  Representative	  periodic	  acid	  schiff	  stain	  slides	  of	  glomerular	  sections	  on	  day	  




































Figure	   5.7	   –	   Glomerular	   macrophage	   infiltration	   in	   wild	   type,	   MASP2/C3	   double	  
knockout	   and	   C3	   knockout	   mice.	   A)	   Day	   7	   CD68	   positive	   macrophage	   infiltration	  
counts.	   Data	   were	   analysed	   using	   a	   one	   way	   ANOVA	   and	   a	   Tukey’s	   multiple	  
comparison	   post	   test	   (***	   =	   p	   <	   0.001).	   B)	   Representative	   immunofluorescence	  
staining	   of	   CD68	   positive	   macrophages	   in	   the	   three	   experimental	   groups	   (x400	  
magnification).	  	  
Similarly,	  when	  assessing	  the	  functional	  parameters,	  there	  was	  no	  difference	  between	  
MASP2/C3	   knockout	   and	   C3	   knockout	   mice.	   We	   measured	   pre-­‐	   and	   post-­‐disease	  
albumin	  creatinine	  ratios	  and	  serum	  creatinine	   levels	  as	  shown	  in	  figures	  5.8	  and	  5.9	  
respectively.	  Haematuria	  was	  also	  assessed	  as	  shown	  in	  figure	  5.10.	  
	  
	  













































Figure	   5.8	   –	   Albumin	   creatinine	   ratio	   levels	   prior	   to	   and	   after	   disease	   induction.	  
Albumin	   creatinine	   ratio	  measurements	   in	   the	   experimental	   groups	   of	  mice	   prior	   to	  
disease	   induction	  on	  day	   -­‐4	   (A)	   and	   after	   disease	   induction	  on	  day	   7	   (B).	  Data	  were	  






































































Figure	   5.9	   –	   Serum	   creatinine	   levels	   prior	   to	   and	   after	   disease	   induction.	   Serum	  
creatinine	  measures	  at	  day	  -­‐1	  (A)	  and	  day	  7	  (B)	  in	  the	  three	  groups	  of	  mice.	  Data	  were	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Figure	   5.10	   –	   Haematuria	   score	   at	   day	   7	   following	   disease	   induction	   in	   the	   three	  
experimental	  groups.	  Haematuria	  was	  scored	  0-­‐4	  on	  day	  7.	  Data	  were	  analysed	  using	  
a	  one	  way	  ANOVA	  and	  a	  Tukey’s	  multiple	  comparison	  post	  test	  (*	  p	  <	  0.05).	  	  
There	  was	  no	  difference	  between	  MASP2/C3	  knockout	  mice	  and	  C3	  knockout	  mice	  in	  
any	  of	  the	  histological	  or	  functional	  parameters	  examined,	  and	  both	  had	  significantly	  
less	  disease	  than	  wild	  type	  mice.	  This	  meant	  that	  we	  were	  unable	  to	  determine	  if	  the	  
increase	   in	  disease	   in	  MASP2	  deficient	  mice	   (compared	  to	  wild	   type	  mice)	  depended	  
on	  C3	  activation	  with	  this	  experiment.	  However,	  we	  found	  no	  difference	  in	  circulating	  
C3	   levels	   in	  untreated	  MASP2	  deficient	  mice	  compared	  to	  wild	  type	  mice	  nor	  did	  we	  
find	   a	   difference	   in	   glomerular	   C3	   deposition	   in	   diseased	   MASP2	   deficient	   mice	  
compared	  to	  diseased	  wild	  type	  mice	  (figure	  5.11).	  This	  suggested	  that	  there	  was	  no	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Figure	  5.11	  –	  Serum	  C3	  and	  glomerular	  C3	  deposition	  in	  wild	  type	  mice	  and	  MASP2	  
deficient	  mice.	  Serum	  C3	  was	  measured	  in	  non-­‐diseased	  animals.	  Data	  were	  analysed	  
using	  a	  student’s	  t	  test	  (NS	  =	  non	  significant).	  
We	  also	  demonstrated	   the	  presence	  of	  MBL	   in	   diseased	   glomeruli	   in	   both	  wild	   type	  





Figure	  5.12	  –	  Glomerular	  MBL	  deposition	  in	  wild	  type	  and	  MASP2	  deficient	  mice.	  Day	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5.5	   Evidence	   for	   increased	   prothrombin	   activation	   in	   MASP2	   deficient	  
mice	  
Cross-­‐talk	  between	  the	  complement	  and	  coagulation	  cascade	  has	  been	  well	  described	  
in	  the	  literature	  (see	  section	  1.10.8).	  MASP2	  is	  able	  to	  cleave	  prothrombin	  to	  thrombin	  
at	  the	  same	  site	  as	  factor	  Xa,	  though	  it	  is	  far	  less	  efficient,	  cleaving	  approximately	  20%	  
of	   prothrombin	   in	   comparison	   to	   factor	   Xa	   [197].	   So	   under	   normal	   circumstances	  
MASP2	   may	   limit	   factor	   Xa	   mediated	   cleavage	   of	   prothrombin.	   In	   the	   absence	   of	  
MASP2	  there	  may	  be	  more	  factor	  Xa	  activity	  leading	  to	  increased	  thrombin	  generation	  
and	   consumption	   with	   increased	   fibrin	   generation.	   Since	   fibrin	   generation	   is	   an	  
essential	   feature	   of	   glomerular	   crescent	   formation,	   we	   wondered	   if	   the	   increased	  
disease	   in	   MASP2	   deficient	   mice	   might	   be	   explained	   by	   over-­‐activation	   of	   the	  
coagulation	  cascade.	  We	  measured	  prothrombin	  fragment	  1.2,	  which	   is	  a	  breakdown	  
product	  of	  prothrombin	  activation	   in	   the	  plasma	  of	  untreated	  MASP2	  mice	  and	  wild	  







Figure	   5.13	   –	   Prothrombin	   fragment	   1.2	   levels	   in	   plasma	   of	  wild	   type	   and	  MASP2	  
knockout	  mice.	  Data	  were	  analysed	  using	  a	  student’s	  t	  test	  (*	  =	  p	  <	  0.05).	  
The	  prothrombin	  fragment	  1.2	  levels	  were	  elevated	  in	  MASP2	  deficient	  mice	  compared	  
to	  wild	  type	  mice	  suggesting	  increased	  prothrombin	  activation.	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We	   then	  measured	   residual	   thrombin	   generation	   in	   the	   plasma	   of	  MASP2	   deficient	  
mice	  compared	  to	  wild	  type	  mice	  and	  figure	  5.14	  shows	  a	  typical	  trace	  (thrombogram)	  
of	  thrombin	  generation	  over	  time	  in	  a	  wild	  type	  and	  MASP2	  deficient	  mouse.	  	  
	  
Figure	   5.14	   –	   Representative	   thrombin	   generation	   thrombogram	   from	   a	  wild	   type	  
mouse	  and	  MASP2	  knockout	  mouse	  over	  time.	  
The	  parameters	  when	  analysing	  thrombin	  generation	  include	  the	  lag	  time	  (time	  taken	  
for	   thrombin	  concentration	  to	  reach	  5nM),	   the	  endogenous	  thrombin	  potential	   (ETP,	  
area	  under	   the	   curve	  of	   the	   thrombin	  generation	   curve),	   the	   time	   to	  peak	   thrombin	  
generation	  and	  the	  ETP	  peak.	  
MASP2	  deficient	  mice	  had	  an	  increase	  in	  the	  lag	  time	  and	  a	  decrease	  in	  the	  overall	  ETP	  
as	   shown	   in	   figure	   5.15.	   No	   significant	   difference	   in	   time	   to	   peak,	   peak	   thrombin	  
generation	  (ETP	  peak)	  or	  fibrinogen	  concentration	  was	  seen,	  but	  these	  are	  crude	  tests	  























Figure	  5.15	   -­‐	  Coagulation	  parameters	   in	  plasma	   from	  wild	   type	  or	  MASP2	  deficient	  
mice.	   Each	   graph	   represents	   the	   parameter	   indicated	   and	   each	   symbol	   represents	  
plasma	   from	   a	   separate	  mouse.	   Data	  was	   analysed	   using	   a	   student’s	   t	   test	   (*	   =	   p	   <	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The	  decrease	  in	  ETP	  suggested	  a	  reduction	  in	  residual	  thrombin	  generation	  in	  plasma,	  
due	  to	  consumption	  of	  prothrombin.	  	  
5.6	   Factor	   B	   and	   C4	   deficient	   mice	   are	   not	   protected	   in	   the	   passive	  
transfer	  model	  
We	  had	  confirmed	  that	  complement	  was	  essential	   for	  disease	   in	  the	  passive	  transfer	  
model	   as	   evidenced	   by	   our	   results	   in	   C3	   deficient	   mice	   (section	   5.4),	   but	   had	   also	  
shown	  that	   the	   lectin	  pathway	  was	  not	  essential	   for	   this	  complement	  activation,	  nor	  
was	  properdin,	  as	  surprisingly	  properdin	  knockout	  mice	  were	  not	  protected.	  In	  view	  of	  
this,	   we	   revisited	   the	   role	   of	   the	   alternative	   pathway	   and	   classical	   pathway	   in	   this	  
model	  by	  studying	  factor	  B	  deficient	  and	  C4	  deficient	  mice.	  The	  experiments	  on	  factor	  
B	  mice	  were	  performed	  with	  Dr	  Simon	  Freeley.	  	  
MPO-­‐ANCA	   was	   generated	   from	   a	   group	   of	   MPO-­‐deficient	   mice	   that	   had	   been	  
immunised	  with	  10μg	  MPO	  (RZ=0.55)	  as	  described	  in	  section	  2.3.2	  and	  2.4.1.	  	  
There	  was	   no	   significant	   difference	   in	   the	   neutrophil	   counts	   on	   day	   -­‐1	   in	   peripheral	  
blood	  between	  wild	  type	  and	  factor	  B	  deficient	  mice	  (mean	  neutrophil	  counts	  X107/ml	  
in	  wild	  type	  mice	  1.69±0.19,	  factor	  B	  deficient	  mice	  1.79±0.17).	  
As	  shown	  in	  figure	  5.16,	  the	  histological	  parameters	  of	  wild	  type	  and	  factor	  B	  deficient	  
mice	  were	  not	  significantly	  different.	  Similarly,	   the	   functional	  parameters	   in	   terms	  of	  
albumin	   creatinine	   ratio,	   haematuria	   and	   serum	   creatinine	   were	   not	   significantly	  
different	  between	  the	  two	  groups	  (figure	  5.17).	  
We	   used	   genomic	   DNA	   from	   the	   kidney	   tissue	   and	   re-­‐confirmed	   that	   the	   factor	   B	  
deficient	  mice	  were	  indeed	  factor	  B	  knockout	  mice.	  The	  genotyping	  experiments	  were	  




















Figure	  5.16	   -­‐	  Glomerular	   crescents	   (A)	  and	  macrophage	   infiltration	   (B)	   in	  wild	   type	  
and	   factor	   B	   deficient	   mice.	   Graphical	   presentation	   of	   data	   with	   representative	  
periodic	   acid	   schiff	   stain	   slides	   and	   CD68	   immunofluorescence	   stains	   of	   glomerular	  
sections	  in	  the	  two	  groups	  (x400	  magnification).	  Data	  were	  analysed	  using	  a	  student’s	  t	  
test	  (NS	  =	  non	  significant).	  
	  




















































Figure	   5.17	   –	   Albumin	   creatinine	   ratio,	   haematuria	   score	   and	   serum	   creatinine	   in	  
wild	  type	  and	  factor	  B	  deficient	  mice.	  Data	  were	  analysed	  using	  a	  student’s	  t	  test	  (NS	  
=	  non	  significant).	  
Our	  data	   in	  both	  properdin	  and	   factor	  B	  deficient	  mice	   therefore	  suggested	   that	   the	  
alternative	   pathway	  was	   not	   essential	   for	   disease	   induction,	   in	   contrast	   to	   previous	  
reports	  [207].	  Since	  we	  had	  not	  shown	  a	  requirement	  for	  the	  alternative	  pathway,	  we	  
decided	  to	  revisit	  the	  role	  of	  the	  classical	  pathway	  and	  compared	  wild	  type	  mice	  with	  
C4	  deficient	  mice.	  
There	  was	   no	   significant	   difference	   in	   the	   neutrophil	   counts	   on	   day	   -­‐1	   in	   peripheral	  
blood	  between	  wild	   type	   and	  C4	  deficient	  mice	   (mean	  neutrophil	   counts	   X107/ml	   in	  
wild	  type	  mice	  0.45±0.07,	  C4	  deficient	  mice	  0.46±0.05).	  As	  shown	  in	  figure	  5.18,	  there	  
was	  no	  significant	  difference	  in	  crescent	  counts	  or	  glomerular	  macrophage	  infiltration	  
in	   C4	   deficient	   mice	   and	   wild	   type	   mice.	   Similarly,	   there	   was	   no	   difference	   in	   the	  
albumin	  creatinine	  ratio,	  haematuria	  score	  or	  serum	  creatinine	  between	  groups	  at	  day	  
7	  (figure	  5.19).	  
	  











































































Figure	  5.18	   -­‐	  Glomerular	   crescents	   (A)	  and	  macrophage	   infiltration	   (B)	   in	  wild	   type	  
and	   C4	   deficient	   mice.	   Graphical	   presentation	   of	   data	   with	   representative	   periodic	  
acid	  schiff	  stain	  slides	  and	  CD68	  immunofluorescence	  stains	  of	  glomerular	  sections	  in	  
the	  two	  groups	  (x400	  magnification).	  Data	  were	  analysed	  using	  a	  student’s	  t	  test	  (NS	  =	  
non	  significant).	  
	  



















































Figure	  5.19	  -­‐	  Albumin	  creatinine	  ratio,	  haematuria	  score	  and	  serum	  creatinine	  in	  wild	  
type	  and	  C4	  deficient	  mice.	   The	  albumin	  creatinine	   ratio	  and	  serum	  creatinine	  were	  
measured	  at	  baseline	  (day	  -­‐1)	  and	  day	  7.	  Data	  were	  analysed	  using	  a	  student’s	  t	  test	  
(NS	  =	  non	  significant).	  
Overall,	  we	  have	  shown	  that	  despite	  a	  requirement	  for	  C3	  (section	  5.4),	  there	  was	  no	  
absolute	  requirement	  for	  properdin	  (previous	  work),	  factor	  B	  or	  C4	  (section	  5.6)	  in	  the	  
passive	  transfer	  model	  of	  MPO-­‐ANCA	  vasculitis.	  This	  suggests	  a	  possible	  redundancy	  in	  
the	  complement	  pathway	  when	  utilising	  knockout	  mice.	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5.7	  Circulating	  and	  not	  bone	  marrow	  derived	  C5	  mediates	  disease	  	  
We	  had	  shown	  in	  section	  3.5	  that	  neutrophils	  are	  capable	  of	  expressing	  C3	  and	  C5	  as	  
well	   as	   the	   respective	   anaphylatoxins.	   Other	   leucocytes	   including	   T	   cells,	   B	   cells,	  
monocytes	   and	  macrophages	   have	   also	   been	   shown	   to	   express	   C3	   and	   C5	   [187].	   As	  
discussed,	   locally	   derived	   complement	   may	   have	   distinct	   functions	   compared	   to	  
systemically	  generated	  complement	  and	  this	  has	  not	  been	  explored	  in	  the	  context	  of	  
AAV.	   We	   next	   examined	   if	   leucocyte	   derived	   complement	   was	   important	   in	  
pathogenesis	   and	   constructed	   four	   groups	   of	   bone	  marrow	   chimeric	  mice	   from	  wild	  
type	  or	  C5	  deficient	  donors	  and	  recipients	  as	  described	   in	  section	  2.3.3,	  and	   induced	  
MPO-­‐ANCA	  vasculitis	  using	  the	  passive	  transfer	  model	  (see	  section	  2.3.5).	  MPO-­‐ANCA	  
was	   generated	   from	   a	   group	   of	  MPO-­‐deficient	  mice	   that	   had	   been	   immunised	  with	  
10μg	  MPO	  (RZ=0.69)	  as	  described	  in	  section	  2.3.2	  and	  2.4.1.	  	  
A	   parallel	   cohort	   of	   chimeras	  were	   also	  made	  between	  wild	   type	  C57BL/6	  mice	   and	  
C57BL/6	   mice	   congenic	   for	   CD45.1	   (B6.SJL-­‐Ptprca	   Pepcb/BoyJ).	   Chimerism	   was	  
determined	  by	  flow	  cytometry	  for	  CD45.2	  and	  was	  >90%	  in	  all	  cases	  (n=7).	  	  	  
There	  was	   no	   significant	   difference	   in	   the	   neutrophil	   counts	   on	   day	   -­‐1	   in	   peripheral	  
blood	  between	  mice	  in	  the	  four	  groups	  (mean	  neutrophil	  counts	  X107/ml	  in	  wild	  type	  
recipients	  with	  wild	  type	  donor	  bone	  marrow	  1.62±0.11,	  wild	  type	  recipients	  with	  C5	  
deficient	  donor	  bone	  marrow	  1.75±0.07,	  C5	  deficient	  recipients	  with	  wild	  type	  donor	  
bone	   marrow	   1.86±0.06	   and	   C5	   deficient	   recipients	   with	   C5	   deficient	   donor	   bone	  
marrow	  1.96±0.1).	  
Histological	   measures	   of	   disease	   showed	   crescentic	   glomerulonephritis	   was	   more	  
severe	   in	   both	   groups	   of	   C5	   sufficient	   recipients	   compared	   to	   both	   groups	   of	   C5	  
deficient	  recipients,	  as	  indicated	  by	  more	  crescents	  and	  CD68+	  macrophage	  infiltration	  















Figure	  5.20	  -­‐	  Glomerular	  crescent	  formation	  following	  passive	  transfer	  of	  MPO-­‐ANCA	  
in	  the	  bone	  marrow	  chmeric	  mice.	  Graph	  depicting	  day	  7	  glomerular	  crescent	  counts	  
in	   the	   four	   experimental	   groups	   of	   mice.	   C5	   KO	   to	  WT	   depicts	   wild	   type	  mice	   that	  
received	   C5	   deficient	   bone	   marrow;	   WT	   to	   C5	   KO	   depicts	   C5	   deficient	   mice	   that	  
received	  wild	   type	   bone	  marrow.	   Each	   symbol	   is	   data	   from	   a	   separate	  mouse.	   Data	  
were	  analysed	  using	  one	  way	  ANOVA	  and	  a	  Tukey’s	  multiple	  comparison	  post	  test	  (**	  
=	  p	  <	  0.01,	  *	  =	  p	  <	  0.05,	  NS	  =	  non	  significant).	  Associated	  representative	  periodic	  acid	  
schiff	  stain	  slides	  of	  glomerular	  sections	  on	  day	  7	  of	  the	  passive	  transfer	  model	  in	  each	  

































Figure	  5.21	  -­‐	  Glomerular	  macrophage	  infiltration	  following	  passive	  transfer	  of	  MPO-­‐
ANCA	  in	  the	  bone	  marrow	  chmeric	  mice.	  Graph	  depicting	  day	  7	  glomerular	  CD68+	  cell	  
infiltration	   in	   the	   four	   experimental	   groups	   of	  mice.	   C5	   KO	   to	  WT	   depicts	  wild	   type	  
mice	  that	  received	  C5	  deficient	  bone	  marrow;	  WT	  to	  C5	  KO	  depicts	  C5	  deficient	  mice	  
that	   received	  wild	   type	   bone	  marrow.	   Each	   symbol	   is	   data	   from	   a	   separate	  mouse.	  
Data	  were	  analysed	  using	  a	  one	  way	  ANOVA	  and	  a	  Tukey’s	  multiple	  comparison	  post	  
test	  (**	  =	  p	  <	  0.01,	  *	  =	  p	  <	  0.05,	  NS	  =	  non	  significant).	  Associated	  representative	  CD68	  
immunofluorescence	   stains	   of	   glomerular	   sections	   on	   day	   7	   of	   the	   passive	   transfer	  
model	  in	  each	  experimental	  group	  (x400	  magnification).	  
There	  were	  no	  differences	   in	  baseline	  urine	   albumin	   creatinine	   ratio	   (figure	  5.22)	  or	  
serum	  creatinine	  (figure	  5.23).	  At	  day	  7,	  serum	  creatinine	  was	  higher	  in	  both	  groups	  of	  
C5	   sufficient	   recipients,	   compared	   to	   both	   groups	   of	   C5	   deficient	   recipients.	   The	  
presence	   or	   absence	   of	   C5	   in	   the	   bone	   marrow	   compartment	   again	   had	   no	   effect	  
(figure	  5.23).	  Wild	  type	  mice	  receiving	  C5	  deficient	  bone	  marrow	  had	  more	  haematuria	  
and	  a	  higher	  albumin	  creatinine	   ratio	   than	  both	  C5	  deficient	   recipient	  groups	   (figure	  
5.22).	  	  
















































Figure	   5.22	   -­‐	   Albumin	   creatinine	   ratio	   and	   haematuria	   score	   in	   the	   bone	   marrow	  
chimeric	  mice.	  The	  albumin	  creatinine	  ratio	  was	  measured	  at	  baseline	  (day	  -­‐1)	  and	  day	  
7,	  whilst	  the	  haematuria	  score	  for	  day	  7	  is	  shown.	  Data	  were	  analysed	  using	  a	  one	  way	  

























































































Figure	   5.23	   –	   Baseline	   and	   day	   7	   serum	   creatinine	  measures	   in	   the	   bone	  marrow	  
chimeric	  mice.	   Data	  were	   analysed	   using	   a	   one	  way	   ANOVA	   and	   a	   Tukey’s	  multiple	  
comparison	  post	  test	  (*	  =	  p	  <	  0.05,	  NS	  =	  non	  significant).	  
These	  results	  show	  that	  C5	  within	  the	  bone	  marrow-­‐derived	  cells	   is	  not	   important	   in	  
pathogenesis	  and	  that	  systemic	  C5	  from	  the	  liver	  or	  other	  cells	  is	  required	  for	  disease.	  
5.8	  Discussion	  
We	  had	  previously	  shown	  that	  GCSF	   levels	  were	   raised	   in	  serum	  samples	  of	  patients	  
with	  active	  AAV	  compared	  to	  healthy	  age	  matched	  controls.	  GCSF	  was	  also	  shown	  to	  
prime	  human	  neutrophils	  to	  the	  response	  of	  MPO-­‐ANCA.	  In	  vivo,	  GCSF	  in	  the	  presence	  
of	   LPS	   administration	   exacerbated	   disease	   in	   the	   passive	   transfer	   model	   and	  
interestingly	   led	   to	   an	   increase	   in	   serum	   creatinine,	   few	   studies	   have	   shown	   a	  
difference	  in	  serum	  creatinine	  [119].	  This	  suggested	  the	  importance	  of	  the	  role	  of	  GCSF	  
in	  pathogenesis.	  As	  part	  of	  the	  current	  thesis	  we	  tested	  the	  effect	  of	  GCSF	  alone	  in	  the	  
absence	   of	   concurrent	   LPS	   administration.	  We	   showed	   that	   both	   LPS	   and	   GCSF	   are	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required	  to	  exacerbate	  disease	   in	   the	  passive	  transfer	  model	  of	  vasculitis,	   suggesting	  
GCSF	  acts	  synergistically	  with	  LPS.	  We	  also	  show	  that	  GCSF	  is	  necessary	  together	  with	  
LPS	  to	  produce	  a	  robust	  model	  of	  disease.	  
We	  have	  made	  a	  number	  of	  observations	   in	  this	  model	  that	  are	  of	  clinical	  relevance,	  
given	  the	  current	  interest	  in	  targeting	  complement	  in	  patients	  with	  AAV.	  Of	  note,	  none	  
of	   our	   results	   were	   influenced	   by	   differences	   between	   mouse	   strains	   or	   circulating	  
neutrophil	  counts	  in	  responses	  to	  GCSF.	  Firstly,	  the	  protective	  role	  of	  C3	  deficiency	  has	  
not	  previously	  been	  reported	  in	  this	  model.	  Here	  we	  have	  shown	  for	  the	  first	  time	  that	  
C3	  deficient	  mice	  are	  protected.	   It	   is	   important	  to	  note	  that	  we	  have	  confirmed	  that	  
complement	  is	  important	  in	  this	  model	  in	  our	  laboratory,	  given	  the	  lack	  of	  protection	  
we	   have	   previously	   seen	   in	   properdin	   deficient	   and	   MASP2	   deficient	   mice	   (Simon	  
Freeley,	  The	   role	  of	  complement	  and	  GCSF	   in	  ANCA	  associated	  vasculitis,	  PhD	  Thesis	  
2013,	  King’s	  College	  London).	  	  
Disease	  in	  MASP2	  deficient	  mice	  was	  increased	  compared	  to	  wild	  type	  mice	  in	  previous	  
studies	  performed	  within	  our	  laboratory	  (Simon	  Freeley,	  The	  role	  of	  complement	  and	  
GCSF	   in	   ANCA	   associated	   vasculitis,	   PhD	   Thesis	   2013,	   King’s	   College	   London).	   We	  
wondered	   if	   the	   increased	  disease	  required	  complement	  activation.	  MASP1	  has	  been	  
shown	  to	  activate	   factor	  D	  and	  MASP3	  can	  activate	  both	   factor	  B	  and	   factor	  D	   [300,	  
301].	  Therefore	  the	  absence	  of	  MASP2	  could	  result	  in	  an	  increase	  in	  circulating	  MASP1	  
and	  MASP3,	  which	  could	  potentially	  enhance	  alternative	  pathway	  activation	  and	  lead	  
to	  worsening	  disease.	  Our	   results	   in	  mice	  deficient	   in	   both	  MASP2	   and	  C3	  were	  not	  
conclusive.	  However,	  the	  similarity	  in	  levels	  of	  circulating	  and	  deposited	  C3	  in	  wild	  type	  
and	  MASP2	   deficient	  mice	   suggested	   that	   the	   increased	   disease	   in	  MASP2	   deficient	  
mice	  was	  not	  due	  to	  increased	  complement	  activation.	  	  	  
We	  therefore	  sought	  an	  alternative	  explanation	  for	  the	   increased	  crescent	   formation	  
in	  MASP2	   deficient	   mice,	   and	   wondered	   if	   cross	   talk	   with	   the	   coagulation	   pathway	  
could	   be	   involved.	   A	   link	   between	   coagulation	   and	   crescentic	   glomerulonephritis	   is	  
well	  established.	  Fibrin	  deposition,	  initiated	  physiologically	  by	  tissue	  factor,	  promotes	  
disease	  [302].	  We	  confirmed	  that	  MBL	  is	  deposited	  in	  glomeruli	  of	  mice	  with	  crescentic	  
glomerulonephritis	  due	  to	  MPO-­‐ANCA	  as	  this	  would	  be	  a	  requirement	  for	  an	  effect	  on	  
glomerular	  fibrin	  formation.	  
|	  Page	  211	  
Activation	  of	  either	  the	  intrinsic	  or	  extrinsic	  pathways	  of	  the	  coagulation	  cascade	  leads	  
to	  the	  formation	  of	  a	  prothrombinase	  complex	  composed	  of	  factors	  Va	  and	  Xa,	  which	  
cleave	   prothrombin	   to	   thrombin.	   Thrombin	   then	   activates	   fibrinogen	   leading	   to	   the	  
deposition	  of	  cross-­‐linked	  fibrin.	  As	  discussed,	  cleavage	  of	  prothrombin	  by	  MASP2	  has	  
been	  shown	  to	  occur	  at	  the	  same	  molecular	  site	  as	  a	  factor	  Xa	  but	  in	  a	  far	  less	  efficient	  
manner	  [197]. Our	  data	  show	  evidence	  of	  increased	  prothrombin	  activation	  in	  MASP2	  
deficient	  mice	  compared	  to	  wild	  type	  mice.	  Therefore	  a	  plausible	  explanation	  for	  the	  
increase	   in	   crescentic	   glomerulonephritis	   seen	   in	   MASP2	   deficient	   mice	   is	   their	  
tendency	   to	   enhanced	   fibrin	   generation.	   The	   molecular	   basis	   for	   the	   increased	  
prothrombin	  activation	  we	  observed	  is	  unclear.	  	  	  
We	  have	  also	  shown	  that	  there	  was	  no	  absolute	  requirement	  for	  properdin	  (previous	  
work),	  factor	  B	  or	  C4	  in	  the	  passive	  transfer	  model	  of	  MPO-­‐ANCA	  vasculitis.	  The	  most	  
plausible	  explanation	  may	  be	  that	  both	  the	  alternative	  and	  the	  classical	  pathway	  are	  
required,	   but	   the	   absence	   of	   either	   pathway	   on	   its	   own	  may	   offer	   only	   insufficient	  
protection	  due	  to	  their	  redundancy.	  The	  presence	  of	  an	   intact	  classical	  or	  alternative	  
pathway	  alone	  may	  be	  sufficient	  to	  cause	  C3	  activation.	  An	  alternative	  explanation	  is	  
that	  both	  C3	  and	  C5	  are	  activated	  independently	  of	  C4	  or	  factor	  B.	  	  
It	   is	  not	  clear	  why	  our	  data	  differ	   from	  a	  previous	   report	   showing	  a	   requirement	   for	  
factor	  B	  in	  the	  development	  of	  MPO-­‐ANCA	  vasculitis	  using	  the	  passive	  transfer	  model	  
[207].	  The	   factor	  B	  knockout	  mice	  used	   in	  our	  data	  and	  the	  published	  data	  are	   from	  
the	  same	  group	  (Colten	  et	  al).	  Our	  model	  has	  some	  differences	  to	  the	  other	  published	  
passive	  transfer	  models,	  including	  the	  use	  of	  LPS	  and	  GCSF	  and	  this	  is	  a	  possible	  factor.	  
Another	   variable	   to	   consider	   is	   the	   nature	   of	   the	   MPO-­‐ANCA	   IgG	   used	   to	   induce	  
disease.	   As	   discussed	   above,	   both	   the	   alternative	   and	   classical	   pathway	   may	   be	  
involved	  with	  neither	  alone	  being	  essential	   for	  disease.	   If	   this	  was	  the	  case,	  then	  the	  
relative	  ability	  of	  specific	  MPO-­‐ANCA	  IgG	  preparations	  to	  activate	  the	  classical	  pathway	  
may	  be	   important.	   If	  an	  antibody	  preparation	  activates	  the	  classical	  pathway	  weakly,	  
then	  disease	  may	  be	  more	  strongly	  reliant	  on	  the	  alternative	  pathway	  activation	  and	  as	  
a	  result	  factor	  B	  deficient	  mice	  may	  be	  protected.	  One	  way	  of	  addressing	  this	  may	  be	  
to	   compare	   disease	   in	   factor	   B	   C4	   double	   deficient	   mice	   compared	   to	   factor	   B	  
knockout	  mice.	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Circulating	   complement	   components	   are	   derived	   primarily	   from	   the	   liver,	   but	   it	   has	  
recently	   become	   clear	   that	   complement	   proteins	   are	   found	   not	   only	   in	   serum	   and	  
plasma	  but	  also	  within	  leukocytes	  [187,	  210].	  More	  recent	  data	  has	  shown	  that	  resting	  
human	  CD4	  T	  cells	  contain	  intracellular	  stores	  of	  C3	  and	  that	  the	  protease	  cathepsin	  L	  
cleaves	   C3	   into	   C3a	   and	   C3b	  with	   important	   roles	   described	   for	   T	   cell	   function	   and	  
homeostasis	  [188,	  191].	  However,	  despite	  these	  developments	  highlighting	  the	  role	  of	  
complement	  components	  within	  leukocytes,	  our	  data	  show	  that	  activation	  of	  C5	  from	  
other	  sources	  is	  important	  in	  AAV.	  Since	  synthesis	  of	  C5	  from	  murine	  or	  human	  renal	  
cells	   has	   not	   been	  described,	   our	   results	  most	   likely	   reflect	   a	   role	   for	   circulating	  C5.	  	  
Based	   on	   our	   data,	   an	   alternative	   therapeutic	   approach	   to	   C5a	   receptor	   blockade	  
would	   be	   to	   prevent	   C5	   secretion	   by	   the	   liver.	   This	   would	   not	   interfere	   with	   the	  
important	  homeostatic	  interactions	  between	  leukocyte-­‐derived	  C5a	  and	  C5a	  receptors	  
that	  may	  be	  affected	  by	   generic	  C5a	   receptor	  blockade.	   Such	  an	  approach	  has	  been	  
developed	   using	   N-­‐acetylgalactosamine-­‐conjugated	   siRNA	   to	   target	   the	   hepatocyte	  
asialoglycoprotein	   receptor.	   A	   phase	   1/2	   clinical	   trial	   in	   patients	   with	   paroxysmal	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Chapter	  6	  –	  Conclusion	  	  
6.1	  Summary	  of	  results	  
Chapter	  3	  
We	   set	   up	   various	   methods	   of	   assessing	   neutrophil	   activation	   in	   our	   laboratory	  
including	  two	  readouts	  of	  respiratory	  burst	  (DHR123	  assay	  and	  the	  luminometer	  assay)	  
and	   four	   readouts	  of	  degranulation	   (lactoferrin	  ELISA,	  MPO	  assay,	  CD66b	  and	  CD11b	  
expression).	  	  
This	   chapter	   was	   divided	   into	   two	   sections.	   Firstly,	   using	   randomly	   selected	   twenty	  
polyclonal	   patient	   samples	   (11	   MPO-­‐ANCA	   and	   9	   PR3-­‐ANCA)	   and	   ten	   control	   IgG	  
fractions	  from	  healthy	  donors,	  we	  found	  no	  significant	  difference	  in	  respiratory	  burst	  
output	   or	   degranulation	   of	   TNFα	   primed	   human	   neutrophils	   from	   two	   separate	  
donors.	   Polyclonal	  mouse	  MPO-­‐ANCA	   did	   not	   consistently	   cause	   a	   significant	   rise	   in	  
ROS	   production	   either	   as	   measured	   by	   the	   luminometer	   assay	   in	   comparison	   to	  
polyclonal	  control	  IgG.	  	  
As	  detailed	   in	  section	  3.6,	   there	  are	  various	  studies	  using	   limited	  numbers	  of	  patient	  
derived	   ANCA	   and	   control	   IgG	   from	   healthy	   donors	   that	   show	   ANCA	   activate	  
neutrophils	   in	   vitro.	  Where	   large	   selections	   of	   ANCA	   and	   control	   IgG	   samples	   were	  
used	   in	  multiple	  donors	   there	  are	   inconsistencies	   in	   the	  ability	  of	  ANCA	   to	   stimulate	  
TNFα	  primed	  neutrophils	  to	  undergo	  respiratory	  burst	  or	  degranulation,	  validating	  our	  
results	  [95,	  256].	  
As	  discussed	  in	  section	  3.6,	  various	  other	  factors	  may	  also	  compound	  the	  inconsistent	  
data.	  The	  use	  of	  non-­‐affinity	  purified	  ANCA	  means	  the	  precise	  concentration	  of	  MPO-­‐
ANCA	  and	  PR3-­‐ANCA	  in	  each	  antibody	  preparation	  is	  unknown.	  The	  subclass	  of	  IgG	  in	  
the	  polyclonal	  samples	  are	  also	  variable.	  Furthermore,	  the	  expression	  of	  MPO	  and	  PR3	  
on	   the	   neutrophil	   surface	   in	   response	   to	   TNFα	   priming	   in	   different	   donors	   (not	  
assessed	  in	  our	  studies)	  may	  vary	  and	  hence	  the	  exposure	  of	  ANCA	  to	  the	  antigen	  will	  
vary.	   Lastly	   the	  ANCA	   samples	   vary	   in	   epitope	   specificity	   and	  affinity.	   These	   variable	  
factors	  may	  explain	  the	  differential	  response	  noted	  in	  studies.	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It	   is	   also	   important	   to	   note	   that	   the	   simplified	   in	   vitro	   studies	   carried	   out	   do	   not	  
accurately	  reflect	  in	  vivo	  mechanisms.	  Isolating	  neutrophils	  from	  peripheral	  blood	  and	  
treating	   them	  with	  TNFα	  and	  polyclonal	  ANCA	   in	   isolation,	  without	   the	  neighbouring	  
cells	   they	   interact	  with	  nor	   the	   systemic	   /	   local	  milieu	  of	  proteins	   such	  as	   cytokines,	  
chemokines	  and	  complement	  components	  does	  not	  reflect	  the	  accurate	  events	  in	  vivo.	  	  	  
The	  second	  part	  of	  this	  chapter	  suggests	  that	  neutrophils	  are	  capable	  of	  expressing	  C3	  
and	   C5	   as	   well	   as	   their	   respective	   anaphylatoxins	   as	   shown	   by	   FACS	   studies.	   The	  
expression	   of	   these	   complement	   components	   was	   not	   altered	   by	   polyclonal	   or	  
monoclonal	   ANCA	   nor	   fMLP	   induced	   activation	   either	   within	   the	   intracellular	  
compartment	   or	   on	   the	   cell	   surface.	   However,	   we	   showed	   that	   TNFα	   primed	  
neutrophils	   when	   stimulated	   by	   ANCA	   had	   higher	   concentrations	   of	   C5a	   in	   the	  
supernatant	  than	  TNFα	  primed	  neutrophils	  incubated	  with	  control	  IgG.	  The	  results	  for	  
C3a	  generation	  were	  not	  consistent	  between	  two	  donors.	  It	  is	  a	  possibility	  that	  ANCA	  
alter	  the	  processing	  of	  C5	  into	  its	  anaphylatoxin	  in	  neutrophils.	  This	  may	  occur	  through	  
conventional	   convertases	   or	   local	   proteases	   within	   the	   neutrophils	   themselves.	  
However,	  we	   need	   to	   assess	   these	   findings	   further	   using	   other	   techniques	   including	  
RT-­‐qPCR	  and	  confocal	  microscopy.	  
Chapter	  4	  
In	   chapter	   4	  we	   set	   up	   and	  used	   various	   in	   vitro	   techniques	   to	   assess	   the	   impact	   of	  
ANCA	  on	  monocyte	  function	  and	  macrophage	  development.	  We	  used	  the	  same	  ANCA	  
and	   control	   IgG	   isolated	   in	   chapter	   3	   to	   show	   consistent	   effects.	   We	   showed	   that	  
polyclonal	  MPO-­‐ANCA	  consistently	   reduced	   IL6	  and	   IL10	  production	   from	  monocytes	  
isolated	  from	  three	  healthy	  donors	   in	  response	  to	  LPS.	  This	  effect	  was	  dependent	  on	  
the	  Fc	  portion	  of	  MPO-­‐ANCA	  and	  it	  appears	  the	  enzymatic	  activity	  of	  MPO	  itself.	  Using	  
gene	   expression	   microarrays	   we	   showed	   that	   MPO-­‐ANCA	   profoundly	   inhibits	   TLR4	  
mediated	  signalling.	  A	  possible	  mechanism	  for	  the	  TLR4	  inhibition	  was	  identified	  using	  
mass	   spectrometry.	   Analysis	   of	   phospholipids	   extracted	   from	   LPS	   stimulated	  
monocytes	  that	  had	  been	  incubated	  with	  MPO-­‐ANCA	  showed	  a	  significantly	  increased	  
abundance	   of	   a	   phosphatidylcholine	   species	   at	   m/z	   828.8	   that	   was	   tentatively	  
identified	   as	   PEIPC,	   which	   has	   been	   shown	   to	   inhibit	   LPS	   induced	   pro-­‐inflammatory	  
effects	  [279].	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Interestingly,	  we	  demonstrated	  that	  MPO-­‐ANCA	  increases	  survival	  and	  differentiation	  
of	   monocytes	   into	   macrophages	   with	   an	   M2-­‐like	   phenotype	   in	   culture	   as	   well	   as	  
increasing	   CSF1	   production.	   The	   monocytes	   incubated	   with	   MPO-­‐ANCA	   developed	  
macrophages	  with	  increased	  CD206	  and	  reduced	  CD80	  expression	  and	  secreted	  higher	  
levels	   of	   TGFβ	   than	   those	   incubated	   with	   control	   IgG	   in	   keeping	   with	   an	   M2-­‐like	  
macrophage	   phenotype.	   Functionally	   the	   supernatant	   of	   the	   macrophages	   acquired	  
from	   exposure	   to	   MPO-­‐ANCA	   promote	   CD4	   T	   cells	   to	   develop	   a	   more	   regulatory	  
phenotype	  by	  inducing	  a	  higher	  IL10	  /	  IFNγ	  ratio	  and	  more	  TGFβ	  production	  compared	  
to	  controls.	  These	  results	  suggest	  that	  MPO-­‐ANCA	  may	  well	  promote	  the	  development	  
of	  a	  milieu	  that	  could	  potentially	  promote	  fibrosis	  and	  chronicity	  in	  AAV	  possibly	  in	  an	  
attempt	  to	  dampen	  down	  inflammation.	  	  
However,	   as	  discussed	  earlier,	   interpreting	  and	  correlating	  data	   from	   in	   vitro	   studies	  
into	   in	   vivo	   events	   should	   be	   done	   with	   the	   knowledge	   that	   there	   are	   many	  
confounding	   factors	   that	   are	   not	   taken	   into	   account	   whilst	   performing	   the	   in	   vitro	  
studies.	  	  
Chapter	  5	  
The	  final	  results	  chapter	  confirmed	  the	  fact	  that	  GCSF	  acts	  synergistically	  with	  LPS	  to	  
produce	  a	  robust	  model	  of	  disease	  using	  the	  passive	  antibody	  transfer	  technique.	  Both	  
GCSF	  and	  LPS	  are	   required	   to	   induce	   sufficient	  disease	   that	  would	  allow	  comparison	  
across	   different	  mouse	   genotypes	   as	  well	   as	   identify	   any	   potential	   differences	   using	  
therapeutic	   agents.	   Of	   note	   our	   passive	   transfer	   model	   varies	   from	   the	   published	  
literature	  as	  we	  find	  that	  the	  use	  of	  GCSF	  and	  LPS	  (rather	  than	  LPS	  alone)	  with	  MPO-­‐
ANCA	  is	  necessary	  to	  induce	  robust	  disease.	  This	  difference	  in	  disease	  model	  induction	  
may	  account	   for	  some	  of	   the	  key	  differences	  we	  present	  compared	  to	   the	  published	  
literature.	  	  
In	   this	   chapter,	   we	   confirmed	   that	   complement	   is	   crucial	   to	   pathogenesis	   as	   we	  
showed	  that	  C3	  knockout	  mice	  were	  protected	  from	  disease	  development.	  
We	  had	  previously	  shown	  that	  MASP2	  deficiency	  surprisingly	  exacerbated	  disease	  and	  
we	  sought	  to	  define	  possible	  explanations	  for	  this	  observation.	  We	  compared	  disease	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in	  mice	  deficient	  in	  both	  MASP2	  and	  C3	  with	  C3	  deficient	  mice	  to	  ascertain	  if	  this	  effect	  
was	  complement	  dependent,	  but	  we	  were	  unable	  to	  draw	  any	  conclusions	  as	  in	  both	  
groups	  there	  was	  very	  mild	  disease.	  However,	  in	  MASP2	  deficient	  mice	  serum	  C3	  levels	  
and	  glomerular	  C3	  deposition	  was	  similar	  to	  that	  in	  wild	  type	  mice	  suggesting	  that	  the	  
exacerbation	   in	   disease	   was	   not	   necessarily	   complement	   dependent.	   We	   showed	  
evidence	   of	   cross	   talk	   between	   the	   complement	   pathway	   and	   coagulation	   pathway	  
with	  increased	  prothrombin	  activation	  in	  MASP2	  deficient	  mice	  compared	  to	  wild	  type	  
mice.	  This	  may	  be	  a	  contributing	  factor	  to	  disease	  in	  MASP2	  deficient	  mice.	  
In	   this	   chapter	   we	   also	   suggest	   that	   there	   is	   a	   redundancy	   between	   the	   initiating	  
pathways	   of	   complement	   activation	   as	   properdin	   (previous	   work),	   factor	   B	   or	   C4	  
deficient	  mice	  are	  not	  protected	  from	  disease	  in	  the	  passive	  transfer	  model.	  Lastly	  we	  
show	  that	  circulating	  complement	  component	  C5	  as	  opposed	  to	  leucocyte	  derived	  C5	  
is	   important	   in	  AAV	  pathogenesis.	  This	  suggests	  that	  more	  directed	  therapy	  targeting	  
C5	  secretion	  from	  the	  liver	  may	  be	  more	  beneficial	  and	  would	  limit	  the	  effect	  on	  local	  
homeostatic	  functions	  of	  C5.	  
6.2	  Limitations	  
Our	   data	   does	   not	   necessarily	   suggest	   that	   ANCA	   are	   not	   pathogenic	   nor	   does	   it	  
undermine	   the	   role	   of	   neutrophils	   in	   pathogenesis,	   but	   it	   does	   highlight	   the	  
inconsistencies	  of	  using	  limited	  numbers	  of	  samples	  and	  the	  need	  for	  more	  robust	   in	  
vitro	  measures	  of	  the	  effect	  of	  ANCA.	  Extrapolating	  data	  from	   in	  vitro	  studies	  have	  to	  
be	   done	   so	   with	   caution,	   as	   they	  may	   not	   necessarily	   convey	   the	  mechanisms	   that	  
occur	   in	   vivo.	   Neutrophils	   in	   vivo	   will	   interact	   with	   various	   other	   cells	   including	  
endothelial	   cells,	  which	  may	  be	  crucial	   to	  pathogenesis.	  Another	   factor	   that	  must	  be	  
considered	  is	  the	  use	  of	  whole	  non-­‐affinity	  purified	  IgG	  fractions	  in	  these	  assays	  means	  
that	  the	  percentage	  of	  MPO-­‐ANCA	  or	  PR3-­‐ANCA	  in	  the	  samples	  is	  unknown.	  Hence,	  it	  
is	  possible	  that	  strong	  neutrophil	  responses	  were	  not	  achieved	  with	  the	  ANCA	  samples	  
simply	  because	  they	  are	  composed	  of	  low	  proportions	  of	  PR3-­‐ANCA	  or	  MPO-­‐ANCA	  IgG	  
versus	   other	   contaminating	   IgG.	   The	   ANCA	   present	   within	   samples	   will	   also	   vary	   in	  
epitope	   specificity	   and	   affinity,	   which	   may	   account	   for	   differences	   in	   neutrophil	  
activation	   as	   suggested	   by	   Roth	  et	   al	   [94].	   Another	   possibility	   is	   that	   ANCA’s	   role	   in	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AAV	   pathogenesis	   is	   not	   mediated	   through	   neutrophil	   respiratory	   burst	   or	  
degranulation,	   but	   through	   differing	   mechanisms	   including	   a	   possible	   role	   on	  
processing	   of	   complement	   components	   as	   well	   as	   the	   effects	   on	   monocyte	   and	  
macrophage	  function.	  	  
The	  in	  vitro	  studies	  of	  the	  impact	  of	  ANCA	  on	  monocytes	  need	  further	  characterisation	  
with	  in	  vivo	  work	  in	  murine	  models.	  This	  will	  clarify	  the	  potential	  clinical	  importance	  of	  
the	  effects	  noted.	  
6.3	  Future	  work	  
We	  have	  reported	  various	  important	  and	  novel	  discoveries	  in	  the	  last	  three	  chapters	  of	  
this	  thesis.	  Results	  arising	  from	  this	  work	  provide	  other	  avenues	  of	  research	  that	  need	  
to	  be	  pursued.	  
As	   discussed	   the	   use	   of	   affinity	   purified	   ANCA	   in	   neutrophil	   and	   monocyte	   assays	  
would	   provide	   more	   controlled	   conditions,	   as	   we	   would	   have	   ANCA	   of	   known	  
concentration	   and	   specificity.	   To	   mimic	   in	   vivo	   conditions	   activation	   conditions,	  
endothelial	  cell	  and	  neutrophil	  co-­‐cultures	  could	  be	  used.	  	  
We	  have	  shown	  that	  MPO-­‐ANCA	  increase	  TGFβ	  secretion	  from	  macrophages	  as	  well	  as	  
CD4	  T	   cells	   and	   this	  may	  promote	   fibrosis.	  A	  wound	  healing	  assay	   can	  be	  utilised	   to	  
demonstrate	   this.	   The	  migration	   of	   cells	   such	   as	   fibroblasts	   can	   be	  monitored	   using	  
time	  lapse	  imaging	  in	  the	  presence	  of	  treated	  macrophage	  or	  CD4	  T	  cell	  supernatants.	  
To	   ascertain	   a	   role	   for	   monocytes	   and	   macrophages	   in	   AAV	   pathogenesis,	   various	  
methods	  of	  blocking	  monocyte	  recruitment	  and	  depleting	  macrophages	  can	  be	  used	  in	  
vivo.	  A	  CCR2	  (MCP-­‐1	  receptor)	   inhibitor	  or	  CCR2	  deficient	  mice	  can	  be	  utilised	   [269].	  
Liposomal	   clodronate	   can	   be	   administered	   systemically	   or	   locally.	   Liposomal	  
clodronate	  is	  ingested	  by	  and	  accumulates	  in	  macrophages,	  resulting	  in	  cell	  apoptosis	  
thereby	   depleting	  macrophages	   in	   various	   tissues	   [303].	   Another	   technique	   involves	  
the	   use	   of	   conditional	   macrophage	   ablation	   transgenic	   mice,	   based	   upon	   CD11b	  
promoter	  mediated	  expression	  of	  the	  human	  diphtheria	  toxin	  receptor	   [304].	  A	  CSF1	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receptor	  inhibitor	  can	  also	  be	  utilised	  to	  demonstrate	  the	  role	  of	  ANCA	  on	  monocytes	  
and	  macrophages	  in	  vivo.	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Appendix	  
Probeset	  ID	   Symbol	   p-­‐value	  (V	  vs.	  L)	   Fold-­‐Change	  (V	  vs.	  L)	  
SPRY2	   SPRY2	   0.000071	   13.186	   V	  up	  vs	  L	  
FOSB	   FOSB	   0.000032	   6.366	   V	  up	  vs	  L	  
EDN1	   EDN1	   0.000603	   5.944	   V	  up	  vs	  L	  
HSPA7	   HSPA7	   0.000747	   5.655	   V	  up	  vs	  L	  
TM4SF1	   TM4SF1	   0.000993	   5.560	   V	  up	  vs	  L	  
RDH13	   RDH13	   0.000915	   5.311	   V	  up	  vs	  L	  
HSPA6	   HSPA6	   0.000213	   5.130	   V	  up	  vs	  L	  
SCG5	   SCG5	   0.002770	   4.951	   V	  up	  vs	  L	  
SPINK1	   SPINK1	   0.000158	   4.873	   V	  up	  vs	  L	  
TMEM158	   TMEM158	   0.004643	   4.407	   V	  up	  vs	  L	  
TFPI2	   TFPI2	   0.000062	   4.381	   V	  up	  vs	  L	  
PLCXD1	   PLCXD1	   0.000102	   4.358	   V	  up	  vs	  L	  
SPP1	   SPP1	   0.000312	   4.279	   V	  up	  vs	  L	  
MMP1	   MMP1	   0.003097	   4.274	   V	  up	  vs	  L	  
KBTBD8	   KBTBD8	   0.000174	   4.244	   V	  up	  vs	  L	  
TIMM8A	   TIMM8A	   0.000024	   4.087	   V	  up	  vs	  L	  
TM4SF19	   TM4SF19	   0.001296	   3.849	   V	  up	  vs	  L	  
ADCY3	   ADCY3	   0.011415	   3.847	   V	  up	  vs	  L	  
HS.578401	   	  	   0.000134	   3.766	   V	  up	  vs	  L	  
ACRC	   ACRC	   0.007537	   3.747	   V	  up	  vs	  L	  
ANKRD57	   ANKRD57	   0.014863	   3.726	   V	  up	  vs	  L	  
CCND1	   CCND1	   0.006761	   3.721	   V	  up	  vs	  L	  
C10ORF54	   C10orf54	   0.000596	   3.583	   V	  up	  vs	  L	  
DHRS9	   DHRS9	   0.002876	   3.465	   V	  up	  vs	  L	  
MYADM	   MYADM	   0.005008	   3.367	   V	  up	  vs	  L	  
GEM	   GEM	   0.001474	   3.356	   V	  up	  vs	  L	  
MAPK13	   MAPK13	   0.001982	   3.346	   V	  up	  vs	  L	  
YARS	   YARS	   0.004247	   3.331	   V	  up	  vs	  L	  
SGK1	   SGK1	   0.047400	   3.312	   V	  up	  vs	  L	  
BAG3	   BAG3	   0.002524	   3.230	   V	  up	  vs	  L	  
BHLHB2	   BHLHB2	   0.000117	   3.209	   V	  up	  vs	  L	  
KLF5	   KLF5	   0.002543	   3.207	   V	  up	  vs	  L	  
MOAP1	   MOAP1	   0.004579	   3.173	   V	  up	  vs	  L	  
SGMS2	   SGMS2	   0.001623	   3.160	   V	  up	  vs	  L	  
RGS2	   RGS2	   0.002297	   3.131	   V	  up	  vs	  L	  
GNPDA1	   GNPDA1	   0.000130	   3.114	   V	  up	  vs	  L	  
CD300LF	   CD300LF	   0.019427	   3.047	   V	  up	  vs	  L	  
RNASET2	   RNASET2	   0.004643	   2.939	   V	  up	  vs	  L	  
CRTAM	   CRTAM	   0.000216	   2.926	   V	  up	  vs	  L	  
HLA-­‐DMA	   HLA-­‐DMA	   0.000306	   2.924	   V	  up	  vs	  L	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C10ORF128	   C10orf128	   0.009899	   2.912	   V	  up	  vs	  L	  
TCTEX1D2	   TCTEX1D2	   0.003180	   2.893	   V	  up	  vs	  L	  
C14ORF109	   C14orf109	   0.017840	   2.875	   V	  up	  vs	  L	  
HS.519750	   	  	   0.001485	   2.870	   V	  up	  vs	  L	  
MATK	   MATK	   0.046663	   2.856	   V	  up	  vs	  L	  
TRAPPC6A	   TRAPPC6A	   0.000048	   2.840	   V	  up	  vs	  L	  
HBEGF	   HBEGF	   0.000159	   2.810	   V	  up	  vs	  L	  
DNAJB1	   DNAJB1	   0.019811	   2.792	   V	  up	  vs	  L	  
HLA-­‐DMB	   HLA-­‐DMB	   0.004464	   2.788	   V	  up	  vs	  L	  
LY96	   LY96	   0.006694	   2.779	   V	  up	  vs	  L	  
LTA4H	   LTA4H	   0.009489	   2.773	   V	  up	  vs	  L	  
EGR1	   EGR1	   0.019702	   2.743	   V	  up	  vs	  L	  
LOC401588	   LOC401588	   0.000101	   2.717	   V	  up	  vs	  L	  
HS.499716	   	  	   0.000305	   2.715	   V	  up	  vs	  L	  
CLEC7A	   CLEC7A	   0.001533	   2.704	   V	  up	  vs	  L	  
LOC650803	   LOC650803	   0.019936	   2.702	   V	  up	  vs	  L	  
ZFR2	   ZFR2	   0.039214	   2.701	   V	  up	  vs	  L	  
RP5-­‐1022P6.2	   RP5-­‐1022P6.2	   0.000008	   2.689	   V	  up	  vs	  L	  
RRAGD	   RRAGD	   0.000554	   2.674	   V	  up	  vs	  L	  
C20ORF20	   C20orf20	   0.017479	   2.659	   V	  up	  vs	  L	  
GMFG	   GMFG	   0.000043	   2.656	   V	  up	  vs	  L	  
S1PR3	   S1PR3	   0.000048	   2.608	   V	  up	  vs	  L	  
NR4A2	   NR4A2	   0.003510	   2.606	   V	  up	  vs	  L	  
EPS8	   EPS8	   0.028303	   2.604	   V	  up	  vs	  L	  
BLVRB	   BLVRB	   0.011541	   2.598	   V	  up	  vs	  L	  
TKTL1	   TKTL1	   0.003197	   2.597	   V	  up	  vs	  L	  
SGK	   SGK	   0.010119	   2.566	   V	  up	  vs	  L	  
EVI2B	   EVI2B	   0.004196	   2.563	   V	  up	  vs	  L	  
JUN	   JUN	   0.001560	   2.553	   V	  up	  vs	  L	  
CD163	   CD163	   0.008699	   2.548	   V	  up	  vs	  L	  
AMICA1	   AMICA1	   0.016664	   2.539	   V	  up	  vs	  L	  
ZFAND2A	   ZFAND2A	   0.002735	   2.536	   V	  up	  vs	  L	  
NP	   NP	   0.000003	   2.524	   V	  up	  vs	  L	  
ITGAM	   ITGAM	   0.047991	   2.478	   V	  up	  vs	  L	  
SLC20A1	   SLC20A1	   0.000636	   2.474	   V	  up	  vs	  L	  
ZNF165	   ZNF165	   0.004834	   2.456	   V	  up	  vs	  L	  
LAT2	   LAT2	   0.000454	   2.456	   V	  up	  vs	  L	  
WBP5	   WBP5	   0.000660	   2.452	   V	  up	  vs	  L	  
LOC606724	   LOC606724	   0.001915	   2.431	   V	  up	  vs	  L	  
HCST	   HCST	   0.032321	   2.424	   V	  up	  vs	  L	  
KLF10	   KLF10	   0.008145	   2.424	   V	  up	  vs	  L	  
HEXB	   HEXB	   0.009101	   2.404	   V	  up	  vs	  L	  
CAT	   CAT	   0.030306	   2.404	   V	  up	  vs	  L	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FLJ22662	   FLJ22662	   0.049372	   2.400	   V	  up	  vs	  L	  
PRCP	   PRCP	   0.016426	   2.398	   V	  up	  vs	  L	  
ADRB2	   ADRB2	   0.034683	   2.382	   V	  up	  vs	  L	  
HSPA1A	   HSPA1A	   0.000561	   2.380	   V	  up	  vs	  L	  
CXCR4	   CXCR4	   0.001505	   2.377	   V	  up	  vs	  L	  
RRN3P2	   RRN3P2	   0.007610	   2.370	   V	  up	  vs	  L	  
ZNF622	   ZNF622	   0.005351	   2.355	   V	  up	  vs	  L	  
TMEM91	   TMEM91	   0.043597	   2.346	   V	  up	  vs	  L	  
RRP12	   RRP12	   0.008489	   2.324	   V	  up	  vs	  L	  
LOC653340	   LOC653340	   0.016887	   2.315	   V	  up	  vs	  L	  
DLL1	   DLL1	   0.002146	   2.313	   V	  up	  vs	  L	  
ITGB2	   ITGB2	   0.000106	   2.296	   V	  up	  vs	  L	  
LIPN	   LIPN	   0.006026	   2.291	   V	  up	  vs	  L	  
LOC649555	   LOC649555	   0.002140	   2.290	   V	  up	  vs	  L	  
CIRH1A	   CIRH1A	   0.028322	   2.275	   V	  up	  vs	  L	  
HPSE	   HPSE	   0.000187	   2.268	   V	  up	  vs	  L	  
KLF2	   KLF2	   0.008723	   2.250	   V	  up	  vs	  L	  
LPCAT2	   LPCAT2	   0.003737	   2.250	   V	  up	  vs	  L	  
GARS	   GARS	   0.042652	   2.237	   V	  up	  vs	  L	  
LOC100131693	   LOC100131693	   0.000138	   2.223	   V	  up	  vs	  L	  
CSF3R	   CSF3R	   0.004808	   2.216	   V	  up	  vs	  L	  
MGC61598	   MGC61598	   0.017988	   2.214	   V	  up	  vs	  L	  
WAS	   WAS	   0.031084	   2.211	   V	  up	  vs	  L	  
ARHGDIB	   ARHGDIB	   0.005862	   2.205	   V	  up	  vs	  L	  
HAVCR2	   HAVCR2	   0.007684	   2.198	   V	  up	  vs	  L	  
KLHL6	   KLHL6	   0.012178	   2.192	   V	  up	  vs	  L	  
HSPA1L	   HSPA1L	   0.000334	   2.190	   V	  up	  vs	  L	  
SDSL	   SDSL	   0.000841	   2.189	   V	  up	  vs	  L	  
CSF1	   CSF1	   0.037481	   2.182	   V	  up	  vs	  L	  
SELL	   SELL	   0.021519	   2.181	   V	  up	  vs	  L	  
MAPKAPK3	   MAPKAPK3	   0.032212	   2.176	   V	  up	  vs	  L	  
CD36	   CD36	   0.048588	   2.172	   V	  up	  vs	  L	  
NFE2	   NFE2	   0.009396	   2.171	   V	  up	  vs	  L	  
C13ORF15	   C13orf15	   0.001744	   2.170	   V	  up	  vs	  L	  
ANXA1	   ANXA1	   0.013141	   2.168	   V	  up	  vs	  L	  
BEX1	   BEX1	   0.008838	   2.153	   V	  up	  vs	  L	  
FCN1	   FCN1	   0.000976	   2.145	   V	  up	  vs	  L	  
MOGAT1	   MOGAT1	   0.027321	   2.142	   V	  up	  vs	  L	  
ITGA5	   ITGA5	   0.009433	   2.139	   V	  up	  vs	  L	  
FCGR2C	   FCGR2C	   0.004543	   2.134	   V	  up	  vs	  L	  
FRG1	   FRG1	   0.003810	   2.134	   V	  up	  vs	  L	  
LY86	   LY86	   0.007807	   2.115	   V	  up	  vs	  L	  
C14ORF169	   C14orf169	   0.000032	   2.112	   V	  up	  vs	  L	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LOC341784	   LOC341784	   0.008479	   2.108	   V	  up	  vs	  L	  
EGR3	   EGR3	   0.005902	   2.100	   V	  up	  vs	  L	  
LOC100130264	   LOC100130264	   0.010399	   2.098	   V	  up	  vs	  L	  
FGL2	   FGL2	   0.025072	   2.093	   V	  up	  vs	  L	  
ABL2	   ABL2	   0.000913	   2.093	   V	  up	  vs	  L	  
TXNIP	   TXNIP	   0.006734	   2.092	   V	  up	  vs	  L	  
HSPA9	   HSPA9	   0.030929	   2.086	   V	  up	  vs	  L	  
ITPRIP	   ITPRIP	   0.004080	   2.084	   V	  up	  vs	  L	  
ST3GAL6	   ST3GAL6	   0.000648	   2.078	   V	  up	  vs	  L	  
SLC7A5	   SLC7A5	   0.008462	   2.076	   V	  up	  vs	  L	  
IRF8	   IRF8	   0.006033	   2.075	   V	  up	  vs	  L	  
NPC1	   NPC1	   0.001141	   2.075	   V	  up	  vs	  L	  
CCND2	   CCND2	   0.012223	   2.075	   V	  up	  vs	  L	  
DPEP2	   DPEP2	   0.037195	   2.073	   V	  up	  vs	  L	  
LOC651524	   LOC651524	   0.001530	   2.065	   V	  up	  vs	  L	  
ADNP2	   ADNP2	   0.012049	   2.063	   V	  up	  vs	  L	  
WDSOF1	   WDSOF1	   0.000265	   2.063	   V	  up	  vs	  L	  
RNMTL1	   RNMTL1	   0.016817	   2.060	   V	  up	  vs	  L	  
TMEM38B	   TMEM38B	   0.000109	   2.060	   V	  up	  vs	  L	  
GLIPR1	   GLIPR1	   0.026192	   2.057	   V	  up	  vs	  L	  
GSTK1	   GSTK1	   0.005044	   2.051	   V	  up	  vs	  L	  
FCGRT	   FCGRT	   0.006694	   2.050	   V	  up	  vs	  L	  
ICAM3	   ICAM3	   0.007482	   2.049	   V	  up	  vs	  L	  
NRIP3	   NRIP3	   0.001887	   2.047	   V	  up	  vs	  L	  
BEX2	   BEX2	   0.012564	   2.032	   V	  up	  vs	  L	  
SPRED1	   SPRED1	   0.004196	   2.032	   V	  up	  vs	  L	  
PPARG	   PPARG	   0.000522	   2.031	   V	  up	  vs	  L	  
CKS2	   CKS2	   0.017299	   2.030	   V	  up	  vs	  L	  
MIR221	   MIR221	   0.001681	   2.029	   V	  up	  vs	  L	  
ZMIZ1	   ZMIZ1	   0.005859	   2.023	   V	  up	  vs	  L	  
LOC100129186	   LOC100129186	   0.005218	   2.023	   V	  up	  vs	  L	  
LOC646626	   LOC646626	   0.035687	   2.020	   V	  up	  vs	  L	  
LOC728653	   LOC728653	   0.025872	   2.019	   V	  up	  vs	  L	  
NME1	   NME1	   0.012915	   2.017	   V	  up	  vs	  L	  
CFD	   CFD	   0.014690	   2.011	   V	  up	  vs	  L	  
CD4	   CD4	   0.000288	   2.009	   V	  up	  vs	  L	  
LOC732415	   LOC732415	   0.031567	   2.006	   V	  up	  vs	  L	  
HS.575725	   	  	   0.032917	   2.005	   V	  up	  vs	  L	  
DEDD2	   DEDD2	   0.005377	   2.004	   V	  up	  vs	  L	  
RUSC2	   RUSC2	   0.024516	   2.004	   V	  up	  vs	  L	  
ZSCAN5A	   ZSCAN5A	   0.017001	   1.995	   V	  up	  vs	  L	  
C5AR1	   C5AR1	   0.006303	   1.992	   V	  up	  vs	  L	  
RNF130	   RNF130	   0.039708	   1.991	   V	  up	  vs	  L	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DUSP6	   DUSP6	   0.005137	   1.987	   V	  up	  vs	  L	  
TRIB1	   TRIB1	   0.002358	   1.987	   V	  up	  vs	  L	  
HDDC2	   HDDC2	   0.049152	   1.982	   V	  up	  vs	  L	  
B3GNT5	   B3GNT5	   0.003763	   1.978	   V	  up	  vs	  L	  
LOC100132918	   LOC100132918	   0.020961	   1.977	   V	  up	  vs	  L	  
PPT1	   PPT1	   0.047816	   1.976	   V	  up	  vs	  L	  
LOC728247	   LOC728247	   0.005937	   1.975	   V	  up	  vs	  L	  
CCR1	   CCR1	   0.002324	   1.975	   V	  up	  vs	  L	  
TDRD9	   TDRD9	   0.000570	   1.967	   V	  up	  vs	  L	  
VGF	   VGF	   0.001039	   1.967	   V	  up	  vs	  L	  
OBFC2A	   OBFC2A	   0.035676	   1.966	   V	  up	  vs	  L	  
TMEM49	   TMEM49	   0.002417	   1.966	   V	  up	  vs	  L	  
LOC100131565	   LOC100131565	   0.026087	   1.957	   V	  up	  vs	  L	  
CHSY1	   CHSY1	   0.000028	   1.951	   V	  up	  vs	  L	  
CKLF	   CKLF	   0.002881	   1.949	   V	  up	  vs	  L	  
AVPI1	   AVPI1	   0.005331	   1.949	   V	  up	  vs	  L	  
NOP58	   NOP58	   0.009265	   1.946	   V	  up	  vs	  L	  
RGS16	   RGS16	   0.002011	   1.939	   V	  up	  vs	  L	  
FOSL1	   FOSL1	   0.000599	   1.932	   V	  up	  vs	  L	  
PLIN2	   PLIN2	   0.034011	   1.923	   V	  up	  vs	  L	  
ZNF185	   ZNF185	   0.000493	   1.923	   V	  up	  vs	  L	  
HEBP2	   HEBP2	   0.004207	   1.923	   V	  up	  vs	  L	  
VPS37B	   VPS37B	   0.000146	   1.922	   V	  up	  vs	  L	  
FKBP15	   FKBP15	   0.027567	   1.921	   V	  up	  vs	  L	  
BCAP31	   BCAP31	   0.019058	   1.921	   V	  up	  vs	  L	  
ACTN1	   ACTN1	   0.027083	   1.919	   V	  up	  vs	  L	  
SERTAD1	   SERTAD1	   0.006594	   1.912	   V	  up	  vs	  L	  
SAAL1	   SAAL1	   0.005925	   1.911	   V	  up	  vs	  L	  
LOC730050	   LOC730050	   0.002782	   1.909	   V	  up	  vs	  L	  
CRY1	   CRY1	   0.012246	   1.903	   V	  up	  vs	  L	  
SMCR7L	   SMCR7L	   0.038361	   1.902	   V	  up	  vs	  L	  
SLC2A3	   SLC2A3	   0.012256	   1.894	   V	  up	  vs	  L	  
CHD1	   CHD1	   0.000904	   1.891	   V	  up	  vs	  L	  
C9ORF47	   C9orf47	   0.001586	   1.890	   V	  up	  vs	  L	  
LOC338758	   LOC338758	   0.004420	   1.888	   V	  up	  vs	  L	  
LOC729608	   LOC729608	   0.010290	   1.881	   V	  up	  vs	  L	  
COL15A1	   COL15A1	   0.033273	   1.876	   V	  up	  vs	  L	  
LONRF3	   LONRF3	   0.002545	   1.875	   V	  up	  vs	  L	  
PRNP	   PRNP	   0.003144	   1.874	   V	  up	  vs	  L	  
HS.79881	   	  	   0.003345	   1.873	   V	  up	  vs	  L	  
PI3	   PI3	   0.009117	   1.872	   V	  up	  vs	  L	  
EFHD2	   EFHD2	   0.017430	   1.868	   V	  up	  vs	  L	  
TLR1	   TLR1	   0.020650	   1.867	   V	  up	  vs	  L	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RPF2	   RPF2	   0.003689	   1.865	   V	  up	  vs	  L	  
S100A8	   S100A8	   0.002476	   1.863	   V	  up	  vs	  L	  
TNFSF14	   TNFSF14	   0.004482	   1.855	   V	  up	  vs	  L	  
C12ORF23	   C12orf23	   0.022393	   1.853	   V	  up	  vs	  L	  
TSC22D2	   TSC22D2	   0.000383	   1.851	   V	  up	  vs	  L	  
MRPS17	   MRPS17	   0.009786	   1.848	   V	  up	  vs	  L	  
RRP15	   RRP15	   0.000830	   1.846	   V	  up	  vs	  L	  
RBM15	   RBM15	   0.003013	   1.840	   V	  up	  vs	  L	  
HS.415576	   	  	   0.030609	   1.837	   V	  up	  vs	  L	  
LOC441505	   LOC441505	   0.005516	   1.835	   V	  up	  vs	  L	  
LOC389137	   LOC389137	   0.000977	   1.832	   V	  up	  vs	  L	  
DNTTIP2	   DNTTIP2	   0.001168	   1.830	   V	  up	  vs	  L	  
ZNF593	   ZNF593	   0.020556	   1.828	   V	  up	  vs	  L	  
PIK3CG	   PIK3CG	   0.004381	   1.827	   V	  up	  vs	  L	  
NIP7	   NIP7	   0.020361	   1.827	   V	  up	  vs	  L	  
CD93	   CD93	   0.026750	   1.825	   V	  up	  vs	  L	  
UAP1	   UAP1	   0.004718	   1.824	   V	  up	  vs	  L	  
ADAM15	   ADAM15	   0.008174	   1.819	   V	  up	  vs	  L	  
RPS23	   RPS23	   0.029799	   1.816	   V	  up	  vs	  L	  
DENND2D	   DENND2D	   0.020310	   1.815	   V	  up	  vs	  L	  
PSCD4	   PSCD4	   0.009933	   1.815	   V	  up	  vs	  L	  
CPVL	   CPVL	   0.006055	   1.814	   V	  up	  vs	  L	  
RRAD	   RRAD	   0.006110	   1.813	   V	  up	  vs	  L	  
NOLC1	   NOLC1	   0.041637	   1.813	   V	  up	  vs	  L	  
TMC6	   TMC6	   0.018023	   1.813	   V	  up	  vs	  L	  
JOSD1	   JOSD1	   0.020662	   1.812	   V	  up	  vs	  L	  
ACSL3	   ACSL3	   0.000996	   1.808	   V	  up	  vs	  L	  
UTP11L	   UTP11L	   0.005009	   1.805	   V	  up	  vs	  L	  
LOC651745	   LOC651745	   0.015966	   1.802	   V	  up	  vs	  L	  
UBL3	   UBL3	   0.032190	   1.798	   V	  up	  vs	  L	  
HS.578899	   	  	   0.038429	   1.795	   V	  up	  vs	  L	  
NAAA	   NAAA	   0.032335	   1.795	   V	  up	  vs	  L	  
LOC730081	   LOC730081	   0.008237	   1.793	   V	  up	  vs	  L	  
ERCC1	   ERCC1	   0.003349	   1.789	   V	  up	  vs	  L	  
TBC1D2	   TBC1D2	   0.002472	   1.786	   V	  up	  vs	  L	  
NEU1	   NEU1	   0.035552	   1.783	   V	  up	  vs	  L	  
ARHGAP4	   ARHGAP4	   0.013796	   1.781	   V	  up	  vs	  L	  
TRMT5	   TRMT5	   0.009340	   1.780	   V	  up	  vs	  L	  
IARS	   IARS	   0.003439	   1.780	   V	  up	  vs	  L	  
LOC645430	   LOC645430	   0.033480	   1.779	   V	  up	  vs	  L	  
KIFC2	   KIFC2	   0.021975	   1.777	   V	  up	  vs	  L	  
TSPO	   TSPO	   0.004738	   1.776	   V	  up	  vs	  L	  
EIF3E	   EIF3E	   0.000473	   1.775	   V	  up	  vs	  L	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UPP1	   UPP1	   0.031380	   1.773	   V	  up	  vs	  L	  
EIF1AD	   EIF1AD	   0.016551	   1.769	   V	  up	  vs	  L	  
USPL1	   USPL1	   0.016812	   1.766	   V	  up	  vs	  L	  
SNORD10	   SNORD10	   0.040630	   1.766	   V	  up	  vs	  L	  
NFIL3	   NFIL3	   0.041685	   1.765	   V	  up	  vs	  L	  
KIAA2018	   KIAA2018	   0.000112	   1.764	   V	  up	  vs	  L	  
BIN2	   BIN2	   0.012503	   1.760	   V	  up	  vs	  L	  
CXORF15	   CXorf15	   0.033288	   1.755	   V	  up	  vs	  L	  
CD244	   CD244	   0.028158	   1.754	   V	  up	  vs	  L	  
SETDB2	   SETDB2	   0.015730	   1.752	   V	  up	  vs	  L	  
PPP1R15A	   PPP1R15A	   0.043244	   1.751	   V	  up	  vs	  L	  
IL10RA	   IL10RA	   0.006155	   -­‐1.752	   V	  down	  vs	  L	  
RASSF4	   RASSF4	   0.001676	   -­‐1.754	   V	  down	  vs	  L	  
LOC648927	   LOC648927	   0.042133	   -­‐1.756	   V	  down	  vs	  L	  
TAP2	   TAP2	   0.016799	   -­‐1.757	   V	  down	  vs	  L	  
TLR2	   TLR2	   0.002189	   -­‐1.760	   V	  down	  vs	  L	  
EZH2	   EZH2	   0.023912	   -­‐1.771	   V	  down	  vs	  L	  
RNF145	   RNF145	   0.042431	   -­‐1.772	   V	  down	  vs	  L	  
RAP2C	   RAP2C	   0.000423	   -­‐1.774	   V	  down	  vs	  L	  
GTF2E2	   GTF2E2	   0.043590	   -­‐1.776	   V	  down	  vs	  L	  
LOC100132184	   LOC100132184	   0.011217	   -­‐1.776	   V	  down	  vs	  L	  
ZC3H5	   ZC3H5	   0.007776	   -­‐1.778	   V	  down	  vs	  L	  
GORASP1	   GORASP1	   0.004667	   -­‐1.784	   V	  down	  vs	  L	  
USP41	   USP41	   0.001310	   -­‐1.784	   V	  down	  vs	  L	  
ANXA7	   ANXA7	   0.000476	   -­‐1.784	   V	  down	  vs	  L	  
FLJ45340	   FLJ45340	   0.028706	   -­‐1.785	   V	  down	  vs	  L	  
EXT1	   EXT1	   0.003088	   -­‐1.789	   V	  down	  vs	  L	  
SLC30A1	   SLC30A1	   0.018869	   -­‐1.789	   V	  down	  vs	  L	  
LCOR	   LCOR	   0.004382	   -­‐1.791	   V	  down	  vs	  L	  
IL6	   IL6	   0.003732	   -­‐1.792	   V	  down	  vs	  L	  
HS.543261	   	  	   0.004053	   -­‐1.792	   V	  down	  vs	  L	  
CNKSR3	   CNKSR3	   0.042870	   -­‐1.794	   V	  down	  vs	  L	  
ETV6	   ETV6	   0.036272	   -­‐1.795	   V	  down	  vs	  L	  
CHMP5	   CHMP5	   0.003562	   -­‐1.797	   V	  down	  vs	  L	  
AGRN	   AGRN	   0.005148	   -­‐1.797	   V	  down	  vs	  L	  
CAB39	   CAB39	   0.001094	   -­‐1.801	   V	  down	  vs	  L	  
GK	   GK	   0.019992	   -­‐1.803	   V	  down	  vs	  L	  
PI4K2B	   PI4K2B	   0.001144	   -­‐1.803	   V	  down	  vs	  L	  
ICAM1	   ICAM1	   0.008132	   -­‐1.804	   V	  down	  vs	  L	  
PRF1	   PRF1	   0.000462	   -­‐1.813	   V	  down	  vs	  L	  
VRK2	   VRK2	   0.000826	   -­‐1.814	   V	  down	  vs	  L	  
BRD7	   BRD7	   0.002933	   -­‐1.817	   V	  down	  vs	  L	  
CYTIP	   CYTIP	   0.000348	   -­‐1.817	   V	  down	  vs	  L	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LAIR2	   LAIR2	   0.012794	   -­‐1.823	   V	  down	  vs	  L	  
DRAM1	   DRAM1	   0.000352	   -­‐1.825	   V	  down	  vs	  L	  
LOC641851	   LOC641851	   0.002178	   -­‐1.826	   V	  down	  vs	  L	  
OASL	   OASL	   0.002776	   -­‐1.827	   V	  down	  vs	  L	  
TSC22D1	   TSC22D1	   0.000523	   -­‐1.827	   V	  down	  vs	  L	  
CCL22	   CCL22	   0.000067	   -­‐1.827	   V	  down	  vs	  L	  
VDAC1	   VDAC1	   0.040363	   -­‐1.828	   V	  down	  vs	  L	  
PSCD1	   PSCD1	   0.001322	   -­‐1.829	   V	  down	  vs	  L	  
RAP2A	   RAP2A	   0.020076	   -­‐1.831	   V	  down	  vs	  L	  
FBXL11	   FBXL11	   0.006427	   -­‐1.832	   V	  down	  vs	  L	  
NBN	   NBN	   0.001004	   -­‐1.834	   V	  down	  vs	  L	  
CDKN2B	   CDKN2B	   0.011664	   -­‐1.838	   V	  down	  vs	  L	  
DCAF7	   DCAF7	   0.009156	   -­‐1.838	   V	  down	  vs	  L	  
CD99	   CD99	   0.023569	   -­‐1.842	   V	  down	  vs	  L	  
CLIC4	   CLIC4	   0.000534	   -­‐1.845	   V	  down	  vs	  L	  
KANK1	   KANK1	   0.004983	   -­‐1.847	   V	  down	  vs	  L	  
CDC42SE2	   CDC42SE2	   0.006919	   -­‐1.847	   V	  down	  vs	  L	  
LOC440280	   LOC440280	   0.036112	   -­‐1.849	   V	  down	  vs	  L	  
XRN1	   XRN1	   0.000533	   -­‐1.849	   V	  down	  vs	  L	  
LMO2	   LMO2	   0.002904	   -­‐1.852	   V	  down	  vs	  L	  
PSCDBP	   PSCDBP	   0.006825	   -­‐1.855	   V	  down	  vs	  L	  
MYST3	   MYST3	   0.024113	   -­‐1.855	   V	  down	  vs	  L	  
AGPAT4	   AGPAT4	   0.005280	   -­‐1.856	   V	  down	  vs	  L	  
HS.548433	   	  	   0.040660	   -­‐1.857	   V	  down	  vs	  L	  
IKBKE	   IKBKE	   0.019386	   -­‐1.859	   V	  down	  vs	  L	  
TMEM165	   TMEM165	   0.000838	   -­‐1.861	   V	  down	  vs	  L	  
AKR1B1	   AKR1B1	   0.006632	   -­‐1.865	   V	  down	  vs	  L	  
LYSMD2	   LYSMD2	   0.018688	   -­‐1.868	   V	  down	  vs	  L	  
HCK	   HCK	   0.022712	   -­‐1.873	   V	  down	  vs	  L	  
TRIM8	   TRIM8	   0.024887	   -­‐1.874	   V	  down	  vs	  L	  
CYTH1	   CYTH1	   0.002072	   -­‐1.878	   V	  down	  vs	  L	  
MLLT6	   MLLT6	   0.002042	   -­‐1.879	   V	  down	  vs	  L	  
LOC283767	   LOC283767	   0.019117	   -­‐1.880	   V	  down	  vs	  L	  
GCH1	   GCH1	   0.003080	   -­‐1.886	   V	  down	  vs	  L	  
MTSS1	   MTSS1	   0.004211	   -­‐1.886	   V	  down	  vs	  L	  
HSH2D	   HSH2D	   0.035475	   -­‐1.890	   V	  down	  vs	  L	  
VPS29	   VPS29	   0.004843	   -­‐1.893	   V	  down	  vs	  L	  
PHF11	   PHF11	   0.007358	   -­‐1.897	   V	  down	  vs	  L	  
PNRC1	   PNRC1	   0.007441	   -­‐1.898	   V	  down	  vs	  L	  
PCID2	   PCID2	   0.007797	   -­‐1.901	   V	  down	  vs	  L	  
BRWD2	   BRWD2	   0.000255	   -­‐1.901	   V	  down	  vs	  L	  
HIP1	   HIP1	   0.020669	   -­‐1.902	   V	  down	  vs	  L	  
CALR	   CALR	   0.017602	   -­‐1.902	   V	  down	  vs	  L	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TDRD6	   TDRD6	   0.004910	   -­‐1.904	   V	  down	  vs	  L	  
PLA2G4A	   PLA2G4A	   0.001367	   -­‐1.907	   V	  down	  vs	  L	  
NIPA1	   NIPA1	   0.039318	   -­‐1.910	   V	  down	  vs	  L	  
HS.24119	   	  	   0.011730	   -­‐1.912	   V	  down	  vs	  L	  
FLNB	   FLNB	   0.005577	   -­‐1.923	   V	  down	  vs	  L	  
PML	   PML	   0.002966	   -­‐1.933	   V	  down	  vs	  L	  
C13ORF31	   C13orf31	   0.012436	   -­‐1.938	   V	  down	  vs	  L	  
NCOA3	   NCOA3	   0.000629	   -­‐1.942	   V	  down	  vs	  L	  
RNF19B	   RNF19B	   0.001010	   -­‐1.943	   V	  down	  vs	  L	  
SRD5A1	   SRD5A1	   0.014419	   -­‐1.946	   V	  down	  vs	  L	  
DNAJB6	   DNAJB6	   0.024329	   -­‐1.947	   V	  down	  vs	  L	  
GATAD2B	   GATAD2B	   0.036649	   -­‐1.948	   V	  down	  vs	  L	  
AIDA	   AIDA	   0.010117	   -­‐1.948	   V	  down	  vs	  L	  
HS.373429	   	  	   0.001578	   -­‐1.950	   V	  down	  vs	  L	  
IFITM3	   IFITM3	   0.033823	   -­‐1.952	   V	  down	  vs	  L	  
MRPS24	   MRPS24	   0.027574	   -­‐1.955	   V	  down	  vs	  L	  
LOC392635	   LOC392635	   0.005505	   -­‐1.960	   V	  down	  vs	  L	  
LYN	   LYN	   0.028292	   -­‐1.963	   V	  down	  vs	  L	  
CYBA	   CYBA	   0.043477	   -­‐1.976	   V	  down	  vs	  L	  
FMNL3	   FMNL3	   0.037915	   -­‐1.985	   V	  down	  vs	  L	  
STAT5A	   STAT5A	   0.027632	   -­‐1.987	   V	  down	  vs	  L	  
CUL4A	   CUL4A	   0.000588	   -­‐1.988	   V	  down	  vs	  L	  
LOC100130308	   LOC100130308	   0.000049	   -­‐1.989	   V	  down	  vs	  L	  
HS.444683	   	  	   0.008296	   -­‐1.993	   V	  down	  vs	  L	  
SSB	   SSB	   0.014954	   -­‐1.996	   V	  down	  vs	  L	  
MAMLD1	   MAMLD1	   0.002156	   -­‐1.996	   V	  down	  vs	  L	  
ATXN1	   ATXN1	   0.004187	   -­‐2.002	   V	  down	  vs	  L	  
LOC100130199	   LOC100130199	   0.025688	   -­‐2.002	   V	  down	  vs	  L	  
IFI6	   IFI6	   0.044171	   -­‐2.007	   V	  down	  vs	  L	  
TRIM56	   TRIM56	   0.038358	   -­‐2.011	   V	  down	  vs	  L	  
FAM60A	   FAM60A	   0.007010	   -­‐2.014	   V	  down	  vs	  L	  
LOC731881	   LOC731881	   0.006499	   -­‐2.017	   V	  down	  vs	  L	  
MIR155HG	   MIR155HG	   0.002796	   -­‐2.021	   V	  down	  vs	  L	  
GCKR	   GCKR	   0.008260	   -­‐2.022	   V	  down	  vs	  L	  
LOC730818	   LOC730818	   0.005311	   -­‐2.035	   V	  down	  vs	  L	  
SMPDL3A	   SMPDL3A	   0.007234	   -­‐2.042	   V	  down	  vs	  L	  
LRIG1	   LRIG1	   0.000544	   -­‐2.043	   V	  down	  vs	  L	  
DDX60	   DDX60	   0.006053	   -­‐2.045	   V	  down	  vs	  L	  
CEP350	   CEP350	   0.004395	   -­‐2.052	   V	  down	  vs	  L	  
MARCKSL1	   MARCKSL1	   0.010032	   -­‐2.066	   V	  down	  vs	  L	  
TNFSF13B	   TNFSF13B	   0.000891	   -­‐2.068	   V	  down	  vs	  L	  
CXCL1	   CXCL1	   0.002353	   -­‐2.071	   V	  down	  vs	  L	  
LY6E	   LY6E	   0.010107	   -­‐2.071	   V	  down	  vs	  L	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CD226	   CD226	   0.010346	   -­‐2.071	   V	  down	  vs	  L	  
FAM49A	   FAM49A	   0.007740	   -­‐2.074	   V	  down	  vs	  L	  
IFNAR2	   IFNAR2	   0.001052	   -­‐2.079	   V	  down	  vs	  L	  
CD274	   CD274	   0.000092	   -­‐2.081	   V	  down	  vs	  L	  
RNF144B	   RNF144B	   0.002292	   -­‐2.083	   V	  down	  vs	  L	  
PPP3CC	   PPP3CC	   0.007673	   -­‐2.083	   V	  down	  vs	  L	  
TDRD7	   TDRD7	   0.027315	   -­‐2.085	   V	  down	  vs	  L	  
PARP4	   PARP4	   0.001739	   -­‐2.088	   V	  down	  vs	  L	  
LMNA	   LMNA	   0.000040	   -­‐2.094	   V	  down	  vs	  L	  
CD80	   CD80	   0.027499	   -­‐2.097	   V	  down	  vs	  L	  
RAB13	   RAB13	   0.012171	   -­‐2.098	   V	  down	  vs	  L	  
KIAA0020	   KIAA0020	   0.008083	   -­‐2.100	   V	  down	  vs	  L	  
KYNU	   KYNU	   0.006476	   -­‐2.114	   V	  down	  vs	  L	  
SEMA4A	   SEMA4A	   0.024022	   -­‐2.117	   V	  down	  vs	  L	  
MX1	   MX1	   0.036117	   -­‐2.118	   V	  down	  vs	  L	  
HS.4988	   	  	   0.000137	   -­‐2.120	   V	  down	  vs	  L	  
EPS15	   EPS15	   0.005330	   -­‐2.121	   V	  down	  vs	  L	  
CD38	   CD38	   0.003121	   -­‐2.131	   V	  down	  vs	  L	  
PGD	   PGD	   0.001177	   -­‐2.133	   V	  down	  vs	  L	  
GRAMD1A	   GRAMD1A	   0.005924	   -­‐2.147	   V	  down	  vs	  L	  
C3ORF59	   C3orf59	   0.004025	   -­‐2.159	   V	  down	  vs	  L	  
SLC41A2	   SLC41A2	   0.000255	   -­‐2.159	   V	  down	  vs	  L	  
PIM2	   PIM2	   0.025429	   -­‐2.161	   V	  down	  vs	  L	  
CCDC56	   CCDC56	   0.001368	   -­‐2.163	   V	  down	  vs	  L	  
TNFAIP2	   TNFAIP2	   0.000395	   -­‐2.167	   V	  down	  vs	  L	  
FTSJD2	   FTSJD2	   0.006566	   -­‐2.175	   V	  down	  vs	  L	  
TRAFD1	   TRAFD1	   0.009058	   -­‐2.180	   V	  down	  vs	  L	  
TBC1D9	   TBC1D9	   0.000171	   -­‐2.194	   V	  down	  vs	  L	  
DDX58	   DDX58	   0.000969	   -­‐2.195	   V	  down	  vs	  L	  
TRIM25	   TRIM25	   0.013563	   -­‐2.198	   V	  down	  vs	  L	  
USP18	   USP18	   0.002771	   -­‐2.209	   V	  down	  vs	  L	  
ITGAV	   ITGAV	   0.000348	   -­‐2.211	   V	  down	  vs	  L	  
PSTPIP2	   PSTPIP2	   0.003578	   -­‐2.214	   V	  down	  vs	  L	  
SAMHD1	   SAMHD1	   0.029193	   -­‐2.219	   V	  down	  vs	  L	  
LOC647886	   LOC647886	   0.000966	   -­‐2.221	   V	  down	  vs	  L	  
BST2	   BST2	   0.000169	   -­‐2.221	   V	  down	  vs	  L	  
EIF1B	   EIF1B	   0.003191	   -­‐2.230	   V	  down	  vs	  L	  
HS3ST3B1	   HS3ST3B1	   0.001144	   -­‐2.231	   V	  down	  vs	  L	  
HS.10862	   	  	   0.008978	   -­‐2.234	   V	  down	  vs	  L	  
ZNRF2	   ZNRF2	   0.000718	   -­‐2.236	   V	  down	  vs	  L	  
LHFPL2	   LHFPL2	   0.015588	   -­‐2.236	   V	  down	  vs	  L	  
CEP135	   CEP135	   0.000565	   -­‐2.237	   V	  down	  vs	  L	  
LOC650369	   LOC650369	   0.006389	   -­‐2.239	   V	  down	  vs	  L	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LOC728772	   LOC728772	   0.000246	   -­‐2.246	   V	  down	  vs	  L	  
AKR1C3	   AKR1C3	   0.011845	   -­‐2.248	   V	  down	  vs	  L	  
LOC389465	   LOC389465	   0.004077	   -­‐2.252	   V	  down	  vs	  L	  
TMEM123	   TMEM123	   0.000359	   -­‐2.253	   V	  down	  vs	  L	  
DYNLT1	   DYNLT1	   0.001640	   -­‐2.255	   V	  down	  vs	  L	  
KIAA1033	   KIAA1033	   0.029452	   -­‐2.264	   V	  down	  vs	  L	  
RSAD2	   RSAD2	   0.001430	   -­‐2.269	   V	  down	  vs	  L	  
NUB1	   NUB1	   0.004017	   -­‐2.273	   V	  down	  vs	  L	  
LOC654192	   LOC654192	   0.021931	   -­‐2.284	   V	  down	  vs	  L	  
ALCAM	   ALCAM	   0.000510	   -­‐2.301	   V	  down	  vs	  L	  
GBP5	   GBP5	   0.009783	   -­‐2.301	   V	  down	  vs	  L	  
LILRB2	   LILRB2	   0.000127	   -­‐2.302	   V	  down	  vs	  L	  
GPR68	   GPR68	   0.000149	   -­‐2.307	   V	  down	  vs	  L	  
IFI44	   IFI44	   0.002226	   -­‐2.312	   V	  down	  vs	  L	  
SDHAP2	   SDHAP2	   0.008859	   -­‐2.313	   V	  down	  vs	  L	  
IFIT2	   IFIT2	   0.023064	   -­‐2.318	   V	  down	  vs	  L	  
PTPRJ	   PTPRJ	   0.002800	   -­‐2.322	   V	  down	  vs	  L	  
GJB2	   GJB2	   0.000372	   -­‐2.328	   V	  down	  vs	  L	  
C20ORF103	   C20orf103	   0.011135	   -­‐2.332	   V	  down	  vs	  L	  
LOC100132891	   LOC100132891	   0.000501	   -­‐2.346	   V	  down	  vs	  L	  
IFIH1	   IFIH1	   0.002245	   -­‐2.347	   V	  down	  vs	  L	  
MCOLN2	   MCOLN2	   0.007147	   -­‐2.348	   V	  down	  vs	  L	  
TNFAIP6	   TNFAIP6	   0.000074	   -­‐2.352	   V	  down	  vs	  L	  
EPB41L3	   EPB41L3	   0.003210	   -­‐2.364	   V	  down	  vs	  L	  
DLD	   DLD	   0.012856	   -­‐2.370	   V	  down	  vs	  L	  
SLC25A28	   SLC25A28	   0.011804	   -­‐2.370	   V	  down	  vs	  L	  
GBP4	   GBP4	   0.036738	   -­‐2.373	   V	  down	  vs	  L	  
VCAN	   VCAN	   0.011008	   -­‐2.381	   V	  down	  vs	  L	  
MTF1	   MTF1	   0.011708	   -­‐2.396	   V	  down	  vs	  L	  
TNFRSF9	   TNFRSF9	   0.005947	   -­‐2.397	   V	  down	  vs	  L	  
CXCL10	   CXCL10	   0.023142	   -­‐2.398	   V	  down	  vs	  L	  
NECAP2	   NECAP2	   0.012718	   -­‐2.402	   V	  down	  vs	  L	  
ADORA2A	   ADORA2A	   0.007940	   -­‐2.415	   V	  down	  vs	  L	  
IFI35	   IFI35	   0.004997	   -­‐2.438	   V	  down	  vs	  L	  
UBE2L6	   UBE2L6	   0.002716	   -­‐2.444	   V	  down	  vs	  L	  
NCK2	   NCK2	   0.001706	   -­‐2.446	   V	  down	  vs	  L	  
IL19	   IL19	   0.001256	   -­‐2.449	   V	  down	  vs	  L	  
CALM1	   CALM1	   0.000365	   -­‐2.453	   V	  down	  vs	  L	  
C1ORF24	   C1orf24	   0.004627	   -­‐2.462	   V	  down	  vs	  L	  
EREG	   EREG	   0.000357	   -­‐2.468	   V	  down	  vs	  L	  
G0S2	   G0S2	   0.001042	   -­‐2.501	   V	  down	  vs	  L	  
PCMTD1	   PCMTD1	   0.004991	   -­‐2.513	   V	  down	  vs	  L	  
FAM129A	   FAM129A	   0.000228	   -­‐2.522	   V	  down	  vs	  L	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TAP1	   TAP1	   0.002696	   -­‐2.526	   V	  down	  vs	  L	  
STAT4	   STAT4	   0.000153	   -­‐2.532	   V	  down	  vs	  L	  
SP110	   SP110	   0.000050	   -­‐2.549	   V	  down	  vs	  L	  
MST4	   MST4	   0.000003	   -­‐2.549	   V	  down	  vs	  L	  
SLFN5	   SLFN5	   0.001878	   -­‐2.551	   V	  down	  vs	  L	  
LOC400759	   LOC400759	   0.000754	   -­‐2.552	   V	  down	  vs	  L	  
DHX58	   DHX58	   0.000315	   -­‐2.553	   V	  down	  vs	  L	  
DTX3L	   DTX3L	   0.001896	   -­‐2.554	   V	  down	  vs	  L	  
TNFSF10	   TNFSF10	   0.018134	   -­‐2.562	   V	  down	  vs	  L	  
DNCL1	   DNCL1	   0.001365	   -­‐2.593	   V	  down	  vs	  L	  
LOC54103	   LOC54103	   0.000155	   -­‐2.602	   V	  down	  vs	  L	  
PID1	   PID1	   0.002281	   -­‐2.616	   V	  down	  vs	  L	  
CD47	   CD47	   0.006623	   -­‐2.619	   V	  down	  vs	  L	  
PPPDE2	   PPPDE2	   0.001020	   -­‐2.621	   V	  down	  vs	  L	  
LOC645116	   LOC645116	   0.000934	   -­‐2.656	   V	  down	  vs	  L	  
ATF7IP	   ATF7IP	   0.003593	   -­‐2.681	   V	  down	  vs	  L	  
RFTN1	   RFTN1	   0.026179	   -­‐2.711	   V	  down	  vs	  L	  
CCL8	   CCL8	   0.002528	   -­‐2.715	   V	  down	  vs	  L	  
DFNA5	   DFNA5	   0.046430	   -­‐2.717	   V	  down	  vs	  L	  
FAM46A	   FAM46A	   0.002502	   -­‐2.723	   V	  down	  vs	  L	  
PARP12	   PARP12	   0.000371	   -­‐2.723	   V	  down	  vs	  L	  
MAP3K8	   MAP3K8	   0.015186	   -­‐2.729	   V	  down	  vs	  L	  
MAP3K4	   MAP3K4	   0.003555	   -­‐2.730	   V	  down	  vs	  L	  
THBS1	   THBS1	   0.000057	   -­‐2.733	   V	  down	  vs	  L	  
CRIM1	   CRIM1	   0.001606	   -­‐2.736	   V	  down	  vs	  L	  
MAFB	   MAFB	   0.006871	   -­‐2.766	   V	  down	  vs	  L	  
PTEN	   PTEN	   0.029513	   -­‐2.784	   V	  down	  vs	  L	  
CCL23	   CCL23	   0.001763	   -­‐2.789	   V	  down	  vs	  L	  
AKR1C4	   AKR1C4	   0.000041	   -­‐2.792	   V	  down	  vs	  L	  
RHOU	   RHOU	   0.001879	   -­‐2.802	   V	  down	  vs	  L	  
DYNLL1	   DYNLL1	   0.000913	   -­‐2.815	   V	  down	  vs	  L	  
C21ORF71	   C21orf71	   0.013196	   -­‐2.817	   V	  down	  vs	  L	  
HS.125087	   	  	   0.000085	   -­‐2.827	   V	  down	  vs	  L	  
ANPEP	   ANPEP	   0.002234	   -­‐2.853	   V	  down	  vs	  L	  
LAP3	   LAP3	   0.001399	   -­‐2.868	   V	  down	  vs	  L	  
APOL3	   APOL3	   0.000621	   -­‐2.881	   V	  down	  vs	  L	  
STAT1	   STAT1	   0.002806	   -­‐2.903	   V	  down	  vs	  L	  
EMR1	   EMR1	   0.000067	   -­‐2.906	   V	  down	  vs	  L	  
SPATS2L	   SPATS2L	   0.000539	   -­‐2.921	   V	  down	  vs	  L	  
INSIG2	   INSIG2	   0.004336	   -­‐2.938	   V	  down	  vs	  L	  
PARP14	   PARP14	   0.000187	   -­‐2.945	   V	  down	  vs	  L	  
GBP1	   GBP1	   0.000364	   -­‐3.001	   V	  down	  vs	  L	  
HS.580229	   	  	   0.017107	   -­‐3.030	   V	  down	  vs	  L	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TRIM22	   TRIM22	   0.000168	   -­‐3.056	   V	  down	  vs	  L	  
PARP9	   PARP9	   0.008289	   -­‐3.059	   V	  down	  vs	  L	  
ABTB2	   ABTB2	   0.001586	   -­‐3.081	   V	  down	  vs	  L	  
MTE	   MTE	   0.000330	   -­‐3.092	   V	  down	  vs	  L	  
KIAA1618	   KIAA1618	   0.033384	   -­‐3.095	   V	  down	  vs	  L	  
PLSCR1	   PLSCR1	   0.012568	   -­‐3.096	   V	  down	  vs	  L	  
RASGRP1	   RASGRP1	   0.006485	   -­‐3.113	   V	  down	  vs	  L	  
SAMD9	   SAMD9	   0.000592	   -­‐3.181	   V	  down	  vs	  L	  
MOV10	   MOV10	   0.000478	   -­‐3.198	   V	  down	  vs	  L	  
PLA2G7	   PLA2G7	   0.000361	   -­‐3.201	   V	  down	  vs	  L	  
KCNJ2	   KCNJ2	   0.000230	   -­‐3.201	   V	  down	  vs	  L	  
SLC39A8	   SLC39A8	   0.000242	   -­‐3.201	   V	  down	  vs	  L	  
EBI3	   EBI3	   0.010783	   -­‐3.203	   V	  down	  vs	  L	  
SIGLEC1	   SIGLEC1	   0.011522	   -­‐3.215	   V	  down	  vs	  L	  
NT5C3	   NT5C3	   0.001436	   -­‐3.258	   V	  down	  vs	  L	  
NDP	   NDP	   0.002337	   -­‐3.298	   V	  down	  vs	  L	  
C17ORF96	   C17orf96	   0.003819	   -­‐3.300	   V	  down	  vs	  L	  
C7ORF60	   C7orf60	   0.000102	   -­‐3.322	   V	  down	  vs	  L	  
IRG1	   IRG1	   0.001713	   -­‐3.351	   V	  down	  vs	  L	  
LOC730249	   LOC730249	   0.000379	   -­‐3.387	   V	  down	  vs	  L	  
LOC441019	   LOC441019	   0.005500	   -­‐3.398	   V	  down	  vs	  L	  
HERC5	   HERC5	   0.018064	   -­‐3.438	   V	  down	  vs	  L	  
EHF	   EHF	   0.043619	   -­‐3.454	   V	  down	  vs	  L	  
EPSTI1	   EPSTI1	   0.001649	   -­‐3.455	   V	  down	  vs	  L	  
SAMD9L	   SAMD9L	   0.001510	   -­‐3.541	   V	  down	  vs	  L	  
EIF2AK2	   EIF2AK2	   0.004127	   -­‐3.550	   V	  down	  vs	  L	  
MN1	   MN1	   0.000269	   -­‐3.593	   V	  down	  vs	  L	  
MX2	   MX2	   0.001635	   -­‐3.670	   V	  down	  vs	  L	  
OAS2	   OAS2	   0.002514	   -­‐3.711	   V	  down	  vs	  L	  
ITGB8	   ITGB8	   0.000202	   -­‐3.721	   V	  down	  vs	  L	  
C3ORF1	   C3orf1	   0.003038	   -­‐3.757	   V	  down	  vs	  L	  
CMPK2	   CMPK2	   0.000125	   -­‐3.772	   V	  down	  vs	  L	  
STAT2	   STAT2	   0.000166	   -­‐3.824	   V	  down	  vs	  L	  
MSC	   MSC	   0.000931	   -­‐3.845	   V	  down	  vs	  L	  
ADA	   ADA	   0.016461	   -­‐3.919	   V	  down	  vs	  L	  
RGL1	   RGL1	   0.000255	   -­‐4.024	   V	  down	  vs	  L	  
IFIT3	   IFIT3	   0.000182	   -­‐4.039	   V	  down	  vs	  L	  
IFI44L	   IFI44L	   0.012556	   -­‐4.121	   V	  down	  vs	  L	  
PLAC8	   PLAC8	   0.000039	   -­‐4.145	   V	  down	  vs	  L	  
TMOD1	   TMOD1	   0.002983	   -­‐4.224	   V	  down	  vs	  L	  
IL7R	   IL7R	   0.006079	   -­‐4.231	   V	  down	  vs	  L	  
OAS3	   OAS3	   0.000669	   -­‐4.376	   V	  down	  vs	  L	  
APOBEC3A	   APOBEC3A	   0.000457	   -­‐4.409	   V	  down	  vs	  L	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RIN2	   RIN2	   0.000288	   -­‐4.444	   V	  down	  vs	  L	  
OAS1	   OAS1	   0.000494	   -­‐4.493	   V	  down	  vs	  L	  
HERC6	   HERC6	   0.008357	   -­‐4.520	   V	  down	  vs	  L	  
ISG15	   ISG15	   0.003331	   -­‐4.846	   V	  down	  vs	  L	  
MT1A	   MT1A	   0.000117	   -­‐5.029	   V	  down	  vs	  L	  
IFIT1	   IFIT1	   0.000221	   -­‐5.964	   V	  down	  vs	  L	  
INDO	   INDO	   0.000836	   -­‐6.760	   V	  down	  vs	  L	  
MT2A	   MT2A	   0.000307	   -­‐7.072	   V	  down	  vs	  L	  
IDO1	   IDO1	   0.000151	   -­‐7.500	   V	  down	  vs	  L	  
CFB	   CFB	   0.001571	   -­‐7.781	   V	  down	  vs	  L	  
Supplementary	   table	  1	   -­‐	   List	  of	   the	  566	  genes	  depicted	   in	   the	  volcano	  plot	   shown	   In	  
figure	  4.9,	  comparing	  monocytes	  activated	  for	  6	  hours	  with	  either	  MPO-­‐ANCA	  (V,	  n=3)	  
or	  control	  IgG	  (L,	  n=3)	  in	  the	  presence	  of	  LPS.	  Threshold	  for	  significance	  is	  1.75	  fold	  in	  
both	  directions	  and	  p-­‐value	  of	  <0.05.	  	  
	  
